id	sid	tid	token	lemma	pos
cord-011310-fm578rm5	1	1	key	key	NNP
cord-011310-fm578rm5	1	2	:	:	:
cord-011310-fm578rm5	1	3	cord-011310-fm578rm5	cord-011310-fm578rm5	.
cord-011310-fm578rm5	2	1	authors	author	NNS
cord-011310-fm578rm5	2	2	:	:	:
cord-011310-fm578rm5	2	3	Leja	Leja	NNP
cord-011310-fm578rm5	2	4	,	,	,
cord-011310-fm578rm5	2	5	Mārcis	Mārcis	NNP
cord-011310-fm578rm5	2	6	;	;	:
cord-011310-fm578rm5	2	7	Dumpis	Dumpis	NNP
cord-011310-fm578rm5	2	8	,	,	,
cord-011310-fm578rm5	2	9	Uga	Uga	NNP
cord-011310-fm578rm5	2	10	title	title	NN
cord-011310-fm578rm5	2	11	:	:	:
cord-011310-fm578rm5	3	1	What	what	WP
cord-011310-fm578rm5	3	2	Would	Would	MD
cord-011310-fm578rm5	3	3	the	the	DT
cord-011310-fm578rm5	3	4	Screen	screen	NN
cord-011310-fm578rm5	3	5	-	-	HYPH
cord-011310-fm578rm5	3	6	and	and	CC
cord-011310-fm578rm5	3	7	-	-	HYPH
cord-011310-fm578rm5	3	8	Treat	Treat	NNP
cord-011310-fm578rm5	3	9	Strategy	Strategy	NNP
cord-011310-fm578rm5	3	10	for	for	IN
cord-011310-fm578rm5	3	11	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	3	12	pylori	pylori	NN
cord-011310-fm578rm5	4	1	Mean	mean	VB
cord-011310-fm578rm5	4	2	in	in	IN
cord-011310-fm578rm5	4	3	Terms	term	NNS
cord-011310-fm578rm5	4	4	of	of	IN
cord-011310-fm578rm5	4	5	Antibiotic	antibiotic	JJ
cord-011310-fm578rm5	4	6	Consumption	consumption	NN
cord-011310-fm578rm5	4	7	?	?	.
cord-011310-fm578rm5	5	1	date	date	NN
cord-011310-fm578rm5	5	2	:	:	:
cord-011310-fm578rm5	5	3	2019	2019	CD
cord-011310-fm578rm5	5	4	-	-	SYM
cord-011310-fm578rm5	5	5	10	10	CD
cord-011310-fm578rm5	5	6	-	-	SYM
cord-011310-fm578rm5	5	7	28	28	CD
cord-011310-fm578rm5	5	8	journal	journal	NN
cord-011310-fm578rm5	5	9	:	:	:
cord-011310-fm578rm5	6	1	Dig	dig	VB
cord-011310-fm578rm5	6	2	Dis	Dis	NNP
cord-011310-fm578rm5	6	3	Sci	Sci	NNP
cord-011310-fm578rm5	6	4	DOI	DOI	NNP
cord-011310-fm578rm5	6	5	:	:	:
cord-011310-fm578rm5	6	6	10.1007	10.1007	CD
cord-011310-fm578rm5	6	7	/	/	SYM
cord-011310-fm578rm5	6	8	s10620	s10620	NN
cord-011310-fm578rm5	6	9	-	-	HYPH
cord-011310-fm578rm5	6	10	019	019	CD
cord-011310-fm578rm5	6	11	-	-	HYPH
cord-011310-fm578rm5	6	12	05893-z	05893-z	NNP
cord-011310-fm578rm5	6	13	sha	sha	NNP
cord-011310-fm578rm5	6	14	:	:	:
cord-011310-fm578rm5	7	1	a93f7f2e7341b30b8fec646dfedb22668822aa83	a93f7f2e7341b30b8fec646dfedb22668822aa83	NFP
cord-011310-fm578rm5	7	2	doc_id	doc_id	CD
cord-011310-fm578rm5	7	3	:	:	:
cord-011310-fm578rm5	8	1	11310	11310	CD
cord-011310-fm578rm5	8	2	cord_uid	cord_uid	NNS
cord-011310-fm578rm5	8	3	:	:	:
cord-011310-fm578rm5	9	1	fm578rm5	fm578rm5	UH
cord-011310-fm578rm5	10	1	Several	several	JJ
cord-011310-fm578rm5	10	2	guidelines	guideline	NNS
cord-011310-fm578rm5	10	3	recommend	recommend	VBP
cord-011310-fm578rm5	10	4	the	the	DT
cord-011310-fm578rm5	10	5	screen	screen	NN
cord-011310-fm578rm5	10	6	-	-	HYPH
cord-011310-fm578rm5	10	7	and	and	CC
cord-011310-fm578rm5	10	8	-	-	HYPH
cord-011310-fm578rm5	10	9	treat	treat	VB
cord-011310-fm578rm5	10	10	strategy	strategy	NN
cord-011310-fm578rm5	10	11	,	,	,
cord-011310-fm578rm5	10	12	i.e.	i.e.	FW
cord-011310-fm578rm5	10	13	active	active	JJ
cord-011310-fm578rm5	10	14	search	search	NN
cord-011310-fm578rm5	10	15	for	for	IN
cord-011310-fm578rm5	10	16	the	the	DT
cord-011310-fm578rm5	10	17	presence	presence	NN
cord-011310-fm578rm5	10	18	of	of	IN
cord-011310-fm578rm5	10	19	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	10	20	pylori	pylori	NN
cord-011310-fm578rm5	10	21	infection	infection	NN
cord-011310-fm578rm5	10	22	and	and	CC
cord-011310-fm578rm5	10	23	its	-PRON-	PRP$
cord-011310-fm578rm5	10	24	eradication	eradication	NN
cord-011310-fm578rm5	10	25	to	to	TO
cord-011310-fm578rm5	10	26	prevent	prevent	VB
cord-011310-fm578rm5	10	27	the	the	DT
cord-011310-fm578rm5	10	28	possibility	possibility	NN
cord-011310-fm578rm5	10	29	of	of	IN
cord-011310-fm578rm5	10	30	gastric	gastric	JJ
cord-011310-fm578rm5	10	31	cancer	cancer	NN
cord-011310-fm578rm5	10	32	.	.	.
cord-011310-fm578rm5	11	1	It	-PRON-	PRP
cord-011310-fm578rm5	11	2	is	be	VBZ
cord-011310-fm578rm5	11	3	thought	think	VBN
cord-011310-fm578rm5	11	4	that	that	IN
cord-011310-fm578rm5	11	5	a	a	DT
cord-011310-fm578rm5	11	6	relatively	relatively	RB
cord-011310-fm578rm5	11	7	short	short	JJ
cord-011310-fm578rm5	11	8	duration	duration	NN
cord-011310-fm578rm5	11	9	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	11	10	regimen	regimen	NN
cord-011310-fm578rm5	11	11	given	give	VBN
cord-011310-fm578rm5	11	12	once	once	RB
cord-011310-fm578rm5	11	13	in	in	IN
cord-011310-fm578rm5	11	14	a	a	DT
cord-011310-fm578rm5	11	15	lifetime	lifetime	NN
cord-011310-fm578rm5	11	16	would	would	MD
cord-011310-fm578rm5	11	17	not	not	RB
cord-011310-fm578rm5	11	18	significantly	significantly	RB
cord-011310-fm578rm5	11	19	increase	increase	VB
cord-011310-fm578rm5	11	20	overall	overall	JJ
cord-011310-fm578rm5	11	21	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	11	22	consumption	consumption	NN
cord-011310-fm578rm5	11	23	.	.	.
cord-011310-fm578rm5	12	1	However	however	RB
cord-011310-fm578rm5	12	2	,	,	,
cord-011310-fm578rm5	12	3	this	this	DT
cord-011310-fm578rm5	12	4	would	would	MD
cord-011310-fm578rm5	12	5	mean	mean	VB
cord-011310-fm578rm5	12	6	offering	offer	VBG
cord-011310-fm578rm5	12	7	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	12	8	treatment	treatment	NN
cord-011310-fm578rm5	12	9	to	to	IN
cord-011310-fm578rm5	12	10	the	the	DT
cord-011310-fm578rm5	12	11	majority	majority	NN
cord-011310-fm578rm5	12	12	of	of	IN
cord-011310-fm578rm5	12	13	the	the	DT
cord-011310-fm578rm5	12	14	population	population	NN
cord-011310-fm578rm5	12	15	in	in	IN
cord-011310-fm578rm5	12	16	countries	country	NNS
cord-011310-fm578rm5	12	17	with	with	IN
cord-011310-fm578rm5	12	18	the	the	DT
cord-011310-fm578rm5	12	19	biggest	big	JJS
cord-011310-fm578rm5	12	20	burden	burden	NN
cord-011310-fm578rm5	12	21	of	of	IN
cord-011310-fm578rm5	12	22	gastric	gastric	JJ
cord-011310-fm578rm5	12	23	cancer	cancer	NN
cord-011310-fm578rm5	12	24	who	who	WP
cord-011310-fm578rm5	12	25	would	would	MD
cord-011310-fm578rm5	12	26	,	,	,
cord-011310-fm578rm5	12	27	therefore	therefore	RB
cord-011310-fm578rm5	12	28	,	,	,
cord-011310-fm578rm5	12	29	have	have	VBP
cord-011310-fm578rm5	12	30	the	the	DT
cord-011310-fm578rm5	12	31	greatest	great	JJS
cord-011310-fm578rm5	12	32	benefit	benefit	NN
cord-011310-fm578rm5	12	33	from	from	IN
cord-011310-fm578rm5	12	34	such	such	PDT
cord-011310-fm578rm5	12	35	a	a	DT
cord-011310-fm578rm5	12	36	strategy	strategy	NN
cord-011310-fm578rm5	12	37	.	.	.
cord-011310-fm578rm5	13	1	So	so	RB
cord-011310-fm578rm5	13	2	far	far	RB
cord-011310-fm578rm5	13	3	,	,	,
cord-011310-fm578rm5	13	4	no	no	DT
cord-011310-fm578rm5	13	5	country	country	NN
cord-011310-fm578rm5	13	6	has	have	VBZ
cord-011310-fm578rm5	13	7	implemented	implement	VBN
cord-011310-fm578rm5	13	8	an	an	DT
cord-011310-fm578rm5	13	9	eradication	eradication	NN
cord-011310-fm578rm5	13	10	strategy	strategy	NN
cord-011310-fm578rm5	13	11	.	.	.
cord-011310-fm578rm5	14	1	With	with	IN
cord-011310-fm578rm5	14	2	an	an	DT
cord-011310-fm578rm5	14	3	example	example	NN
cord-011310-fm578rm5	14	4	based	base	VBN
cord-011310-fm578rm5	14	5	on	on	IN
cord-011310-fm578rm5	14	6	the	the	DT
cord-011310-fm578rm5	14	7	current	current	JJ
cord-011310-fm578rm5	14	8	situation	situation	NN
cord-011310-fm578rm5	14	9	in	in	IN
cord-011310-fm578rm5	14	10	Latvia	Latvia	NNP
cord-011310-fm578rm5	14	11	,	,	,
cord-011310-fm578rm5	14	12	we	-PRON-	PRP
cord-011310-fm578rm5	14	13	have	have	VBP
cord-011310-fm578rm5	14	14	estimated	estimate	VBN
cord-011310-fm578rm5	14	15	the	the	DT
cord-011310-fm578rm5	14	16	increase	increase	NN
cord-011310-fm578rm5	14	17	in	in	IN
cord-011310-fm578rm5	14	18	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	14	19	consumption	consumption	NN
cord-011310-fm578rm5	14	20	if	if	IN
cord-011310-fm578rm5	14	21	the	the	DT
cord-011310-fm578rm5	14	22	screen	screen	NN
cord-011310-fm578rm5	14	23	-	-	HYPH
cord-011310-fm578rm5	14	24	and	and	CC
cord-011310-fm578rm5	14	25	-	-	HYPH
cord-011310-fm578rm5	14	26	treat	treat	VB
cord-011310-fm578rm5	14	27	strategy	strategy	NN
cord-011310-fm578rm5	14	28	was	be	VBD
cord-011310-fm578rm5	14	29	applied	apply	VBN
cord-011310-fm578rm5	14	30	.	.	.
cord-011310-fm578rm5	15	1	Depending	depend	VBG
cord-011310-fm578rm5	15	2	on	on	IN
cord-011310-fm578rm5	15	3	the	the	DT
cord-011310-fm578rm5	15	4	scenario	scenario	NN
cord-011310-fm578rm5	15	5	that	that	WDT
cord-011310-fm578rm5	15	6	might	may	MD
cord-011310-fm578rm5	15	7	be	be	VB
cord-011310-fm578rm5	15	8	chosen	choose	VBN
cord-011310-fm578rm5	15	9	,	,	,
cord-011310-fm578rm5	15	10	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	15	11	consumption	consumption	NN
cord-011310-fm578rm5	15	12	would	would	MD
cord-011310-fm578rm5	15	13	increase	increase	VB
cord-011310-fm578rm5	15	14	up	up	RP
cord-011310-fm578rm5	15	15	to	to	IN
cord-011310-fm578rm5	15	16	sixfold	sixfold	VB
cord-011310-fm578rm5	15	17	,	,	,
cord-011310-fm578rm5	15	18	and	and	CC
cord-011310-fm578rm5	15	19	amoxicillin	amoxicillin	JJ
cord-011310-fm578rm5	15	20	consumption	consumption	NN
cord-011310-fm578rm5	15	21	would	would	MD
cord-011310-fm578rm5	15	22	double	double	VB
cord-011310-fm578rm5	15	23	if	if	IN
cord-011310-fm578rm5	15	24	the	the	DT
cord-011310-fm578rm5	15	25	recommendations	recommendation	NNS
cord-011310-fm578rm5	15	26	of	of	IN
cord-011310-fm578rm5	15	27	the	the	DT
cord-011310-fm578rm5	15	28	current	current	JJ
cord-011310-fm578rm5	15	29	guideline	guideline	NN
cord-011310-fm578rm5	15	30	in	in	IN
cord-011310-fm578rm5	15	31	the	the	DT
cord-011310-fm578rm5	15	32	local	local	JJ
cord-011310-fm578rm5	15	33	circumstances	circumstance	NNS
cord-011310-fm578rm5	15	34	was	be	VBD
cord-011310-fm578rm5	15	35	applied	apply	VBN
cord-011310-fm578rm5	15	36	.	.	.
cord-011310-fm578rm5	16	1	It	-PRON-	PRP
cord-011310-fm578rm5	16	2	appears	appear	VBZ
cord-011310-fm578rm5	16	3	that	that	IN
cord-011310-fm578rm5	16	4	an	an	DT
cord-011310-fm578rm5	16	5	increase	increase	NN
cord-011310-fm578rm5	16	6	in	in	IN
cord-011310-fm578rm5	16	7	commonly	commonly	RB
cord-011310-fm578rm5	16	8	used	use	VBN
cord-011310-fm578rm5	16	9	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	16	10	consumption	consumption	NN
cord-011310-fm578rm5	16	11	can	can	MD
cord-011310-fm578rm5	16	12	not	not	RB
cord-011310-fm578rm5	16	13	be	be	VB
cord-011310-fm578rm5	16	14	justified	justify	VBN
cord-011310-fm578rm5	16	15	from	from	IN
cord-011310-fm578rm5	16	16	the	the	DT
cord-011310-fm578rm5	16	17	viewpoint	viewpoint	NN
cord-011310-fm578rm5	16	18	of	of	IN
cord-011310-fm578rm5	16	19	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	16	20	stewardship	stewardship	NN
cord-011310-fm578rm5	16	21	policies	policy	NNS
cord-011310-fm578rm5	16	22	.	.	.
cord-011310-fm578rm5	17	1	Solutions	solution	NNS
cord-011310-fm578rm5	17	2	to	to	IN
cord-011310-fm578rm5	17	3	this	this	DT
cord-011310-fm578rm5	17	4	problem	problem	NN
cord-011310-fm578rm5	17	5	could	could	MD
cord-011310-fm578rm5	17	6	be	be	VB
cord-011310-fm578rm5	17	7	the	the	DT
cord-011310-fm578rm5	17	8	use	use	NN
cord-011310-fm578rm5	17	9	of	of	IN
cord-011310-fm578rm5	17	10	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	17	11	that	that	WDT
cord-011310-fm578rm5	17	12	are	be	VBP
cord-011310-fm578rm5	17	13	not	not	RB
cord-011310-fm578rm5	17	14	required	require	VBN
cord-011310-fm578rm5	17	15	for	for	IN
cord-011310-fm578rm5	17	16	treating	treat	VBG
cord-011310-fm578rm5	17	17	life	life	NN
cord-011310-fm578rm5	17	18	-	-	HYPH
cord-011310-fm578rm5	17	19	threatening	threaten	VBG
cord-011310-fm578rm5	17	20	diseases	disease	NNS
cord-011310-fm578rm5	17	21	or	or	CC
cord-011310-fm578rm5	17	22	more	more	RBR
cord-011310-fm578rm5	17	23	narrow	narrow	JJ
cord-011310-fm578rm5	17	24	selection	selection	NN
cord-011310-fm578rm5	17	25	of	of	IN
cord-011310-fm578rm5	17	26	the	the	DT
cord-011310-fm578rm5	17	27	target	target	NN
cord-011310-fm578rm5	17	28	group	group	NN
cord-011310-fm578rm5	17	29	,	,	,
cord-011310-fm578rm5	17	30	e.g.	e.g.	DT
cord-011310-fm578rm5	17	31	young	young	JJ
cord-011310-fm578rm5	17	32	people	people	NNS
cord-011310-fm578rm5	17	33	before	before	IN
cord-011310-fm578rm5	17	34	family	family	NN
cord-011310-fm578rm5	17	35	planning	plan	VBG
cord-011310-fm578rm5	17	36	to	to	TO
cord-011310-fm578rm5	17	37	avoid	avoid	VB
cord-011310-fm578rm5	17	38	transmission	transmission	NN
cord-011310-fm578rm5	17	39	to	to	IN
cord-011310-fm578rm5	17	40	offspring	offspring	NN
cord-011310-fm578rm5	17	41	.	.	.
cord-011310-fm578rm5	18	1	Additional	additional	JJ
cord-011310-fm578rm5	18	2	costs	cost	NNS
cord-011310-fm578rm5	18	3	related	relate	VBN
cord-011310-fm578rm5	18	4	to	to	IN
cord-011310-fm578rm5	18	5	the	the	DT
cord-011310-fm578rm5	18	6	increase	increase	NN
cord-011310-fm578rm5	18	7	in	in	IN
cord-011310-fm578rm5	18	8	resistome	resistome	NNP
cord-011310-fm578rm5	18	9	should	should	MD
cord-011310-fm578rm5	18	10	be	be	VB
cord-011310-fm578rm5	18	11	considered	consider	VBN
cord-011310-fm578rm5	18	12	for	for	IN
cord-011310-fm578rm5	18	13	future	future	JJ
cord-011310-fm578rm5	18	14	cost	cost	NN
cord-011310-fm578rm5	18	15	-	-	HYPH
cord-011310-fm578rm5	18	16	effectiveness	effectiveness	NN
cord-011310-fm578rm5	18	17	modelling	modelling	NN
cord-011310-fm578rm5	18	18	of	of	IN
cord-011310-fm578rm5	18	19	the	the	DT
cord-011310-fm578rm5	18	20	screen	screen	NN
cord-011310-fm578rm5	18	21	-	-	HYPH
cord-011310-fm578rm5	18	22	and	and	CC
cord-011310-fm578rm5	18	23	-	-	HYPH
cord-011310-fm578rm5	18	24	treat	treat	VB
cord-011310-fm578rm5	18	25	strategy	strategy	NN
cord-011310-fm578rm5	18	26	.	.	.
cord-011310-fm578rm5	19	1	Although	although	IN
cord-011310-fm578rm5	19	2	declining	decline	VBG
cord-011310-fm578rm5	19	3	in	in	IN
cord-011310-fm578rm5	19	4	incidence	incidence	NN
cord-011310-fm578rm5	19	5	,	,	,
cord-011310-fm578rm5	19	6	gastric	gastric	JJ
cord-011310-fm578rm5	19	7	cancer	cancer	NN
cord-011310-fm578rm5	19	8	will	will	MD
cord-011310-fm578rm5	19	9	remain	remain	VB
cord-011310-fm578rm5	19	10	an	an	DT
cord-011310-fm578rm5	19	11	important	important	JJ
cord-011310-fm578rm5	19	12	healthcare	healthcare	NN
cord-011310-fm578rm5	19	13	issue	issue	NN
cord-011310-fm578rm5	19	14	for	for	IN
cord-011310-fm578rm5	19	15	the	the	DT
cord-011310-fm578rm5	19	16	foreseeable	foreseeable	JJ
cord-011310-fm578rm5	19	17	future	future	NN
cord-011310-fm578rm5	19	18	due	due	JJ
cord-011310-fm578rm5	19	19	to	to	IN
cord-011310-fm578rm5	19	20	aging	age	VBG
cord-011310-fm578rm5	19	21	and	and	CC
cord-011310-fm578rm5	19	22	the	the	DT
cord-011310-fm578rm5	19	23	increase	increase	NN
cord-011310-fm578rm5	19	24	in	in	IN
cord-011310-fm578rm5	19	25	global	global	JJ
cord-011310-fm578rm5	19	26	population	population	NN
cord-011310-fm578rm5	19	27	.	.	.
cord-011310-fm578rm5	20	1	The	the	DT
cord-011310-fm578rm5	20	2	group	group	NN
cord-011310-fm578rm5	20	3	of	of	IN
cord-011310-fm578rm5	20	4	experts	expert	NNS
cord-011310-fm578rm5	20	5	gathered	gather	VBN
cord-011310-fm578rm5	20	6	by	by	IN
cord-011310-fm578rm5	20	7	the	the	DT
cord-011310-fm578rm5	20	8	International	International	NNP
cord-011310-fm578rm5	20	9	Agency	Agency	NNP
cord-011310-fm578rm5	20	10	for	for	IN
cord-011310-fm578rm5	20	11	Research	Research	NNP
cord-011310-fm578rm5	20	12	on	on	IN
cord-011310-fm578rm5	20	13	Cancer	Cancer	NNP
cord-011310-fm578rm5	20	14	(	(	-LRB-
cord-011310-fm578rm5	20	15	IARC	IARC	NNP
cord-011310-fm578rm5	20	16	)	)	-RRB-
cord-011310-fm578rm5	20	17	has	have	VBZ
cord-011310-fm578rm5	20	18	suggested	suggest	VBN
cord-011310-fm578rm5	20	19	implementation	implementation	NN
cord-011310-fm578rm5	20	20	of	of	IN
cord-011310-fm578rm5	20	21	gastric	gastric	JJ
cord-011310-fm578rm5	20	22	cancer	cancer	NN
cord-011310-fm578rm5	20	23	prevention	prevention	NN
cord-011310-fm578rm5	20	24	by	by	IN
cord-011310-fm578rm5	20	25	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	20	26	pylori	pylori	NN
cord-011310-fm578rm5	21	1	(	(	-LRB-
cord-011310-fm578rm5	21	2	H.	H.	NNP
cord-011310-fm578rm5	21	3	pylori	pylori	NN
cord-011310-fm578rm5	21	4	)	)	-RRB-
cord-011310-fm578rm5	21	5	eradication	eradication	NN
cord-011310-fm578rm5	21	6	in	in	IN
cord-011310-fm578rm5	21	7	well	well	RB
cord-011310-fm578rm5	21	8	-	-	HYPH
cord-011310-fm578rm5	21	9	controlled	control	VBN
cord-011310-fm578rm5	21	10	research	research	NN
cord-011310-fm578rm5	21	11	settings	setting	NNS
cord-011310-fm578rm5	21	12	(	(	-LRB-
cord-011310-fm578rm5	21	13	ML	ML	NNP
cord-011310-fm578rm5	21	14	was	be	VBD
cord-011310-fm578rm5	21	15	part	part	NN
cord-011310-fm578rm5	21	16	of	of	IN
cord-011310-fm578rm5	21	17	the	the	DT
cord-011310-fm578rm5	21	18	working	work	VBG
cord-011310-fm578rm5	21	19	group	group	NN
cord-011310-fm578rm5	21	20	)	)	-RRB-
cord-011310-fm578rm5	22	1	[	[	-LRB-
cord-011310-fm578rm5	22	2	1	1	CD
cord-011310-fm578rm5	22	3	]	]	-RRB-
cord-011310-fm578rm5	22	4	.	.	.
cord-011310-fm578rm5	23	1	The	the	DT
cord-011310-fm578rm5	23	2	annual	annual	JJ
cord-011310-fm578rm5	23	3	total	total	JJ
cord-011310-fm578rm5	23	4	number	number	NN
cord-011310-fm578rm5	23	5	of	of	IN
cord-011310-fm578rm5	23	6	new	new	JJ
cord-011310-fm578rm5	23	7	cases	case	NNS
cord-011310-fm578rm5	23	8	accounts	account	VBZ
cord-011310-fm578rm5	23	9	for	for	IN
cord-011310-fm578rm5	23	10	~	~	CD
cord-011310-fm578rm5	23	11	one	one	CD
cord-011310-fm578rm5	23	12	million	million	CD
cord-011310-fm578rm5	23	13	,	,	,
cord-011310-fm578rm5	23	14	responsible	responsible	JJ
cord-011310-fm578rm5	23	15	for	for	IN
cord-011310-fm578rm5	23	16	>	>	$
cord-011310-fm578rm5	23	17	8	8	CD
cord-011310-fm578rm5	23	18	%	%	NN
cord-011310-fm578rm5	23	19	of	of	IN
cord-011310-fm578rm5	23	20	global	global	JJ
cord-011310-fm578rm5	23	21	cancer	cancer	NN
cord-011310-fm578rm5	23	22	-	-	HYPH
cord-011310-fm578rm5	23	23	related	relate	VBN
cord-011310-fm578rm5	23	24	deaths	death	NNS
cord-011310-fm578rm5	23	25	each	each	DT
cord-011310-fm578rm5	23	26	year	year	NN
cord-011310-fm578rm5	23	27	[	[	-LRB-
cord-011310-fm578rm5	23	28	2	2	CD
cord-011310-fm578rm5	23	29	]	]	-RRB-
cord-011310-fm578rm5	23	30	.	.	.
cord-011310-fm578rm5	24	1	This	this	DT
cord-011310-fm578rm5	24	2	number	number	NN
cord-011310-fm578rm5	24	3	is	be	VBZ
cord-011310-fm578rm5	24	4	estimated	estimate	VBN
cord-011310-fm578rm5	24	5	to	to	TO
cord-011310-fm578rm5	24	6	remain	remain	VB
cord-011310-fm578rm5	24	7	stable	stable	JJ
cord-011310-fm578rm5	24	8	for	for	IN
cord-011310-fm578rm5	24	9	at	at	IN
cord-011310-fm578rm5	24	10	least	least	JJS
cord-011310-fm578rm5	24	11	the	the	DT
cord-011310-fm578rm5	24	12	next	next	JJ
cord-011310-fm578rm5	24	13	30	30	CD
cord-011310-fm578rm5	24	14	years	year	NNS
cord-011310-fm578rm5	24	15	if	if	IN
cord-011310-fm578rm5	24	16	no	no	DT
cord-011310-fm578rm5	24	17	prevention	prevention	NN
cord-011310-fm578rm5	24	18	measures	measure	NNS
cord-011310-fm578rm5	24	19	are	be	VBP
cord-011310-fm578rm5	24	20	implemented	implement	VBN
cord-011310-fm578rm5	24	21	[	[	-LRB-
cord-011310-fm578rm5	24	22	3	3	CD
cord-011310-fm578rm5	24	23	]	]	-RRB-
cord-011310-fm578rm5	24	24	.	.	.
cord-011310-fm578rm5	25	1	Infection	infection	NN
cord-011310-fm578rm5	25	2	with	with	IN
cord-011310-fm578rm5	25	3	H.	H.	NNP
cord-011310-fm578rm5	25	4	pylori	pylori	NN
cord-011310-fm578rm5	25	5	is	be	VBZ
cord-011310-fm578rm5	25	6	the	the	DT
cord-011310-fm578rm5	25	7	key	key	JJ
cord-011310-fm578rm5	25	8	risk	risk	NN
cord-011310-fm578rm5	25	9	factor	factor	NN
cord-011310-fm578rm5	25	10	for	for	IN
cord-011310-fm578rm5	25	11	this	this	DT
cord-011310-fm578rm5	25	12	type	type	NN
cord-011310-fm578rm5	25	13	of	of	IN
cord-011310-fm578rm5	25	14	cancer	cancer	NN
cord-011310-fm578rm5	25	15	,	,	,
cord-011310-fm578rm5	25	16	responsible	responsible	JJ
cord-011310-fm578rm5	25	17	for	for	IN
cord-011310-fm578rm5	25	18	~	~	CD
cord-011310-fm578rm5	25	19	90	90	CD
cord-011310-fm578rm5	25	20	%	%	NN
cord-011310-fm578rm5	25	21	of	of	IN
cord-011310-fm578rm5	25	22	the	the	DT
cord-011310-fm578rm5	25	23	distal	distal	JJ
cord-011310-fm578rm5	25	24	(	(	-LRB-
cord-011310-fm578rm5	25	25	non	non	JJ
cord-011310-fm578rm5	25	26	-	-	JJ
cord-011310-fm578rm5	25	27	cardia	cardia	JJ
cord-011310-fm578rm5	25	28	)	)	-RRB-
cord-011310-fm578rm5	25	29	cancer	cancer	NN
cord-011310-fm578rm5	25	30	cases	case	NNS
cord-011310-fm578rm5	25	31	[	[	-LRB-
cord-011310-fm578rm5	25	32	4	4	CD
cord-011310-fm578rm5	25	33	,	,	,
cord-011310-fm578rm5	25	34	5	5	CD
cord-011310-fm578rm5	25	35	]	]	-RRB-
cord-011310-fm578rm5	25	36	.	.	.
cord-011310-fm578rm5	26	1	Several	several	JJ
cord-011310-fm578rm5	26	2	prevention	prevention	NN
cord-011310-fm578rm5	26	3	strategies	strategy	NNS
cord-011310-fm578rm5	26	4	,	,	,
cord-011310-fm578rm5	26	5	including	include	VBG
cord-011310-fm578rm5	26	6	primary	primary	JJ
cord-011310-fm578rm5	26	7	and	and	CC
cord-011310-fm578rm5	26	8	secondary	secondary	JJ
cord-011310-fm578rm5	26	9	prevention	prevention	NN
cord-011310-fm578rm5	26	10	are	be	VBP
cord-011310-fm578rm5	26	11	suggested	suggest	VBN
cord-011310-fm578rm5	26	12	to	to	TO
cord-011310-fm578rm5	26	13	decrease	decrease	VB
cord-011310-fm578rm5	26	14	the	the	DT
cord-011310-fm578rm5	26	15	mortality	mortality	NN
cord-011310-fm578rm5	26	16	caused	cause	VBN
cord-011310-fm578rm5	26	17	by	by	IN
cord-011310-fm578rm5	26	18	gastric	gastric	JJ
cord-011310-fm578rm5	26	19	cancer	cancer	NN
cord-011310-fm578rm5	26	20	.	.	.
cord-011310-fm578rm5	27	1	Only	only	RB
cord-011310-fm578rm5	27	2	about	about	RB
cord-011310-fm578rm5	27	3	1	1	CD
cord-011310-fm578rm5	27	4	-	-	SYM
cord-011310-fm578rm5	27	5	2	2	CD
cord-011310-fm578rm5	27	6	%	%	NN
cord-011310-fm578rm5	27	7	of	of	IN
cord-011310-fm578rm5	27	8	individuals	individual	NNS
cord-011310-fm578rm5	27	9	infected	infect	VBN
cord-011310-fm578rm5	27	10	with	with	IN
cord-011310-fm578rm5	27	11	H.	H.	NNP
cord-011310-fm578rm5	27	12	pylori	pylori	NN
cord-011310-fm578rm5	27	13	are	be	VBP
cord-011310-fm578rm5	27	14	likely	likely	JJ
cord-011310-fm578rm5	27	15	to	to	TO
cord-011310-fm578rm5	27	16	develop	develop	VB
cord-011310-fm578rm5	27	17	gastric	gastric	JJ
cord-011310-fm578rm5	27	18	cancer	cancer	NN
cord-011310-fm578rm5	27	19	in	in	IN
cord-011310-fm578rm5	27	20	their	-PRON-	PRP$
cord-011310-fm578rm5	27	21	lifetime	lifetime	NN
cord-011310-fm578rm5	27	22	[	[	-LRB-
cord-011310-fm578rm5	27	23	6	6	CD
cord-011310-fm578rm5	27	24	,	,	,
cord-011310-fm578rm5	27	25	7	7	CD
cord-011310-fm578rm5	27	26	]	]	-RRB-
cord-011310-fm578rm5	27	27	.	.	.
cord-011310-fm578rm5	28	1	Ideally	ideally	RB
cord-011310-fm578rm5	28	2	,	,	,
cord-011310-fm578rm5	28	3	only	only	RB
cord-011310-fm578rm5	28	4	the	the	DT
cord-011310-fm578rm5	28	5	bacteria	bacteria	NNS
cord-011310-fm578rm5	28	6	potentially	potentially	RB
cord-011310-fm578rm5	28	7	leading	lead	VBG
cord-011310-fm578rm5	28	8	to	to	IN
cord-011310-fm578rm5	28	9	cancer	cancer	NN
cord-011310-fm578rm5	28	10	or	or	CC
cord-011310-fm578rm5	28	11	other	other	JJ
cord-011310-fm578rm5	28	12	diseases	disease	NNS
cord-011310-fm578rm5	28	13	should	should	MD
cord-011310-fm578rm5	28	14	be	be	VB
cord-011310-fm578rm5	28	15	eradicated	eradicate	VBN
cord-011310-fm578rm5	28	16	;	;	:
cord-011310-fm578rm5	28	17	however	however	RB
cord-011310-fm578rm5	28	18	,	,	,
cord-011310-fm578rm5	28	19	risk	risk	NN
cord-011310-fm578rm5	28	20	stratification	stratification	NN
cord-011310-fm578rm5	28	21	attempts	attempt	NNS
cord-011310-fm578rm5	28	22	based	base	VBN
cord-011310-fm578rm5	28	23	on	on	IN
cord-011310-fm578rm5	28	24	H.	h.	NN
cord-011310-fm578rm5	28	25	pylori	pylori	NN
cord-011310-fm578rm5	28	26	virulence	virulence	NN
cord-011310-fm578rm5	28	27	factor	factor	NN
cord-011310-fm578rm5	28	28	identification	identification	NN
cord-011310-fm578rm5	28	29	or	or	CC
cord-011310-fm578rm5	28	30	host	host	NN
cord-011310-fm578rm5	28	31	susceptibility	susceptibility	NN
cord-011310-fm578rm5	28	32	,	,	,
cord-011310-fm578rm5	28	33	e.g.	e.g.	RB
cord-011310-fm578rm5	28	34	by	by	IN
cord-011310-fm578rm5	28	35	detecting	detect	VBG
cord-011310-fm578rm5	28	36	the	the	DT
cord-011310-fm578rm5	28	37	relevant	relevant	JJ
cord-011310-fm578rm5	28	38	polymorphisms	polymorphism	NNS
cord-011310-fm578rm5	28	39	of	of	IN
cord-011310-fm578rm5	28	40	proinflammatory	proinflammatory	JJ
cord-011310-fm578rm5	28	41	cytokines	cytokine	NNS
cord-011310-fm578rm5	28	42	,	,	,
cord-011310-fm578rm5	28	43	have	have	VBP
cord-011310-fm578rm5	28	44	not	not	RB
cord-011310-fm578rm5	28	45	led	lead	VBN
cord-011310-fm578rm5	28	46	to	to	IN
cord-011310-fm578rm5	28	47	a	a	DT
cord-011310-fm578rm5	28	48	strategy	strategy	NN
cord-011310-fm578rm5	28	49	that	that	WDT
cord-011310-fm578rm5	28	50	could	could	MD
cord-011310-fm578rm5	28	51	be	be	VB
cord-011310-fm578rm5	28	52	recommended	recommend	VBN
cord-011310-fm578rm5	28	53	for	for	IN
cord-011310-fm578rm5	28	54	routine	routine	JJ
cord-011310-fm578rm5	28	55	practice	practice	NN
cord-011310-fm578rm5	28	56	[	[	-LRB-
cord-011310-fm578rm5	28	57	8	8	CD
cord-011310-fm578rm5	28	58	]	]	-RRB-
cord-011310-fm578rm5	28	59	.	.	.
cord-011310-fm578rm5	29	1	Vaccine	vaccine	NN
cord-011310-fm578rm5	29	2	development	development	NN
cord-011310-fm578rm5	29	3	still	still	RB
cord-011310-fm578rm5	29	4	does	do	VBZ
cord-011310-fm578rm5	29	5	not	not	RB
cord-011310-fm578rm5	29	6	provide	provide	VB
cord-011310-fm578rm5	29	7	encouraging	encouraging	JJ
cord-011310-fm578rm5	29	8	results	result	NNS
cord-011310-fm578rm5	29	9	suggesting	suggest	VBG
cord-011310-fm578rm5	29	10	that	that	IN
cord-011310-fm578rm5	29	11	it	-PRON-	PRP
cord-011310-fm578rm5	29	12	is	be	VBZ
cord-011310-fm578rm5	29	13	close	close	JJ
cord-011310-fm578rm5	29	14	to	to	IN
cord-011310-fm578rm5	29	15	a	a	DT
cord-011310-fm578rm5	29	16	routine	routine	JJ
cord-011310-fm578rm5	29	17	practice	practice	NN
cord-011310-fm578rm5	29	18	[	[	-LRB-
cord-011310-fm578rm5	29	19	9	9	CD
cord-011310-fm578rm5	29	20	]	]	-RRB-
cord-011310-fm578rm5	29	21	.	.	.
cord-011310-fm578rm5	30	1	Eradication	eradication	NN
cord-011310-fm578rm5	30	2	of	of	IN
cord-011310-fm578rm5	30	3	H.	H.	NNP
cord-011310-fm578rm5	30	4	pylori	pylori	NN
cord-011310-fm578rm5	30	5	in	in	IN
cord-011310-fm578rm5	30	6	adults	adult	NNS
cord-011310-fm578rm5	30	7	hosting	host	VBG
cord-011310-fm578rm5	30	8	the	the	DT
cord-011310-fm578rm5	30	9	infection	infection	NN
cord-011310-fm578rm5	30	10	appears	appear	VBZ
cord-011310-fm578rm5	30	11	to	to	TO
cord-011310-fm578rm5	30	12	be	be	VB
cord-011310-fm578rm5	30	13	the	the	DT
cord-011310-fm578rm5	30	14	most	most	RBS
cord-011310-fm578rm5	30	15	effective	effective	JJ
cord-011310-fm578rm5	30	16	prevention	prevention	NN
cord-011310-fm578rm5	30	17	strategy	strategy	NN
cord-011310-fm578rm5	30	18	.	.	.
cord-011310-fm578rm5	31	1	The	the	DT
cord-011310-fm578rm5	31	2	only	only	JJ
cord-011310-fm578rm5	31	3	reliable	reliable	JJ
cord-011310-fm578rm5	31	4	approach	approach	NN
cord-011310-fm578rm5	31	5	to	to	TO
cord-011310-fm578rm5	31	6	eliminate	eliminate	VB
cord-011310-fm578rm5	31	7	the	the	DT
cord-011310-fm578rm5	31	8	infection	infection	NN
cord-011310-fm578rm5	31	9	is	be	VBZ
cord-011310-fm578rm5	31	10	simultaneous	simultaneous	JJ
cord-011310-fm578rm5	31	11	use	use	NN
cord-011310-fm578rm5	31	12	of	of	IN
cord-011310-fm578rm5	31	13	at	at	RB
cord-011310-fm578rm5	31	14	least	least	RBS
cord-011310-fm578rm5	31	15	two	two	CD
cord-011310-fm578rm5	31	16	different	different	JJ
cord-011310-fm578rm5	31	17	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	31	18	in	in	IN
cord-011310-fm578rm5	31	19	combination	combination	NN
cord-011310-fm578rm5	31	20	with	with	IN
cord-011310-fm578rm5	31	21	potent	potent	JJ
cord-011310-fm578rm5	31	22	acid	acid	NN
cord-011310-fm578rm5	31	23	suppression	suppression	NN
cord-011310-fm578rm5	31	24	using	use	VBG
cord-011310-fm578rm5	31	25	a	a	DT
cord-011310-fm578rm5	31	26	proton	proton	NN
cord-011310-fm578rm5	31	27	pump	pump	NN
cord-011310-fm578rm5	31	28	inhibitor	inhibitor	NN
cord-011310-fm578rm5	31	29	or	or	CC
cord-011310-fm578rm5	31	30	a	a	DT
cord-011310-fm578rm5	31	31	potassium	potassium	NN
cord-011310-fm578rm5	31	32	-	-	HYPH
cord-011310-fm578rm5	31	33	competitive	competitive	JJ
cord-011310-fm578rm5	31	34	acid	acid	NN
cord-011310-fm578rm5	31	35	blocker	blocker	NN
cord-011310-fm578rm5	31	36	(	(	-LRB-
cord-011310-fm578rm5	31	37	PCAB	PCAB	NNP
cord-011310-fm578rm5	31	38	)	)	-RRB-
cord-011310-fm578rm5	31	39	[	[	-LRB-
cord-011310-fm578rm5	31	40	10	10	CD
cord-011310-fm578rm5	31	41	]	]	-RRB-
cord-011310-fm578rm5	31	42	.	.	.
cord-011310-fm578rm5	32	1	A	a	DT
cord-011310-fm578rm5	32	2	screen	screen	NN
cord-011310-fm578rm5	32	3	-	-	HYPH
cord-011310-fm578rm5	32	4	and	and	CC
cord-011310-fm578rm5	32	5	-	-	HYPH
cord-011310-fm578rm5	32	6	treat	treat	VB
cord-011310-fm578rm5	32	7	strategy	strategy	NN
cord-011310-fm578rm5	32	8	would	would	MD
cord-011310-fm578rm5	32	9	mean	mean	VB
cord-011310-fm578rm5	32	10	active	active	JJ
cord-011310-fm578rm5	32	11	testing	testing	NN
cord-011310-fm578rm5	32	12	for	for	IN
cord-011310-fm578rm5	32	13	presence	presence	NN
cord-011310-fm578rm5	32	14	of	of	IN
cord-011310-fm578rm5	32	15	H.	H.	NNP
cord-011310-fm578rm5	32	16	pylori	pylori	NN
cord-011310-fm578rm5	32	17	in	in	IN
cord-011310-fm578rm5	32	18	the	the	DT
cord-011310-fm578rm5	32	19	(	(	-LRB-
cord-011310-fm578rm5	32	20	mostly	mostly	RB
cord-011310-fm578rm5	32	21	healthy	healthy	JJ
cord-011310-fm578rm5	32	22	)	)	-RRB-
cord-011310-fm578rm5	32	23	general	general	JJ
cord-011310-fm578rm5	32	24	population	population	NN
cord-011310-fm578rm5	32	25	,	,	,
cord-011310-fm578rm5	32	26	and	and	CC
cord-011310-fm578rm5	32	27	offering	offer	VBG
cord-011310-fm578rm5	32	28	eradication	eradication	NN
cord-011310-fm578rm5	32	29	to	to	IN
cord-011310-fm578rm5	32	30	those	those	DT
cord-011310-fm578rm5	32	31	testing	testing	NN
cord-011310-fm578rm5	32	32	positive	positive	JJ
cord-011310-fm578rm5	32	33	[	[	-LRB-
cord-011310-fm578rm5	32	34	11	11	CD
cord-011310-fm578rm5	32	35	]	]	-RRB-
cord-011310-fm578rm5	32	36	.	.	.
cord-011310-fm578rm5	33	1	It	-PRON-	PRP
cord-011310-fm578rm5	33	2	is	be	VBZ
cord-011310-fm578rm5	33	3	expected	expect	VBN
cord-011310-fm578rm5	33	4	that	that	IN
cord-011310-fm578rm5	33	5	H.	h.	NN
cord-011310-fm578rm5	33	6	pylori	pylori	NN
cord-011310-fm578rm5	33	7	eradication	eradication	NN
cord-011310-fm578rm5	33	8	would	would	MD
cord-011310-fm578rm5	33	9	reduce	reduce	VB
cord-011310-fm578rm5	33	10	the	the	DT
cord-011310-fm578rm5	33	11	risk	risk	NN
cord-011310-fm578rm5	33	12	of	of	IN
cord-011310-fm578rm5	33	13	gastric	gastric	JJ
cord-011310-fm578rm5	33	14	cancer	cancer	NN
cord-011310-fm578rm5	33	15	in	in	IN
cord-011310-fm578rm5	33	16	the	the	DT
cord-011310-fm578rm5	33	17	population	population	NN
cord-011310-fm578rm5	33	18	for	for	IN
cord-011310-fm578rm5	33	19	~	~	CD
cord-011310-fm578rm5	33	20	34	34	CD
cord-011310-fm578rm5	33	21	%	%	NN
cord-011310-fm578rm5	33	22	[	[	-LRB-
cord-011310-fm578rm5	33	23	11	11	CD
cord-011310-fm578rm5	33	24	]	]	-RRB-
cord-011310-fm578rm5	33	25	.	.	.
cord-011310-fm578rm5	34	1	Such	such	PDT
cord-011310-fm578rm5	34	2	a	a	DT
cord-011310-fm578rm5	34	3	strategy	strategy	NN
cord-011310-fm578rm5	34	4	should	should	MD
cord-011310-fm578rm5	34	5	comply	comply	VB
cord-011310-fm578rm5	34	6	with	with	IN
cord-011310-fm578rm5	34	7	the	the	DT
cord-011310-fm578rm5	34	8	principles	principle	NNS
cord-011310-fm578rm5	34	9	of	of	IN
cord-011310-fm578rm5	34	10	good	good	JJ
cord-011310-fm578rm5	34	11	governance	governance	NN
cord-011310-fm578rm5	34	12	and	and	CC
cord-011310-fm578rm5	34	13	organization	organization	NN
cord-011310-fm578rm5	34	14	,	,	,
cord-011310-fm578rm5	34	15	and	and	CC
cord-011310-fm578rm5	34	16	the	the	DT
cord-011310-fm578rm5	34	17	benefits	benefit	NNS
cord-011310-fm578rm5	34	18	should	should	MD
cord-011310-fm578rm5	34	19	be	be	VB
cord-011310-fm578rm5	34	20	well	well	RB
cord-011310-fm578rm5	34	21	-	-	HYPH
cord-011310-fm578rm5	34	22	balanced	balance	VBN
cord-011310-fm578rm5	34	23	against	against	IN
cord-011310-fm578rm5	34	24	the	the	DT
cord-011310-fm578rm5	34	25	risks	risk	NNS
cord-011310-fm578rm5	34	26	that	that	WDT
cord-011310-fm578rm5	34	27	any	any	DT
cord-011310-fm578rm5	34	28	potential	potential	JJ
cord-011310-fm578rm5	34	29	intervention	intervention	NN
cord-011310-fm578rm5	34	30	could	could	MD
cord-011310-fm578rm5	34	31	create	create	VB
cord-011310-fm578rm5	34	32	[	[	-LRB-
cord-011310-fm578rm5	34	33	12	12	CD
cord-011310-fm578rm5	34	34	]	]	-RRB-
cord-011310-fm578rm5	34	35	.	.	.
cord-011310-fm578rm5	35	1	Several	several	JJ
cord-011310-fm578rm5	35	2	risks	risk	NNS
cord-011310-fm578rm5	35	3	have	have	VBP
cord-011310-fm578rm5	35	4	been	be	VBN
cord-011310-fm578rm5	35	5	suggested	suggest	VBN
cord-011310-fm578rm5	35	6	for	for	IN
cord-011310-fm578rm5	35	7	population	population	NN
cord-011310-fm578rm5	35	8	-	-	HYPH
cord-011310-fm578rm5	35	9	based	base	VBN
cord-011310-fm578rm5	35	10	H.	h.	NN
cord-011310-fm578rm5	35	11	pylori	pylori	NN
cord-011310-fm578rm5	35	12	eradication	eradication	NN
cord-011310-fm578rm5	35	13	;	;	:
cord-011310-fm578rm5	35	14	however	however	RB
cord-011310-fm578rm5	35	15	,	,	,
cord-011310-fm578rm5	35	16	the	the	DT
cord-011310-fm578rm5	35	17	possible	possible	JJ
cord-011310-fm578rm5	35	18	adverse	adverse	JJ
cord-011310-fm578rm5	35	19	effects	effect	NNS
cord-011310-fm578rm5	35	20	related	relate	VBN
cord-011310-fm578rm5	35	21	to	to	IN
cord-011310-fm578rm5	35	22	increased	increase	VBN
cord-011310-fm578rm5	35	23	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	35	24	consumption	consumption	NN
cord-011310-fm578rm5	35	25	probably	probably	RB
cord-011310-fm578rm5	35	26	are	be	VBP
cord-011310-fm578rm5	35	27	the	the	DT
cord-011310-fm578rm5	35	28	most	most	RBS
cord-011310-fm578rm5	35	29	significant	significant	JJ
cord-011310-fm578rm5	35	30	.	.	.
cord-011310-fm578rm5	36	1	Resistant	resistant	JJ
cord-011310-fm578rm5	36	2	H.	H.	NNP
cord-011310-fm578rm5	36	3	pylori	pylori	NN
cord-011310-fm578rm5	36	4	strains	strain	NNS
cord-011310-fm578rm5	36	5	are	be	VBP
cord-011310-fm578rm5	36	6	emerging	emerge	VBG
cord-011310-fm578rm5	36	7	due	due	IN
cord-011310-fm578rm5	36	8	to	to	IN
cord-011310-fm578rm5	36	9	high	high	JJ
cord-011310-fm578rm5	36	10	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	36	11	consumption	consumption	NN
cord-011310-fm578rm5	36	12	[	[	-LRB-
cord-011310-fm578rm5	36	13	13	13	CD
cord-011310-fm578rm5	36	14	]	]	-RRB-
cord-011310-fm578rm5	36	15	.	.	.
cord-011310-fm578rm5	37	1	However	however	RB
cord-011310-fm578rm5	37	2	,	,	,
cord-011310-fm578rm5	37	3	the	the	DT
cord-011310-fm578rm5	37	4	most	most	RBS
cord-011310-fm578rm5	37	5	significant	significant	JJ
cord-011310-fm578rm5	37	6	risks	risk	NNS
cord-011310-fm578rm5	37	7	will	will	MD
cord-011310-fm578rm5	37	8	probably	probably	RB
cord-011310-fm578rm5	37	9	be	be	VB
cord-011310-fm578rm5	37	10	related	relate	VBN
cord-011310-fm578rm5	37	11	to	to	IN
cord-011310-fm578rm5	37	12	induction	induction	NN
cord-011310-fm578rm5	37	13	of	of	IN
cord-011310-fm578rm5	37	14	resistance	resistance	NN
cord-011310-fm578rm5	37	15	in	in	IN
cord-011310-fm578rm5	37	16	other	other	JJ
cord-011310-fm578rm5	37	17	clinically	clinically	RB
cord-011310-fm578rm5	37	18	relevant	relevant	JJ
cord-011310-fm578rm5	37	19	bacteria	bacteria	NNS
cord-011310-fm578rm5	37	20	than	than	IN
cord-011310-fm578rm5	37	21	H.	H.	NNP
cord-011310-fm578rm5	37	22	pylori	pylori	NN
cord-011310-fm578rm5	37	23	and	and	CC
cord-011310-fm578rm5	37	24	increase	increase	VB
cord-011310-fm578rm5	37	25	the	the	DT
cord-011310-fm578rm5	37	26	pool	pool	NN
cord-011310-fm578rm5	37	27	of	of	IN
cord-011310-fm578rm5	37	28	resistant	resistant	JJ
cord-011310-fm578rm5	37	29	genes	gene	NNS
cord-011310-fm578rm5	37	30	in	in	IN
cord-011310-fm578rm5	37	31	the	the	DT
cord-011310-fm578rm5	37	32	gut	gut	NN
cord-011310-fm578rm5	37	33	and	and	CC
cord-011310-fm578rm5	37	34	upper	upper	JJ
cord-011310-fm578rm5	37	35	respiratory	respiratory	JJ
cord-011310-fm578rm5	37	36	system	system	NN
cord-011310-fm578rm5	37	37	[	[	-LRB-
cord-011310-fm578rm5	37	38	14	14	CD
cord-011310-fm578rm5	37	39	]	]	-RRB-
cord-011310-fm578rm5	37	40	[	[	-LRB-
cord-011310-fm578rm5	37	41	15	15	CD
cord-011310-fm578rm5	37	42	]	]	-RRB-
cord-011310-fm578rm5	37	43	[	[	-LRB-
cord-011310-fm578rm5	37	44	16	16	CD
cord-011310-fm578rm5	37	45	]	]	-RRB-
cord-011310-fm578rm5	37	46	.	.	.
cord-011310-fm578rm5	38	1	The	the	DT
cord-011310-fm578rm5	38	2	currently	currently	RB
cord-011310-fm578rm5	38	3	recommended	recommend	VBN
cord-011310-fm578rm5	38	4	choice	choice	NN
cord-011310-fm578rm5	38	5	of	of	IN
cord-011310-fm578rm5	38	6	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	38	7	depends	depend	VBZ
cord-011310-fm578rm5	38	8	on	on	IN
cord-011310-fm578rm5	38	9	the	the	DT
cord-011310-fm578rm5	38	10	local	local	JJ
cord-011310-fm578rm5	38	11	resistance	resistance	NN
cord-011310-fm578rm5	38	12	pattern	pattern	NN
cord-011310-fm578rm5	38	13	of	of	IN
cord-011310-fm578rm5	38	14	H.	h.	NN
cord-011310-fm578rm5	38	15	pylori	pylori	NN
cord-011310-fm578rm5	38	16	,	,	,
cord-011310-fm578rm5	38	17	unless	unless	IN
cord-011310-fm578rm5	38	18	susceptibility	susceptibility	NN
cord-011310-fm578rm5	38	19	-	-	HYPH
cord-011310-fm578rm5	38	20	based	base	VBN
cord-011310-fm578rm5	38	21	individual	individual	JJ
cord-011310-fm578rm5	38	22	therapy	therapy	NN
cord-011310-fm578rm5	38	23	is	be	VBZ
cord-011310-fm578rm5	38	24	prescribed	prescribe	VBN
cord-011310-fm578rm5	38	25	[	[	-LRB-
cord-011310-fm578rm5	38	26	10	10	CD
cord-011310-fm578rm5	38	27	,	,	,
cord-011310-fm578rm5	38	28	11	11	CD
cord-011310-fm578rm5	38	29	]	]	-RRB-
cord-011310-fm578rm5	38	30	.	.	.
cord-011310-fm578rm5	39	1	Clarithromycin	Clarithromycin	NNP
cord-011310-fm578rm5	39	2	and	and	CC
cord-011310-fm578rm5	39	3	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	39	4	are	be	VBP
cord-011310-fm578rm5	39	5	the	the	DT
cord-011310-fm578rm5	39	6	most	most	RBS
cord-011310-fm578rm5	39	7	widely	widely	RB
cord-011310-fm578rm5	39	8	prescribed	prescribe	VBN
cord-011310-fm578rm5	39	9	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	39	10	,	,	,
cord-011310-fm578rm5	39	11	frequently	frequently	RB
cord-011310-fm578rm5	39	12	used	use	VBN
cord-011310-fm578rm5	39	13	in	in	IN
cord-011310-fm578rm5	39	14	both	both	CC
cord-011310-fm578rm5	39	15	low	low	JJ
cord-011310-fm578rm5	39	16	and	and	CC
cord-011310-fm578rm5	39	17	high	high	JJ
cord-011310-fm578rm5	39	18	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	39	19	-	-	HYPH
cord-011310-fm578rm5	39	20	resistant	resistant	JJ
cord-011310-fm578rm5	39	21	regions	region	NNS
cord-011310-fm578rm5	39	22	.	.	.
cord-011310-fm578rm5	40	1	According	accord	VBG
cord-011310-fm578rm5	40	2	to	to	IN
cord-011310-fm578rm5	40	3	the	the	DT
cord-011310-fm578rm5	40	4	guidelines	guideline	NNS
cord-011310-fm578rm5	40	5	,	,	,
cord-011310-fm578rm5	40	6	the	the	DT
cord-011310-fm578rm5	40	7	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	40	8	-	-	HYPH
cord-011310-fm578rm5	40	9	containing	contain	VBG
cord-011310-fm578rm5	40	10	regimen	regimen	NN
cord-011310-fm578rm5	40	11	is	be	VBZ
cord-011310-fm578rm5	40	12	the	the	DT
cord-011310-fm578rm5	40	13	choice	choice	NN
cord-011310-fm578rm5	40	14	where	where	WRB
cord-011310-fm578rm5	40	15	H.	H.	NNP
cord-011310-fm578rm5	40	16	pylori	pylori	NN
cord-011310-fm578rm5	40	17	is	be	VBZ
cord-011310-fm578rm5	40	18	clearly	clearly	RB
cord-011310-fm578rm5	40	19	sensitive	sensitive	JJ
cord-011310-fm578rm5	40	20	to	to	IN
cord-011310-fm578rm5	40	21	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	40	22	(	(	-LRB-
cord-011310-fm578rm5	40	23	for	for	IN
cord-011310-fm578rm5	40	24	individualized	individualized	JJ
cord-011310-fm578rm5	40	25	treatment	treatment	NN
cord-011310-fm578rm5	40	26	)	)	-RRB-
cord-011310-fm578rm5	40	27	or	or	CC
cord-011310-fm578rm5	40	28	if	if	IN
cord-011310-fm578rm5	40	29	H.	H.	NNP
cord-011310-fm578rm5	40	30	pylori	pylori	NN
cord-011310-fm578rm5	40	31	resistance	resistance	NN
cord-011310-fm578rm5	40	32	to	to	IN
cord-011310-fm578rm5	40	33	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	40	34	does	do	VBZ
cord-011310-fm578rm5	40	35	not	not	RB
cord-011310-fm578rm5	40	36	exceed	exceed	VB
cord-011310-fm578rm5	40	37	15	15	CD
cord-011310-fm578rm5	40	38	%	%	NN
cord-011310-fm578rm5	40	39	in	in	IN
cord-011310-fm578rm5	40	40	the	the	DT
cord-011310-fm578rm5	40	41	reference	reference	NN
cord-011310-fm578rm5	40	42	population	population	NN
cord-011310-fm578rm5	40	43	[	[	-LRB-
cord-011310-fm578rm5	40	44	11	11	CD
cord-011310-fm578rm5	40	45	]	]	-RRB-
cord-011310-fm578rm5	40	46	.	.	.
cord-011310-fm578rm5	41	1	Although	although	IN
cord-011310-fm578rm5	41	2	the	the	DT
cord-011310-fm578rm5	41	3	resistance	resistance	NN
cord-011310-fm578rm5	41	4	of	of	IN
cord-011310-fm578rm5	41	5	H.	H.	NNP
cord-011310-fm578rm5	41	6	pylori	pylori	NN
cord-011310-fm578rm5	41	7	to	to	IN
cord-011310-fm578rm5	41	8	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	41	9	correlates	correlate	VBZ
cord-011310-fm578rm5	41	10	to	to	IN
cord-011310-fm578rm5	41	11	the	the	DT
cord-011310-fm578rm5	41	12	overall	overall	JJ
cord-011310-fm578rm5	41	13	use	use	NN
cord-011310-fm578rm5	41	14	of	of	IN
cord-011310-fm578rm5	41	15	this	this	DT
cord-011310-fm578rm5	41	16	antibiotic	antibiotic	NN
cord-011310-fm578rm5	41	17	in	in	IN
cord-011310-fm578rm5	41	18	a	a	DT
cord-011310-fm578rm5	41	19	particular	particular	JJ
cord-011310-fm578rm5	41	20	population	population	NN
cord-011310-fm578rm5	41	21	,	,	,
cord-011310-fm578rm5	41	22	the	the	DT
cord-011310-fm578rm5	41	23	choice	choice	NN
cord-011310-fm578rm5	41	24	of	of	IN
cord-011310-fm578rm5	41	25	treatment	treatment	NN
cord-011310-fm578rm5	41	26	solely	solely	RB
cord-011310-fm578rm5	41	27	depends	depend	VBZ
cord-011310-fm578rm5	41	28	on	on	IN
cord-011310-fm578rm5	41	29	H.	h.	NN
cord-011310-fm578rm5	41	30	pylori	pylori	NN
cord-011310-fm578rm5	41	31	resistance	resistance	NN
cord-011310-fm578rm5	41	32	.	.	.
cord-011310-fm578rm5	42	1	Furthermore	furthermore	RB
cord-011310-fm578rm5	42	2	,	,	,
cord-011310-fm578rm5	42	3	no	no	DT
cord-011310-fm578rm5	42	4	differences	difference	NNS
cord-011310-fm578rm5	42	5	in	in	IN
cord-011310-fm578rm5	42	6	the	the	DT
cord-011310-fm578rm5	42	7	eradication	eradication	NN
cord-011310-fm578rm5	42	8	regimen	regimen	NN
cord-011310-fm578rm5	42	9	are	be	VBP
cord-011310-fm578rm5	42	10	currently	currently	RB
cord-011310-fm578rm5	42	11	recommended	recommend	VBN
cord-011310-fm578rm5	42	12	,	,	,
cord-011310-fm578rm5	42	13	depending	depend	VBG
cord-011310-fm578rm5	42	14	on	on	IN
cord-011310-fm578rm5	42	15	whether	whether	IN
cord-011310-fm578rm5	42	16	the	the	DT
cord-011310-fm578rm5	42	17	treatment	treatment	NN
cord-011310-fm578rm5	42	18	is	be	VBZ
cord-011310-fm578rm5	42	19	given	give	VBN
cord-011310-fm578rm5	42	20	for	for	IN
cord-011310-fm578rm5	42	21	a	a	DT
cord-011310-fm578rm5	42	22	clinically	clinically	RB
cord-011310-fm578rm5	42	23	evident	evident	JJ
cord-011310-fm578rm5	42	24	disease	disease	NN
cord-011310-fm578rm5	42	25	,	,	,
cord-011310-fm578rm5	42	26	e.g.	e.g.	RB
cord-011310-fm578rm5	42	27	for	for	IN
cord-011310-fm578rm5	42	28	complicated	complicated	JJ
cord-011310-fm578rm5	42	29	ulcer	ulcer	NN
cord-011310-fm578rm5	42	30	disease	disease	NN
cord-011310-fm578rm5	42	31	or	or	CC
cord-011310-fm578rm5	42	32	MALT	malt	NN
cord-011310-fm578rm5	42	33	lymphoma	lymphoma	NN
cord-011310-fm578rm5	42	34	from	from	IN
cord-011310-fm578rm5	42	35	prevention	prevention	NN
cord-011310-fm578rm5	42	36	strategies	strategy	NNS
cord-011310-fm578rm5	42	37	in	in	IN
cord-011310-fm578rm5	42	38	population	population	NN
cord-011310-fm578rm5	42	39	-	-	HYPH
cord-011310-fm578rm5	42	40	based	base	VBN
cord-011310-fm578rm5	42	41	settings	setting	NNS
cord-011310-fm578rm5	42	42	.	.	.
cord-011310-fm578rm5	43	1	The	the	DT
cord-011310-fm578rm5	43	2	author	author	NN
cord-011310-fm578rm5	43	3	viewpoint	viewpoint	NN
cord-011310-fm578rm5	43	4	is	be	VBZ
cord-011310-fm578rm5	43	5	that	that	IN
cord-011310-fm578rm5	43	6	negative	negative	JJ
cord-011310-fm578rm5	43	7	effects	effect	NNS
cord-011310-fm578rm5	43	8	upon	upon	IN
cord-011310-fm578rm5	43	9	the	the	DT
cord-011310-fm578rm5	43	10	gut	gut	NN
cord-011310-fm578rm5	43	11	microbiome	microbiome	NN
cord-011310-fm578rm5	43	12	would	would	MD
cord-011310-fm578rm5	43	13	not	not	RB
cord-011310-fm578rm5	43	14	be	be	VB
cord-011310-fm578rm5	43	15	a	a	DT
cord-011310-fm578rm5	43	16	significant	significant	JJ
cord-011310-fm578rm5	43	17	concern	concern	NN
cord-011310-fm578rm5	43	18	in	in	IN
cord-011310-fm578rm5	43	19	the	the	DT
cord-011310-fm578rm5	43	20	case	case	NN
cord-011310-fm578rm5	43	21	of	of	IN
cord-011310-fm578rm5	43	22	treating	treat	VBG
cord-011310-fm578rm5	43	23	patients	patient	NNS
cord-011310-fm578rm5	43	24	with	with	IN
cord-011310-fm578rm5	43	25	a	a	DT
cord-011310-fm578rm5	43	26	clinically	clinically	RB
cord-011310-fm578rm5	43	27	significant	significant	JJ
cord-011310-fm578rm5	43	28	disease	disease	NN
cord-011310-fm578rm5	43	29	,	,	,
cord-011310-fm578rm5	43	30	yet	yet	CC
cord-011310-fm578rm5	43	31	should	should	MD
cord-011310-fm578rm5	43	32	be	be	VB
cord-011310-fm578rm5	43	33	considered	consider	VBN
cord-011310-fm578rm5	43	34	in	in	IN
cord-011310-fm578rm5	43	35	preventive	preventive	JJ
cord-011310-fm578rm5	43	36	interventions	intervention	NNS
cord-011310-fm578rm5	43	37	.	.	.
cord-011310-fm578rm5	44	1	The	the	DT
cord-011310-fm578rm5	44	2	European	European	NNP
cord-011310-fm578rm5	44	3	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	44	4	V	V	NNP
cord-011310-fm578rm5	44	5	/	/	SYM
cord-011310-fm578rm5	44	6	Florence	Florence	NNP
cord-011310-fm578rm5	44	7	consensus	consensus	NN
cord-011310-fm578rm5	44	8	(	(	-LRB-
cord-011310-fm578rm5	44	9	ML	ML	NNP
cord-011310-fm578rm5	44	10	was	be	VBD
cord-011310-fm578rm5	44	11	part	part	NN
cord-011310-fm578rm5	44	12	of	of	IN
cord-011310-fm578rm5	44	13	the	the	DT
cord-011310-fm578rm5	44	14	working	work	VBG
cord-011310-fm578rm5	44	15	group	group	NN
cord-011310-fm578rm5	44	16	)	)	-RRB-
cord-011310-fm578rm5	44	17	recommended	recommend	VBD
cord-011310-fm578rm5	44	18	the	the	DT
cord-011310-fm578rm5	44	19	screenand	screenand	NN
cord-011310-fm578rm5	44	20	-	-	HYPH
cord-011310-fm578rm5	44	21	treat	treat	VB
cord-011310-fm578rm5	44	22	strategy	strategy	NN
cord-011310-fm578rm5	44	23	in	in	IN
cord-011310-fm578rm5	44	24	communities	community	NNS
cord-011310-fm578rm5	44	25	at	at	IN
cord-011310-fm578rm5	44	26	high	high	JJ
cord-011310-fm578rm5	44	27	risk	risk	NN
cord-011310-fm578rm5	44	28	of	of	IN
cord-011310-fm578rm5	44	29	gastric	gastric	JJ
cord-011310-fm578rm5	44	30	cancer	cancer	NN
cord-011310-fm578rm5	44	31	and	and	CC
cord-011310-fm578rm5	44	32	consideration	consideration	NN
cord-011310-fm578rm5	44	33	of	of	IN
cord-011310-fm578rm5	44	34	this	this	DT
cord-011310-fm578rm5	44	35	approach	approach	NN
cord-011310-fm578rm5	44	36	in	in	IN
cord-011310-fm578rm5	44	37	communities	community	NNS
cord-011310-fm578rm5	44	38	with	with	IN
cord-011310-fm578rm5	44	39	intermediate	intermediate	JJ
cord-011310-fm578rm5	44	40	to	to	IN
cord-011310-fm578rm5	44	41	low	low	JJ
cord-011310-fm578rm5	44	42	risk	risk	NN
cord-011310-fm578rm5	44	43	of	of	IN
cord-011310-fm578rm5	44	44	gastric	gastric	JJ
cord-011310-fm578rm5	44	45	cancer	cancer	NN
cord-011310-fm578rm5	44	46	[	[	-LRB-
cord-011310-fm578rm5	44	47	11	11	CD
cord-011310-fm578rm5	44	48	]	]	-RRB-
cord-011310-fm578rm5	44	49	.	.	.
cord-011310-fm578rm5	45	1	Kyoto	Kyoto	NNP
cord-011310-fm578rm5	45	2	global	global	JJ
cord-011310-fm578rm5	45	3	consensus	consensus	NN
cord-011310-fm578rm5	45	4	has	have	VBZ
cord-011310-fm578rm5	45	5	for	for	IN
cord-011310-fm578rm5	45	6	the	the	DT
cord-011310-fm578rm5	45	7	first	first	JJ
cord-011310-fm578rm5	45	8	time	time	NN
cord-011310-fm578rm5	45	9	categorized	categorize	VBN
cord-011310-fm578rm5	45	10	H.	h.	NN
cord-011310-fm578rm5	45	11	pylori	pylori	NN
cord-011310-fm578rm5	45	12	gastritis	gastritis	NN
cord-011310-fm578rm5	45	13	as	as	IN
cord-011310-fm578rm5	45	14	an	an	DT
cord-011310-fm578rm5	45	15	infectious	infectious	JJ
cord-011310-fm578rm5	45	16	disease	disease	NN
cord-011310-fm578rm5	45	17	,	,	,
cord-011310-fm578rm5	45	18	irrespective	irrespective	RB
cord-011310-fm578rm5	45	19	of	of	IN
cord-011310-fm578rm5	45	20	symptoms	symptom	NNS
cord-011310-fm578rm5	45	21	and	and	CC
cord-011310-fm578rm5	45	22	complications	complication	NNS
cord-011310-fm578rm5	45	23	[	[	-LRB-
cord-011310-fm578rm5	45	24	17	17	CD
cord-011310-fm578rm5	45	25	]	]	-RRB-
cord-011310-fm578rm5	45	26	,	,	,
cord-011310-fm578rm5	45	27	which	which	WDT
cord-011310-fm578rm5	45	28	has	have	VBZ
cord-011310-fm578rm5	45	29	been	be	VBN
cord-011310-fm578rm5	45	30	reinforced	reinforce	VBN
cord-011310-fm578rm5	45	31	by	by	IN
cord-011310-fm578rm5	45	32	the	the	DT
cord-011310-fm578rm5	45	33	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	45	34	V	V	NNP
cord-011310-fm578rm5	45	35	[	[	-LRB-
cord-011310-fm578rm5	45	36	11	11	CD
cord-011310-fm578rm5	45	37	]	]	-RRB-
cord-011310-fm578rm5	45	38	and	and	CC
cord-011310-fm578rm5	45	39	Brazilian	brazilian	JJ
cord-011310-fm578rm5	45	40	consensus	consensus	NN
cord-011310-fm578rm5	45	41	[	[	-LRB-
cord-011310-fm578rm5	45	42	18	18	CD
cord-011310-fm578rm5	45	43	]	]	-RRB-
cord-011310-fm578rm5	45	44	.	.	.
cord-011310-fm578rm5	46	1	All	all	DT
cord-011310-fm578rm5	46	2	H.	H.	NNP
cord-011310-fm578rm5	46	3	pylori	pylori	NN
cord-011310-fm578rm5	47	1	infected	infected	JJ
cord-011310-fm578rm5	47	2	subjects	subject	NNS
cord-011310-fm578rm5	47	3	are	be	VBP
cord-011310-fm578rm5	47	4	recommended	recommend	VBN
cord-011310-fm578rm5	47	5	to	to	TO
cord-011310-fm578rm5	47	6	undergo	undergo	VB
cord-011310-fm578rm5	47	7	eradication	eradication	NN
cord-011310-fm578rm5	47	8	therapy	therapy	NN
cord-011310-fm578rm5	47	9	according	accord	VBG
cord-011310-fm578rm5	47	10	to	to	IN
cord-011310-fm578rm5	47	11	the	the	DT
cord-011310-fm578rm5	47	12	Kyoto	Kyoto	NNP
cord-011310-fm578rm5	47	13	consensus	consensus	NN
cord-011310-fm578rm5	47	14	unless	unless	IN
cord-011310-fm578rm5	47	15	there	there	EX
cord-011310-fm578rm5	47	16	are	be	VBP
cord-011310-fm578rm5	47	17	competing	compete	VBG
cord-011310-fm578rm5	47	18	considerations	consideration	NNS
cord-011310-fm578rm5	47	19	,	,	,
cord-011310-fm578rm5	47	20	such	such	JJ
cord-011310-fm578rm5	47	21	as	as	IN
cord-011310-fm578rm5	47	22	comorbidities	comorbiditie	NNS
cord-011310-fm578rm5	47	23	,	,	,
cord-011310-fm578rm5	47	24	re	re	NN
cord-011310-fm578rm5	47	25	-	-	NN
cord-011310-fm578rm5	47	26	infection	infection	NN
cord-011310-fm578rm5	47	27	rates	rate	NNS
cord-011310-fm578rm5	47	28	in	in	IN
cord-011310-fm578rm5	47	29	their	-PRON-	PRP$
cord-011310-fm578rm5	47	30	communities	community	NNS
cord-011310-fm578rm5	47	31	,	,	,
cord-011310-fm578rm5	47	32	competing	compete	VBG
cord-011310-fm578rm5	47	33	health	health	NN
cord-011310-fm578rm5	47	34	priorities	priority	NNS
cord-011310-fm578rm5	47	35	of	of	IN
cord-011310-fm578rm5	47	36	society	society	NN
cord-011310-fm578rm5	47	37	or	or	CC
cord-011310-fm578rm5	47	38	financial	financial	JJ
cord-011310-fm578rm5	47	39	issues	issue	NNS
cord-011310-fm578rm5	47	40	[	[	-LRB-
cord-011310-fm578rm5	47	41	17	17	CD
cord-011310-fm578rm5	47	42	]	]	-RRB-
cord-011310-fm578rm5	47	43	.	.	.
cord-011310-fm578rm5	48	1	The	the	DT
cord-011310-fm578rm5	48	2	recent	recent	JJ
cord-011310-fm578rm5	48	3	guidelines	guideline	NNS
cord-011310-fm578rm5	48	4	of	of	IN
cord-011310-fm578rm5	48	5	ASEAN	ASEAN	NNP
cord-011310-fm578rm5	48	6	(	(	-LRB-
cord-011310-fm578rm5	48	7	Association	Association	NNP
cord-011310-fm578rm5	48	8	Southeast	Southeast	NNP
cord-011310-fm578rm5	48	9	Asian	Asian	NNP
cord-011310-fm578rm5	48	10	Nations	Nations	NNPS
cord-011310-fm578rm5	48	11	)	)	-RRB-
cord-011310-fm578rm5	48	12	countries	country	NNS
cord-011310-fm578rm5	48	13	support	support	VBP
cord-011310-fm578rm5	48	14	eradication	eradication	NN
cord-011310-fm578rm5	48	15	to	to	TO
cord-011310-fm578rm5	48	16	prevent	prevent	VB
cord-011310-fm578rm5	48	17	gastric	gastric	JJ
cord-011310-fm578rm5	48	18	cancer	cancer	NN
cord-011310-fm578rm5	48	19	by	by	IN
cord-011310-fm578rm5	48	20	considering	consider	VBG
cord-011310-fm578rm5	48	21	this	this	DT
cord-011310-fm578rm5	48	22	strategy	strategy	NN
cord-011310-fm578rm5	48	23	as	as	IN
cord-011310-fm578rm5	48	24	costeffective	costeffective	JJ
cord-011310-fm578rm5	48	25	,	,	,
cord-011310-fm578rm5	48	26	depending	depend	VBG
cord-011310-fm578rm5	48	27	on	on	IN
cord-011310-fm578rm5	48	28	the	the	DT
cord-011310-fm578rm5	48	29	disease	disease	NN
cord-011310-fm578rm5	48	30	burden	burden	NN
cord-011310-fm578rm5	48	31	in	in	IN
cord-011310-fm578rm5	48	32	the	the	DT
cord-011310-fm578rm5	48	33	relevant	relevant	JJ
cord-011310-fm578rm5	48	34	community	community	NN
cord-011310-fm578rm5	48	35	[	[	-LRB-
cord-011310-fm578rm5	48	36	19	19	CD
cord-011310-fm578rm5	48	37	]	]	-RRB-
cord-011310-fm578rm5	48	38	.	.	.
cord-011310-fm578rm5	49	1	A	a	DT
cord-011310-fm578rm5	49	2	similar	similar	JJ
cord-011310-fm578rm5	49	3	opinion	opinion	NN
cord-011310-fm578rm5	49	4	was	be	VBD
cord-011310-fm578rm5	49	5	formed	form	VBN
cord-011310-fm578rm5	49	6	in	in	IN
cord-011310-fm578rm5	49	7	the	the	DT
cord-011310-fm578rm5	49	8	Second	Second	NNP
cord-011310-fm578rm5	49	9	Asia	Asia	NNP
cord-011310-fm578rm5	49	10	-	-	HYPH
cord-011310-fm578rm5	49	11	Pacific	Pacific	NNP
cord-011310-fm578rm5	49	12	Consensus	Consensus	NNP
cord-011310-fm578rm5	49	13	Guidelines	Guidelines	NNPS
cord-011310-fm578rm5	49	14	for	for	IN
cord-011310-fm578rm5	49	15	H.	H.	NNP
cord-011310-fm578rm5	49	16	pylori	pylori	NN
cord-011310-fm578rm5	49	17	infection	infection	NN
cord-011310-fm578rm5	49	18	a	a	DT
cord-011310-fm578rm5	49	19	decade	decade	NN
cord-011310-fm578rm5	49	20	ago	ago	RB
cord-011310-fm578rm5	49	21	for	for	IN
cord-011310-fm578rm5	49	22	communities	community	NNS
cord-011310-fm578rm5	49	23	with	with	IN
cord-011310-fm578rm5	49	24	high	high	JJ
cord-011310-fm578rm5	49	25	incidence	incidence	NN
cord-011310-fm578rm5	49	26	of	of	IN
cord-011310-fm578rm5	49	27	gastric	gastric	JJ
cord-011310-fm578rm5	49	28	cancer	cancer	NN
cord-011310-fm578rm5	49	29	[	[	-LRB-
cord-011310-fm578rm5	49	30	20	20	CD
cord-011310-fm578rm5	49	31	]	]	-RRB-
cord-011310-fm578rm5	49	32	.	.	.
cord-011310-fm578rm5	50	1	At	at	IN
cord-011310-fm578rm5	50	2	the	the	DT
cord-011310-fm578rm5	50	3	same	same	JJ
cord-011310-fm578rm5	50	4	time	time	NN
cord-011310-fm578rm5	50	5	,	,	,
cord-011310-fm578rm5	50	6	some	some	DT
cord-011310-fm578rm5	50	7	of	of	IN
cord-011310-fm578rm5	50	8	the	the	DT
cord-011310-fm578rm5	50	9	guidelines	guideline	NNS
cord-011310-fm578rm5	50	10	and	and	CC
cord-011310-fm578rm5	50	11	expert	expert	NN
cord-011310-fm578rm5	50	12	group	group	NN
cord-011310-fm578rm5	50	13	recommendations	recommendation	NNS
cord-011310-fm578rm5	50	14	are	be	VBP
cord-011310-fm578rm5	50	15	less	less	RBR
cord-011310-fm578rm5	50	16	enthusiastic	enthusiastic	JJ
cord-011310-fm578rm5	50	17	regarding	regard	VBG
cord-011310-fm578rm5	50	18	population	population	NN
cord-011310-fm578rm5	50	19	-	-	HYPH
cord-011310-fm578rm5	50	20	based	base	VBN
cord-011310-fm578rm5	50	21	eradication	eradication	NN
cord-011310-fm578rm5	50	22	.	.	.
cord-011310-fm578rm5	51	1	The	the	DT
cord-011310-fm578rm5	51	2	American	American	NNP
cord-011310-fm578rm5	51	3	College	College	NNP
cord-011310-fm578rm5	51	4	of	of	IN
cord-011310-fm578rm5	51	5	Gastroenterology	Gastroenterology	NNP
cord-011310-fm578rm5	51	6	does	do	VBZ
cord-011310-fm578rm5	51	7	not	not	RB
cord-011310-fm578rm5	51	8	recommend	recommend	VB
cord-011310-fm578rm5	51	9	active	active	JJ
cord-011310-fm578rm5	51	10	search	search	NN
cord-011310-fm578rm5	51	11	of	of	IN
cord-011310-fm578rm5	51	12	H.	h.	NN
cord-011310-fm578rm5	51	13	pylori	pylori	NN
cord-011310-fm578rm5	51	14	in	in	IN
cord-011310-fm578rm5	51	15	an	an	DT
cord-011310-fm578rm5	51	16	asymptomatic	asymptomatic	JJ
cord-011310-fm578rm5	51	17	population	population	NN
cord-011310-fm578rm5	51	18	[	[	-LRB-
cord-011310-fm578rm5	51	19	21	21	CD
cord-011310-fm578rm5	51	20	]	]	-RRB-
cord-011310-fm578rm5	51	21	.	.	.
cord-011310-fm578rm5	52	1	An	an	DT
cord-011310-fm578rm5	52	2	expert	expert	NN
cord-011310-fm578rm5	52	3	group	group	NN
cord-011310-fm578rm5	52	4	hosted	host	VBN
cord-011310-fm578rm5	52	5	by	by	IN
cord-011310-fm578rm5	52	6	IARC	IARC	NNP
cord-011310-fm578rm5	52	7	has	have	VBZ
cord-011310-fm578rm5	52	8	suggested	suggest	VBN
cord-011310-fm578rm5	52	9	the	the	DT
cord-011310-fm578rm5	52	10	need	need	NN
cord-011310-fm578rm5	52	11	for	for	IN
cord-011310-fm578rm5	52	12	interventional	interventional	JJ
cord-011310-fm578rm5	52	13	strategies	strategy	NNS
cord-011310-fm578rm5	52	14	to	to	TO
cord-011310-fm578rm5	52	15	decrease	decrease	VB
cord-011310-fm578rm5	52	16	the	the	DT
cord-011310-fm578rm5	52	17	burden	burden	NN
cord-011310-fm578rm5	52	18	of	of	IN
cord-011310-fm578rm5	52	19	gastric	gastric	JJ
cord-011310-fm578rm5	52	20	cancer	cancer	NN
cord-011310-fm578rm5	52	21	[	[	-LRB-
cord-011310-fm578rm5	52	22	1	1	CD
cord-011310-fm578rm5	52	23	,	,	,
cord-011310-fm578rm5	52	24	22	22	CD
cord-011310-fm578rm5	52	25	]	]	-RRB-
cord-011310-fm578rm5	52	26	;	;	:
cord-011310-fm578rm5	52	27	however	however	RB
cord-011310-fm578rm5	52	28	,	,	,
cord-011310-fm578rm5	52	29	experts	expert	NNS
cord-011310-fm578rm5	52	30	recommended	recommend	VBD
cord-011310-fm578rm5	52	31	that	that	IN
cord-011310-fm578rm5	52	32	this	this	DT
cord-011310-fm578rm5	52	33	be	be	VB
cord-011310-fm578rm5	52	34	done	do	VBN
cord-011310-fm578rm5	52	35	by	by	IN
cord-011310-fm578rm5	52	36	the	the	DT
cord-011310-fm578rm5	52	37	means	mean	NNS
cord-011310-fm578rm5	52	38	of	of	IN
cord-011310-fm578rm5	52	39	well	well	RB
cord-011310-fm578rm5	52	40	-	-	HYPH
cord-011310-fm578rm5	52	41	designed	design	VBN
cord-011310-fm578rm5	52	42	clinical	clinical	JJ
cord-011310-fm578rm5	52	43	studies	study	NNS
cord-011310-fm578rm5	52	44	evaluating	evaluate	VBG
cord-011310-fm578rm5	52	45	the	the	DT
cord-011310-fm578rm5	52	46	feasibility	feasibility	NN
cord-011310-fm578rm5	52	47	,	,	,
cord-011310-fm578rm5	52	48	acceptance	acceptance	NN
cord-011310-fm578rm5	52	49	,	,	,
cord-011310-fm578rm5	52	50	costs	cost	NNS
cord-011310-fm578rm5	52	51	,	,	,
cord-011310-fm578rm5	52	52	effectiveness	effectiveness	NN
cord-011310-fm578rm5	52	53	and	and	CC
cord-011310-fm578rm5	52	54	adverse	adverse	JJ
cord-011310-fm578rm5	52	55	consequences	consequence	NNS
cord-011310-fm578rm5	52	56	.	.	.
cord-011310-fm578rm5	53	1	A	a	DT
cord-011310-fm578rm5	53	2	European	european	JJ
cord-011310-fm578rm5	53	3	expert	expert	NN
cord-011310-fm578rm5	53	4	group	group	NN
cord-011310-fm578rm5	53	5	(	(	-LRB-
cord-011310-fm578rm5	53	6	ML	ML	NNP
cord-011310-fm578rm5	53	7	was	be	VBD
cord-011310-fm578rm5	53	8	part	part	NN
cord-011310-fm578rm5	53	9	of	of	IN
cord-011310-fm578rm5	53	10	the	the	DT
cord-011310-fm578rm5	53	11	working	work	VBG
cord-011310-fm578rm5	53	12	group	group	NN
cord-011310-fm578rm5	53	13	)	)	-RRB-
cord-011310-fm578rm5	53	14	within	within	IN
cord-011310-fm578rm5	53	15	the	the	DT
cord-011310-fm578rm5	53	16	EU	EU	NNP
cord-011310-fm578rm5	53	17	Joint	Joint	NNP
cord-011310-fm578rm5	53	18	Action	Action	NNP
cord-011310-fm578rm5	53	19	in	in	IN
cord-011310-fm578rm5	53	20	Cancer	Cancer	NNP
cord-011310-fm578rm5	53	21	Control	Control	NNP
cord-011310-fm578rm5	53	22	(	(	-LRB-
cord-011310-fm578rm5	53	23	CanCon	CanCon	NNP
cord-011310-fm578rm5	53	24	)	)	-RRB-
cord-011310-fm578rm5	53	25	has	have	VBZ
cord-011310-fm578rm5	53	26	been	be	VBN
cord-011310-fm578rm5	53	27	even	even	RB
cord-011310-fm578rm5	53	28	more	more	RBR
cord-011310-fm578rm5	53	29	critical	critical	JJ
cord-011310-fm578rm5	53	30	-	-	:
cord-011310-fm578rm5	53	31	they	-PRON-	PRP
cord-011310-fm578rm5	53	32	concluded	conclude	VBD
cord-011310-fm578rm5	53	33	that	that	IN
cord-011310-fm578rm5	53	34	,	,	,
cord-011310-fm578rm5	53	35	as	as	IN
cord-011310-fm578rm5	53	36	of	of	IN
cord-011310-fm578rm5	53	37	today	today	NN
cord-011310-fm578rm5	53	38	,	,	,
cord-011310-fm578rm5	53	39	there	there	EX
cord-011310-fm578rm5	53	40	is	be	VBZ
cord-011310-fm578rm5	53	41	no	no	DT
cord-011310-fm578rm5	53	42	screening	screening	NN
cord-011310-fm578rm5	53	43	method	method	NN
cord-011310-fm578rm5	53	44	that	that	WDT
cord-011310-fm578rm5	53	45	can	can	MD
cord-011310-fm578rm5	53	46	be	be	VB
cord-011310-fm578rm5	53	47	readily	readily	RB
cord-011310-fm578rm5	53	48	recommended	recommend	VBN
cord-011310-fm578rm5	53	49	for	for	IN
cord-011310-fm578rm5	53	50	implementation	implementation	NN
cord-011310-fm578rm5	53	51	in	in	IN
cord-011310-fm578rm5	53	52	the	the	DT
cord-011310-fm578rm5	53	53	EU	EU	NNP
cord-011310-fm578rm5	53	54	Member	Member	NNP
cord-011310-fm578rm5	53	55	States	States	NNP
cord-011310-fm578rm5	53	56	,	,	,
cord-011310-fm578rm5	53	57	although	although	IN
cord-011310-fm578rm5	53	58	there	there	EX
cord-011310-fm578rm5	53	59	seems	seem	VBZ
cord-011310-fm578rm5	53	60	to	to	TO
cord-011310-fm578rm5	53	61	be	be	VB
cord-011310-fm578rm5	53	62	a	a	DT
cord-011310-fm578rm5	53	63	need	need	NN
cord-011310-fm578rm5	53	64	for	for	IN
cord-011310-fm578rm5	53	65	one	one	CD
cord-011310-fm578rm5	53	66	[	[	-LRB-
cord-011310-fm578rm5	53	67	12	12	CD
cord-011310-fm578rm5	53	68	]	]	-RRB-
cord-011310-fm578rm5	53	69	.	.	.
cord-011310-fm578rm5	54	1	This	this	DT
cord-011310-fm578rm5	54	2	also	also	RB
cord-011310-fm578rm5	54	3	included	include	VBD
cord-011310-fm578rm5	54	4	the	the	DT
cord-011310-fm578rm5	54	5	screen	screen	NN
cord-011310-fm578rm5	54	6	-	-	HYPH
cord-011310-fm578rm5	54	7	and	and	CC
cord-011310-fm578rm5	54	8	-	-	HYPH
cord-011310-fm578rm5	54	9	treat	treat	VB
cord-011310-fm578rm5	54	10	strategy	strategy	NN
cord-011310-fm578rm5	54	11	for	for	IN
cord-011310-fm578rm5	54	12	H.	h.	NN
cord-011310-fm578rm5	54	13	pylori	pylori	NN
cord-011310-fm578rm5	54	14	.	.	.
cord-011310-fm578rm5	55	1	There	there	EX
cord-011310-fm578rm5	55	2	is	be	VBZ
cord-011310-fm578rm5	55	3	common	common	JJ
cord-011310-fm578rm5	55	4	agreement	agreement	NN
cord-011310-fm578rm5	55	5	[	[	-LRB-
cord-011310-fm578rm5	55	6	8	8	CD
cord-011310-fm578rm5	55	7	,	,	,
cord-011310-fm578rm5	55	8	11	11	CD
cord-011310-fm578rm5	55	9	,	,	,
cord-011310-fm578rm5	55	10	17	17	CD
cord-011310-fm578rm5	55	11	]	]	-RRB-
cord-011310-fm578rm5	55	12	that	that	IN
cord-011310-fm578rm5	55	13	the	the	DT
cord-011310-fm578rm5	55	14	optimal	optimal	JJ
cord-011310-fm578rm5	55	15	timing	timing	NN
cord-011310-fm578rm5	55	16	for	for	IN
cord-011310-fm578rm5	55	17	eradicating	eradicate	VBG
cord-011310-fm578rm5	55	18	H.	H.	NNP
cord-011310-fm578rm5	55	19	pylori	pylori	NN
cord-011310-fm578rm5	55	20	must	must	MD
cord-011310-fm578rm5	55	21	come	come	VB
cord-011310-fm578rm5	55	22	before	before	IN
cord-011310-fm578rm5	55	23	the	the	DT
cord-011310-fm578rm5	55	24	development	development	NN
cord-011310-fm578rm5	55	25	of	of	IN
cord-011310-fm578rm5	55	26	precancerous	precancerous	JJ
cord-011310-fm578rm5	55	27	lesions	lesion	NNS
cord-011310-fm578rm5	55	28	,	,	,
cord-011310-fm578rm5	55	29	since	since	IN
cord-011310-fm578rm5	55	30	a	a	DT
cord-011310-fm578rm5	55	31	proportion	proportion	NN
cord-011310-fm578rm5	55	32	of	of	IN
cord-011310-fm578rm5	55	33	the	the	DT
cord-011310-fm578rm5	55	34	subjects	subject	NNS
cord-011310-fm578rm5	55	35	could	could	MD
cord-011310-fm578rm5	55	36	be	be	VB
cord-011310-fm578rm5	55	37	progressing	progress	VBG
cord-011310-fm578rm5	55	38	to	to	IN
cord-011310-fm578rm5	55	39	gastric	gastric	JJ
cord-011310-fm578rm5	55	40	cancer	cancer	NN
cord-011310-fm578rm5	55	41	if	if	IN
cord-011310-fm578rm5	55	42	eradicated	eradicate	VBN
cord-011310-fm578rm5	55	43	at	at	IN
cord-011310-fm578rm5	55	44	the	the	DT
cord-011310-fm578rm5	55	45	stage	stage	NN
cord-011310-fm578rm5	55	46	that	that	IN
cord-011310-fm578rm5	55	47	precancerous	precancerous	JJ
cord-011310-fm578rm5	55	48	lesions	lesion	NNS
cord-011310-fm578rm5	55	49	(	(	-LRB-
cord-011310-fm578rm5	55	50	atrophy	atrophy	NN
cord-011310-fm578rm5	55	51	,	,	,
cord-011310-fm578rm5	55	52	intestinal	intestinal	JJ
cord-011310-fm578rm5	55	53	metaplasia	metaplasia	NN
cord-011310-fm578rm5	55	54	,	,	,
cord-011310-fm578rm5	55	55	dysplasia	dysplasia	NN
cord-011310-fm578rm5	55	56	)	)	-RRB-
cord-011310-fm578rm5	55	57	become	become	VBP
cord-011310-fm578rm5	55	58	evident	evident	JJ
cord-011310-fm578rm5	55	59	.	.	.
cord-011310-fm578rm5	56	1	In	in	IN
cord-011310-fm578rm5	56	2	Japan	Japan	NNP
cord-011310-fm578rm5	56	3	,	,	,
cord-011310-fm578rm5	56	4	currently	currently	RB
cord-011310-fm578rm5	56	5	eradication	eradication	NN
cord-011310-fm578rm5	56	6	therapy	therapy	NN
cord-011310-fm578rm5	56	7	is	be	VBZ
cord-011310-fm578rm5	56	8	reimbursed	reimburse	VBN
cord-011310-fm578rm5	56	9	for	for	IN
cord-011310-fm578rm5	56	10	all	all	PDT
cord-011310-fm578rm5	56	11	the	the	DT
cord-011310-fm578rm5	56	12	individuals	individual	NNS
cord-011310-fm578rm5	56	13	with	with	IN
cord-011310-fm578rm5	56	14	H.	H.	NNP
cord-011310-fm578rm5	56	15	pylori	pylori	NN
cord-011310-fm578rm5	56	16	infection	infection	NN
cord-011310-fm578rm5	56	17	and	and	CC
cord-011310-fm578rm5	56	18	active	active	JJ
cord-011310-fm578rm5	56	19	gastritis	gastritis	NN
cord-011310-fm578rm5	56	20	(	(	-LRB-
cord-011310-fm578rm5	56	21	in	in	IN
cord-011310-fm578rm5	56	22	addition	addition	NN
cord-011310-fm578rm5	56	23	to	to	IN
cord-011310-fm578rm5	56	24	the	the	DT
cord-011310-fm578rm5	56	25	ongoing	ongoing	JJ
cord-011310-fm578rm5	56	26	screening	screening	NN
cord-011310-fm578rm5	56	27	activities	activity	NNS
cord-011310-fm578rm5	56	28	for	for	IN
cord-011310-fm578rm5	56	29	1	1	CD
cord-011310-fm578rm5	56	30	3	3	CD
cord-011310-fm578rm5	56	31	gastric	gastric	JJ
cord-011310-fm578rm5	56	32	cancer	cancer	NN
cord-011310-fm578rm5	56	33	)	)	-RRB-
cord-011310-fm578rm5	56	34	,	,	,
cord-011310-fm578rm5	56	35	which	which	WDT
cord-011310-fm578rm5	56	36	means	mean	VBZ
cord-011310-fm578rm5	56	37	that	that	IN
cord-011310-fm578rm5	56	38	endoscopy	endoscopy	NN
cord-011310-fm578rm5	56	39	is	be	VBZ
cord-011310-fm578rm5	56	40	required	require	VBN
cord-011310-fm578rm5	56	41	to	to	TO
cord-011310-fm578rm5	56	42	confirm	confirm	VB
cord-011310-fm578rm5	56	43	the	the	DT
cord-011310-fm578rm5	56	44	condition	condition	NN
cord-011310-fm578rm5	56	45	.	.	.
cord-011310-fm578rm5	57	1	Thereafter	thereafter	RB
cord-011310-fm578rm5	57	2	,	,	,
cord-011310-fm578rm5	57	3	significant	significant	JJ
cord-011310-fm578rm5	57	4	increase	increase	NN
cord-011310-fm578rm5	57	5	in	in	IN
cord-011310-fm578rm5	57	6	eradication	eradication	NN
cord-011310-fm578rm5	57	7	therapies	therapy	NNS
cord-011310-fm578rm5	57	8	has	have	VBZ
cord-011310-fm578rm5	57	9	occurred	occur	VBN
cord-011310-fm578rm5	57	10	[	[	-LRB-
cord-011310-fm578rm5	57	11	23	23	CD
cord-011310-fm578rm5	57	12	]	]	-RRB-
cord-011310-fm578rm5	57	13	,	,	,
cord-011310-fm578rm5	57	14	yet	yet	CC
cord-011310-fm578rm5	57	15	this	this	DT
cord-011310-fm578rm5	57	16	can	can	MD
cord-011310-fm578rm5	57	17	not	not	RB
cord-011310-fm578rm5	57	18	be	be	VB
cord-011310-fm578rm5	57	19	considered	consider	VBN
cord-011310-fm578rm5	57	20	an	an	DT
cord-011310-fm578rm5	57	21	organized	organized	JJ
cord-011310-fm578rm5	57	22	screening	screening	NN
cord-011310-fm578rm5	57	23	strategy	strategy	NN
cord-011310-fm578rm5	57	24	.	.	.
cord-011310-fm578rm5	58	1	In	in	IN
cord-011310-fm578rm5	58	2	Korea	Korea	NNP
cord-011310-fm578rm5	58	3	,	,	,
cord-011310-fm578rm5	58	4	a	a	DT
cord-011310-fm578rm5	58	5	high	high	JJ
cord-011310-fm578rm5	58	6	gastric	gastric	JJ
cord-011310-fm578rm5	58	7	cancer	cancer	NN
cord-011310-fm578rm5	58	8	incidence	incidence	NN
cord-011310-fm578rm5	58	9	country	country	NN
cord-011310-fm578rm5	58	10	with	with	IN
cord-011310-fm578rm5	58	11	a	a	DT
cord-011310-fm578rm5	58	12	gastric	gastric	JJ
cord-011310-fm578rm5	58	13	cancer	cancer	NN
cord-011310-fm578rm5	58	14	screening	screening	NN
cord-011310-fm578rm5	58	15	program	program	NN
cord-011310-fm578rm5	58	16	[	[	-LRB-
cord-011310-fm578rm5	58	17	24	24	CD
cord-011310-fm578rm5	58	18	]	]	-RRB-
cord-011310-fm578rm5	58	19	,	,	,
cord-011310-fm578rm5	58	20	H.	H.	NNP
cord-011310-fm578rm5	58	21	pylori	pylori	NN
cord-011310-fm578rm5	58	22	management	management	NN
cord-011310-fm578rm5	58	23	guidelines	guideline	NNS
cord-011310-fm578rm5	58	24	do	do	VBP
cord-011310-fm578rm5	58	25	not	not	RB
cord-011310-fm578rm5	58	26	address	address	VB
cord-011310-fm578rm5	58	27	the	the	DT
cord-011310-fm578rm5	58	28	search	search	NN
cord-011310-fm578rm5	58	29	for	for	IN
cord-011310-fm578rm5	58	30	the	the	DT
cord-011310-fm578rm5	58	31	presence	presence	NN
cord-011310-fm578rm5	58	32	of	of	IN
cord-011310-fm578rm5	58	33	the	the	DT
cord-011310-fm578rm5	58	34	bacteria	bacteria	NNS
cord-011310-fm578rm5	58	35	in	in	IN
cord-011310-fm578rm5	58	36	general	general	JJ
cord-011310-fm578rm5	58	37	population	population	NN
cord-011310-fm578rm5	58	38	[	[	-LRB-
cord-011310-fm578rm5	58	39	25	25	CD
cord-011310-fm578rm5	58	40	]	]	-RRB-
cord-011310-fm578rm5	58	41	.	.	.
cord-011310-fm578rm5	59	1	The	the	DT
cord-011310-fm578rm5	59	2	country	country	NN
cord-011310-fm578rm5	59	3	probably	probably	RB
cord-011310-fm578rm5	59	4	closest	close	JJS
cord-011310-fm578rm5	59	5	to	to	IN
cord-011310-fm578rm5	59	6	the	the	DT
cord-011310-fm578rm5	59	7	real	real	JJ
cord-011310-fm578rm5	59	8	implementation	implementation	NN
cord-011310-fm578rm5	59	9	of	of	IN
cord-011310-fm578rm5	59	10	screen	screen	NN
cord-011310-fm578rm5	59	11	-	-	HYPH
cord-011310-fm578rm5	59	12	and	and	CC
cord-011310-fm578rm5	59	13	-	-	HYPH
cord-011310-fm578rm5	59	14	treat	treat	VB
cord-011310-fm578rm5	59	15	strategy	strategy	NN
cord-011310-fm578rm5	59	16	in	in	IN
cord-011310-fm578rm5	59	17	an	an	DT
cord-011310-fm578rm5	59	18	organized	organized	JJ
cord-011310-fm578rm5	59	19	way	way	NN
cord-011310-fm578rm5	59	20	is	be	VBZ
cord-011310-fm578rm5	59	21	Slovenia	Slovenia	NNP
cord-011310-fm578rm5	59	22	,	,	,
cord-011310-fm578rm5	59	23	where	where	WRB
cord-011310-fm578rm5	59	24	the	the	DT
cord-011310-fm578rm5	59	25	professional	professional	JJ
cord-011310-fm578rm5	59	26	society	society	NN
cord-011310-fm578rm5	59	27	has	have	VBZ
cord-011310-fm578rm5	59	28	issued	issue	VBN
cord-011310-fm578rm5	59	29	guidelines	guideline	NNS
cord-011310-fm578rm5	59	30	for	for	IN
cord-011310-fm578rm5	59	31	such	such	PDT
cord-011310-fm578rm5	59	32	a	a	DT
cord-011310-fm578rm5	59	33	strategy	strategy	NN
cord-011310-fm578rm5	59	34	[	[	-LRB-
cord-011310-fm578rm5	59	35	26	26	CD
cord-011310-fm578rm5	59	36	]	]	-RRB-
cord-011310-fm578rm5	59	37	;	;	:
cord-011310-fm578rm5	59	38	it	-PRON-	PRP
cord-011310-fm578rm5	59	39	must	must	MD
cord-011310-fm578rm5	59	40	be	be	VB
cord-011310-fm578rm5	59	41	mentioned	mention	VBN
cord-011310-fm578rm5	59	42	that	that	IN
cord-011310-fm578rm5	59	43	this	this	DT
cord-011310-fm578rm5	59	44	country	country	NN
cord-011310-fm578rm5	59	45	has	have	VBZ
cord-011310-fm578rm5	59	46	considerable	considerable	JJ
cord-011310-fm578rm5	59	47	experience	experience	NN
cord-011310-fm578rm5	59	48	in	in	IN
cord-011310-fm578rm5	59	49	implementing	implement	VBG
cord-011310-fm578rm5	59	50	other	other	JJ
cord-011310-fm578rm5	59	51	types	type	NNS
cord-011310-fm578rm5	59	52	of	of	IN
cord-011310-fm578rm5	59	53	cancer	cancer	NN
cord-011310-fm578rm5	59	54	screening	screening	NN
cord-011310-fm578rm5	59	55	in	in	IN
cord-011310-fm578rm5	59	56	an	an	DT
cord-011310-fm578rm5	59	57	organized	organized	JJ
cord-011310-fm578rm5	59	58	manner	manner	NN
cord-011310-fm578rm5	59	59	,	,	,
cord-011310-fm578rm5	59	60	including	include	VBG
cord-011310-fm578rm5	59	61	screening	screening	NN
cord-011310-fm578rm5	59	62	for	for	IN
cord-011310-fm578rm5	59	63	colorectal	colorectal	JJ
cord-011310-fm578rm5	59	64	cancer	cancer	NN
cord-011310-fm578rm5	59	65	.	.	.
cord-011310-fm578rm5	60	1	Fourteen	fourteen	CD
cord-011310-fm578rm5	60	2	-	-	HYPH
cord-011310-fm578rm5	60	3	day	day	NN
cord-011310-fm578rm5	60	4	duration	duration	NN
cord-011310-fm578rm5	60	5	of	of	IN
cord-011310-fm578rm5	60	6	eradication	eradication	NN
cord-011310-fm578rm5	60	7	therapies	therapy	NNS
cord-011310-fm578rm5	60	8	,	,	,
cord-011310-fm578rm5	60	9	including	include	VBG
cord-011310-fm578rm5	60	10	for	for	IN
cord-011310-fm578rm5	60	11	bismuth	bismuth	NN
cord-011310-fm578rm5	60	12	-	-	HYPH
cord-011310-fm578rm5	60	13	containing	contain	VBG
cord-011310-fm578rm5	60	14	therapies	therapy	NNS
cord-011310-fm578rm5	60	15	,	,	,
cord-011310-fm578rm5	60	16	is	be	VBZ
cord-011310-fm578rm5	60	17	currently	currently	RB
cord-011310-fm578rm5	60	18	recommended	recommend	VBN
cord-011310-fm578rm5	60	19	by	by	IN
cord-011310-fm578rm5	60	20	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	60	21	V	V	NNP
cord-011310-fm578rm5	60	22	,	,	,
cord-011310-fm578rm5	60	23	unless	unless	IN
cord-011310-fm578rm5	60	24	shorter	short	JJR
cord-011310-fm578rm5	60	25	duration	duration	NN
cord-011310-fm578rm5	60	26	therapies	therapy	NNS
cord-011310-fm578rm5	60	27	(	(	-LRB-
cord-011310-fm578rm5	60	28	10	10	CD
cord-011310-fm578rm5	60	29	days	day	NNS
cord-011310-fm578rm5	60	30	)	)	-RRB-
cord-011310-fm578rm5	60	31	are	be	VBP
cord-011310-fm578rm5	60	32	proven	prove	VBN
cord-011310-fm578rm5	60	33	effective	effective	JJ
cord-011310-fm578rm5	60	34	locally	locally	RB
cord-011310-fm578rm5	60	35	[	[	-LRB-
cord-011310-fm578rm5	60	36	11	11	CD
cord-011310-fm578rm5	60	37	]	]	-RRB-
cord-011310-fm578rm5	60	38	.	.	.
cord-011310-fm578rm5	61	1	Similarly	similarly	RB
cord-011310-fm578rm5	61	2	,	,	,
cord-011310-fm578rm5	61	3	the	the	DT
cord-011310-fm578rm5	61	4	Toronto	Toronto	NNP
cord-011310-fm578rm5	61	5	consensus	consensus	NN
cord-011310-fm578rm5	61	6	recommends	recommend	VBZ
cord-011310-fm578rm5	61	7	a	a	DT
cord-011310-fm578rm5	61	8	14-day	14-day	CD
cord-011310-fm578rm5	61	9	treatment	treatment	NN
cord-011310-fm578rm5	61	10	[	[	-LRB-
cord-011310-fm578rm5	61	11	27	27	CD
cord-011310-fm578rm5	61	12	]	]	-RRB-
cord-011310-fm578rm5	61	13	.	.	.
cord-011310-fm578rm5	62	1	It	-PRON-	PRP
cord-011310-fm578rm5	62	2	is	be	VBZ
cord-011310-fm578rm5	62	3	noteworthy	noteworthy	JJ
cord-011310-fm578rm5	62	4	that	that	IN
cord-011310-fm578rm5	62	5	the	the	DT
cord-011310-fm578rm5	62	6	recommended	recommend	VBN
cord-011310-fm578rm5	62	7	duration	duration	NN
cord-011310-fm578rm5	62	8	of	of	IN
cord-011310-fm578rm5	62	9	treatment	treatment	NN
cord-011310-fm578rm5	62	10	has	have	VBZ
cord-011310-fm578rm5	62	11	extended	extend	VBN
cord-011310-fm578rm5	62	12	with	with	IN
cord-011310-fm578rm5	62	13	the	the	DT
cord-011310-fm578rm5	62	14	time	time	NN
cord-011310-fm578rm5	62	15	to	to	TO
cord-011310-fm578rm5	62	16	achieve	achieve	VB
cord-011310-fm578rm5	62	17	higher	high	JJR
cord-011310-fm578rm5	62	18	effectiveness	effectiveness	NN
cord-011310-fm578rm5	62	19	of	of	IN
cord-011310-fm578rm5	62	20	these	these	DT
cord-011310-fm578rm5	62	21	therapies	therapy	NNS
cord-011310-fm578rm5	62	22	.	.	.
cord-011310-fm578rm5	63	1	In	in	IN
cord-011310-fm578rm5	63	2	2005	2005	CD
cord-011310-fm578rm5	63	3	,	,	,
cord-011310-fm578rm5	63	4	the	the	DT
cord-011310-fm578rm5	63	5	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	63	6	III	III	NNP
cord-011310-fm578rm5	63	7	consensus	consensus	NN
cord-011310-fm578rm5	63	8	considered	consider	VBN
cord-011310-fm578rm5	63	9	7	7	CD
cord-011310-fm578rm5	63	10	days	day	NNS
cord-011310-fm578rm5	63	11	as	as	IN
cord-011310-fm578rm5	63	12	a	a	DT
cord-011310-fm578rm5	63	13	valid	valid	JJ
cord-011310-fm578rm5	63	14	duration	duration	NN
cord-011310-fm578rm5	63	15	for	for	IN
cord-011310-fm578rm5	63	16	treatment	treatment	NN
cord-011310-fm578rm5	63	17	[	[	-LRB-
cord-011310-fm578rm5	63	18	28	28	CD
cord-011310-fm578rm5	63	19	]	]	-RRB-
cord-011310-fm578rm5	63	20	.	.	.
cord-011310-fm578rm5	64	1	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	64	2	IV	IV	NNP
cord-011310-fm578rm5	64	3	in	in	IN
cord-011310-fm578rm5	64	4	2010	2010	CD
cord-011310-fm578rm5	64	5	extended	extended	JJ
cord-011310-fm578rm5	64	6	treatment	treatment	NN
cord-011310-fm578rm5	64	7	to	to	IN
cord-011310-fm578rm5	64	8	10	10	CD
cord-011310-fm578rm5	64	9	-	-	SYM
cord-011310-fm578rm5	64	10	14	14	CD
cord-011310-fm578rm5	64	11	days	day	NNS
cord-011310-fm578rm5	64	12	giving	give	VBG
cord-011310-fm578rm5	64	13	a	a	DT
cord-011310-fm578rm5	64	14	gain	gain	NN
cord-011310-fm578rm5	64	15	of	of	IN
cord-011310-fm578rm5	64	16	~	~	CD
cord-011310-fm578rm5	64	17	5	5	CD
cord-011310-fm578rm5	64	18	%	%	NN
cord-011310-fm578rm5	64	19	in	in	IN
cord-011310-fm578rm5	64	20	the	the	DT
cord-011310-fm578rm5	64	21	success	success	NN
cord-011310-fm578rm5	64	22	rates	rate	NNS
cord-011310-fm578rm5	64	23	[	[	-LRB-
cord-011310-fm578rm5	64	24	29	29	CD
cord-011310-fm578rm5	64	25	]	]	-RRB-
cord-011310-fm578rm5	64	26	.	.	.
cord-011310-fm578rm5	65	1	The	the	DT
cord-011310-fm578rm5	65	2	general	general	NN
cord-011310-fm578rm5	65	3	WHO	WHO	NNP
cord-011310-fm578rm5	65	4	principles	principle	VBZ
cord-011310-fm578rm5	65	5	for	for	IN
cord-011310-fm578rm5	65	6	screening	screening	NN
cord-011310-fm578rm5	65	7	have	have	VBP
cord-011310-fm578rm5	65	8	been	be	VBN
cord-011310-fm578rm5	65	9	set	set	VBN
cord-011310-fm578rm5	65	10	more	more	JJR
cord-011310-fm578rm5	65	11	than	than	IN
cord-011310-fm578rm5	65	12	half	half	PDT
cord-011310-fm578rm5	65	13	a	a	DT
cord-011310-fm578rm5	65	14	century	century	NN
cord-011310-fm578rm5	65	15	ago	ago	RB
cord-011310-fm578rm5	65	16	by	by	IN
cord-011310-fm578rm5	65	17	Wilson	Wilson	NNP
cord-011310-fm578rm5	65	18	and	and	CC
cord-011310-fm578rm5	65	19	Jungner	Jungner	NNP
cord-011310-fm578rm5	65	20	[	[	-LRB-
cord-011310-fm578rm5	65	21	30	30	CD
cord-011310-fm578rm5	65	22	]	]	-RRB-
cord-011310-fm578rm5	65	23	,	,	,
cord-011310-fm578rm5	65	24	and	and	CC
cord-011310-fm578rm5	65	25	they	-PRON-	PRP
cord-011310-fm578rm5	65	26	are	be	VBP
cord-011310-fm578rm5	65	27	still	still	RB
cord-011310-fm578rm5	65	28	used	use	VBN
cord-011310-fm578rm5	65	29	as	as	IN
cord-011310-fm578rm5	65	30	of	of	IN
cord-011310-fm578rm5	65	31	today	today	NN
cord-011310-fm578rm5	65	32	although	although	IN
cord-011310-fm578rm5	65	33	updated	update	VBN
cord-011310-fm578rm5	65	34	in	in	IN
cord-011310-fm578rm5	65	35	the	the	DT
cord-011310-fm578rm5	65	36	new	new	JJ
cord-011310-fm578rm5	65	37	genomic	genomic	JJ
cord-011310-fm578rm5	65	38	era	era	NN
cord-011310-fm578rm5	65	39	[	[	-LRB-
cord-011310-fm578rm5	65	40	31	31	CD
cord-011310-fm578rm5	65	41	]	]	-RRB-
cord-011310-fm578rm5	65	42	.	.	.
cord-011310-fm578rm5	66	1	Furthermore	furthermore	RB
cord-011310-fm578rm5	66	2	,	,	,
cord-011310-fm578rm5	66	3	principles	principle	NNS
cord-011310-fm578rm5	66	4	of	of	IN
cord-011310-fm578rm5	66	5	good	good	JJ
cord-011310-fm578rm5	66	6	screening	screening	NN
cord-011310-fm578rm5	66	7	organization	organization	NN
cord-011310-fm578rm5	66	8	and	and	CC
cord-011310-fm578rm5	66	9	governance	governance	NN
cord-011310-fm578rm5	66	10	have	have	VBP
cord-011310-fm578rm5	66	11	been	be	VBN
cord-011310-fm578rm5	66	12	consistently	consistently	RB
cord-011310-fm578rm5	66	13	emphasized	emphasize	VBN
cord-011310-fm578rm5	66	14	by	by	IN
cord-011310-fm578rm5	66	15	the	the	DT
cord-011310-fm578rm5	66	16	expert	expert	JJ
cord-011310-fm578rm5	66	17	groups	group	NNS
cord-011310-fm578rm5	66	18	[	[	-LRB-
cord-011310-fm578rm5	66	19	12	12	CD
cord-011310-fm578rm5	66	20	]	]	-RRB-
cord-011310-fm578rm5	66	21	.	.	.
cord-011310-fm578rm5	67	1	The	the	DT
cord-011310-fm578rm5	67	2	above	above	JJ
cord-011310-fm578rm5	67	3	principles	principle	NNS
cord-011310-fm578rm5	67	4	include	include	VBP
cord-011310-fm578rm5	67	5	implementation	implementation	NN
cord-011310-fm578rm5	67	6	of	of	IN
cord-011310-fm578rm5	67	7	the	the	DT
cord-011310-fm578rm5	67	8	program	program	NN
cord-011310-fm578rm5	67	9	only	only	RB
cord-011310-fm578rm5	67	10	when	when	WRB
cord-011310-fm578rm5	67	11	sufficient	sufficient	JJ
cord-011310-fm578rm5	67	12	scientific	scientific	JJ
cord-011310-fm578rm5	67	13	evidence	evidence	NN
cord-011310-fm578rm5	67	14	(	(	-LRB-
cord-011310-fm578rm5	67	15	with	with	IN
cord-011310-fm578rm5	67	16	proven	prove	VBN
cord-011310-fm578rm5	67	17	effects	effect	NNS
cord-011310-fm578rm5	67	18	on	on	IN
cord-011310-fm578rm5	67	19	the	the	DT
cord-011310-fm578rm5	67	20	mortality	mortality	NN
cord-011310-fm578rm5	67	21	as	as	IN
cord-011310-fm578rm5	67	22	the	the	DT
cord-011310-fm578rm5	67	23	end	end	NN
cord-011310-fm578rm5	67	24	-	-	HYPH
cord-011310-fm578rm5	67	25	point	point	NN
cord-011310-fm578rm5	67	26	)	)	-RRB-
cord-011310-fm578rm5	67	27	is	be	VBZ
cord-011310-fm578rm5	67	28	available	available	JJ
cord-011310-fm578rm5	67	29	and	and	CC
cord-011310-fm578rm5	67	30	following	follow	VBG
cord-011310-fm578rm5	67	31	thorough	thorough	JJ
cord-011310-fm578rm5	67	32	cost	cost	NN
cord-011310-fm578rm5	67	33	effectiveness	effectiveness	NN
cord-011310-fm578rm5	67	34	analysis	analysis	NN
cord-011310-fm578rm5	67	35	,	,	,
cord-011310-fm578rm5	67	36	precise	precise	JJ
cord-011310-fm578rm5	67	37	definition	definition	NN
cord-011310-fm578rm5	67	38	of	of	IN
cord-011310-fm578rm5	67	39	the	the	DT
cord-011310-fm578rm5	67	40	target	target	NN
cord-011310-fm578rm5	67	41	population	population	NN
cord-011310-fm578rm5	67	42	as	as	RB
cord-011310-fm578rm5	67	43	well	well	RB
cord-011310-fm578rm5	67	44	as	as	IN
cord-011310-fm578rm5	67	45	invitation	invitation	NN
cord-011310-fm578rm5	67	46	strategy	strategy	NN
cord-011310-fm578rm5	67	47	,	,	,
cord-011310-fm578rm5	67	48	piloting	pilot	VBG
cord-011310-fm578rm5	67	49	of	of	IN
cord-011310-fm578rm5	67	50	a	a	DT
cord-011310-fm578rm5	67	51	screening	screening	NN
cord-011310-fm578rm5	67	52	system	system	NN
cord-011310-fm578rm5	67	53	,	,	,
cord-011310-fm578rm5	67	54	setting	set	VBG
cord-011310-fm578rm5	67	55	up	up	RP
cord-011310-fm578rm5	67	56	a	a	DT
cord-011310-fm578rm5	67	57	robust	robust	JJ
cord-011310-fm578rm5	67	58	quality	quality	NN
cord-011310-fm578rm5	67	59	assurance	assurance	NN
cord-011310-fm578rm5	67	60	system	system	NN
cord-011310-fm578rm5	67	61	before	before	IN
cord-011310-fm578rm5	67	62	the	the	DT
cord-011310-fm578rm5	67	63	system	system	NN
cord-011310-fm578rm5	67	64	is	be	VBZ
cord-011310-fm578rm5	67	65	launched	launch	VBN
cord-011310-fm578rm5	67	66	in	in	IN
cord-011310-fm578rm5	67	67	full	full	JJ
cord-011310-fm578rm5	67	68	operation	operation	NN
cord-011310-fm578rm5	67	69	.	.	.
cord-011310-fm578rm5	68	1	H.	H.	NNP
cord-011310-fm578rm5	68	2	pylori	pylori	NN
cord-011310-fm578rm5	68	3	infection	infection	NN
cord-011310-fm578rm5	68	4	is	be	VBZ
cord-011310-fm578rm5	68	5	highly	highly	RB
cord-011310-fm578rm5	68	6	prevalent	prevalent	JJ
cord-011310-fm578rm5	68	7	,	,	,
cord-011310-fm578rm5	68	8	affecting	affect	VBG
cord-011310-fm578rm5	68	9	about	about	IN
cord-011310-fm578rm5	68	10	half	half	NN
cord-011310-fm578rm5	68	11	of	of	IN
cord-011310-fm578rm5	68	12	the	the	DT
cord-011310-fm578rm5	68	13	global	global	JJ
cord-011310-fm578rm5	68	14	population	population	NN
cord-011310-fm578rm5	68	15	[	[	-LRB-
cord-011310-fm578rm5	68	16	32	32	CD
cord-011310-fm578rm5	68	17	]	]	-RRB-
cord-011310-fm578rm5	68	18	;	;	:
cord-011310-fm578rm5	68	19	the	the	DT
cord-011310-fm578rm5	68	20	prevalence	prevalence	NN
cord-011310-fm578rm5	68	21	of	of	IN
cord-011310-fm578rm5	68	22	precancerous	precancerous	JJ
cord-011310-fm578rm5	68	23	lesions	lesion	NNS
cord-011310-fm578rm5	68	24	in	in	IN
cord-011310-fm578rm5	68	25	the	the	DT
cord-011310-fm578rm5	68	26	general	general	JJ
cord-011310-fm578rm5	68	27	population	population	NN
cord-011310-fm578rm5	68	28	is	be	VBZ
cord-011310-fm578rm5	68	29	also	also	RB
cord-011310-fm578rm5	68	30	considerable	considerable	JJ
cord-011310-fm578rm5	68	31	[	[	-LRB-
cord-011310-fm578rm5	68	32	33	33	CD
cord-011310-fm578rm5	68	33	]	]	-RRB-
cord-011310-fm578rm5	68	34	.	.	.
cord-011310-fm578rm5	69	1	Therefore	therefore	RB
cord-011310-fm578rm5	69	2	,	,	,
cord-011310-fm578rm5	69	3	population	population	NN
cord-011310-fm578rm5	69	4	-	-	HYPH
cord-011310-fm578rm5	69	5	based	base	VBN
cord-011310-fm578rm5	69	6	efforts	effort	NNS
cord-011310-fm578rm5	69	7	such	such	JJ
cord-011310-fm578rm5	69	8	as	as	IN
cord-011310-fm578rm5	69	9	the	the	DT
cord-011310-fm578rm5	69	10	screen	screen	NN
cord-011310-fm578rm5	69	11	-	-	HYPH
cord-011310-fm578rm5	69	12	and	and	CC
cord-011310-fm578rm5	69	13	-	-	HYPH
cord-011310-fm578rm5	69	14	treat	treat	VB
cord-011310-fm578rm5	69	15	strategy	strategy	NN
cord-011310-fm578rm5	69	16	should	should	MD
cord-011310-fm578rm5	69	17	follow	follow	VB
cord-011310-fm578rm5	69	18	the	the	DT
cord-011310-fm578rm5	69	19	general	general	JJ
cord-011310-fm578rm5	69	20	rules	rule	NNS
cord-011310-fm578rm5	69	21	of	of	IN
cord-011310-fm578rm5	69	22	screening	screening	NN
cord-011310-fm578rm5	69	23	.	.	.
cord-011310-fm578rm5	70	1	It	-PRON-	PRP
cord-011310-fm578rm5	70	2	must	must	MD
cord-011310-fm578rm5	70	3	be	be	VB
cord-011310-fm578rm5	70	4	mentioned	mention	VBN
cord-011310-fm578rm5	70	5	that	that	IN
cord-011310-fm578rm5	70	6	the	the	DT
cord-011310-fm578rm5	70	7	current	current	JJ
cord-011310-fm578rm5	70	8	H.	H.	NNP
cord-011310-fm578rm5	70	9	pylori	pylori	NN
cord-011310-fm578rm5	70	10	management	management	NN
cord-011310-fm578rm5	70	11	guidelines	guideline	NNS
cord-011310-fm578rm5	70	12	so	so	RB
cord-011310-fm578rm5	70	13	far	far	RB
cord-011310-fm578rm5	70	14	are	be	VBP
cord-011310-fm578rm5	70	15	lacking	lack	VBG
cord-011310-fm578rm5	70	16	this	this	DT
cord-011310-fm578rm5	70	17	approach	approach	NN
cord-011310-fm578rm5	70	18	.	.	.
cord-011310-fm578rm5	71	1	Adverse	adverse	JJ
cord-011310-fm578rm5	71	2	events	event	NNS
cord-011310-fm578rm5	71	3	related	relate	VBN
cord-011310-fm578rm5	71	4	to	to	IN
cord-011310-fm578rm5	71	5	H.	h.	NN
cord-011310-fm578rm5	71	6	pylori	pylori	NN
cord-011310-fm578rm5	71	7	eradication	eradication	NN
cord-011310-fm578rm5	71	8	therapy	therapy	NN
cord-011310-fm578rm5	71	9	are	be	VBP
cord-011310-fm578rm5	71	10	common	common	JJ
cord-011310-fm578rm5	71	11	,	,	,
cord-011310-fm578rm5	71	12	but	but	CC
cord-011310-fm578rm5	71	13	usually	usually	RB
cord-011310-fm578rm5	71	14	they	-PRON-	PRP
cord-011310-fm578rm5	71	15	are	be	VBP
cord-011310-fm578rm5	71	16	mild	mild	JJ
cord-011310-fm578rm5	71	17	and	and	CC
cord-011310-fm578rm5	71	18	of	of	IN
cord-011310-fm578rm5	71	19	short	short	JJ
cord-011310-fm578rm5	71	20	-	-	HYPH
cord-011310-fm578rm5	71	21	term	term	NN
cord-011310-fm578rm5	71	22	duration	duration	NN
cord-011310-fm578rm5	71	23	;	;	:
cord-011310-fm578rm5	71	24	the	the	DT
cord-011310-fm578rm5	71	25	most	most	RBS
cord-011310-fm578rm5	71	26	common	common	JJ
cord-011310-fm578rm5	71	27	symptoms	symptom	NNS
cord-011310-fm578rm5	71	28	are	be	VBP
cord-011310-fm578rm5	71	29	diarrhea	diarrhea	JJ
cord-011310-fm578rm5	71	30	,	,	,
cord-011310-fm578rm5	71	31	nausea	nausea	NN
cord-011310-fm578rm5	71	32	and/or	and/or	CC
cord-011310-fm578rm5	71	33	vomiting	vomiting	NN
cord-011310-fm578rm5	71	34	,	,	,
cord-011310-fm578rm5	71	35	epigastric	epigastric	JJ
cord-011310-fm578rm5	71	36	pain	pain	NN
cord-011310-fm578rm5	71	37	,	,	,
cord-011310-fm578rm5	71	38	and	and	CC
cord-011310-fm578rm5	71	39	altered	alter	VBN
cord-011310-fm578rm5	71	40	taste	taste	NN
cord-011310-fm578rm5	71	41	[	[	-LRB-
cord-011310-fm578rm5	71	42	34	34	CD
cord-011310-fm578rm5	71	43	]	]	-RRB-
cord-011310-fm578rm5	71	44	.	.	.
cord-011310-fm578rm5	72	1	A	a	DT
cord-011310-fm578rm5	72	2	large	large	JJ
cord-011310-fm578rm5	72	3	systemic	systemic	JJ
cord-011310-fm578rm5	72	4	review	review	NN
cord-011310-fm578rm5	72	5	performed	perform	VBN
cord-011310-fm578rm5	72	6	in	in	IN
cord-011310-fm578rm5	72	7	2004	2004	CD
cord-011310-fm578rm5	72	8	demonstrated	demonstrate	VBD
cord-011310-fm578rm5	72	9	adverse	adverse	JJ
cord-011310-fm578rm5	72	10	effects	effect	NNS
cord-011310-fm578rm5	72	11	in	in	IN
cord-011310-fm578rm5	72	12	22	22	CD
cord-011310-fm578rm5	72	13	%	%	NN
cord-011310-fm578rm5	72	14	of	of	IN
cord-011310-fm578rm5	72	15	the	the	DT
cord-011310-fm578rm5	72	16	subjects	subject	NNS
cord-011310-fm578rm5	72	17	receiving	receive	VBG
cord-011310-fm578rm5	72	18	eradication	eradication	NN
cord-011310-fm578rm5	72	19	therapy	therapy	NN
cord-011310-fm578rm5	72	20	for	for	IN
cord-011310-fm578rm5	72	21	peptic	peptic	JJ
cord-011310-fm578rm5	72	22	ulcer	ulcer	NN
cord-011310-fm578rm5	72	23	compared	compare	VBN
cord-011310-fm578rm5	72	24	to	to	IN
cord-011310-fm578rm5	72	25	8	8	CD
cord-011310-fm578rm5	72	26	%	%	NN
cord-011310-fm578rm5	72	27	in	in	IN
cord-011310-fm578rm5	72	28	patients	patient	NNS
cord-011310-fm578rm5	72	29	on	on	IN
cord-011310-fm578rm5	72	30	a	a	DT
cord-011310-fm578rm5	72	31	proton	proton	NN
cord-011310-fm578rm5	72	32	pump	pump	NN
cord-011310-fm578rm5	72	33	inhibitor	inhibitor	NN
cord-011310-fm578rm5	72	34	(	(	-LRB-
cord-011310-fm578rm5	72	35	PPI	PPI	NNP
cord-011310-fm578rm5	72	36	)	)	-RRB-
cord-011310-fm578rm5	72	37	or	or	CC
cord-011310-fm578rm5	72	38	no	no	DT
cord-011310-fm578rm5	72	39	treatment	treatment	NN
cord-011310-fm578rm5	72	40	(	(	-LRB-
cord-011310-fm578rm5	72	41	RR	RR	NNP
cord-011310-fm578rm5	72	42	2.28	2.28	CD
cord-011310-fm578rm5	72	43	;	;	:
cord-011310-fm578rm5	72	44	95	95	CD
cord-011310-fm578rm5	72	45	%	%	NN
cord-011310-fm578rm5	72	46	CI	ci	NN
cord-011310-fm578rm5	72	47	:	:	:
cord-011310-fm578rm5	72	48	1.72	1.72	CD
cord-011310-fm578rm5	72	49	to	to	IN
cord-011310-fm578rm5	72	50	3.02	3.02	CD
cord-011310-fm578rm5	72	51	)	)	-RRB-
cord-011310-fm578rm5	72	52	[	[	-LRB-
cord-011310-fm578rm5	72	53	34	34	CD
cord-011310-fm578rm5	72	54	]	]	-RRB-
cord-011310-fm578rm5	72	55	.	.	.
cord-011310-fm578rm5	73	1	Treatment	treatment	NN
cord-011310-fm578rm5	73	2	with	with	IN
cord-011310-fm578rm5	73	3	oral	oral	JJ
cord-011310-fm578rm5	73	4	and	and	CC
cord-011310-fm578rm5	73	5	parenteral	parenteral	JJ
cord-011310-fm578rm5	73	6	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	73	7	results	result	VBZ
cord-011310-fm578rm5	73	8	in	in	IN
cord-011310-fm578rm5	73	9	a	a	DT
cord-011310-fm578rm5	73	10	rapid	rapid	JJ
cord-011310-fm578rm5	73	11	and	and	CC
cord-011310-fm578rm5	73	12	significant	significant	JJ
cord-011310-fm578rm5	73	13	alteration	alteration	NN
cord-011310-fm578rm5	73	14	of	of	IN
cord-011310-fm578rm5	73	15	the	the	DT
cord-011310-fm578rm5	73	16	intestinal	intestinal	JJ
cord-011310-fm578rm5	73	17	microbiota	microbiota	NN
cord-011310-fm578rm5	73	18	.	.	.
cord-011310-fm578rm5	74	1	The	the	DT
cord-011310-fm578rm5	74	2	most	most	RBS
cord-011310-fm578rm5	74	3	obvious	obvious	JJ
cord-011310-fm578rm5	74	4	outcome	outcome	NN
cord-011310-fm578rm5	74	5	of	of	IN
cord-011310-fm578rm5	74	6	disruption	disruption	NN
cord-011310-fm578rm5	74	7	of	of	IN
cord-011310-fm578rm5	74	8	normal	normal	JJ
cord-011310-fm578rm5	74	9	gut	gut	NN
cord-011310-fm578rm5	74	10	microbiome	microbiome	NN
cord-011310-fm578rm5	74	11	is	be	VBZ
cord-011310-fm578rm5	74	12	Clostridium	clostridium	NN
cord-011310-fm578rm5	74	13	difficile	difficile	NN
cord-011310-fm578rm5	74	14	infection	infection	NN
cord-011310-fm578rm5	74	15	(	(	-LRB-
cord-011310-fm578rm5	74	16	CDI	CDI	NNP
cord-011310-fm578rm5	74	17	)	)	-RRB-
cord-011310-fm578rm5	74	18	.	.	.
cord-011310-fm578rm5	75	1	CDI	CDI	NNP
cord-011310-fm578rm5	75	2	is	be	VBZ
cord-011310-fm578rm5	75	3	a	a	DT
cord-011310-fm578rm5	75	4	major	major	JJ
cord-011310-fm578rm5	75	5	threat	threat	NN
cord-011310-fm578rm5	75	6	to	to	IN
cord-011310-fm578rm5	75	7	both	both	DT
cord-011310-fm578rm5	75	8	outpatients	outpatient	NNS
cord-011310-fm578rm5	75	9	and	and	CC
cord-011310-fm578rm5	75	10	those	those	DT
cord-011310-fm578rm5	75	11	hospitalized	hospitalize	VBN
cord-011310-fm578rm5	75	12	.	.	.
cord-011310-fm578rm5	76	1	Although	although	IN
cord-011310-fm578rm5	76	2	any	any	DT
cord-011310-fm578rm5	76	3	antimicrobium	antimicrobium	NN
cord-011310-fm578rm5	76	4	can	can	MD
cord-011310-fm578rm5	76	5	predispose	predispose	VB
cord-011310-fm578rm5	76	6	a	a	DT
cord-011310-fm578rm5	76	7	patient	patient	NN
cord-011310-fm578rm5	76	8	to	to	IN
cord-011310-fm578rm5	76	9	CDI	CDI	NNP
cord-011310-fm578rm5	76	10	,	,	,
cord-011310-fm578rm5	76	11	the	the	DT
cord-011310-fm578rm5	76	12	risk	risk	NN
cord-011310-fm578rm5	76	13	is	be	VBZ
cord-011310-fm578rm5	76	14	especially	especially	RB
cord-011310-fm578rm5	76	15	great	great	JJ
cord-011310-fm578rm5	76	16	when	when	WRB
cord-011310-fm578rm5	76	17	using	use	VBG
cord-011310-fm578rm5	76	18	broad	broad	JJ
cord-011310-fm578rm5	76	19	-	-	HYPH
cord-011310-fm578rm5	76	20	spectrum	spectrum	NN
cord-011310-fm578rm5	76	21	antimicrobials	antimicrobial	NNS
cord-011310-fm578rm5	76	22	,	,	,
cord-011310-fm578rm5	76	23	which	which	WDT
cord-011310-fm578rm5	76	24	disrupt	disrupt	VBP
cord-011310-fm578rm5	76	25	normal	normal	JJ
cord-011310-fm578rm5	76	26	enteric	enteric	JJ
cord-011310-fm578rm5	76	27	flora	flora	NNS
cord-011310-fm578rm5	76	28	[	[	-LRB-
cord-011310-fm578rm5	76	29	35	35	CD
cord-011310-fm578rm5	76	30	]	]	-RRB-
cord-011310-fm578rm5	76	31	.	.	.
cord-011310-fm578rm5	77	1	Prolonged	prolonged	JJ
cord-011310-fm578rm5	77	2	treatment	treatment	NN
cord-011310-fm578rm5	77	3	with	with	IN
cord-011310-fm578rm5	77	4	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	77	5	agents	agent	NNS
cord-011310-fm578rm5	77	6	is	be	VBZ
cord-011310-fm578rm5	77	7	also	also	RB
cord-011310-fm578rm5	77	8	associated	associate	VBN
cord-011310-fm578rm5	77	9	with	with	IN
cord-011310-fm578rm5	77	10	an	an	DT
cord-011310-fm578rm5	77	11	increased	increase	VBN
cord-011310-fm578rm5	77	12	risk	risk	NN
cord-011310-fm578rm5	77	13	of	of	IN
cord-011310-fm578rm5	77	14	CDI	CDI	NNP
cord-011310-fm578rm5	77	15	by	by	IN
cord-011310-fm578rm5	77	16	extending	extend	VBG
cord-011310-fm578rm5	77	17	the	the	DT
cord-011310-fm578rm5	77	18	time	time	NN
cord-011310-fm578rm5	77	19	disruption	disruption	NN
cord-011310-fm578rm5	77	20	of	of	IN
cord-011310-fm578rm5	77	21	normal	normal	JJ
cord-011310-fm578rm5	77	22	enteric	enteric	JJ
cord-011310-fm578rm5	77	23	flora	flora	NNS
cord-011310-fm578rm5	77	24	[	[	-LRB-
cord-011310-fm578rm5	77	25	36	36	CD
cord-011310-fm578rm5	77	26	]	]	-RRB-
cord-011310-fm578rm5	77	27	.	.	.
cord-011310-fm578rm5	78	1	Although	although	IN
cord-011310-fm578rm5	78	2	not	not	RB
cord-011310-fm578rm5	78	3	being	be	VBG
cord-011310-fm578rm5	78	4	a	a	DT
cord-011310-fm578rm5	78	5	typical	typical	JJ
cord-011310-fm578rm5	78	6	adverse	adverse	JJ
cord-011310-fm578rm5	78	7	event	event	NN
cord-011310-fm578rm5	78	8	,	,	,
cord-011310-fm578rm5	78	9	a	a	DT
cord-011310-fm578rm5	78	10	number	number	NN
cord-011310-fm578rm5	78	11	of	of	IN
cord-011310-fm578rm5	78	12	cases	case	NNS
cord-011310-fm578rm5	78	13	have	have	VBP
cord-011310-fm578rm5	78	14	been	be	VBN
cord-011310-fm578rm5	78	15	published	publish	VBN
cord-011310-fm578rm5	78	16	on	on	IN
cord-011310-fm578rm5	78	17	CDI	CDI	NNP
cord-011310-fm578rm5	78	18	after	after	IN
cord-011310-fm578rm5	78	19	eradication	eradication	NN
cord-011310-fm578rm5	78	20	therapy	therapy	NN
cord-011310-fm578rm5	78	21	of	of	IN
cord-011310-fm578rm5	78	22	H.	H.	NNP
cord-011310-fm578rm5	78	23	pylori	pylori	NN
cord-011310-fm578rm5	78	24	[	[	-LRB-
cord-011310-fm578rm5	78	25	37	37	CD
cord-011310-fm578rm5	78	26	]	]	-RRB-
cord-011310-fm578rm5	78	27	.	.	.
cord-011310-fm578rm5	79	1	Awareness	awareness	NN
cord-011310-fm578rm5	79	2	of	of	IN
cord-011310-fm578rm5	79	3	the	the	DT
cord-011310-fm578rm5	79	4	complication	complication	NN
cord-011310-fm578rm5	79	5	is	be	VBZ
cord-011310-fm578rm5	79	6	particularly	particularly	RB
cord-011310-fm578rm5	79	7	important	important	JJ
cord-011310-fm578rm5	79	8	when	when	WRB
cord-011310-fm578rm5	79	9	both	both	DT
cord-011310-fm578rm5	79	10	duration	duration	NN
cord-011310-fm578rm5	79	11	and	and	CC
cord-011310-fm578rm5	79	12	indications	indication	NNS
cord-011310-fm578rm5	79	13	for	for	IN
cord-011310-fm578rm5	79	14	H.	h.	NN
cord-011310-fm578rm5	79	15	pylori	pylori	NN
cord-011310-fm578rm5	79	16	eradication	eradication	NN
cord-011310-fm578rm5	79	17	therapy	therapy	NN
cord-011310-fm578rm5	79	18	have	have	VBP
cord-011310-fm578rm5	79	19	been	be	VBN
cord-011310-fm578rm5	79	20	extended	extend	VBN
cord-011310-fm578rm5	79	21	.	.	.
cord-011310-fm578rm5	80	1	Significant	significant	JJ
cord-011310-fm578rm5	80	2	perturbation	perturbation	NN
cord-011310-fm578rm5	80	3	of	of	IN
cord-011310-fm578rm5	80	4	the	the	DT
cord-011310-fm578rm5	80	5	gut	gut	NN
cord-011310-fm578rm5	80	6	microbiome	microbiome	NN
cord-011310-fm578rm5	80	7	might	may	MD
cord-011310-fm578rm5	80	8	follow	follow	VB
cord-011310-fm578rm5	80	9	the	the	DT
cord-011310-fm578rm5	80	10	use	use	NN
cord-011310-fm578rm5	80	11	of	of	IN
cord-011310-fm578rm5	80	12	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	80	13	;	;	:
cord-011310-fm578rm5	80	14	however	however	RB
cord-011310-fm578rm5	80	15	,	,	,
cord-011310-fm578rm5	80	16	in	in	IN
cord-011310-fm578rm5	80	17	the	the	DT
cord-011310-fm578rm5	80	18	majority	majority	NN
cord-011310-fm578rm5	80	19	of	of	IN
cord-011310-fm578rm5	80	20	cases	case	NNS
cord-011310-fm578rm5	80	21	the	the	DT
cord-011310-fm578rm5	80	22	gut	gut	NN
cord-011310-fm578rm5	80	23	microflora	microflora	NN
cord-011310-fm578rm5	80	24	would	would	MD
cord-011310-fm578rm5	80	25	be	be	VB
cord-011310-fm578rm5	80	26	expected	expect	VBN
cord-011310-fm578rm5	80	27	to	to	TO
cord-011310-fm578rm5	80	28	return	return	VB
cord-011310-fm578rm5	80	29	to	to	IN
cord-011310-fm578rm5	80	30	its	-PRON-	PRP$
cord-011310-fm578rm5	80	31	initial	initial	JJ
cord-011310-fm578rm5	80	32	state	state	NN
cord-011310-fm578rm5	80	33	within	within	IN
cord-011310-fm578rm5	80	34	a	a	DT
cord-011310-fm578rm5	80	35	few	few	JJ
cord-011310-fm578rm5	80	36	months	month	NNS
cord-011310-fm578rm5	80	37	[	[	-LRB-
cord-011310-fm578rm5	80	38	38	38	CD
cord-011310-fm578rm5	80	39	,	,	,
cord-011310-fm578rm5	80	40	39	39	CD
cord-011310-fm578rm5	80	41	]	]	-RRB-
cord-011310-fm578rm5	80	42	.	.	.
cord-011310-fm578rm5	81	1	Resistome	Resistome	NNP
cord-011310-fm578rm5	81	2	is	be	VBZ
cord-011310-fm578rm5	81	3	defined	define	VBN
cord-011310-fm578rm5	81	4	as	as	IN
cord-011310-fm578rm5	81	5	a	a	DT
cord-011310-fm578rm5	81	6	collection	collection	NN
cord-011310-fm578rm5	81	7	of	of	IN
cord-011310-fm578rm5	81	8	all	all	DT
cord-011310-fm578rm5	81	9	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	81	10	resistance	resistance	NN
cord-011310-fm578rm5	81	11	genes	gene	NNS
cord-011310-fm578rm5	81	12	and	and	CC
cord-011310-fm578rm5	81	13	their	-PRON-	PRP$
cord-011310-fm578rm5	81	14	precursors	precursor	NNS
cord-011310-fm578rm5	81	15	in	in	IN
cord-011310-fm578rm5	81	16	both	both	CC
cord-011310-fm578rm5	81	17	pathogenetic	pathogenetic	JJ
cord-011310-fm578rm5	81	18	and	and	CC
cord-011310-fm578rm5	81	19	non	non	JJ
cord-011310-fm578rm5	81	20	-	-	JJ
cord-011310-fm578rm5	81	21	pathogenic	pathogenic	JJ
cord-011310-fm578rm5	81	22	bacteria	bacteria	NNS
cord-011310-fm578rm5	81	23	[	[	-LRB-
cord-011310-fm578rm5	81	24	40	40	CD
cord-011310-fm578rm5	81	25	]	]	-RRB-
cord-011310-fm578rm5	81	26	.	.	.
cord-011310-fm578rm5	82	1	The	the	DT
cord-011310-fm578rm5	82	2	gut	gut	NN
cord-011310-fm578rm5	82	3	microbiota	microbiota	NN
cord-011310-fm578rm5	82	4	is	be	VBZ
cord-011310-fm578rm5	82	5	a	a	DT
cord-011310-fm578rm5	82	6	large	large	JJ
cord-011310-fm578rm5	82	7	reservoir	reservoir	NN
cord-011310-fm578rm5	82	8	of	of	IN
cord-011310-fm578rm5	82	9	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	82	10	-	-	HYPH
cord-011310-fm578rm5	82	11	resistance	resistance	NN
cord-011310-fm578rm5	82	12	genes	gene	NNS
cord-011310-fm578rm5	82	13	[	[	-LRB-
cord-011310-fm578rm5	82	14	41	41	CD
cord-011310-fm578rm5	82	15	]	]	-RRB-
cord-011310-fm578rm5	82	16	;	;	:
cord-011310-fm578rm5	82	17	an	an	DT
cord-011310-fm578rm5	82	18	average	average	JJ
cord-011310-fm578rm5	82	19	number	number	NN
cord-011310-fm578rm5	82	20	of	of	IN
cord-011310-fm578rm5	82	21	21	21	CD
cord-011310-fm578rm5	82	22	such	such	JJ
cord-011310-fm578rm5	82	23	genes	gene	NNS
cord-011310-fm578rm5	82	24	per	per	IN
cord-011310-fm578rm5	82	25	sample	sample	NN
cord-011310-fm578rm5	82	26	has	have	VBZ
cord-011310-fm578rm5	82	27	been	be	VBN
cord-011310-fm578rm5	82	28	reported	report	VBN
cord-011310-fm578rm5	82	29	[	[	-LRB-
cord-011310-fm578rm5	82	30	42	42	CD
cord-011310-fm578rm5	82	31	]	]	-RRB-
cord-011310-fm578rm5	82	32	.	.	.
cord-011310-fm578rm5	83	1	Many	many	JJ
cord-011310-fm578rm5	83	2	earlier	early	RBR
cord-011310-fm578rm5	83	3	and	and	CC
cord-011310-fm578rm5	83	4	more	more	JJR
cord-011310-fm578rm5	83	5	recent	recent	JJ
cord-011310-fm578rm5	83	6	studies	study	NNS
cord-011310-fm578rm5	83	7	have	have	VBP
cord-011310-fm578rm5	83	8	suggested	suggest	VBN
cord-011310-fm578rm5	83	9	long	long	RB
cord-011310-fm578rm5	83	10	-	-	HYPH
cord-011310-fm578rm5	83	11	lasting	last	VBG
cord-011310-fm578rm5	83	12	persistence	persistence	NN
cord-011310-fm578rm5	83	13	of	of	IN
cord-011310-fm578rm5	83	14	resistant	resistant	JJ
cord-011310-fm578rm5	83	15	pharyngeal	pharyngeal	NN
cord-011310-fm578rm5	83	16	and/or	and/or	CC
cord-011310-fm578rm5	83	17	gut	gut	NN
cord-011310-fm578rm5	83	18	bacteria	bacteria	NNS
cord-011310-fm578rm5	83	19	following	follow	VBG
cord-011310-fm578rm5	83	20	the	the	DT
cord-011310-fm578rm5	83	21	use	use	NN
cord-011310-fm578rm5	83	22	of	of	IN
cord-011310-fm578rm5	83	23	traditional	traditional	JJ
cord-011310-fm578rm5	83	24	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	83	25	used	use	VBN
cord-011310-fm578rm5	83	26	to	to	TO
cord-011310-fm578rm5	83	27	eradicate	eradicate	VB
cord-011310-fm578rm5	83	28	H.	H.	NNP
cord-011310-fm578rm5	83	29	pylori	pylori	NN
cord-011310-fm578rm5	83	30	.	.	.
cord-011310-fm578rm5	84	1	One	one	CD
cord-011310-fm578rm5	84	2	-	-	HYPH
cord-011310-fm578rm5	84	3	week	week	NN
cord-011310-fm578rm5	84	4	treatment	treatment	NN
cord-011310-fm578rm5	84	5	of	of	IN
cord-011310-fm578rm5	84	6	healthy	healthy	JJ
cord-011310-fm578rm5	84	7	volunteers	volunteer	NNS
cord-011310-fm578rm5	84	8	with	with	IN
cord-011310-fm578rm5	84	9	macrolides	macrolide	NNS
cord-011310-fm578rm5	84	10	(	(	-LRB-
cord-011310-fm578rm5	84	11	azithromycin	azithromycin	NNP
cord-011310-fm578rm5	84	12	or	or	CC
cord-011310-fm578rm5	84	13	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	84	14	)	)	-RRB-
cord-011310-fm578rm5	84	15	has	have	VBZ
cord-011310-fm578rm5	84	16	been	be	VBN
cord-011310-fm578rm5	84	17	associated	associate	VBN
cord-011310-fm578rm5	84	18	to	to	IN
cord-011310-fm578rm5	84	19	a	a	DT
cord-011310-fm578rm5	84	20	significantly	significantly	RB
cord-011310-fm578rm5	84	21	increased	increase	VBN
cord-011310-fm578rm5	84	22	proportion	proportion	NN
cord-011310-fm578rm5	84	23	of	of	IN
cord-011310-fm578rm5	84	24	macrolide	macrolide	JJ
cord-011310-fm578rm5	84	25	-	-	HYPH
cord-011310-fm578rm5	84	26	resistant	resistant	JJ
cord-011310-fm578rm5	84	27	streptococci	streptococcus	NNS
cord-011310-fm578rm5	84	28	in	in	IN
cord-011310-fm578rm5	84	29	the	the	DT
cord-011310-fm578rm5	84	30	pharynx	pharynx	NN
cord-011310-fm578rm5	84	31	compared	compare	VBN
cord-011310-fm578rm5	84	32	to	to	IN
cord-011310-fm578rm5	84	33	a	a	DT
cord-011310-fm578rm5	84	34	placebo	placebo	NN
cord-011310-fm578rm5	84	35	-	-	HYPH
cord-011310-fm578rm5	84	36	treated	treat	VBN
cord-011310-fm578rm5	84	37	group	group	NN
cord-011310-fm578rm5	84	38	;	;	:
cord-011310-fm578rm5	84	39	resistant	resistant	JJ
cord-011310-fm578rm5	84	40	streptococci	streptococcus	NNS
cord-011310-fm578rm5	84	41	were	be	VBD
cord-011310-fm578rm5	84	42	present	present	JJ
cord-011310-fm578rm5	84	43	for	for	IN
cord-011310-fm578rm5	84	44	up	up	IN
cord-011310-fm578rm5	84	45	to	to	TO
cord-011310-fm578rm5	84	46	180	180	CD
cord-011310-fm578rm5	84	47	days	day	NNS
cord-011310-fm578rm5	84	48	following	follow	VBG
cord-011310-fm578rm5	84	49	treatment	treatment	NN
cord-011310-fm578rm5	84	50	[	[	-LRB-
cord-011310-fm578rm5	84	51	16	16	CD
cord-011310-fm578rm5	84	52	]	]	-RRB-
cord-011310-fm578rm5	84	53	.	.	.
cord-011310-fm578rm5	85	1	Similar	similar	JJ
cord-011310-fm578rm5	85	2	data	datum	NNS
cord-011310-fm578rm5	85	3	on	on	IN
cord-011310-fm578rm5	85	4	macrolide	macrolide	JJ
cord-011310-fm578rm5	85	5	-	-	HYPH
cord-011310-fm578rm5	85	6	resistant	resistant	JJ
cord-011310-fm578rm5	85	7	streptococci	streptococcus	NNS
cord-011310-fm578rm5	85	8	persistence	persistence	NN
cord-011310-fm578rm5	85	9	in	in	IN
cord-011310-fm578rm5	85	10	the	the	DT
cord-011310-fm578rm5	85	11	pharynx	pharynx	NN
cord-011310-fm578rm5	85	12	for	for	IN
cord-011310-fm578rm5	85	13	more	more	JJR
cord-011310-fm578rm5	85	14	than	than	IN
cord-011310-fm578rm5	85	15	1	1	CD
cord-011310-fm578rm5	85	16	year	year	NN
cord-011310-fm578rm5	85	17	in	in	IN
cord-011310-fm578rm5	85	18	patients	patient	NNS
cord-011310-fm578rm5	85	19	receiving	receive	VBG
cord-011310-fm578rm5	85	20	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	85	21	-	-	HYPH
cord-011310-fm578rm5	85	22	containing	contain	VBG
cord-011310-fm578rm5	85	23	H.	h.	NN
cord-011310-fm578rm5	85	24	pylori	pylori	NN
cord-011310-fm578rm5	85	25	eradication	eradication	NN
cord-011310-fm578rm5	85	26	regimens	regimen	NNS
cord-011310-fm578rm5	85	27	have	have	VBP
cord-011310-fm578rm5	85	28	been	be	VBN
cord-011310-fm578rm5	85	29	reported	report	VBN
cord-011310-fm578rm5	85	30	by	by	IN
cord-011310-fm578rm5	85	31	others	other	NNS
cord-011310-fm578rm5	85	32	[	[	-LRB-
cord-011310-fm578rm5	85	33	43	43	CD
cord-011310-fm578rm5	85	34	]	]	-RRB-
cord-011310-fm578rm5	85	35	.	.	.
cord-011310-fm578rm5	86	1	Another	another	DT
cord-011310-fm578rm5	86	2	study	study	NN
cord-011310-fm578rm5	86	3	has	have	VBZ
cord-011310-fm578rm5	86	4	addressed	address	VBN
cord-011310-fm578rm5	86	5	the	the	DT
cord-011310-fm578rm5	86	6	presence	presence	NN
cord-011310-fm578rm5	86	7	of	of	IN
cord-011310-fm578rm5	86	8	resistant	resistant	JJ
cord-011310-fm578rm5	86	9	Staphylococcus	Staphylococcus	NNP
cord-011310-fm578rm5	86	10	,	,	,
cord-011310-fm578rm5	86	11	Streptococcus	Streptococcus	NNP
cord-011310-fm578rm5	86	12	,	,	,
cord-011310-fm578rm5	86	13	Enterococcus	Enterococcus	NNP
cord-011310-fm578rm5	86	14	and	and	CC
cord-011310-fm578rm5	86	15	Bacteroides	Bacteroides	NNP
cord-011310-fm578rm5	86	16	spp	spp	NNS
cord-011310-fm578rm5	86	17	.	.	.
cord-011310-fm578rm5	87	1	in	in	IN
cord-011310-fm578rm5	87	2	samples	sample	NNS
cord-011310-fm578rm5	87	3	from	from	IN
cord-011310-fm578rm5	87	4	nostrils	nostril	NNS
cord-011310-fm578rm5	87	5	,	,	,
cord-011310-fm578rm5	87	6	throat	throat	NN
cord-011310-fm578rm5	87	7	and	and	CC
cord-011310-fm578rm5	87	8	feces	fece	NNS
cord-011310-fm578rm5	87	9	before	before	RB
cord-011310-fm578rm5	87	10	,	,	,
cord-011310-fm578rm5	87	11	2	2	CD
cord-011310-fm578rm5	87	12	weeks	week	NNS
cord-011310-fm578rm5	87	13	and	and	CC
cord-011310-fm578rm5	87	14	1	1	CD
cord-011310-fm578rm5	87	15	year	year	NN
cord-011310-fm578rm5	87	16	following	follow	VBG
cord-011310-fm578rm5	87	17	triple	triple	JJ
cord-011310-fm578rm5	87	18	H.	h.	NN
cord-011310-fm578rm5	87	19	pylori	pylori	NN
cord-011310-fm578rm5	87	20	eradication	eradication	NN
cord-011310-fm578rm5	87	21	therapy	therapy	NN
cord-011310-fm578rm5	87	22	(	(	-LRB-
cord-011310-fm578rm5	87	23	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	87	24	,	,	,
cord-011310-fm578rm5	87	25	metronidazole	metronidazole	NNP
cord-011310-fm578rm5	87	26	and	and	CC
cord-011310-fm578rm5	87	27	omeprazole	omeprazole	NN
cord-011310-fm578rm5	87	28	for	for	IN
cord-011310-fm578rm5	87	29	7	7	CD
cord-011310-fm578rm5	87	30	days	day	NNS
cord-011310-fm578rm5	87	31	)	)	-RRB-
cord-011310-fm578rm5	87	32	in	in	IN
cord-011310-fm578rm5	87	33	a	a	DT
cord-011310-fm578rm5	87	34	group	group	NN
cord-011310-fm578rm5	87	35	with	with	IN
cord-011310-fm578rm5	87	36	peptic	peptic	JJ
cord-011310-fm578rm5	87	37	ulcer	ulcer	NN
cord-011310-fm578rm5	87	38	disease	disease	NN
cord-011310-fm578rm5	87	39	,	,	,
cord-011310-fm578rm5	87	40	as	as	RB
cord-011310-fm578rm5	87	41	well	well	RB
cord-011310-fm578rm5	87	42	as	as	IN
cord-011310-fm578rm5	87	43	a	a	DT
cord-011310-fm578rm5	87	44	control	control	NN
cord-011310-fm578rm5	87	45	group	group	NN
cord-011310-fm578rm5	87	46	not	not	RB
cord-011310-fm578rm5	87	47	receiving	receive	VBG
cord-011310-fm578rm5	87	48	this	this	DT
cord-011310-fm578rm5	87	49	treatment	treatment	NN
cord-011310-fm578rm5	87	50	[	[	-LRB-
cord-011310-fm578rm5	87	51	44	44	CD
cord-011310-fm578rm5	87	52	]	]	-RRB-
cord-011310-fm578rm5	87	53	.	.	.
cord-011310-fm578rm5	88	1	Resistant	resistant	JJ
cord-011310-fm578rm5	88	2	isolates	isolate	NNS
cord-011310-fm578rm5	88	3	,	,	,
cord-011310-fm578rm5	88	4	in	in	IN
cord-011310-fm578rm5	88	5	particular	particular	JJ
cord-011310-fm578rm5	88	6	of	of	IN
cord-011310-fm578rm5	88	7	Staphylococci	Staphylococci	NNP
cord-011310-fm578rm5	88	8	and	and	CC
cord-011310-fm578rm5	88	9	Streptococci	Streptococci	NNP
cord-011310-fm578rm5	88	10	were	be	VBD
cord-011310-fm578rm5	88	11	higher	high	JJR
cord-011310-fm578rm5	88	12	after	after	IN
cord-011310-fm578rm5	88	13	1	1	CD
cord-011310-fm578rm5	88	14	year	year	NN
cord-011310-fm578rm5	88	15	,	,	,
cord-011310-fm578rm5	88	16	but	but	CC
cord-011310-fm578rm5	88	17	not	not	RB
cord-011310-fm578rm5	88	18	in	in	IN
cord-011310-fm578rm5	88	19	the	the	DT
cord-011310-fm578rm5	88	20	control	control	NN
cord-011310-fm578rm5	88	21	group	group	NN
cord-011310-fm578rm5	88	22	.	.	.
cord-011310-fm578rm5	89	1	Another	another	DT
cord-011310-fm578rm5	89	2	study	study	NN
cord-011310-fm578rm5	89	3	based	base	VBN
cord-011310-fm578rm5	89	4	on	on	IN
cord-011310-fm578rm5	89	5	the	the	DT
cord-011310-fm578rm5	89	6	same	same	JJ
cord-011310-fm578rm5	89	7	patient	patient	NN
cord-011310-fm578rm5	89	8	data	datum	NNS
cord-011310-fm578rm5	89	9	demonstrated	demonstrate	VBD
cord-011310-fm578rm5	89	10	that	that	IN
cord-011310-fm578rm5	89	11	this	this	DT
cord-011310-fm578rm5	89	12	treatment	treatment	NN
cord-011310-fm578rm5	89	13	facilitated	facilitate	VBD
cord-011310-fm578rm5	89	14	the	the	DT
cord-011310-fm578rm5	89	15	selection	selection	NN
cord-011310-fm578rm5	89	16	of	of	IN
cord-011310-fm578rm5	89	17	highly	highly	RB
cord-011310-fm578rm5	89	18	resistant	resistant	JJ
cord-011310-fm578rm5	89	19	enterococci	enterococci	NNS
cord-011310-fm578rm5	89	20	present	present	NN
cord-011310-fm578rm5	89	21	,	,	,
cord-011310-fm578rm5	89	22	even	even	RB
cord-011310-fm578rm5	89	23	3	3	CD
cord-011310-fm578rm5	89	24	years	year	NNS
cord-011310-fm578rm5	89	25	after	after	IN
cord-011310-fm578rm5	89	26	treatment	treatment	NN
cord-011310-fm578rm5	89	27	[	[	-LRB-
cord-011310-fm578rm5	89	28	45	45	CD
cord-011310-fm578rm5	89	29	]	]	-RRB-
cord-011310-fm578rm5	89	30	.	.	.
cord-011310-fm578rm5	90	1	The	the	DT
cord-011310-fm578rm5	90	2	same	same	JJ
cord-011310-fm578rm5	90	3	group	group	NN
cord-011310-fm578rm5	90	4	has	have	VBZ
cord-011310-fm578rm5	90	5	also	also	RB
cord-011310-fm578rm5	90	6	addressed	address	VBN
cord-011310-fm578rm5	90	7	erm(B	erm(B	NNP
cord-011310-fm578rm5	90	8	)	)	-RRB-
cord-011310-fm578rm5	91	1	gene	gene	NN
cord-011310-fm578rm5	91	2	levels	level	NNS
cord-011310-fm578rm5	91	3	(	(	-LRB-
cord-011310-fm578rm5	91	4	one	one	CD
cord-011310-fm578rm5	91	5	of	of	IN
cord-011310-fm578rm5	91	6	the	the	DT
cord-011310-fm578rm5	91	7	mechanisms	mechanism	NNS
cord-011310-fm578rm5	91	8	for	for	IN
cord-011310-fm578rm5	91	9	macrolide	macrolide	JJ
cord-011310-fm578rm5	91	10	resistance	resistance	NN
cord-011310-fm578rm5	91	11	)	)	-RRB-
cord-011310-fm578rm5	91	12	both	both	CC
cord-011310-fm578rm5	91	13	in	in	IN
cord-011310-fm578rm5	91	14	throat	throat	NN
cord-011310-fm578rm5	91	15	and	and	CC
cord-011310-fm578rm5	91	16	fecal	fecal	JJ
cord-011310-fm578rm5	91	17	samples	sample	NNS
cord-011310-fm578rm5	91	18	.	.	.
cord-011310-fm578rm5	92	1	These	these	DT
cord-011310-fm578rm5	92	2	levels	level	NNS
cord-011310-fm578rm5	92	3	increased	increase	VBD
cord-011310-fm578rm5	92	4	dramatically	dramatically	RB
cord-011310-fm578rm5	92	5	by	by	IN
cord-011310-fm578rm5	92	6	3	3	CD
cord-011310-fm578rm5	92	7	-	-	SYM
cord-011310-fm578rm5	92	8	5	5	CD
cord-011310-fm578rm5	92	9	orders	order	NNS
cord-011310-fm578rm5	92	10	of	of	IN
cord-011310-fm578rm5	92	11	magnitude	magnitude	NN
cord-011310-fm578rm5	92	12	immediately	immediately	RB
cord-011310-fm578rm5	92	13	after	after	IN
cord-011310-fm578rm5	92	14	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	92	15	treatment	treatment	NN
cord-011310-fm578rm5	92	16	.	.	.
cord-011310-fm578rm5	93	1	In	in	IN
cord-011310-fm578rm5	93	2	a	a	DT
cord-011310-fm578rm5	93	3	proportion	proportion	NN
cord-011310-fm578rm5	93	4	of	of	IN
cord-011310-fm578rm5	93	5	the	the	DT
cord-011310-fm578rm5	93	6	subjects	subject	NNS
cord-011310-fm578rm5	93	7	,	,	,
cord-011310-fm578rm5	93	8	erm(B	erm(B	NNP
cord-011310-fm578rm5	93	9	)	)	-RRB-
cord-011310-fm578rm5	93	10	remained	remain	VBD
cord-011310-fm578rm5	93	11	elevated	elevated	JJ
cord-011310-fm578rm5	93	12	4	4	CD
cord-011310-fm578rm5	93	13	years	year	NNS
cord-011310-fm578rm5	93	14	after	after	IN
cord-011310-fm578rm5	93	15	treatment	treatment	NN
cord-011310-fm578rm5	93	16	[	[	-LRB-
cord-011310-fm578rm5	93	17	46	46	CD
cord-011310-fm578rm5	93	18	]	]	-RRB-
cord-011310-fm578rm5	93	19	.	.	.
cord-011310-fm578rm5	94	1	However	however	RB
cord-011310-fm578rm5	94	2	,	,	,
cord-011310-fm578rm5	94	3	the	the	DT
cord-011310-fm578rm5	94	4	small	small	JJ
cord-011310-fm578rm5	94	5	sample	sample	NN
cord-011310-fm578rm5	94	6	of	of	IN
cord-011310-fm578rm5	94	7	subjects	subject	NNS
cord-011310-fm578rm5	94	8	in	in	IN
cord-011310-fm578rm5	94	9	this	this	DT
cord-011310-fm578rm5	94	10	study	study	NN
cord-011310-fm578rm5	94	11	should	should	MD
cord-011310-fm578rm5	94	12	be	be	VB
cord-011310-fm578rm5	94	13	noted	note	VBN
cord-011310-fm578rm5	94	14	.	.	.
cord-011310-fm578rm5	95	1	More	more	RBR
cord-011310-fm578rm5	95	2	recently	recently	RB
cord-011310-fm578rm5	95	3	,	,	,
cord-011310-fm578rm5	95	4	larger	large	JJR
cord-011310-fm578rm5	95	5	studies	study	NNS
cord-011310-fm578rm5	95	6	applying	apply	VBG
cord-011310-fm578rm5	95	7	16S	16S	NNP
cord-011310-fm578rm5	95	8	rRNA	rRNA	NNP
cord-011310-fm578rm5	95	9	gene	gene	NN
cord-011310-fm578rm5	95	10	and	and	CC
cord-011310-fm578rm5	95	11	metagenomic	metagenomic	NNP
cord-011310-fm578rm5	95	12	sequencing	sequencing	NN
cord-011310-fm578rm5	95	13	have	have	VBP
cord-011310-fm578rm5	95	14	been	be	VBN
cord-011310-fm578rm5	95	15	reported	report	VBN
cord-011310-fm578rm5	95	16	by	by	IN
cord-011310-fm578rm5	95	17	Yap	Yap	NNP
cord-011310-fm578rm5	95	18	et	et	NNP
cord-011310-fm578rm5	95	19	al	al	NNP
cord-011310-fm578rm5	95	20	.	.	.
cord-011310-fm578rm5	96	1	[	[	-LRB-
cord-011310-fm578rm5	96	2	15	15	CD
cord-011310-fm578rm5	96	3	]	]	-RRB-
cord-011310-fm578rm5	96	4	who	who	WP
cord-011310-fm578rm5	96	5	investigated	investigate	VBD
cord-011310-fm578rm5	96	6	stool	stool	NN
cord-011310-fm578rm5	96	7	samples	sample	NNS
cord-011310-fm578rm5	96	8	in	in	IN
cord-011310-fm578rm5	96	9	17-year	17-year	JJ
cord-011310-fm578rm5	96	10	-	-	HYPH
cord-011310-fm578rm5	96	11	old	old	JJ
cord-011310-fm578rm5	96	12	volunteers	volunteer	NNS
cord-011310-fm578rm5	96	13	from	from	IN
cord-011310-fm578rm5	96	14	Malaysia	Malaysia	NNP
cord-011310-fm578rm5	96	15	before	before	IN
cord-011310-fm578rm5	96	16	H.	H.	NNP
cord-011310-fm578rm5	96	17	pylori	pylori	NN
cord-011310-fm578rm5	96	18	eradication	eradication	NN
cord-011310-fm578rm5	96	19	,	,	,
cord-011310-fm578rm5	96	20	and	and	CC
cord-011310-fm578rm5	96	21	at	at	IN
cord-011310-fm578rm5	96	22	6	6	CD
cord-011310-fm578rm5	96	23	,	,	,
cord-011310-fm578rm5	96	24	12	12	CD
cord-011310-fm578rm5	96	25	,	,	,
cord-011310-fm578rm5	96	26	18	18	CD
cord-011310-fm578rm5	96	27	months	month	NNS
cord-011310-fm578rm5	96	28	thereafter	thereafter	RB
cord-011310-fm578rm5	96	29	.	.	.
cord-011310-fm578rm5	97	1	Despite	despite	IN
cord-011310-fm578rm5	97	2	microbial	microbial	JJ
cord-011310-fm578rm5	97	3	diversity	diversity	NN
cord-011310-fm578rm5	97	4	was	be	VBD
cord-011310-fm578rm5	97	5	similar	similar	JJ
cord-011310-fm578rm5	97	6	pre	pre	JJ
cord-011310-fm578rm5	97	7	-	-	JJ
cord-011310-fm578rm5	97	8	and	and	CC
cord-011310-fm578rm5	97	9	post	post	JJ
cord-011310-fm578rm5	97	10	-	-	JJ
cord-011310-fm578rm5	97	11	H.	h.	JJ
cord-011310-fm578rm5	97	12	pylori	pylori	NN
cord-011310-fm578rm5	97	13	eradication	eradication	NN
cord-011310-fm578rm5	97	14	with	with	IN
cord-011310-fm578rm5	97	15	no	no	DT
cord-011310-fm578rm5	97	16	significant	significant	JJ
cord-011310-fm578rm5	97	17	differences	difference	NNS
cord-011310-fm578rm5	97	18	in	in	IN
cord-011310-fm578rm5	97	19	richness	richness	NN
cord-011310-fm578rm5	97	20	and	and	CC
cord-011310-fm578rm5	97	21	evenness	evenness	NN
cord-011310-fm578rm5	97	22	of	of	IN
cord-011310-fm578rm5	97	23	bacterial	bacterial	JJ
cord-011310-fm578rm5	97	24	species	specie	NNS
cord-011310-fm578rm5	97	25	,	,	,
cord-011310-fm578rm5	97	26	changes	change	NNS
cord-011310-fm578rm5	97	27	in	in	IN
cord-011310-fm578rm5	97	28	the	the	DT
cord-011310-fm578rm5	97	29	bacterial	bacterial	JJ
cord-011310-fm578rm5	97	30	communities	community	NNS
cord-011310-fm578rm5	97	31	at	at	IN
cord-011310-fm578rm5	97	32	the	the	DT
cord-011310-fm578rm5	97	33	phylum	phylum	NN
cord-011310-fm578rm5	97	34	and	and	CC
cord-011310-fm578rm5	97	35	genus	genus	NN
cord-011310-fm578rm5	97	36	levels	level	NNS
cord-011310-fm578rm5	97	37	were	be	VBD
cord-011310-fm578rm5	97	38	noted	note	VBN
cord-011310-fm578rm5	97	39	,	,	,
cord-011310-fm578rm5	97	40	e.g.	e.g.	RB
cord-011310-fm578rm5	97	41	,	,	,
cord-011310-fm578rm5	97	42	the	the	DT
cord-011310-fm578rm5	97	43	relative	relative	JJ
cord-011310-fm578rm5	97	44	abundance	abundance	NN
cord-011310-fm578rm5	97	45	of	of	IN
cord-011310-fm578rm5	97	46	Bacterioidetes	Bacterioidetes	NNPS
cord-011310-fm578rm5	97	47	decreased	decrease	VBD
cord-011310-fm578rm5	97	48	and	and	CC
cord-011310-fm578rm5	97	49	Firmicutes	Firmicutes	NNPS
cord-011310-fm578rm5	97	50	increased	increase	VBD
cord-011310-fm578rm5	97	51	.	.	.
cord-011310-fm578rm5	98	1	An	an	DT
cord-011310-fm578rm5	98	2	important	important	JJ
cord-011310-fm578rm5	98	3	study	study	NN
cord-011310-fm578rm5	98	4	primarily	primarily	RB
cord-011310-fm578rm5	98	5	addressing	address	VBG
cord-011310-fm578rm5	98	6	metabolic	metabolic	JJ
cord-011310-fm578rm5	98	7	effects	effect	NNS
cord-011310-fm578rm5	98	8	of	of	IN
cord-011310-fm578rm5	98	9	H.	h.	NN
cord-011310-fm578rm5	98	10	pylori	pylori	NN
cord-011310-fm578rm5	98	11	eradication	eradication	NN
cord-011310-fm578rm5	98	12	in	in	IN
cord-011310-fm578rm5	98	13	general	general	JJ
cord-011310-fm578rm5	98	14	population	population	NN
cord-011310-fm578rm5	98	15	in	in	IN
cord-011310-fm578rm5	98	16	Taiwan	Taiwan	NNP
cord-011310-fm578rm5	98	17	was	be	VBD
cord-011310-fm578rm5	98	18	recently	recently	RB
cord-011310-fm578rm5	98	19	published	publish	VBN
cord-011310-fm578rm5	98	20	[	[	-LRB-
cord-011310-fm578rm5	98	21	47	47	CD
cord-011310-fm578rm5	98	22	]	]	-RRB-
cord-011310-fm578rm5	98	23	.	.	.
cord-011310-fm578rm5	99	1	Significant	significant	JJ
cord-011310-fm578rm5	99	2	perturbation	perturbation	NN
cord-011310-fm578rm5	99	3	of	of	IN
cord-011310-fm578rm5	99	4	gut	gut	NN
cord-011310-fm578rm5	99	5	microbiota	microbiota	NN
cord-011310-fm578rm5	99	6	in	in	IN
cord-011310-fm578rm5	99	7	short	short	JJ
cord-011310-fm578rm5	99	8	-	-	HYPH
cord-011310-fm578rm5	99	9	term	term	NN
cord-011310-fm578rm5	99	10	was	be	VBD
cord-011310-fm578rm5	99	11	revealed	reveal	VBN
cord-011310-fm578rm5	99	12	,	,	,
cord-011310-fm578rm5	99	13	and	and	CC
cord-011310-fm578rm5	99	14	it	-PRON-	PRP
cord-011310-fm578rm5	99	15	was	be	VBD
cord-011310-fm578rm5	99	16	significantly	significantly	RB
cord-011310-fm578rm5	99	17	greater	great	JJR
cord-011310-fm578rm5	99	18	for	for	IN
cord-011310-fm578rm5	99	19	concomitant	concomitant	JJ
cord-011310-fm578rm5	99	20	and	and	CC
cord-011310-fm578rm5	99	21	bismuth	bismuth	JJ
cord-011310-fm578rm5	99	22	quadruple	quadruple	JJ
cord-011310-fm578rm5	99	23	therapies	therapy	NNS
cord-011310-fm578rm5	99	24	than	than	IN
cord-011310-fm578rm5	99	25	for	for	IN
cord-011310-fm578rm5	99	26	a	a	DT
cord-011310-fm578rm5	99	27	standard	standard	JJ
cord-011310-fm578rm5	99	28	triple	triple	NN
cord-011310-fm578rm5	99	29	.	.	.
cord-011310-fm578rm5	100	1	Bismuth	bismuth	JJ
cord-011310-fm578rm5	100	2	quadruple	quadruple	JJ
cord-011310-fm578rm5	100	3	therapy	therapy	NN
cord-011310-fm578rm5	100	4	,	,	,
cord-011310-fm578rm5	100	5	on	on	IN
cord-011310-fm578rm5	100	6	the	the	DT
cord-011310-fm578rm5	100	7	other	other	JJ
cord-011310-fm578rm5	100	8	hand	hand	NN
cord-011310-fm578rm5	100	9	,	,	,
cord-011310-fm578rm5	100	10	was	be	VBD
cord-011310-fm578rm5	100	11	not	not	RB
cord-011310-fm578rm5	100	12	associated	associate	VBN
cord-011310-fm578rm5	100	13	with	with	IN
cord-011310-fm578rm5	100	14	an	an	DT
cord-011310-fm578rm5	100	15	increase	increase	NN
cord-011310-fm578rm5	100	16	in	in	IN
cord-011310-fm578rm5	100	17	resistance	resistance	NN
cord-011310-fm578rm5	100	18	in	in	IN
cord-011310-fm578rm5	100	19	E.	E.	NNP
cord-011310-fm578rm5	100	20	coli	coli	NNS
cord-011310-fm578rm5	100	21	.	.	.
cord-011310-fm578rm5	101	1	The	the	DT
cord-011310-fm578rm5	101	2	authors	author	NNS
cord-011310-fm578rm5	101	3	also	also	RB
cord-011310-fm578rm5	101	4	demonstrated	demonstrate	VBD
cord-011310-fm578rm5	101	5	that	that	IN
cord-011310-fm578rm5	101	6	for	for	IN
cord-011310-fm578rm5	101	7	other	other	JJ
cord-011310-fm578rm5	101	8	therapies	therapy	NNS
cord-011310-fm578rm5	101	9	the	the	DT
cord-011310-fm578rm5	101	10	resistance	resistance	NN
cord-011310-fm578rm5	101	11	rates	rate	NNS
cord-011310-fm578rm5	101	12	of	of	IN
cord-011310-fm578rm5	101	13	E.	E.	NNP
cord-011310-fm578rm5	101	14	coli	coli	NNS
cord-011310-fm578rm5	101	15	and	and	CC
cord-011310-fm578rm5	101	16	K.	K.	NNP
cord-011310-fm578rm5	101	17	pneumoniae	pneumoniae	NNS
cord-011310-fm578rm5	101	18	to	to	IN
cord-011310-fm578rm5	101	19	certain	certain	JJ
cord-011310-fm578rm5	101	20	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	101	21	were	be	VBD
cord-011310-fm578rm5	101	22	restored	restore	VBN
cord-011310-fm578rm5	101	23	at	at	IN
cord-011310-fm578rm5	101	24	week	week	NN
cord-011310-fm578rm5	101	25	8	8	CD
cord-011310-fm578rm5	101	26	and	and	CC
cord-011310-fm578rm5	101	27	1	1	CD
cord-011310-fm578rm5	101	28	year	year	NN
cord-011310-fm578rm5	101	29	after	after	IN
cord-011310-fm578rm5	101	30	therapy	therapy	NN
cord-011310-fm578rm5	101	31	[	[	-LRB-
cord-011310-fm578rm5	101	32	47	47	CD
cord-011310-fm578rm5	101	33	]	]	-RRB-
cord-011310-fm578rm5	101	34	.	.	.
cord-011310-fm578rm5	102	1	However	however	RB
cord-011310-fm578rm5	102	2	,	,	,
cord-011310-fm578rm5	102	3	this	this	DT
cord-011310-fm578rm5	102	4	study	study	NN
cord-011310-fm578rm5	102	5	focussed	focusse	VBD
cord-011310-fm578rm5	102	6	only	only	RB
cord-011310-fm578rm5	102	7	on	on	IN
cord-011310-fm578rm5	102	8	gut	gut	NN
cord-011310-fm578rm5	102	9	microbiome	microbiome	NN
cord-011310-fm578rm5	102	10	and	and	CC
cord-011310-fm578rm5	102	11	effect	effect	NN
cord-011310-fm578rm5	102	12	on	on	IN
cord-011310-fm578rm5	102	13	resistance	resistance	NN
cord-011310-fm578rm5	102	14	rates	rate	NNS
cord-011310-fm578rm5	102	15	in	in	IN
cord-011310-fm578rm5	102	16	Gram	gram	NN
cord-011310-fm578rm5	102	17	-	-	HYPH
cord-011310-fm578rm5	102	18	negative	negative	JJ
cord-011310-fm578rm5	102	19	bacteria	bacteria	NNS
cord-011310-fm578rm5	102	20	.	.	.
cord-011310-fm578rm5	103	1	Widespread	widespread	JJ
cord-011310-fm578rm5	103	2	use	use	NN
cord-011310-fm578rm5	103	3	of	of	IN
cord-011310-fm578rm5	103	4	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	103	5	and	and	CC
cord-011310-fm578rm5	103	6	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	103	7	causes	cause	VBZ
cord-011310-fm578rm5	103	8	concern	concern	NN
cord-011310-fm578rm5	103	9	about	about	IN
cord-011310-fm578rm5	103	10	resistance	resistance	NN
cord-011310-fm578rm5	103	11	rates	rate	NNS
cord-011310-fm578rm5	103	12	in	in	IN
cord-011310-fm578rm5	103	13	Gram	gram	NN
cord-011310-fm578rm5	103	14	-	-	HYPH
cord-011310-fm578rm5	103	15	positive	positive	JJ
cord-011310-fm578rm5	103	16	bacteria	bacteria	NNS
cord-011310-fm578rm5	103	17	such	such	JJ
cord-011310-fm578rm5	103	18	as	as	IN
cord-011310-fm578rm5	103	19	Str	Str	NNP
cord-011310-fm578rm5	103	20	.	.	.
cord-011310-fm578rm5	104	1	pneumoniae	pneumoniae	NN
cord-011310-fm578rm5	104	2	and	and	CC
cord-011310-fm578rm5	104	3	S.	S.	NNP
cord-011310-fm578rm5	104	4	aureus	aureus	NN
cord-011310-fm578rm5	104	5	[	[	-LRB-
cord-011310-fm578rm5	104	6	48	48	CD
cord-011310-fm578rm5	104	7	,	,	,
cord-011310-fm578rm5	104	8	49	49	CD
cord-011310-fm578rm5	104	9	]	]	-RRB-
cord-011310-fm578rm5	104	10	.	.	.
cord-011310-fm578rm5	105	1	Current	current	JJ
cord-011310-fm578rm5	105	2	evolution	evolution	NN
cord-011310-fm578rm5	105	3	of	of	IN
cord-011310-fm578rm5	105	4	sequencing	sequencing	NN
cord-011310-fm578rm5	105	5	methods	method	NNS
cord-011310-fm578rm5	105	6	will	will	MD
cord-011310-fm578rm5	105	7	provide	provide	VB
cord-011310-fm578rm5	105	8	significant	significant	JJ
cord-011310-fm578rm5	105	9	evidence	evidence	NN
cord-011310-fm578rm5	105	10	related	relate	VBN
cord-011310-fm578rm5	105	11	to	to	IN
cord-011310-fm578rm5	105	12	the	the	DT
cord-011310-fm578rm5	105	13	potential	potential	JJ
cord-011310-fm578rm5	105	14	perturbation	perturbation	NN
cord-011310-fm578rm5	105	15	of	of	IN
cord-011310-fm578rm5	105	16	microbiota	microbiota	NN
cord-011310-fm578rm5	105	17	following	follow	VBG
cord-011310-fm578rm5	105	18	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	105	19	treatment	treatment	NN
cord-011310-fm578rm5	105	20	,	,	,
cord-011310-fm578rm5	105	21	including	include	VBG
cord-011310-fm578rm5	105	22	H.	h.	NN
cord-011310-fm578rm5	105	23	pylori	pylori	NN
cord-011310-fm578rm5	105	24	eradication	eradication	NN
cord-011310-fm578rm5	105	25	.	.	.
cord-011310-fm578rm5	106	1	Several	several	JJ
cord-011310-fm578rm5	106	2	studies	study	NNS
cord-011310-fm578rm5	106	3	comparing	compare	VBG
cord-011310-fm578rm5	106	4	the	the	DT
cord-011310-fm578rm5	106	5	effect	effect	NN
cord-011310-fm578rm5	106	6	of	of	IN
cord-011310-fm578rm5	106	7	different	different	JJ
cord-011310-fm578rm5	106	8	H.	h.	NN
cord-011310-fm578rm5	106	9	pylori	pylori	NN
cord-011310-fm578rm5	106	10	eradication	eradication	NN
cord-011310-fm578rm5	106	11	regimens	regimen	NNS
cord-011310-fm578rm5	106	12	on	on	IN
cord-011310-fm578rm5	106	13	the	the	DT
cord-011310-fm578rm5	106	14	gut	gut	NN
cord-011310-fm578rm5	106	15	microbiome	microbiome	NN
cord-011310-fm578rm5	106	16	or	or	CC
cord-011310-fm578rm5	106	17	resistome	resistome	NNP
cord-011310-fm578rm5	106	18	are	be	VBP
cord-011310-fm578rm5	106	19	in	in	IN
cord-011310-fm578rm5	106	20	progress	progress	NN
cord-011310-fm578rm5	106	21	in	in	IN
cord-011310-fm578rm5	106	22	different	different	JJ
cord-011310-fm578rm5	106	23	countries	country	NNS
cord-011310-fm578rm5	106	24	,	,	,
cord-011310-fm578rm5	106	25	including	include	VBG
cord-011310-fm578rm5	106	26	Taiwan	Taiwan	NNP
cord-011310-fm578rm5	106	27	,	,	,
cord-011310-fm578rm5	106	28	Spain	Spain	NNP
cord-011310-fm578rm5	106	29	and	and	CC
cord-011310-fm578rm5	106	30	Latvia	Latvia	NNP
cord-011310-fm578rm5	106	31	.	.	.
cord-011310-fm578rm5	107	1	In	in	IN
cord-011310-fm578rm5	107	2	most	most	JJS
cord-011310-fm578rm5	107	3	of	of	IN
cord-011310-fm578rm5	107	4	them	-PRON-	PRP
cord-011310-fm578rm5	107	5	,	,	,
cord-011310-fm578rm5	107	6	the	the	DT
cord-011310-fm578rm5	107	7	diversity	diversity	NN
cord-011310-fm578rm5	107	8	of	of	IN
cord-011310-fm578rm5	107	9	microbiota	microbiota	NN
cord-011310-fm578rm5	107	10	is	be	VBZ
cord-011310-fm578rm5	107	11	addressed	address	VBN
cord-011310-fm578rm5	107	12	by	by	IN
cord-011310-fm578rm5	107	13	means	mean	NNS
cord-011310-fm578rm5	107	14	of	of	IN
cord-011310-fm578rm5	107	15	16S	16S	NNP
cord-011310-fm578rm5	107	16	rRNA	rrna	NN
cord-011310-fm578rm5	107	17	gene	gene	NN
cord-011310-fm578rm5	107	18	sequencing	sequencing	NN
cord-011310-fm578rm5	107	19	,	,	,
cord-011310-fm578rm5	107	20	whereas	whereas	IN
cord-011310-fm578rm5	107	21	others	other	NNS
cord-011310-fm578rm5	107	22	apply	apply	VBP
cord-011310-fm578rm5	107	23	metagenome	metagenome	NN
cord-011310-fm578rm5	107	24	sequencing	sequencing	NN
cord-011310-fm578rm5	107	25	.	.	.
cord-011310-fm578rm5	108	1	The	the	DT
cord-011310-fm578rm5	108	2	use	use	NN
cord-011310-fm578rm5	108	3	of	of	IN
cord-011310-fm578rm5	108	4	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	108	5	is	be	VBZ
cord-011310-fm578rm5	108	6	the	the	DT
cord-011310-fm578rm5	108	7	primary	primary	JJ
cord-011310-fm578rm5	108	8	driver	driver	NN
cord-011310-fm578rm5	108	9	for	for	IN
cord-011310-fm578rm5	108	10	the	the	DT
cord-011310-fm578rm5	108	11	development	development	NN
cord-011310-fm578rm5	108	12	of	of	IN
cord-011310-fm578rm5	108	13	resistance	resistance	NN
cord-011310-fm578rm5	108	14	and	and	CC
cord-011310-fm578rm5	108	15	also	also	RB
cord-011310-fm578rm5	108	16	leads	lead	VBZ
cord-011310-fm578rm5	108	17	to	to	IN
cord-011310-fm578rm5	108	18	other	other	JJ
cord-011310-fm578rm5	108	19	adverse	adverse	JJ
cord-011310-fm578rm5	108	20	effects	effect	NNS
cord-011310-fm578rm5	108	21	ranging	range	VBG
cord-011310-fm578rm5	108	22	from	from	IN
cord-011310-fm578rm5	108	23	allergic	allergic	JJ
cord-011310-fm578rm5	108	24	reactions	reaction	NNS
cord-011310-fm578rm5	108	25	to	to	IN
cord-011310-fm578rm5	108	26	CDI	CDI	NNP
cord-011310-fm578rm5	108	27	[	[	-LRB-
cord-011310-fm578rm5	108	28	50	50	CD
cord-011310-fm578rm5	108	29	]	]	-RRB-
cord-011310-fm578rm5	108	30	.	.	.
cord-011310-fm578rm5	109	1	The	the	DT
cord-011310-fm578rm5	109	2	term	term	NN
cord-011310-fm578rm5	109	3	"	"	``
cord-011310-fm578rm5	109	4	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	109	5	stewardship	stewardship	NN
cord-011310-fm578rm5	109	6	"	"	''
cord-011310-fm578rm5	109	7	is	be	VBZ
cord-011310-fm578rm5	109	8	encountered	encounter	VBN
cord-011310-fm578rm5	109	9	in	in	IN
cord-011310-fm578rm5	109	10	a	a	DT
cord-011310-fm578rm5	109	11	growing	grow	VBG
cord-011310-fm578rm5	109	12	number	number	NN
cord-011310-fm578rm5	109	13	and	and	CC
cord-011310-fm578rm5	109	14	increasingly	increasingly	RB
cord-011310-fm578rm5	109	15	diverse	diverse	JJ
cord-011310-fm578rm5	109	16	range	range	NN
cord-011310-fm578rm5	109	17	of	of	IN
cord-011310-fm578rm5	109	18	contexts	context	NNS
cord-011310-fm578rm5	109	19	,	,	,
cord-011310-fm578rm5	109	20	from	from	IN
cord-011310-fm578rm5	109	21	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	109	22	stewardship	stewardship	NN
cord-011310-fm578rm5	109	23	programmes	programme	NNS
cord-011310-fm578rm5	109	24	in	in	IN
cord-011310-fm578rm5	109	25	hospitals	hospital	NNS
cord-011310-fm578rm5	109	26	and	and	CC
cord-011310-fm578rm5	109	27	the	the	DT
cord-011310-fm578rm5	109	28	community	community	NN
cord-011310-fm578rm5	109	29	[	[	-LRB-
cord-011310-fm578rm5	109	30	51	51	CD
cord-011310-fm578rm5	109	31	]	]	-RRB-
cord-011310-fm578rm5	109	32	,	,	,
cord-011310-fm578rm5	109	33	to	to	IN
cord-011310-fm578rm5	109	34	veterinary	veterinary	JJ
cord-011310-fm578rm5	109	35	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	109	36	stewardship	stewardship	NN
cord-011310-fm578rm5	109	37	[	[	-LRB-
cord-011310-fm578rm5	109	38	52	52	CD
cord-011310-fm578rm5	109	39	]	]	-RRB-
cord-011310-fm578rm5	109	40	,	,	,
cord-011310-fm578rm5	109	41	One	one	CD
cord-011310-fm578rm5	109	42	Health	Health	NNP
cord-011310-fm578rm5	109	43	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	109	44	stewardship	stewardship	NN
cord-011310-fm578rm5	109	45	[	[	-LRB-
cord-011310-fm578rm5	109	46	53	53	CD
cord-011310-fm578rm5	109	47	]	]	-RRB-
cord-011310-fm578rm5	109	48	and	and	CC
cord-011310-fm578rm5	109	49	the	the	DT
cord-011310-fm578rm5	109	50	WHO	WHO	NNP
cord-011310-fm578rm5	109	51	global	global	JJ
cord-011310-fm578rm5	109	52	stewardship	stewardship	NN
cord-011310-fm578rm5	109	53	framework	framework	NN
cord-011310-fm578rm5	109	54	[	[	-LRB-
cord-011310-fm578rm5	109	55	54	54	CD
cord-011310-fm578rm5	109	56	]	]	-RRB-
cord-011310-fm578rm5	109	57	.	.	.
cord-011310-fm578rm5	110	1	Because	because	IN
cord-011310-fm578rm5	110	2	of	of	IN
cord-011310-fm578rm5	110	3	the	the	DT
cord-011310-fm578rm5	110	4	rapidly	rapidly	RB
cord-011310-fm578rm5	110	5	increasing	increase	VBG
cord-011310-fm578rm5	110	6	use	use	NN
cord-011310-fm578rm5	110	7	of	of	IN
cord-011310-fm578rm5	110	8	the	the	DT
cord-011310-fm578rm5	110	9	term	term	NN
cord-011310-fm578rm5	110	10	without	without	IN
cord-011310-fm578rm5	110	11	a	a	DT
cord-011310-fm578rm5	110	12	sole	sole	JJ
cord-011310-fm578rm5	110	13	clear	clear	JJ
cord-011310-fm578rm5	110	14	definition	definition	NN
cord-011310-fm578rm5	110	15	,	,	,
cord-011310-fm578rm5	110	16	it	-PRON-	PRP
cord-011310-fm578rm5	110	17	has	have	VBZ
cord-011310-fm578rm5	110	18	evolved	evolve	VBN
cord-011310-fm578rm5	110	19	differently	differently	RB
cord-011310-fm578rm5	110	20	in	in	IN
cord-011310-fm578rm5	110	21	different	different	JJ
cord-011310-fm578rm5	110	22	settings	setting	NNS
cord-011310-fm578rm5	110	23	,	,	,
cord-011310-fm578rm5	110	24	influenced	influence	VBN
cord-011310-fm578rm5	110	25	by	by	IN
cord-011310-fm578rm5	110	26	local	local	JJ
cord-011310-fm578rm5	110	27	interpretations	interpretation	NNS
cord-011310-fm578rm5	110	28	[	[	-LRB-
cord-011310-fm578rm5	110	29	55	55	CD
cord-011310-fm578rm5	110	30	]	]	-RRB-
cord-011310-fm578rm5	110	31	.	.	.
cord-011310-fm578rm5	111	1	In	in	IN
cord-011310-fm578rm5	111	2	general	general	JJ
cord-011310-fm578rm5	111	3	,	,	,
cord-011310-fm578rm5	111	4	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	111	5	stewardship	stewardship	NN
cord-011310-fm578rm5	111	6	programs	program	NNS
cord-011310-fm578rm5	111	7	have	have	VBP
cord-011310-fm578rm5	111	8	a	a	DT
cord-011310-fm578rm5	111	9	direct	direct	JJ
cord-011310-fm578rm5	111	10	responsibility	responsibility	NN
cord-011310-fm578rm5	111	11	to	to	TO
cord-011310-fm578rm5	111	12	ensure	ensure	VB
cord-011310-fm578rm5	111	13	prudent	prudent	JJ
cord-011310-fm578rm5	111	14	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	111	15	prescribing	prescribing	NN
cord-011310-fm578rm5	111	16	.	.	.
cord-011310-fm578rm5	112	1	Reducing	reduce	VBG
cord-011310-fm578rm5	112	2	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	112	3	exposure	exposure	NN
cord-011310-fm578rm5	112	4	should	should	MD
cord-011310-fm578rm5	112	5	minimize	minimize	VB
cord-011310-fm578rm5	112	6	the	the	DT
cord-011310-fm578rm5	112	7	duration	duration	NN
cord-011310-fm578rm5	112	8	and	and	CC
cord-011310-fm578rm5	112	9	extent	extent	NN
cord-011310-fm578rm5	112	10	of	of	IN
cord-011310-fm578rm5	112	11	disruption	disruption	NN
cord-011310-fm578rm5	112	12	of	of	IN
cord-011310-fm578rm5	112	13	the	the	DT
cord-011310-fm578rm5	112	14	microbiome	microbiome	NN
cord-011310-fm578rm5	112	15	,	,	,
cord-011310-fm578rm5	112	16	thereby	thereby	RB
cord-011310-fm578rm5	112	17	reducing	reduce	VBG
cord-011310-fm578rm5	112	18	collateral	collateral	JJ
cord-011310-fm578rm5	112	19	damage	damage	NN
cord-011310-fm578rm5	112	20	and	and	CC
cord-011310-fm578rm5	112	21	improving	improve	VBG
cord-011310-fm578rm5	112	22	patient	patient	JJ
cord-011310-fm578rm5	112	23	outcomes	outcome	NNS
cord-011310-fm578rm5	112	24	.	.	.
cord-011310-fm578rm5	113	1	Prolonged	prolonged	JJ
cord-011310-fm578rm5	113	2	courses	course	NNS
cord-011310-fm578rm5	113	3	of	of	IN
cord-011310-fm578rm5	113	4	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	113	5	also	also	RB
cord-011310-fm578rm5	113	6	increase	increase	VBP
cord-011310-fm578rm5	113	7	the	the	DT
cord-011310-fm578rm5	113	8	risk	risk	NN
cord-011310-fm578rm5	113	9	of	of	IN
cord-011310-fm578rm5	113	10	colonization	colonization	NN
cord-011310-fm578rm5	113	11	with	with	IN
cord-011310-fm578rm5	113	12	multidrug	multidrug	NN
cord-011310-fm578rm5	113	13	resistant	resistant	JJ
cord-011310-fm578rm5	113	14	organisms	organism	NNS
cord-011310-fm578rm5	113	15	.	.	.
cord-011310-fm578rm5	114	1	Therefore	therefore	RB
cord-011310-fm578rm5	114	2	,	,	,
cord-011310-fm578rm5	114	3	the	the	DT
cord-011310-fm578rm5	114	4	chain	chain	NN
cord-011310-fm578rm5	114	5	of	of	IN
cord-011310-fm578rm5	114	6	transmission	transmission	NN
cord-011310-fm578rm5	114	7	increases	increase	VBZ
cord-011310-fm578rm5	114	8	the	the	DT
cord-011310-fm578rm5	114	9	risk	risk	NN
cord-011310-fm578rm5	114	10	of	of	IN
cord-011310-fm578rm5	114	11	horizontally	horizontally	RB
cord-011310-fm578rm5	114	12	infecting	infect	VBG
cord-011310-fm578rm5	114	13	more	more	JJR
cord-011310-fm578rm5	114	14	than	than	IN
cord-011310-fm578rm5	114	15	one	one	CD
cord-011310-fm578rm5	114	16	patient	patient	NN
cord-011310-fm578rm5	114	17	.	.	.
cord-011310-fm578rm5	115	1	Interrupting	interrupt	VBG
cord-011310-fm578rm5	115	2	this	this	DT
cord-011310-fm578rm5	115	3	chain	chain	NN
cord-011310-fm578rm5	115	4	is	be	VBZ
cord-011310-fm578rm5	115	5	as	as	RB
cord-011310-fm578rm5	115	6	important	important	JJ
cord-011310-fm578rm5	115	7	as	as	IN
cord-011310-fm578rm5	115	8	preventing	prevent	VBG
cord-011310-fm578rm5	115	9	the	the	DT
cord-011310-fm578rm5	115	10	development	development	NN
cord-011310-fm578rm5	115	11	of	of	IN
cord-011310-fm578rm5	115	12	resistance	resistance	NN
cord-011310-fm578rm5	115	13	.	.	.
cord-011310-fm578rm5	116	1	Data	datum	NNS
cord-011310-fm578rm5	116	2	from	from	IN
cord-011310-fm578rm5	116	3	developed	develop	VBN
cord-011310-fm578rm5	116	4	nations	nation	NNS
cord-011310-fm578rm5	116	5	suggest	suggest	VBP
cord-011310-fm578rm5	116	6	that	that	IN
cord-011310-fm578rm5	116	7	80	80	CD
cord-011310-fm578rm5	116	8	%	%	NN
cord-011310-fm578rm5	116	9	or	or	CC
cord-011310-fm578rm5	116	10	more	more	JJR
cord-011310-fm578rm5	116	11	of	of	IN
cord-011310-fm578rm5	116	12	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	116	13	prescriptions	prescription	NNS
cord-011310-fm578rm5	116	14	are	be	VBP
cord-011310-fm578rm5	116	15	for	for	IN
cord-011310-fm578rm5	116	16	outpatients	outpatient	NNS
cord-011310-fm578rm5	116	17	[	[	-LRB-
cord-011310-fm578rm5	116	18	56	56	CD
cord-011310-fm578rm5	116	19	]	]	-RRB-
cord-011310-fm578rm5	116	20	.	.	.
cord-011310-fm578rm5	117	1	Therefore	therefore	RB
cord-011310-fm578rm5	117	2	,	,	,
cord-011310-fm578rm5	117	3	limiting	limit	VBG
cord-011310-fm578rm5	117	4	their	-PRON-	PRP$
cord-011310-fm578rm5	117	5	use	use	NN
cord-011310-fm578rm5	117	6	of	of	IN
cord-011310-fm578rm5	117	7	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	117	8	is	be	VBZ
cord-011310-fm578rm5	117	9	essential	essential	JJ
cord-011310-fm578rm5	117	10	in	in	IN
cord-011310-fm578rm5	117	11	reducing	reduce	VBG
cord-011310-fm578rm5	117	12	both	both	CC
cord-011310-fm578rm5	117	13	resistance	resistance	NN
cord-011310-fm578rm5	117	14	and	and	CC
cord-011310-fm578rm5	117	15	adverse	adverse	JJ
cord-011310-fm578rm5	117	16	events	event	NNS
cord-011310-fm578rm5	117	17	.	.	.
cord-011310-fm578rm5	118	1	Over	over	IN
cord-011310-fm578rm5	118	2	the	the	DT
cord-011310-fm578rm5	118	3	last	last	JJ
cord-011310-fm578rm5	118	4	20	20	CD
cord-011310-fm578rm5	118	5	years	year	NNS
cord-011310-fm578rm5	118	6	,	,	,
cord-011310-fm578rm5	118	7	several	several	JJ
cord-011310-fm578rm5	118	8	developed	develop	VBN
cord-011310-fm578rm5	118	9	countries	country	NNS
cord-011310-fm578rm5	118	10	introduced	introduce	VBD
cord-011310-fm578rm5	118	11	nationwide	nationwide	JJ
cord-011310-fm578rm5	118	12	initiatives	initiative	NNS
cord-011310-fm578rm5	118	13	aimed	aim	VBN
cord-011310-fm578rm5	118	14	at	at	IN
cord-011310-fm578rm5	118	15	reduced	reduce	VBN
cord-011310-fm578rm5	118	16	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	118	17	consumption	consumption	NN
cord-011310-fm578rm5	118	18	,	,	,
cord-011310-fm578rm5	118	19	achieved	achieve	VBD
cord-011310-fm578rm5	118	20	a	a	DT
cord-011310-fm578rm5	118	21	drop	drop	NN
cord-011310-fm578rm5	118	22	of	of	IN
cord-011310-fm578rm5	118	23	>	>	SYM
cord-011310-fm578rm5	118	24	30	30	CD
cord-011310-fm578rm5	118	25	%	%	NN
cord-011310-fm578rm5	118	26	.	.	.
cord-011310-fm578rm5	119	1	In	in	IN
cord-011310-fm578rm5	119	2	Sweden	Sweden	NNP
cord-011310-fm578rm5	119	3	between	between	IN
cord-011310-fm578rm5	119	4	1992	1992	CD
cord-011310-fm578rm5	119	5	and	and	CC
cord-011310-fm578rm5	119	6	2016	2016	CD
cord-011310-fm578rm5	119	7	,	,	,
cord-011310-fm578rm5	119	8	the	the	DT
cord-011310-fm578rm5	119	9	number	number	NN
cord-011310-fm578rm5	119	10	of	of	IN
cord-011310-fm578rm5	119	11	prescriptions	prescription	NNS
cord-011310-fm578rm5	119	12	per	per	IN
cord-011310-fm578rm5	119	13	1000	1000	CD
cord-011310-fm578rm5	119	14	inhabitants	inhabitant	NNS
cord-011310-fm578rm5	119	15	per	per	IN
cord-011310-fm578rm5	119	16	year	year	NN
cord-011310-fm578rm5	119	17	in	in	IN
cord-011310-fm578rm5	119	18	outpatient	outpatient	NN
cord-011310-fm578rm5	119	19	care	care	NN
cord-011310-fm578rm5	119	20	,	,	,
cord-011310-fm578rm5	119	21	including	include	VBG
cord-011310-fm578rm5	119	22	primary	primary	JJ
cord-011310-fm578rm5	119	23	health	health	NN
cord-011310-fm578rm5	119	24	care	care	NN
cord-011310-fm578rm5	119	25	,	,	,
cord-011310-fm578rm5	119	26	decreased	decrease	VBD
cord-011310-fm578rm5	119	27	by	by	IN
cord-011310-fm578rm5	119	28	43	43	CD
cord-011310-fm578rm5	119	29	%	%	NN
cord-011310-fm578rm5	119	30	from	from	IN
cord-011310-fm578rm5	119	31	560	560	CD
cord-011310-fm578rm5	119	32	to	to	IN
cord-011310-fm578rm5	119	33	318	318	CD
cord-011310-fm578rm5	119	34	,	,	,
cord-011310-fm578rm5	119	35	whereas	whereas	IN
cord-011310-fm578rm5	119	36	among	among	IN
cord-011310-fm578rm5	119	37	children	child	NNS
cord-011310-fm578rm5	119	38	aged	age	VBN
cord-011310-fm578rm5	119	39	0	0	CD
cord-011310-fm578rm5	119	40	-	-	SYM
cord-011310-fm578rm5	119	41	4	4	CD
cord-011310-fm578rm5	119	42	years	year	NNS
cord-011310-fm578rm5	119	43	it	-PRON-	PRP
cord-011310-fm578rm5	119	44	decreased	decrease	VBD
cord-011310-fm578rm5	119	45	by	by	IN
cord-011310-fm578rm5	119	46	73	73	CD
cord-011310-fm578rm5	119	47	%	%	NN
cord-011310-fm578rm5	119	48	from	from	IN
cord-011310-fm578rm5	119	49	1328	1328	CD
cord-011310-fm578rm5	119	50	to	to	IN
cord-011310-fm578rm5	119	51	349	349	CD
cord-011310-fm578rm5	119	52	[	[	-LRB-
cord-011310-fm578rm5	119	53	57	57	CD
cord-011310-fm578rm5	119	54	]	]	-RRB-
cord-011310-fm578rm5	119	55	.	.	.
cord-011310-fm578rm5	120	1	Between	between	IN
cord-011310-fm578rm5	120	2	2012	2012	CD
cord-011310-fm578rm5	120	3	and	and	CC
cord-011310-fm578rm5	120	4	2017	2017	CD
cord-011310-fm578rm5	120	5	,	,	,
cord-011310-fm578rm5	120	6	a	a	DT
cord-011310-fm578rm5	120	7	statistically	statistically	RB
cord-011310-fm578rm5	120	8	significant	significant	JJ
cord-011310-fm578rm5	120	9	decreasing	decrease	VBG
cord-011310-fm578rm5	120	10	trend	trend	NN
cord-011310-fm578rm5	120	11	in	in	IN
cord-011310-fm578rm5	120	12	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	120	13	use	use	NN
cord-011310-fm578rm5	120	14	was	be	VBD
cord-011310-fm578rm5	120	15	also	also	RB
cord-011310-fm578rm5	120	16	seen	see	VBN
cord-011310-fm578rm5	120	17	in	in	IN
cord-011310-fm578rm5	120	18	Finland	Finland	NNP
cord-011310-fm578rm5	120	19	,	,	,
cord-011310-fm578rm5	120	20	Luxembourg	Luxembourg	NNP
cord-011310-fm578rm5	120	21	and	and	CC
cord-011310-fm578rm5	120	22	Norway	Norway	NNP
cord-011310-fm578rm5	120	23	[	[	-LRB-
cord-011310-fm578rm5	120	24	58	58	CD
cord-011310-fm578rm5	120	25	]	]	-RRB-
cord-011310-fm578rm5	120	26	.	.	.
cord-011310-fm578rm5	121	1	In	in	IN
cord-011310-fm578rm5	121	2	March	March	NNP
cord-011310-fm578rm5	121	3	2015	2015	CD
cord-011310-fm578rm5	121	4	,	,	,
cord-011310-fm578rm5	121	5	the	the	DT
cord-011310-fm578rm5	121	6	White	White	NNP
cord-011310-fm578rm5	121	7	House	House	NNP
cord-011310-fm578rm5	121	8	released	release	VBD
cord-011310-fm578rm5	121	9	the	the	DT
cord-011310-fm578rm5	121	10	National	National	NNP
cord-011310-fm578rm5	121	11	Action	Action	NNP
cord-011310-fm578rm5	121	12	Plan	Plan	NNP
cord-011310-fm578rm5	121	13	for	for	IN
cord-011310-fm578rm5	121	14	Combating	combat	VBG
cord-011310-fm578rm5	121	15	Antibiotic	Antibiotic	NNP
cord-011310-fm578rm5	121	16	-	-	HYPH
cord-011310-fm578rm5	121	17	Resistant	resistant	JJ
cord-011310-fm578rm5	121	18	Bacteria	Bacteria	NNS
cord-011310-fm578rm5	121	19	,	,	,
cord-011310-fm578rm5	121	20	which	which	WDT
cord-011310-fm578rm5	121	21	set	set	VBD
cord-011310-fm578rm5	121	22	a	a	DT
cord-011310-fm578rm5	121	23	target	target	NN
cord-011310-fm578rm5	121	24	of	of	IN
cord-011310-fm578rm5	121	25	reducing	reduce	VBG
cord-011310-fm578rm5	121	26	inappropriate	inappropriate	JJ
cord-011310-fm578rm5	121	27	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	121	28	use	use	NN
cord-011310-fm578rm5	121	29	in	in	IN
cord-011310-fm578rm5	121	30	the	the	DT
cord-011310-fm578rm5	121	31	outpatient	outpatient	NN
cord-011310-fm578rm5	121	32	setting	set	VBG
cord-011310-fm578rm5	121	33	by	by	IN
cord-011310-fm578rm5	121	34	50	50	CD
cord-011310-fm578rm5	121	35	%	%	NN
cord-011310-fm578rm5	121	36	by	by	IN
cord-011310-fm578rm5	121	37	2020	2020	CD
cord-011310-fm578rm5	121	38	[	[	-LRB-
cord-011310-fm578rm5	121	39	59	59	CD
cord-011310-fm578rm5	121	40	]	]	-RRB-
cord-011310-fm578rm5	121	41	.	.	.
cord-011310-fm578rm5	122	1	In	in	IN
cord-011310-fm578rm5	122	2	light	light	NN
cord-011310-fm578rm5	122	3	of	of	IN
cord-011310-fm578rm5	122	4	these	these	DT
cord-011310-fm578rm5	122	5	trends	trend	NNS
cord-011310-fm578rm5	122	6	,	,	,
cord-011310-fm578rm5	122	7	any	any	DT
cord-011310-fm578rm5	122	8	suggestion	suggestion	NN
cord-011310-fm578rm5	122	9	for	for	IN
cord-011310-fm578rm5	122	10	mass	mass	JJ
cord-011310-fm578rm5	122	11	treatment	treatment	NN
cord-011310-fm578rm5	122	12	of	of	IN
cord-011310-fm578rm5	122	13	infections	infection	NNS
cord-011310-fm578rm5	122	14	that	that	WDT
cord-011310-fm578rm5	122	15	would	would	MD
cord-011310-fm578rm5	122	16	lead	lead	VB
cord-011310-fm578rm5	122	17	to	to	IN
cord-011310-fm578rm5	122	18	an	an	DT
cord-011310-fm578rm5	122	19	increase	increase	NN
cord-011310-fm578rm5	122	20	in	in	IN
cord-011310-fm578rm5	122	21	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	122	22	consumption	consumption	NN
cord-011310-fm578rm5	122	23	will	will	MD
cord-011310-fm578rm5	122	24	be	be	VB
cord-011310-fm578rm5	122	25	carefully	carefully	RB
cord-011310-fm578rm5	122	26	scrutinized	scrutinize	VBN
cord-011310-fm578rm5	122	27	by	by	IN
cord-011310-fm578rm5	122	28	national	national	JJ
cord-011310-fm578rm5	122	29	authorities	authority	NNS
cord-011310-fm578rm5	122	30	and	and	CC
cord-011310-fm578rm5	122	31	experts	expert	NNS
cord-011310-fm578rm5	122	32	.	.	.
cord-011310-fm578rm5	123	1	Amoxicillin	Amoxicillin	NNP
cord-011310-fm578rm5	123	2	and	and	CC
cord-011310-fm578rm5	123	3	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	123	4	,	,	,
cord-011310-fm578rm5	123	5	drugs	drug	NNS
cord-011310-fm578rm5	123	6	of	of	IN
cord-011310-fm578rm5	123	7	choice	choice	NN
cord-011310-fm578rm5	123	8	for	for	IN
cord-011310-fm578rm5	123	9	treatment	treatment	NN
cord-011310-fm578rm5	123	10	of	of	IN
cord-011310-fm578rm5	123	11	H.	H.	NNP
cord-011310-fm578rm5	123	12	pylori	pylori	NN
cord-011310-fm578rm5	123	13	infections	infection	NNS
cord-011310-fm578rm5	123	14	suggested	suggest	VBN
cord-011310-fm578rm5	123	15	by	by	IN
cord-011310-fm578rm5	123	16	current	current	JJ
cord-011310-fm578rm5	123	17	guidelines	guideline	NNS
cord-011310-fm578rm5	123	18	,	,	,
cord-011310-fm578rm5	123	19	have	have	VBP
cord-011310-fm578rm5	123	20	wide	wide	JJ
cord-011310-fm578rm5	123	21	application	application	NN
cord-011310-fm578rm5	123	22	for	for	IN
cord-011310-fm578rm5	123	23	the	the	DT
cord-011310-fm578rm5	123	24	treatment	treatment	NN
cord-011310-fm578rm5	123	25	of	of	IN
cord-011310-fm578rm5	123	26	several	several	JJ
cord-011310-fm578rm5	123	27	community	community	NN
cord-011310-fm578rm5	123	28	-	-	HYPH
cord-011310-fm578rm5	123	29	acquired	acquire	VBN
cord-011310-fm578rm5	123	30	infections	infection	NNS
cord-011310-fm578rm5	123	31	and	and	CC
cord-011310-fm578rm5	123	32	account	account	VBP
cord-011310-fm578rm5	123	33	for	for	IN
cord-011310-fm578rm5	123	34	large	large	JJ
cord-011310-fm578rm5	123	35	proportion	proportion	NN
cord-011310-fm578rm5	123	36	of	of	IN
cord-011310-fm578rm5	123	37	ambulatory	ambulatory	JJ
cord-011310-fm578rm5	123	38	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	123	39	prescriptions	prescription	NNS
cord-011310-fm578rm5	123	40	in	in	IN
cord-011310-fm578rm5	123	41	many	many	JJ
cord-011310-fm578rm5	123	42	countries	country	NNS
cord-011310-fm578rm5	123	43	.	.	.
cord-011310-fm578rm5	124	1	They	-PRON-	PRP
cord-011310-fm578rm5	124	2	are	be	VBP
cord-011310-fm578rm5	124	3	part	part	NN
cord-011310-fm578rm5	124	4	of	of	IN
cord-011310-fm578rm5	124	5	the	the	DT
cord-011310-fm578rm5	124	6	suggested	suggest	VBN
cord-011310-fm578rm5	124	7	first	first	JJ
cord-011310-fm578rm5	124	8	or	or	CC
cord-011310-fm578rm5	124	9	second	second	JJ
cord-011310-fm578rm5	124	10	line	line	NN
cord-011310-fm578rm5	124	11	treatment	treatment	NN
cord-011310-fm578rm5	124	12	regimens	regimen	NNS
cord-011310-fm578rm5	124	13	for	for	IN
cord-011310-fm578rm5	124	14	community	community	NN
cord-011310-fm578rm5	124	15	acquired	acquire	VBD
cord-011310-fm578rm5	124	16	pneumonia	pneumonia	NN
cord-011310-fm578rm5	124	17	[	[	-LRB-
cord-011310-fm578rm5	124	18	60	60	CD
cord-011310-fm578rm5	124	19	]	]	-RRB-
cord-011310-fm578rm5	124	20	[	[	-LRB-
cord-011310-fm578rm5	124	21	61	61	CD
cord-011310-fm578rm5	124	22	]	]	-RRB-
cord-011310-fm578rm5	124	23	[	[	-LRB-
cord-011310-fm578rm5	124	24	62	62	CD
cord-011310-fm578rm5	124	25	]	]	-RRB-
cord-011310-fm578rm5	124	26	[	[	-LRB-
cord-011310-fm578rm5	124	27	63	63	CD
cord-011310-fm578rm5	124	28	]	]	-RRB-
cord-011310-fm578rm5	124	29	.	.	.
cord-011310-fm578rm5	125	1	Amoxicillin	Amoxicillin	NNP
cord-011310-fm578rm5	125	2	or	or	CC
cord-011310-fm578rm5	125	3	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	125	4	/	/	SYM
cord-011310-fm578rm5	125	5	clavulanate	clavulanate	NNP
cord-011310-fm578rm5	125	6	is	be	VBZ
cord-011310-fm578rm5	125	7	often	often	RB
cord-011310-fm578rm5	125	8	suggested	suggest	VBN
cord-011310-fm578rm5	125	9	as	as	IN
cord-011310-fm578rm5	125	10	first	first	JJ
cord-011310-fm578rm5	125	11	-	-	HYPH
cord-011310-fm578rm5	125	12	line	line	NN
cord-011310-fm578rm5	125	13	treatment	treatment	NN
cord-011310-fm578rm5	125	14	for	for	IN
cord-011310-fm578rm5	125	15	otitis	otitis	NN
cord-011310-fm578rm5	125	16	media	medium	NNS
cord-011310-fm578rm5	125	17	,	,	,
cord-011310-fm578rm5	125	18	bacterial	bacterial	JJ
cord-011310-fm578rm5	125	19	rhinosinusitis	rhinosinusitis	NN
cord-011310-fm578rm5	125	20	,	,	,
cord-011310-fm578rm5	125	21	dental	dental	JJ
cord-011310-fm578rm5	125	22	infection	infection	NN
cord-011310-fm578rm5	125	23	and	and	CC
cord-011310-fm578rm5	125	24	urinary	urinary	JJ
cord-011310-fm578rm5	125	25	tract	tract	JJ
cord-011310-fm578rm5	125	26	infections	infection	NNS
cord-011310-fm578rm5	125	27	.	.	.
cord-011310-fm578rm5	126	1	Macrolides	macrolide	NNS
cord-011310-fm578rm5	126	2	are	be	VBP
cord-011310-fm578rm5	126	3	often	often	RB
cord-011310-fm578rm5	126	4	recommended	recommend	VBN
cord-011310-fm578rm5	126	5	as	as	IN
cord-011310-fm578rm5	126	6	replacement	replacement	NN
cord-011310-fm578rm5	126	7	treatment	treatment	NN
cord-011310-fm578rm5	126	8	for	for	IN
cord-011310-fm578rm5	126	9	patients	patient	NNS
cord-011310-fm578rm5	126	10	with	with	IN
cord-011310-fm578rm5	126	11	penicillin	penicillin	NN
cord-011310-fm578rm5	126	12	allergy	allergy	NN
cord-011310-fm578rm5	126	13	.	.	.
cord-011310-fm578rm5	127	1	Use	Use	NNP
cord-011310-fm578rm5	127	2	of	of	IN
cord-011310-fm578rm5	127	3	azithromycin	azithromycin	NNP
cord-011310-fm578rm5	127	4	has	have	VBZ
cord-011310-fm578rm5	127	5	been	be	VBN
cord-011310-fm578rm5	127	6	suggested	suggest	VBN
cord-011310-fm578rm5	127	7	for	for	IN
cord-011310-fm578rm5	127	8	mass	mass	JJ
cord-011310-fm578rm5	127	9	treatment	treatment	NN
cord-011310-fm578rm5	127	10	for	for	IN
cord-011310-fm578rm5	127	11	Chlamydia	Chlamydia	NNP
cord-011310-fm578rm5	127	12	trachomatis	trachomatis	NN
cord-011310-fm578rm5	127	13	eye	eye	NN
cord-011310-fm578rm5	127	14	infections	infection	NNS
cord-011310-fm578rm5	127	15	in	in	IN
cord-011310-fm578rm5	127	16	developing	develop	VBG
cord-011310-fm578rm5	127	17	countries	country	NNS
cord-011310-fm578rm5	127	18	.	.	.
cord-011310-fm578rm5	128	1	This	this	DT
cord-011310-fm578rm5	128	2	has	have	VBZ
cord-011310-fm578rm5	128	3	already	already	RB
cord-011310-fm578rm5	128	4	provoked	provoke	VBN
cord-011310-fm578rm5	128	5	significant	significant	JJ
cord-011310-fm578rm5	128	6	concern	concern	NN
cord-011310-fm578rm5	128	7	on	on	IN
cord-011310-fm578rm5	128	8	its	-PRON-	PRP$
cord-011310-fm578rm5	128	9	potential	potential	JJ
cord-011310-fm578rm5	128	10	adverse	adverse	JJ
cord-011310-fm578rm5	128	11	events	event	NNS
cord-011310-fm578rm5	128	12	,	,	,
cord-011310-fm578rm5	128	13	even	even	RB
cord-011310-fm578rm5	128	14	though	though	IN
cord-011310-fm578rm5	128	15	the	the	DT
cord-011310-fm578rm5	128	16	prevalence	prevalence	NN
cord-011310-fm578rm5	128	17	of	of	IN
cord-011310-fm578rm5	128	18	Chlamydia	Chlamydia	NNP
cord-011310-fm578rm5	128	19	is	be	VBZ
cord-011310-fm578rm5	128	20	significantly	significantly	RB
cord-011310-fm578rm5	128	21	lower	low	JJR
cord-011310-fm578rm5	128	22	than	than	IN
cord-011310-fm578rm5	128	23	H.	H.	NNP
cord-011310-fm578rm5	128	24	pylori	pylori	NN
cord-011310-fm578rm5	128	25	.	.	.
cord-011310-fm578rm5	129	1	Monitoring	monitoring	NN
cord-011310-fm578rm5	129	2	of	of	IN
cord-011310-fm578rm5	129	3	the	the	DT
cord-011310-fm578rm5	129	4	resistance	resistance	NN
cord-011310-fm578rm5	129	5	in	in	IN
cord-011310-fm578rm5	129	6	multiple	multiple	JJ
cord-011310-fm578rm5	129	7	organisms	organism	NNS
cord-011310-fm578rm5	129	8	has	have	VBZ
cord-011310-fm578rm5	129	9	been	be	VBN
cord-011310-fm578rm5	129	10	suggested	suggest	VBN
cord-011310-fm578rm5	129	11	on	on	IN
cord-011310-fm578rm5	129	12	this	this	DT
cord-011310-fm578rm5	129	13	indication	indication	NN
cord-011310-fm578rm5	129	14	[	[	-LRB-
cord-011310-fm578rm5	129	15	64	64	CD
cord-011310-fm578rm5	129	16	]	]	-RRB-
cord-011310-fm578rm5	129	17	.	.	.
cord-011310-fm578rm5	130	1	We	-PRON-	PRP
cord-011310-fm578rm5	130	2	conducted	conduct	VBD
cord-011310-fm578rm5	130	3	an	an	DT
cord-011310-fm578rm5	130	4	exercise	exercise	NN
cord-011310-fm578rm5	130	5	by	by	IN
cord-011310-fm578rm5	130	6	estimating	estimate	VBG
cord-011310-fm578rm5	130	7	the	the	DT
cord-011310-fm578rm5	130	8	expected	expect	VBN
cord-011310-fm578rm5	130	9	increase	increase	NN
cord-011310-fm578rm5	130	10	in	in	IN
cord-011310-fm578rm5	130	11	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	130	12	and	and	CC
cord-011310-fm578rm5	130	13	amoxicillin	amoxicillin	JJ
cord-011310-fm578rm5	130	14	consumption	consumption	NN
cord-011310-fm578rm5	130	15	in	in	IN
cord-011310-fm578rm5	130	16	Latvia	Latvia	NNP
cord-011310-fm578rm5	130	17	if	if	IN
cord-011310-fm578rm5	130	18	an	an	DT
cord-011310-fm578rm5	130	19	H.	h.	NN
cord-011310-fm578rm5	130	20	pylori	pylori	NN
cord-011310-fm578rm5	130	21	eradication	eradication	NN
cord-011310-fm578rm5	130	22	program	program	NN
cord-011310-fm578rm5	130	23	would	would	MD
cord-011310-fm578rm5	130	24	be	be	VB
cord-011310-fm578rm5	130	25	implemented	implement	VBN
cord-011310-fm578rm5	130	26	.	.	.
cord-011310-fm578rm5	131	1	Latvia	Latvia	NNP
cord-011310-fm578rm5	131	2	is	be	VBZ
cord-011310-fm578rm5	131	3	a	a	DT
cord-011310-fm578rm5	131	4	small	small	JJ
cord-011310-fm578rm5	131	5	country	country	NN
cord-011310-fm578rm5	131	6	(	(	-LRB-
cord-011310-fm578rm5	131	7	population	population	NN
cord-011310-fm578rm5	131	8	~	~	NFP
cord-011310-fm578rm5	131	9	two	two	CD
cord-011310-fm578rm5	131	10	million	million	CD
cord-011310-fm578rm5	131	11	)	)	-RRB-
cord-011310-fm578rm5	131	12	in	in	IN
cord-011310-fm578rm5	131	13	northern	northern	JJ
cord-011310-fm578rm5	131	14	Europe	Europe	NNP
cord-011310-fm578rm5	131	15	with	with	IN
cord-011310-fm578rm5	131	16	a	a	DT
cord-011310-fm578rm5	131	17	relatively	relatively	RB
cord-011310-fm578rm5	131	18	low	low	JJ
cord-011310-fm578rm5	131	19	consumption	consumption	NN
cord-011310-fm578rm5	131	20	of	of	IN
cord-011310-fm578rm5	131	21	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	131	22	and	and	CC
cord-011310-fm578rm5	131	23	relatively	relatively	RB
cord-011310-fm578rm5	131	24	high	high	JJ
cord-011310-fm578rm5	131	25	incidence	incidence	NN
cord-011310-fm578rm5	131	26	of	of	IN
cord-011310-fm578rm5	131	27	gastric	gastric	JJ
cord-011310-fm578rm5	131	28	cancerthe	cancerthe	NNP
cord-011310-fm578rm5	131	29	incidence	incidence	NN
cord-011310-fm578rm5	131	30	per	per	IN
cord-011310-fm578rm5	131	31	100,000	100,000	CD
cord-011310-fm578rm5	131	32	inhabitants	inhabitant	NNS
cord-011310-fm578rm5	131	33	in	in	IN
cord-011310-fm578rm5	131	34	both	both	DT
cord-011310-fm578rm5	131	35	genders	gender	NNS
cord-011310-fm578rm5	131	36	is	be	VBZ
cord-011310-fm578rm5	131	37	12.9	12.9	CD
cord-011310-fm578rm5	131	38	(	(	-LRB-
cord-011310-fm578rm5	131	39	ASR	ASR	NNP
cord-011310-fm578rm5	131	40	,	,	,
cord-011310-fm578rm5	131	41	world	world	NN
cord-011310-fm578rm5	131	42	population	population	NN
cord-011310-fm578rm5	131	43	)	)	-RRB-
cord-011310-fm578rm5	131	44	[	[	-LRB-
cord-011310-fm578rm5	131	45	65	65	CD
cord-011310-fm578rm5	131	46	]	]	-RRB-
cord-011310-fm578rm5	131	47	.	.	.
cord-011310-fm578rm5	132	1	We	-PRON-	PRP
cord-011310-fm578rm5	132	2	used	use	VBD
cord-011310-fm578rm5	132	3	data	datum	NNS
cord-011310-fm578rm5	132	4	on	on	IN
cord-011310-fm578rm5	132	5	the	the	DT
cord-011310-fm578rm5	132	6	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	132	7	(	(	-LRB-
cord-011310-fm578rm5	132	8	J01FA09	J01FA09	NNP
cord-011310-fm578rm5	132	9	)	)	-RRB-
cord-011310-fm578rm5	132	10	,	,	,
cord-011310-fm578rm5	132	11	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	132	12	(	(	-LRB-
cord-011310-fm578rm5	132	13	J01CR04	J01CR04	NNP
cord-011310-fm578rm5	132	14	)	)	-RRB-
cord-011310-fm578rm5	132	15	,	,	,
cord-011310-fm578rm5	132	16	and	and	CC
cord-011310-fm578rm5	133	1	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	133	2	beta	beta	NN
cord-011310-fm578rm5	133	3	-	-	HYPH
cord-011310-fm578rm5	133	4	lactam	lactam	NN
cord-011310-fm578rm5	133	5	combination	combination	NN
cord-011310-fm578rm5	133	6	(	(	-LRB-
cord-011310-fm578rm5	133	7	J01CR02	J01CR02	NNP
cord-011310-fm578rm5	133	8	)	)	-RRB-
cord-011310-fm578rm5	133	9	consumption	consumption	NN
cord-011310-fm578rm5	133	10	in	in	IN
cord-011310-fm578rm5	133	11	the	the	DT
cord-011310-fm578rm5	133	12	country	country	NN
cord-011310-fm578rm5	133	13	provided	provide	VBN
cord-011310-fm578rm5	133	14	by	by	IN
cord-011310-fm578rm5	133	15	the	the	DT
cord-011310-fm578rm5	133	16	State	State	NNP
cord-011310-fm578rm5	133	17	Agency	Agency	NNP
cord-011310-fm578rm5	133	18	of	of	IN
cord-011310-fm578rm5	133	19	Medicines	Medicines	NNPS
cord-011310-fm578rm5	133	20	and	and	CC
cord-011310-fm578rm5	133	21	expressed	express	VBD
cord-011310-fm578rm5	133	22	in	in	IN
cord-011310-fm578rm5	133	23	defined	define	VBN
cord-011310-fm578rm5	133	24	daily	daily	JJ
cord-011310-fm578rm5	133	25	doses	dose	NNS
cord-011310-fm578rm5	133	26	(	(	-LRB-
cord-011310-fm578rm5	133	27	DDD	DDD	NNP
cord-011310-fm578rm5	133	28	)	)	-RRB-
cord-011310-fm578rm5	133	29	per	per	IN
cord-011310-fm578rm5	133	30	1000	1000	CD
cord-011310-fm578rm5	133	31	inhabitants	inhabitant	NNS
cord-011310-fm578rm5	133	32	in	in	IN
cord-011310-fm578rm5	133	33	Latvia	Latvia	NNP
cord-011310-fm578rm5	133	34	within	within	IN
cord-011310-fm578rm5	133	35	the	the	DT
cord-011310-fm578rm5	133	36	period	period	NN
cord-011310-fm578rm5	133	37	2014	2014	CD
cord-011310-fm578rm5	133	38	-	-	SYM
cord-011310-fm578rm5	133	39	2018	2018	CD
cord-011310-fm578rm5	133	40	.	.	.
cord-011310-fm578rm5	134	1	Mathematical	mathematical	JJ
cord-011310-fm578rm5	134	2	projection	projection	NN
cord-011310-fm578rm5	134	3	for	for	IN
cord-011310-fm578rm5	134	4	the	the	DT
cord-011310-fm578rm5	134	5	next	next	JJ
cord-011310-fm578rm5	134	6	3	3	CD
cord-011310-fm578rm5	134	7	years	year	NNS
cord-011310-fm578rm5	134	8	was	be	VBD
cord-011310-fm578rm5	134	9	made	make	VBN
cord-011310-fm578rm5	134	10	,	,	,
cord-011310-fm578rm5	134	11	and	and	CC
cord-011310-fm578rm5	134	12	population	population	NN
cord-011310-fm578rm5	134	13	distribution	distribution	NN
cord-011310-fm578rm5	134	14	per	per	IN
cord-011310-fm578rm5	134	15	relevant	relevant	JJ
cord-011310-fm578rm5	134	16	age	age	NN
cord-011310-fm578rm5	134	17	groups	group	NNS
cord-011310-fm578rm5	134	18	from	from	IN
cord-011310-fm578rm5	134	19	the	the	DT
cord-011310-fm578rm5	134	20	official	official	JJ
cord-011310-fm578rm5	134	21	statistics	statistic	NNS
cord-011310-fm578rm5	134	22	was	be	VBD
cord-011310-fm578rm5	134	23	used	use	VBN
cord-011310-fm578rm5	134	24	.	.	.
cord-011310-fm578rm5	135	1	According	accord	VBG
cord-011310-fm578rm5	135	2	to	to	IN
cord-011310-fm578rm5	135	3	the	the	DT
cord-011310-fm578rm5	135	4	guidelines	guideline	NNS
cord-011310-fm578rm5	135	5	[	[	-LRB-
cord-011310-fm578rm5	135	6	11	11	CD
cord-011310-fm578rm5	135	7	]	]	-RRB-
cord-011310-fm578rm5	135	8	,	,	,
cord-011310-fm578rm5	135	9	a	a	DT
cord-011310-fm578rm5	135	10	14-day	14-day	CD
cord-011310-fm578rm5	135	11	eradication	eradication	NN
cord-011310-fm578rm5	135	12	regimen	regimen	NN
cord-011310-fm578rm5	135	13	with	with	IN
cord-011310-fm578rm5	135	14	2	2	CD
cord-011310-fm578rm5	135	15	g	g	NN
cord-011310-fm578rm5	135	16	per	per	IN
cord-011310-fm578rm5	135	17	day	day	NN
cord-011310-fm578rm5	135	18	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	135	19	and	and	CC
cord-011310-fm578rm5	135	20	1	1	CD
cord-011310-fm578rm5	135	21	g	g	NN
cord-011310-fm578rm5	135	22	per	per	IN
cord-011310-fm578rm5	135	23	day	day	NN
cord-011310-fm578rm5	135	24	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	135	25	was	be	VBD
cord-011310-fm578rm5	135	26	used	use	VBN
cord-011310-fm578rm5	135	27	in	in	IN
cord-011310-fm578rm5	135	28	the	the	DT
cord-011310-fm578rm5	135	29	estimates	estimate	NNS
cord-011310-fm578rm5	135	30	,	,	,
cord-011310-fm578rm5	135	31	considering	consider	VBG
cord-011310-fm578rm5	135	32	that	that	IN
cord-011310-fm578rm5	135	33	Latvia	Latvia	NNP
cord-011310-fm578rm5	135	34	still	still	RB
cord-011310-fm578rm5	135	35	belongs	belong	VBZ
cord-011310-fm578rm5	135	36	to	to	IN
cord-011310-fm578rm5	135	37	low	low	JJ
cord-011310-fm578rm5	135	38	H.	h.	NN
cord-011310-fm578rm5	135	39	pylori	pylori	NN
cord-011310-fm578rm5	135	40	resistance	resistance	NN
cord-011310-fm578rm5	135	41	areas	area	NNS
cord-011310-fm578rm5	135	42	to	to	IN
cord-011310-fm578rm5	135	43	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	135	44	,	,	,
cord-011310-fm578rm5	135	45	and	and	CC
cord-011310-fm578rm5	135	46	therefore	therefore	RB
cord-011310-fm578rm5	135	47	,	,	,
cord-011310-fm578rm5	135	48	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	135	49	-	-	HYPH
cord-011310-fm578rm5	135	50	based	base	VBN
cord-011310-fm578rm5	135	51	triple	triple	JJ
cord-011310-fm578rm5	135	52	therapy	therapy	NN
cord-011310-fm578rm5	135	53	could	could	MD
cord-011310-fm578rm5	135	54	be	be	VB
cord-011310-fm578rm5	135	55	considered	consider	VBN
cord-011310-fm578rm5	135	56	the	the	DT
cord-011310-fm578rm5	135	57	first	first	JJ
cord-011310-fm578rm5	135	58	choice	choice	NN
cord-011310-fm578rm5	135	59	.	.	.
cord-011310-fm578rm5	136	1	The	the	DT
cord-011310-fm578rm5	136	2	prevalence	prevalence	NN
cord-011310-fm578rm5	136	3	of	of	IN
cord-011310-fm578rm5	136	4	the	the	DT
cord-011310-fm578rm5	136	5	infection	infection	NN
cord-011310-fm578rm5	136	6	was	be	VBD
cord-011310-fm578rm5	136	7	considered	consider	VBN
cord-011310-fm578rm5	136	8	60	60	CD
cord-011310-fm578rm5	136	9	%	%	NN
cord-011310-fm578rm5	136	10	,	,	,
cord-011310-fm578rm5	136	11	based	base	VBN
cord-011310-fm578rm5	136	12	on	on	IN
cord-011310-fm578rm5	136	13	our	-PRON-	PRP$
cord-011310-fm578rm5	136	14	previous	previous	JJ
cord-011310-fm578rm5	136	15	studies	study	NNS
cord-011310-fm578rm5	136	16	[	[	-LRB-
cord-011310-fm578rm5	136	17	66	66	CD
cord-011310-fm578rm5	136	18	]	]	-RRB-
cord-011310-fm578rm5	136	19	.	.	.
cord-011310-fm578rm5	137	1	Three	three	CD
cord-011310-fm578rm5	137	2	different	different	JJ
cord-011310-fm578rm5	137	3	scenarios	scenario	NNS
cord-011310-fm578rm5	137	4	for	for	IN
cord-011310-fm578rm5	137	5	a	a	DT
cord-011310-fm578rm5	137	6	screen	screen	NN
cord-011310-fm578rm5	137	7	-	-	HYPH
cord-011310-fm578rm5	137	8	and	and	CC
cord-011310-fm578rm5	137	9	-	-	HYPH
cord-011310-fm578rm5	137	10	treat	treat	VB
cord-011310-fm578rm5	137	11	strategy	strategy	NN
cord-011310-fm578rm5	137	12	were	be	VBD
cord-011310-fm578rm5	137	13	evaluated	evaluate	VBN
cord-011310-fm578rm5	137	14	:	:	:
cord-011310-fm578rm5	137	15	(	(	-LRB-
cord-011310-fm578rm5	137	16	1	1	LS
cord-011310-fm578rm5	137	17	)	)	-RRB-
cord-011310-fm578rm5	137	18	eradication	eradication	NN
cord-011310-fm578rm5	137	19	is	be	VBZ
cord-011310-fm578rm5	137	20	limited	limit	VBN
cord-011310-fm578rm5	137	21	every	every	DT
cord-011310-fm578rm5	137	22	year	year	NN
cord-011310-fm578rm5	137	23	just	just	RB
cord-011310-fm578rm5	137	24	to	to	IN
cord-011310-fm578rm5	137	25	persons	person	NNS
cord-011310-fm578rm5	137	26	reaching	reach	VBG
cord-011310-fm578rm5	137	27	adulthood-18	adulthood-18	CD
cord-011310-fm578rm5	137	28	years	year	NNS
cord-011310-fm578rm5	137	29	of	of	IN
cord-011310-fm578rm5	137	30	age	age	NN
cord-011310-fm578rm5	137	31	;	;	:
cord-011310-fm578rm5	137	32	for	for	IN
cord-011310-fm578rm5	137	33	the	the	DT
cord-011310-fm578rm5	137	34	estimates	estimate	NNS
cord-011310-fm578rm5	137	35	we	-PRON-	PRP
cord-011310-fm578rm5	137	36	considered	consider	VBD
cord-011310-fm578rm5	137	37	a	a	DT
cord-011310-fm578rm5	137	38	100	100	CD
cord-011310-fm578rm5	137	39	%	%	NN
cord-011310-fm578rm5	137	40	adherence	adherence	NN
cord-011310-fm578rm5	137	41	rate	rate	NN
cord-011310-fm578rm5	137	42	,	,	,
cord-011310-fm578rm5	137	43	since	since	IN
cord-011310-fm578rm5	137	44	it	-PRON-	PRP
cord-011310-fm578rm5	137	45	was	be	VBD
cord-011310-fm578rm5	137	46	expected	expect	VBN
cord-011310-fm578rm5	137	47	that	that	IN
cord-011310-fm578rm5	137	48	the	the	DT
cord-011310-fm578rm5	137	49	campaign	campaign	NN
cord-011310-fm578rm5	137	50	would	would	MD
cord-011310-fm578rm5	137	51	result	result	VB
cord-011310-fm578rm5	137	52	in	in	IN
cord-011310-fm578rm5	137	53	additional	additional	JJ
cord-011310-fm578rm5	137	54	therapies	therapy	NNS
cord-011310-fm578rm5	137	55	outside	outside	IN
cord-011310-fm578rm5	137	56	the	the	DT
cord-011310-fm578rm5	137	57	target	target	NN
cord-011310-fm578rm5	137	58	group	group	NN
cord-011310-fm578rm5	137	59	;	;	:
cord-011310-fm578rm5	137	60	(	(	-LRB-
cord-011310-fm578rm5	137	61	2	2	LS
cord-011310-fm578rm5	137	62	)	)	-RRB-
cord-011310-fm578rm5	137	63	within	within	IN
cord-011310-fm578rm5	137	64	a	a	DT
cord-011310-fm578rm5	137	65	3-year	3-year	CD
cord-011310-fm578rm5	137	66	period	period	NN
cord-011310-fm578rm5	137	67	,	,	,
cord-011310-fm578rm5	137	68	screen	screen	NN
cord-011310-fm578rm5	137	69	-	-	HYPH
cord-011310-fm578rm5	137	70	and	and	CC
cord-011310-fm578rm5	137	71	-	-	HYPH
cord-011310-fm578rm5	137	72	treat	treat	NN
cord-011310-fm578rm5	137	73	would	would	MD
cord-011310-fm578rm5	137	74	be	be	VB
cord-011310-fm578rm5	137	75	offered	offer	VBN
cord-011310-fm578rm5	137	76	to	to	IN
cord-011310-fm578rm5	137	77	the	the	DT
cord-011310-fm578rm5	137	78	risk	risk	NN
cord-011310-fm578rm5	137	79	-	-	HYPH
cord-011310-fm578rm5	137	80	group	group	NN
cord-011310-fm578rm5	137	81	defined	define	VBN
cord-011310-fm578rm5	137	82	as	as	IN
cord-011310-fm578rm5	137	83	40	40	CD
cord-011310-fm578rm5	137	84	-	-	HYPH
cord-011310-fm578rm5	137	85	64-year	64-year	JJ
cord-011310-fm578rm5	137	86	-	-	HYPH
cord-011310-fm578rm5	137	87	old	old	JJ
cord-011310-fm578rm5	137	88	individuals	individual	NNS
cord-011310-fm578rm5	137	89	;	;	:
cord-011310-fm578rm5	137	90	one	one	CD
cord-011310-fm578rm5	137	91	third	third	NN
cord-011310-fm578rm5	137	92	of	of	IN
cord-011310-fm578rm5	137	93	the	the	DT
cord-011310-fm578rm5	137	94	target	target	NN
cord-011310-fm578rm5	137	95	group	group	NN
cord-011310-fm578rm5	137	96	would	would	MD
cord-011310-fm578rm5	137	97	be	be	VB
cord-011310-fm578rm5	137	98	covered	cover	VBN
cord-011310-fm578rm5	137	99	per	per	IN
cord-011310-fm578rm5	137	100	year	year	NN
cord-011310-fm578rm5	137	101	with	with	IN
cord-011310-fm578rm5	137	102	the	the	DT
cord-011310-fm578rm5	137	103	70	70	CD
cord-011310-fm578rm5	137	104	%	%	NN
cord-011310-fm578rm5	137	105	compliance	compliance	NN
cord-011310-fm578rm5	137	106	as	as	IN
cord-011310-fm578rm5	137	107	an	an	DT
cord-011310-fm578rm5	137	108	assumption	assumption	NN
cord-011310-fm578rm5	137	109	;	;	:
cord-011310-fm578rm5	137	110	(	(	-LRB-
cord-011310-fm578rm5	137	111	3	3	LS
cord-011310-fm578rm5	137	112	)	)	-RRB-
cord-011310-fm578rm5	137	113	within	within	IN
cord-011310-fm578rm5	137	114	a	a	DT
cord-011310-fm578rm5	137	115	3-year	3-year	CD
cord-011310-fm578rm5	137	116	period	period	NN
cord-011310-fm578rm5	137	117	,	,	,
cord-011310-fm578rm5	137	118	screen	screen	NN
cord-011310-fm578rm5	137	119	-	-	HYPH
cord-011310-fm578rm5	137	120	and	and	CC
cord-011310-fm578rm5	137	121	-	-	HYPH
cord-011310-fm578rm5	137	122	treat	treat	NN
cord-011310-fm578rm5	137	123	would	would	MD
cord-011310-fm578rm5	137	124	be	be	VB
cord-011310-fm578rm5	137	125	offered	offer	VBN
cord-011310-fm578rm5	137	126	to	to	IN
cord-011310-fm578rm5	137	127	all	all	DT
cord-011310-fm578rm5	137	128	adult	adult	NN
cord-011310-fm578rm5	137	129	individuals	individual	NNS
cord-011310-fm578rm5	137	130	assuming	assume	VBG
cord-011310-fm578rm5	137	131	a	a	DT
cord-011310-fm578rm5	137	132	similar	similar	JJ
cord-011310-fm578rm5	137	133	70	70	CD
cord-011310-fm578rm5	137	134	%	%	NN
cord-011310-fm578rm5	137	135	compliance	compliance	NN
cord-011310-fm578rm5	137	136	rate	rate	NN
cord-011310-fm578rm5	137	137	.	.	.
cord-011310-fm578rm5	138	1	For	for	IN
cord-011310-fm578rm5	138	2	scenarios	scenario	NNS
cord-011310-fm578rm5	138	3	2	2	CD
cord-011310-fm578rm5	138	4	and	and	CC
cord-011310-fm578rm5	138	5	3	3	CD
cord-011310-fm578rm5	138	6	,	,	,
cord-011310-fm578rm5	138	7	additional	additional	JJ
cord-011310-fm578rm5	138	8	eradication	eradication	NN
cord-011310-fm578rm5	138	9	of	of	IN
cord-011310-fm578rm5	138	10	the	the	DT
cord-011310-fm578rm5	138	11	group	group	NN
cord-011310-fm578rm5	138	12	reaching	reach	VBG
cord-011310-fm578rm5	138	13	adulthood	adulthood	NN
cord-011310-fm578rm5	138	14	was	be	VBD
cord-011310-fm578rm5	138	15	considered	consider	VBN
cord-011310-fm578rm5	138	16	starting	start	VBG
cord-011310-fm578rm5	138	17	from	from	IN
cord-011310-fm578rm5	138	18	year	year	NN
cord-011310-fm578rm5	138	19	2	2	CD
cord-011310-fm578rm5	138	20	.	.	.
cord-011310-fm578rm5	139	1	The	the	DT
cord-011310-fm578rm5	139	2	results	result	NNS
cord-011310-fm578rm5	139	3	are	be	VBP
cord-011310-fm578rm5	139	4	given	give	VBN
cord-011310-fm578rm5	139	5	in	in	IN
cord-011310-fm578rm5	139	6	Fig	Fig	NNP
cord-011310-fm578rm5	139	7	.	.	.
cord-011310-fm578rm5	140	1	1	1	LS
cord-011310-fm578rm5	140	2	.	.	.
cord-011310-fm578rm5	141	1	Scenario	scenario	NN
cord-011310-fm578rm5	141	2	1	1	CD
cord-011310-fm578rm5	141	3	would	would	MD
cord-011310-fm578rm5	141	4	lead	lead	VB
cord-011310-fm578rm5	141	5	to	to	IN
cord-011310-fm578rm5	141	6	a	a	DT
cord-011310-fm578rm5	141	7	moderate	moderate	JJ
cord-011310-fm578rm5	141	8	increase	increase	NN
cord-011310-fm578rm5	141	9	in	in	IN
cord-011310-fm578rm5	141	10	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	141	11	and	and	CC
cord-011310-fm578rm5	141	12	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	141	13	consumption	consumption	NN
cord-011310-fm578rm5	141	14	,	,	,
cord-011310-fm578rm5	141	15	Scenario	scenario	NN
cord-011310-fm578rm5	141	16	2	2	CD
cord-011310-fm578rm5	141	17	to	to	IN
cord-011310-fm578rm5	141	18	~	~	NFP
cord-011310-fm578rm5	141	19	threefold	threefold	JJ
cord-011310-fm578rm5	141	20	increase	increase	NN
cord-011310-fm578rm5	141	21	,	,	,
cord-011310-fm578rm5	141	22	but	but	CC
cord-011310-fm578rm5	141	23	Scenario	scenario	NN
cord-011310-fm578rm5	141	24	3	3	CD
cord-011310-fm578rm5	141	25	to	to	TO
cord-011310-fm578rm5	141	26	more	more	JJR
cord-011310-fm578rm5	141	27	than	than	IN
cord-011310-fm578rm5	141	28	a	a	DT
cord-011310-fm578rm5	141	29	sixfold	sixfold	JJ
cord-011310-fm578rm5	141	30	increase	increase	NN
cord-011310-fm578rm5	141	31	of	of	IN
cord-011310-fm578rm5	141	32	clarithromycin	clarithromycin	NNS
cord-011310-fm578rm5	141	33	,	,	,
cord-011310-fm578rm5	141	34	with	with	IN
cord-011310-fm578rm5	141	35	a	a	DT
cord-011310-fm578rm5	141	36	slightly	slightly	RB
cord-011310-fm578rm5	141	37	lower	low	JJR
cord-011310-fm578rm5	141	38	(	(	-LRB-
cord-011310-fm578rm5	141	39	twofold	twofold	NN
cord-011310-fm578rm5	141	40	)	)	-RRB-
cord-011310-fm578rm5	141	41	increase	increase	NN
cord-011310-fm578rm5	141	42	in	in	IN
cord-011310-fm578rm5	141	43	amoxicillin	amoxicillin	JJ
cord-011310-fm578rm5	141	44	consumption	consumption	NN
cord-011310-fm578rm5	141	45	.	.	.
cord-011310-fm578rm5	142	1	Such	such	PDT
cord-011310-fm578rm5	142	2	an	an	DT
cord-011310-fm578rm5	142	3	increase	increase	NN
cord-011310-fm578rm5	142	4	in	in	IN
cord-011310-fm578rm5	142	5	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	142	6	consumption	consumption	NN
cord-011310-fm578rm5	142	7	would	would	MD
cord-011310-fm578rm5	142	8	move	move	VB
cord-011310-fm578rm5	142	9	Latvia	Latvia	NNP
cord-011310-fm578rm5	142	10	from	from	IN
cord-011310-fm578rm5	142	11	a	a	DT
cord-011310-fm578rm5	142	12	group	group	NN
cord-011310-fm578rm5	142	13	of	of	IN
cord-011310-fm578rm5	142	14	countries	country	NNS
cord-011310-fm578rm5	142	15	with	with	IN
cord-011310-fm578rm5	142	16	low	low	JJ
cord-011310-fm578rm5	142	17	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	142	18	consumption	consumption	NN
cord-011310-fm578rm5	142	19	to	to	IN
cord-011310-fm578rm5	142	20	a	a	DT
cord-011310-fm578rm5	142	21	group	group	NN
cord-011310-fm578rm5	142	22	with	with	IN
cord-011310-fm578rm5	142	23	average	average	JJ
cord-011310-fm578rm5	142	24	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	142	25	consumption	consumption	NN
cord-011310-fm578rm5	142	26	(	(	-LRB-
cord-011310-fm578rm5	142	27	see	see	VB
cord-011310-fm578rm5	142	28	Fig	Fig	NNP
cord-011310-fm578rm5	142	29	.	.	NNP
cord-011310-fm578rm5	142	30	2	2	CD
cord-011310-fm578rm5	142	31	;	;	:
cord-011310-fm578rm5	142	32	data	datum	NNS
cord-011310-fm578rm5	142	33	on	on	IN
cord-011310-fm578rm5	142	34	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	142	35	consumption	consumption	NN
cord-011310-fm578rm5	142	36	 	 	_SP
cord-011310-fm578rm5	142	37	Vaccine	Vaccine	NNP
cord-011310-fm578rm5	142	38	(	(	-LRB-
cord-011310-fm578rm5	142	39	either	either	CC
cord-011310-fm578rm5	142	40	preventive	preventive	JJ
cord-011310-fm578rm5	142	41	or	or	CC
cord-011310-fm578rm5	142	42	therapeutic	therapeutic	JJ
cord-011310-fm578rm5	142	43	)	)	-RRB-
cord-011310-fm578rm5	142	44	would	would	MD
cord-011310-fm578rm5	142	45	be	be	VB
cord-011310-fm578rm5	142	46	potentially	potentially	RB
cord-011310-fm578rm5	142	47	the	the	DT
cord-011310-fm578rm5	142	48	best	good	JJS
cord-011310-fm578rm5	142	49	solution	solution	NN
cord-011310-fm578rm5	142	50	of	of	IN
cord-011310-fm578rm5	142	51	the	the	DT
cord-011310-fm578rm5	142	52	problem	problem	NN
cord-011310-fm578rm5	142	53	[	[	-LRB-
cord-011310-fm578rm5	142	54	10	10	CD
cord-011310-fm578rm5	142	55	,	,	,
cord-011310-fm578rm5	142	56	11	11	CD
cord-011310-fm578rm5	142	57	]	]	-RRB-
cord-011310-fm578rm5	142	58	;	;	:
cord-011310-fm578rm5	142	59	however	however	RB
cord-011310-fm578rm5	142	60	,	,	,
cord-011310-fm578rm5	142	61	current	current	JJ
cord-011310-fm578rm5	142	62	developments	development	NNS
cord-011310-fm578rm5	142	63	have	have	VBP
cord-011310-fm578rm5	142	64	not	not	RB
cord-011310-fm578rm5	142	65	been	be	VBN
cord-011310-fm578rm5	142	66	promising	promise	VBG
cord-011310-fm578rm5	142	67	.	.	.
cord-011310-fm578rm5	143	1	Non	non	JJ
cord-011310-fm578rm5	143	2	-	-	JJ
cord-011310-fm578rm5	143	3	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	143	4	H.	h.	NN
cord-011310-fm578rm5	143	5	pylori	pylori	NN
cord-011310-fm578rm5	143	6	eradication	eradication	NN
cord-011310-fm578rm5	143	7	regimens	regimen	NNS
cord-011310-fm578rm5	143	8	have	have	VBP
cord-011310-fm578rm5	143	9	gained	gain	VBN
cord-011310-fm578rm5	143	10	significant	significant	JJ
cord-011310-fm578rm5	143	11	clinical	clinical	JJ
cord-011310-fm578rm5	143	12	interest	interest	NN
cord-011310-fm578rm5	143	13	.	.	.
cord-011310-fm578rm5	144	1	The	the	DT
cord-011310-fm578rm5	144	2	use	use	NN
cord-011310-fm578rm5	144	3	of	of	IN
cord-011310-fm578rm5	144	4	natural	natural	JJ
cord-011310-fm578rm5	144	5	products	product	NNS
cord-011310-fm578rm5	144	6	,	,	,
cord-011310-fm578rm5	144	7	including	include	VBG
cord-011310-fm578rm5	144	8	various	various	JJ
cord-011310-fm578rm5	144	9	plant	plant	NN
cord-011310-fm578rm5	144	10	(	(	-LRB-
cord-011310-fm578rm5	144	11	even	even	RB
cord-011310-fm578rm5	144	12	mushroom	mushroom	NN
cord-011310-fm578rm5	144	13	)	)	-RRB-
cord-011310-fm578rm5	144	14	and	and	CC
cord-011310-fm578rm5	144	15	fruit	fruit	NN
cord-011310-fm578rm5	144	16	extracts	extract	NNS
cord-011310-fm578rm5	144	17	,	,	,
cord-011310-fm578rm5	144	18	natural	natural	JJ
cord-011310-fm578rm5	144	19	oils	oil	NNS
cord-011310-fm578rm5	144	20	,	,	,
cord-011310-fm578rm5	144	21	Chinese	chinese	JJ
cord-011310-fm578rm5	144	22	herbs	herb	NNS
cord-011310-fm578rm5	144	23	,	,	,
cord-011310-fm578rm5	144	24	garlic	garlic	NN
cord-011310-fm578rm5	144	25	,	,	,
cord-011310-fm578rm5	144	26	ginger	ginger	NN
cord-011310-fm578rm5	144	27	,	,	,
cord-011310-fm578rm5	144	28	green	green	JJ
cord-011310-fm578rm5	144	29	tea	tea	NN
cord-011310-fm578rm5	144	30	,	,	,
cord-011310-fm578rm5	144	31	curcumin	curcumin	NN
cord-011310-fm578rm5	144	32	,	,	,
cord-011310-fm578rm5	144	33	cranberries	cranberry	NNS
cord-011310-fm578rm5	144	34	and	and	CC
cord-011310-fm578rm5	144	35	pistacia	pistacia	NN
cord-011310-fm578rm5	144	36	gum	gum	NN
cord-011310-fm578rm5	144	37	have	have	VBP
cord-011310-fm578rm5	144	38	been	be	VBN
cord-011310-fm578rm5	144	39	studied	study	VBN
cord-011310-fm578rm5	144	40	,	,	,
cord-011310-fm578rm5	144	41	predominantly	predominantly	RB
cord-011310-fm578rm5	144	42	under	under	IN
cord-011310-fm578rm5	144	43	laboratory	laboratory	NN
cord-011310-fm578rm5	144	44	conditions	condition	NNS
cord-011310-fm578rm5	144	45	[	[	-LRB-
cord-011310-fm578rm5	144	46	67	67	CD
cord-011310-fm578rm5	144	47	]	]	-RRB-
cord-011310-fm578rm5	145	1	[	[	-LRB-
cord-011310-fm578rm5	145	2	68	68	CD
cord-011310-fm578rm5	145	3	]	]	-RRB-
cord-011310-fm578rm5	145	4	[	[	-LRB-
cord-011310-fm578rm5	145	5	69	69	CD
cord-011310-fm578rm5	145	6	]	]	-RRB-
cord-011310-fm578rm5	145	7	[	[	-LRB-
cord-011310-fm578rm5	145	8	70	70	CD
cord-011310-fm578rm5	145	9	]	]	-RRB-
cord-011310-fm578rm5	145	10	.	.	.
cord-011310-fm578rm5	146	1	Some	some	DT
cord-011310-fm578rm5	146	2	of	of	IN
cord-011310-fm578rm5	146	3	these	these	DT
cord-011310-fm578rm5	146	4	compounds	compound	NNS
cord-011310-fm578rm5	146	5	had	have	VBD
cord-011310-fm578rm5	146	6	activity	activity	NN
cord-011310-fm578rm5	146	7	against	against	IN
cord-011310-fm578rm5	146	8	H.	H.	NNP
cord-011310-fm578rm5	146	9	pylori	pylori	NN
cord-011310-fm578rm5	146	10	,	,	,
cord-011310-fm578rm5	146	11	but	but	CC
cord-011310-fm578rm5	146	12	the	the	DT
cord-011310-fm578rm5	146	13	results	result	NNS
cord-011310-fm578rm5	146	14	of	of	IN
cord-011310-fm578rm5	146	15	clinical	clinical	JJ
cord-011310-fm578rm5	146	16	evaluations	evaluation	NNS
cord-011310-fm578rm5	146	17	in	in	IN
cord-011310-fm578rm5	146	18	monotherapies	monotherapie	NNS
cord-011310-fm578rm5	146	19	have	have	VBP
cord-011310-fm578rm5	146	20	been	be	VBN
cord-011310-fm578rm5	146	21	less	less	RBR
cord-011310-fm578rm5	146	22	promising	promising	JJ
cord-011310-fm578rm5	146	23	;	;	:
cord-011310-fm578rm5	146	24	also	also	RB
cord-011310-fm578rm5	146	25	,	,	,
cord-011310-fm578rm5	146	26	the	the	DT
cord-011310-fm578rm5	146	27	quality	quality	NN
cord-011310-fm578rm5	146	28	of	of	IN
cord-011310-fm578rm5	146	29	these	these	DT
cord-011310-fm578rm5	146	30	trials	trial	NNS
cord-011310-fm578rm5	146	31	has	have	VBZ
cord-011310-fm578rm5	146	32	been	be	VBN
cord-011310-fm578rm5	146	33	criticized	criticize	VBN
cord-011310-fm578rm5	146	34	[	[	-LRB-
cord-011310-fm578rm5	146	35	67	67	CD
cord-011310-fm578rm5	146	36	]	]	-RRB-
cord-011310-fm578rm5	146	37	.	.	.
cord-011310-fm578rm5	147	1	Probiotics	probiotic	NNS
cord-011310-fm578rm5	147	2	as	as	IN
cord-011310-fm578rm5	147	3	a	a	DT
cord-011310-fm578rm5	147	4	single	single	JJ
cord-011310-fm578rm5	147	5	agent	agent	NN
cord-011310-fm578rm5	147	6	have	have	VBP
cord-011310-fm578rm5	147	7	been	be	VBN
cord-011310-fm578rm5	147	8	also	also	RB
cord-011310-fm578rm5	147	9	used	use	VBN
cord-011310-fm578rm5	147	10	without	without	IN
cord-011310-fm578rm5	147	11	major	major	JJ
cord-011310-fm578rm5	147	12	success	success	NN
cord-011310-fm578rm5	147	13	[	[	-LRB-
cord-011310-fm578rm5	147	14	71	71	CD
cord-011310-fm578rm5	147	15	]	]	-RRB-
cord-011310-fm578rm5	147	16	.	.	.
cord-011310-fm578rm5	148	1	Laboratory	laboratory	NN
cord-011310-fm578rm5	148	2	and	and	CC
cord-011310-fm578rm5	148	3	animal	animal	NN
cord-011310-fm578rm5	148	4	experiments	experiment	NNS
cord-011310-fm578rm5	148	5	show	show	VBP
cord-011310-fm578rm5	148	6	the	the	DT
cord-011310-fm578rm5	148	7	effectiveness	effectiveness	NN
cord-011310-fm578rm5	148	8	of	of	IN
cord-011310-fm578rm5	148	9	several	several	JJ
cord-011310-fm578rm5	148	10	non	non	JJ
cord-011310-fm578rm5	148	11	-	-	JJ
cord-011310-fm578rm5	148	12	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	148	13	treatment	treatment	NN
cord-011310-fm578rm5	148	14	modalities	modality	NNS
cord-011310-fm578rm5	148	15	against	against	IN
cord-011310-fm578rm5	148	16	H.	H.	NNP
cord-011310-fm578rm5	148	17	pylori	pylori	NN
cord-011310-fm578rm5	148	18	.	.	.
cord-011310-fm578rm5	149	1	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	149	2	polypeptides	polypeptide	NNS
cord-011310-fm578rm5	150	1	(	(	-LRB-
cord-011310-fm578rm5	150	2	pH	ph	JJ
cord-011310-fm578rm5	150	3	-	-	HYPH
cord-011310-fm578rm5	150	4	sensitive	sensitive	JJ
cord-011310-fm578rm5	150	5	,	,	,
cord-011310-fm578rm5	150	6	helix	helix	NN
cord-011310-fm578rm5	150	7	-	-	HYPH
cord-011310-fm578rm5	150	8	coil	coil	NN
cord-011310-fm578rm5	150	9	conformation	conformation	NN
cord-011310-fm578rm5	150	10	transitionable	transitionable	NN
cord-011310-fm578rm5	150	11	agent	agent	NN
cord-011310-fm578rm5	150	12	with	with	IN
cord-011310-fm578rm5	150	13	a	a	DT
cord-011310-fm578rm5	150	14	bactericidal	bactericidal	JJ
cord-011310-fm578rm5	150	15	activity	activity	NN
cord-011310-fm578rm5	150	16	)	)	-RRB-
cord-011310-fm578rm5	150	17	have	have	VBP
cord-011310-fm578rm5	150	18	been	be	VBN
cord-011310-fm578rm5	150	19	developed	develop	VBN
cord-011310-fm578rm5	150	20	to	to	TO
cord-011310-fm578rm5	150	21	target	target	VB
cord-011310-fm578rm5	150	22	and	and	CC
cord-011310-fm578rm5	150	23	selectively	selectively	RB
cord-011310-fm578rm5	150	24	eradicate	eradicate	VB
cord-011310-fm578rm5	150	25	H.	H.	NNP
cord-011310-fm578rm5	150	26	pylori	pylori	NN
cord-011310-fm578rm5	150	27	as	as	IN
cord-011310-fm578rm5	150	28	a	a	DT
cord-011310-fm578rm5	150	29	single	single	JJ
cord-011310-fm578rm5	150	30	therapeutic	therapeutic	JJ
cord-011310-fm578rm5	150	31	agent	agent	NN
cord-011310-fm578rm5	150	32	,	,	,
cord-011310-fm578rm5	150	33	without	without	IN
cord-011310-fm578rm5	150	34	significant	significant	JJ
cord-011310-fm578rm5	150	35	effects	effect	NNS
cord-011310-fm578rm5	150	36	on	on	IN
cord-011310-fm578rm5	150	37	commensal	commensal	JJ
cord-011310-fm578rm5	150	38	bacteria	bacteria	NNS
cord-011310-fm578rm5	150	39	[	[	-LRB-
cord-011310-fm578rm5	150	40	72	72	CD
cord-011310-fm578rm5	150	41	]	]	-RRB-
cord-011310-fm578rm5	150	42	.	.	.
cord-011310-fm578rm5	151	1	Another	another	DT
cord-011310-fm578rm5	151	2	group	group	NN
cord-011310-fm578rm5	151	3	developed	develop	VBD
cord-011310-fm578rm5	151	4	docosahexaenoic	docosahexaenoic	NNP
cord-011310-fm578rm5	151	5	acid	acid	NN
cord-011310-fm578rm5	151	6	-	-	HYPH
cord-011310-fm578rm5	151	7	loaded	load	VBN
cord-011310-fm578rm5	151	8	lipid	lipid	NN
cord-011310-fm578rm5	151	9	nanoparticles	nanoparticle	NNS
cord-011310-fm578rm5	151	10	with	with	IN
cord-011310-fm578rm5	151	11	bactericidal	bactericidal	JJ
cord-011310-fm578rm5	151	12	activity	activity	NN
cord-011310-fm578rm5	151	13	against	against	IN
cord-011310-fm578rm5	151	14	H.	H.	NNP
cord-011310-fm578rm5	151	15	pylori	pylori	NN
cord-011310-fm578rm5	151	16	[	[	-LRB-
cord-011310-fm578rm5	151	17	73	73	CD
cord-011310-fm578rm5	151	18	]	]	-RRB-
cord-011310-fm578rm5	151	19	.	.	.
cord-011310-fm578rm5	152	1	This	this	DT
cord-011310-fm578rm5	152	2	bactericidal	bactericidal	JJ
cord-011310-fm578rm5	152	3	in	in	IN
cord-011310-fm578rm5	152	4	Latvia	Latvia	NNP
cord-011310-fm578rm5	152	5	compared	compare	VBN
cord-011310-fm578rm5	152	6	to	to	IN
cord-011310-fm578rm5	152	7	other	other	JJ
cord-011310-fm578rm5	152	8	countries	country	NNS
cord-011310-fm578rm5	152	9	in	in	IN
cord-011310-fm578rm5	152	10	the	the	DT
cord-011310-fm578rm5	152	11	European	European	NNP
cord-011310-fm578rm5	152	12	Union	Union	NNP
cord-011310-fm578rm5	152	13	/	/	SYM
cord-011310-fm578rm5	152	14	European	European	NNP
cord-011310-fm578rm5	152	15	Economic	Economic	NNP
cord-011310-fm578rm5	152	16	area	area	NN
cord-011310-fm578rm5	152	17	,	,	,
cord-011310-fm578rm5	152	18	with	with	IN
cord-011310-fm578rm5	152	19	the	the	DT
cord-011310-fm578rm5	152	20	hypothetical	hypothetical	JJ
cord-011310-fm578rm5	152	21	scenarios	scenario	NNS
cord-011310-fm578rm5	152	22	of	of	IN
cord-011310-fm578rm5	152	23	an	an	DT
cord-011310-fm578rm5	152	24	H.	H.	NNP
cord-011310-fm578rm5	152	25	pylori	pylori	NN
cord-011310-fm578rm5	152	26	screenand	screenand	NN
cord-011310-fm578rm5	152	27	-	-	HYPH
cord-011310-fm578rm5	152	28	treat	treat	NN
cord-011310-fm578rm5	152	29	strategy	strategy	NN
cord-011310-fm578rm5	152	30	expressed	express	VBN
cord-011310-fm578rm5	152	31	as	as	IN
cord-011310-fm578rm5	152	32	DDD	DDD	NNP
cord-011310-fm578rm5	152	33	per	per	IN
cord-011310-fm578rm5	152	34	1000	1000	CD
cord-011310-fm578rm5	152	35	inhabitants	inhabitant	NNS
cord-011310-fm578rm5	152	36	per	per	IN
cord-011310-fm578rm5	152	37	day	day	NN
cord-011310-fm578rm5	152	38	.	.	.
cord-011310-fm578rm5	153	1	Note	note	VB
cord-011310-fm578rm5	153	2	:	:	:
cord-011310-fm578rm5	153	3	The	the	DT
cord-011310-fm578rm5	153	4	bars	bar	NNS
cord-011310-fm578rm5	153	5	in	in	IN
cord-011310-fm578rm5	153	6	blue	blue	JJ
cord-011310-fm578rm5	153	7	indicate	indicate	VBP
cord-011310-fm578rm5	153	8	the	the	DT
cord-011310-fm578rm5	153	9	current	current	JJ
cord-011310-fm578rm5	153	10	consumption	consumption	NN
cord-011310-fm578rm5	153	11	of	of	IN
cord-011310-fm578rm5	153	12	antibacterials	antibacterial	NNS
cord-011310-fm578rm5	153	13	(	(	-LRB-
cord-011310-fm578rm5	153	14	including	include	VBG
cord-011310-fm578rm5	153	15	Latvia	Latvia	NNP
cord-011310-fm578rm5	153	16	)	)	-RRB-
cord-011310-fm578rm5	153	17	.	.	.
cord-011310-fm578rm5	154	1	The	the	DT
cord-011310-fm578rm5	154	2	bars	bar	NNS
cord-011310-fm578rm5	154	3	in	in	IN
cord-011310-fm578rm5	154	4	red	red	JJ
cord-011310-fm578rm5	154	5	are	be	VBP
cord-011310-fm578rm5	154	6	consumption	consumption	NN
cord-011310-fm578rm5	154	7	of	of	IN
cord-011310-fm578rm5	154	8	antibacterials	antibacterial	NNS
cord-011310-fm578rm5	154	9	in	in	IN
cord-011310-fm578rm5	154	10	Latvia	Latvia	NNP
cord-011310-fm578rm5	154	11	with	with	IN
cord-011310-fm578rm5	154	12	various	various	JJ
cord-011310-fm578rm5	154	13	scenarios	scenario	NNS
cord-011310-fm578rm5	154	14	during	during	IN
cord-011310-fm578rm5	154	15	the	the	DT
cord-011310-fm578rm5	154	16	first	first	JJ
cord-011310-fm578rm5	154	17	year	year	NN
cord-011310-fm578rm5	154	18	of	of	IN
cord-011310-fm578rm5	154	19	a	a	DT
cord-011310-fm578rm5	154	20	screenand	screenand	NN
cord-011310-fm578rm5	154	21	-	-	HYPH
cord-011310-fm578rm5	154	22	treat	treat	VB
cord-011310-fm578rm5	154	23	strategy	strategy	NN
cord-011310-fm578rm5	154	24	implementation	implementation	NN
cord-011310-fm578rm5	154	25	.	.	.
cord-011310-fm578rm5	155	1	Scenario	scenario	NN
cord-011310-fm578rm5	155	2	1	1	CD
cord-011310-fm578rm5	155	3	:	:	:
cord-011310-fm578rm5	155	4	eradication	eradication	NN
cord-011310-fm578rm5	155	5	limited	limit	VBN
cord-011310-fm578rm5	155	6	to	to	IN
cord-011310-fm578rm5	155	7	anybody	anybody	NN
cord-011310-fm578rm5	155	8	reaching	reach	VBG
cord-011310-fm578rm5	155	9	18	18	CD
cord-011310-fm578rm5	155	10	years	year	NNS
cord-011310-fm578rm5	155	11	of	of	IN
cord-011310-fm578rm5	155	12	age	age	NN
cord-011310-fm578rm5	155	13	.	.	.
cord-011310-fm578rm5	156	1	Scenario	scenario	NN
cord-011310-fm578rm5	156	2	2	2	CD
cord-011310-fm578rm5	156	3	:	:	:
cord-011310-fm578rm5	156	4	the	the	DT
cord-011310-fm578rm5	156	5	age	age	NN
cord-011310-fm578rm5	156	6	group	group	NN
cord-011310-fm578rm5	156	7	40	40	CD
cord-011310-fm578rm5	156	8	-	-	SYM
cord-011310-fm578rm5	156	9	64	64	CD
cord-011310-fm578rm5	156	10	years	year	NNS
cord-011310-fm578rm5	156	11	invited	invite	VBN
cord-011310-fm578rm5	156	12	for	for	IN
cord-011310-fm578rm5	156	13	screen	screen	NN
cord-011310-fm578rm5	156	14	-	-	HYPH
cord-011310-fm578rm5	156	15	and	and	CC
cord-011310-fm578rm5	156	16	-	-	HYPH
cord-011310-fm578rm5	156	17	treat	treat	NN
cord-011310-fm578rm5	156	18	within	within	IN
cord-011310-fm578rm5	156	19	a	a	DT
cord-011310-fm578rm5	156	20	3-year	3-year	CD
cord-011310-fm578rm5	156	21	period	period	NN
cord-011310-fm578rm5	156	22	;	;	:
cord-011310-fm578rm5	156	23	70	70	CD
cord-011310-fm578rm5	156	24	%	%	NN
cord-011310-fm578rm5	156	25	compliance	compliance	NN
cord-011310-fm578rm5	156	26	.	.	.
cord-011310-fm578rm5	157	1	Scenario	scenario	NN
cord-011310-fm578rm5	157	2	3	3	CD
cord-011310-fm578rm5	157	3	:	:	:
cord-011310-fm578rm5	157	4	all	all	DT
cord-011310-fm578rm5	157	5	adults	adult	NNS
cord-011310-fm578rm5	157	6	invited	invite	VBN
cord-011310-fm578rm5	157	7	for	for	IN
cord-011310-fm578rm5	157	8	screen	screen	NN
cord-011310-fm578rm5	157	9	-	-	HYPH
cord-011310-fm578rm5	157	10	and	and	CC
cord-011310-fm578rm5	157	11	-	-	HYPH
cord-011310-fm578rm5	157	12	treat	treat	NN
cord-011310-fm578rm5	157	13	within	within	IN
cord-011310-fm578rm5	157	14	a	a	DT
cord-011310-fm578rm5	157	15	3-year	3-year	CD
cord-011310-fm578rm5	157	16	period	period	NN
cord-011310-fm578rm5	158	1	;	;	:
cord-011310-fm578rm5	158	2	70	70	CD
cord-011310-fm578rm5	158	3	%	%	NN
cord-011310-fm578rm5	158	4	compliance	compliance	NN
cord-011310-fm578rm5	158	5	agent	agent	NN
cord-011310-fm578rm5	158	6	could	could	MD
cord-011310-fm578rm5	158	7	also	also	RB
cord-011310-fm578rm5	158	8	eradicate	eradicate	VB
cord-011310-fm578rm5	158	9	H.	h.	NN
cord-011310-fm578rm5	158	10	pylori	pylori	NN
cord-011310-fm578rm5	158	11	without	without	IN
cord-011310-fm578rm5	158	12	affecting	affect	VBG
cord-011310-fm578rm5	158	13	the	the	DT
cord-011310-fm578rm5	158	14	other	other	JJ
cord-011310-fm578rm5	158	15	bacteria	bacteria	NNS
cord-011310-fm578rm5	158	16	(	(	-LRB-
cord-011310-fm578rm5	158	17	Lactobacillus	Lactobacillus	NNP
cord-011310-fm578rm5	158	18	,	,	,
cord-011310-fm578rm5	158	19	E.	E.	NNP
cord-011310-fm578rm5	158	20	coli	coli	NNS
cord-011310-fm578rm5	158	21	,	,	,
cord-011310-fm578rm5	158	22	S.	S.	NNP
cord-011310-fm578rm5	158	23	epidermidis	epidermidi	NNS
cord-011310-fm578rm5	158	24	and	and	CC
cord-011310-fm578rm5	158	25	S.	S.	NNP
cord-011310-fm578rm5	158	26	aureus	aureus	NN
cord-011310-fm578rm5	158	27	)	)	-RRB-
cord-011310-fm578rm5	159	1	[	[	-LRB-
cord-011310-fm578rm5	159	2	74	74	CD
cord-011310-fm578rm5	159	3	]	]	-RRB-
cord-011310-fm578rm5	159	4	.	.	.
cord-011310-fm578rm5	160	1	Since	since	IN
cord-011310-fm578rm5	160	2	the	the	DT
cord-011310-fm578rm5	160	3	abovementioned	abovementioned	JJ
cord-011310-fm578rm5	160	4	approaches	approach	NNS
cord-011310-fm578rm5	160	5	are	be	VBP
cord-011310-fm578rm5	160	6	still	still	RB
cord-011310-fm578rm5	160	7	far	far	RB
cord-011310-fm578rm5	160	8	from	from	IN
cord-011310-fm578rm5	160	9	clinical	clinical	JJ
cord-011310-fm578rm5	160	10	practice	practice	NN
cord-011310-fm578rm5	160	11	,	,	,
cord-011310-fm578rm5	160	12	regimens	regimen	NNS
cord-011310-fm578rm5	160	13	that	that	WDT
cord-011310-fm578rm5	160	14	are	be	VBP
cord-011310-fm578rm5	160	15	expected	expect	VBN
cord-011310-fm578rm5	160	16	to	to	TO
cord-011310-fm578rm5	160	17	interfere	interfere	VB
cord-011310-fm578rm5	160	18	less	less	RBR
cord-011310-fm578rm5	160	19	with	with	IN
cord-011310-fm578rm5	160	20	the	the	DT
cord-011310-fm578rm5	160	21	microbiota	microbiota	NN
cord-011310-fm578rm5	160	22	and	and	CC
cord-011310-fm578rm5	160	23	less	less	RBR
cord-011310-fm578rm5	160	24	likely	likely	JJ
cord-011310-fm578rm5	160	25	to	to	TO
cord-011310-fm578rm5	160	26	be	be	VB
cord-011310-fm578rm5	160	27	responsible	responsible	JJ
cord-011310-fm578rm5	160	28	for	for	IN
cord-011310-fm578rm5	160	29	gut	gut	NN
cord-011310-fm578rm5	160	30	(	(	-LRB-
cord-011310-fm578rm5	160	31	and	and	CC
cord-011310-fm578rm5	160	32	other	other	JJ
cord-011310-fm578rm5	160	33	location	location	NN
cord-011310-fm578rm5	160	34	)	)	-RRB-
cord-011310-fm578rm5	161	1	resistome	resistome	NNP
cord-011310-fm578rm5	161	2	development	development	NN
cord-011310-fm578rm5	161	3	are	be	VBP
cord-011310-fm578rm5	161	4	more	more	RBR
cord-011310-fm578rm5	161	5	attractive	attractive	JJ
cord-011310-fm578rm5	161	6	for	for	IN
cord-011310-fm578rm5	161	7	clinical	clinical	JJ
cord-011310-fm578rm5	161	8	applications	application	NNS
cord-011310-fm578rm5	161	9	in	in	IN
cord-011310-fm578rm5	161	10	the	the	DT
cord-011310-fm578rm5	161	11	near	near	JJ
cord-011310-fm578rm5	161	12	future	future	NN
cord-011310-fm578rm5	161	13	.	.	.
cord-011310-fm578rm5	162	1	Single	single	JJ
cord-011310-fm578rm5	162	2	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	162	3	regimens	regimen	NNS
cord-011310-fm578rm5	162	4	,	,	,
cord-011310-fm578rm5	162	5	in	in	IN
cord-011310-fm578rm5	162	6	particular	particular	JJ
cord-011310-fm578rm5	162	7	those	those	DT
cord-011310-fm578rm5	162	8	not	not	RB
cord-011310-fm578rm5	162	9	containing	contain	VBG
cord-011310-fm578rm5	162	10	macrolides	macrolide	NNS
cord-011310-fm578rm5	162	11	,	,	,
cord-011310-fm578rm5	162	12	could	could	MD
cord-011310-fm578rm5	162	13	attract	attract	VB
cord-011310-fm578rm5	162	14	interest	interest	NN
cord-011310-fm578rm5	162	15	in	in	IN
cord-011310-fm578rm5	162	16	this	this	DT
cord-011310-fm578rm5	162	17	respect	respect	NN
cord-011310-fm578rm5	162	18	.	.	.
cord-011310-fm578rm5	163	1	Use	use	NN
cord-011310-fm578rm5	163	2	of	of	IN
cord-011310-fm578rm5	163	3	high	high	JJ
cord-011310-fm578rm5	163	4	-	-	HYPH
cord-011310-fm578rm5	163	5	dose	dose	NN
cord-011310-fm578rm5	163	6	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	163	7	is	be	VBZ
cord-011310-fm578rm5	163	8	one	one	CD
cord-011310-fm578rm5	163	9	case	case	NN
cord-011310-fm578rm5	163	10	,	,	,
cord-011310-fm578rm5	163	11	although	although	IN
cord-011310-fm578rm5	163	12	more	more	RBR
cord-011310-fm578rm5	163	13	frequent	frequent	JJ
cord-011310-fm578rm5	163	14	dosing	dosing	NN
cord-011310-fm578rm5	163	15	is	be	VBZ
cord-011310-fm578rm5	163	16	required	require	VBN
cord-011310-fm578rm5	163	17	due	due	IN
cord-011310-fm578rm5	163	18	to	to	IN
cord-011310-fm578rm5	163	19	the	the	DT
cord-011310-fm578rm5	163	20	pharmacokinetics	pharmacokinetic	NNS
cord-011310-fm578rm5	163	21	of	of	IN
cord-011310-fm578rm5	163	22	this	this	DT
cord-011310-fm578rm5	163	23	drug	drug	NN
cord-011310-fm578rm5	163	24	.	.	.
cord-011310-fm578rm5	164	1	High	high	JJ
cord-011310-fm578rm5	164	2	-	-	HYPH
cord-011310-fm578rm5	164	3	dose	dose	NN
cord-011310-fm578rm5	164	4	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	164	5	-	-	HYPH
cord-011310-fm578rm5	164	6	based	base	VBN
cord-011310-fm578rm5	164	7	dual	dual	JJ
cord-011310-fm578rm5	164	8	therapy	therapy	NN
cord-011310-fm578rm5	164	9	for	for	IN
cord-011310-fm578rm5	164	10	first	first	JJ
cord-011310-fm578rm5	164	11	-	-	HYPH
cord-011310-fm578rm5	164	12	line	line	NN
cord-011310-fm578rm5	164	13	H.	h.	NN
cord-011310-fm578rm5	164	14	pylori	pylori	NN
cord-011310-fm578rm5	164	15	eradication	eradication	NN
cord-011310-fm578rm5	164	16	has	have	VBZ
cord-011310-fm578rm5	164	17	so	so	RB
cord-011310-fm578rm5	164	18	far	far	RB
cord-011310-fm578rm5	164	19	been	be	VBN
cord-011310-fm578rm5	164	20	evaluated	evaluate	VBN
cord-011310-fm578rm5	164	21	predominantly	predominantly	RB
cord-011310-fm578rm5	164	22	in	in	IN
cord-011310-fm578rm5	164	23	Asia	Asia	NNP
cord-011310-fm578rm5	164	24	[	[	-LRB-
cord-011310-fm578rm5	164	25	75	75	CD
cord-011310-fm578rm5	164	26	,	,	,
cord-011310-fm578rm5	164	27	76	76	CD
cord-011310-fm578rm5	164	28	]	]	-RRB-
cord-011310-fm578rm5	164	29	,	,	,
cord-011310-fm578rm5	164	30	although	although	IN
cord-011310-fm578rm5	164	31	a	a	DT
cord-011310-fm578rm5	164	32	pilot	pilot	NN
cord-011310-fm578rm5	164	33	study	study	NN
cord-011310-fm578rm5	164	34	has	have	VBZ
cord-011310-fm578rm5	164	35	been	be	VBN
cord-011310-fm578rm5	164	36	reported	report	VBN
cord-011310-fm578rm5	164	37	in	in	IN
cord-011310-fm578rm5	164	38	Europe	Europe	NNP
cord-011310-fm578rm5	164	39	[	[	-LRB-
cord-011310-fm578rm5	164	40	77	77	CD
cord-011310-fm578rm5	164	41	]	]	-RRB-
cord-011310-fm578rm5	164	42	.	.	.
cord-011310-fm578rm5	165	1	More	more	RBR
cord-011310-fm578rm5	165	2	profound	profound	JJ
cord-011310-fm578rm5	165	3	reduction	reduction	NN
cord-011310-fm578rm5	165	4	of	of	IN
cord-011310-fm578rm5	165	5	the	the	DT
cord-011310-fm578rm5	165	6	gastric	gastric	JJ
cord-011310-fm578rm5	165	7	acidity	acidity	NN
cord-011310-fm578rm5	165	8	also	also	RB
cord-011310-fm578rm5	165	9	could	could	MD
cord-011310-fm578rm5	165	10	contribute	contribute	VB
cord-011310-fm578rm5	165	11	to	to	IN
cord-011310-fm578rm5	165	12	a	a	DT
cord-011310-fm578rm5	165	13	higher	high	JJR
cord-011310-fm578rm5	165	14	effectiveness	effectiveness	NN
cord-011310-fm578rm5	165	15	of	of	IN
cord-011310-fm578rm5	165	16	the	the	DT
cord-011310-fm578rm5	165	17	therapy	therapy	NN
cord-011310-fm578rm5	165	18	.	.	.
cord-011310-fm578rm5	166	1	Sugimoto	Sugimoto	NNP
cord-011310-fm578rm5	166	2	and	and	CC
cord-011310-fm578rm5	166	3	Yamaoka	Yamaoka	NNP
cord-011310-fm578rm5	166	4	[	[	-LRB-
cord-011310-fm578rm5	166	5	64	64	CD
cord-011310-fm578rm5	166	6	]	]	-RRB-
cord-011310-fm578rm5	166	7	have	have	VBP
cord-011310-fm578rm5	166	8	recently	recently	RB
cord-011310-fm578rm5	166	9	reviewed	review	VBN
cord-011310-fm578rm5	166	10	the	the	DT
cord-011310-fm578rm5	166	11	effectiveness	effectiveness	NN
cord-011310-fm578rm5	166	12	of	of	IN
cord-011310-fm578rm5	166	13	PCAB	PCAB	NNP
cord-011310-fm578rm5	166	14	in	in	IN
cord-011310-fm578rm5	166	15	H.	H.	NNP
cord-011310-fm578rm5	166	16	pylori	pylori	NN
cord-011310-fm578rm5	166	17	eradication	eradication	NN
cord-011310-fm578rm5	166	18	therapies	therapy	NNS
cord-011310-fm578rm5	166	19	compared	compare	VBN
cord-011310-fm578rm5	166	20	to	to	IN
cord-011310-fm578rm5	166	21	the	the	DT
cord-011310-fm578rm5	166	22	traditional	traditional	JJ
cord-011310-fm578rm5	166	23	PPI	PPI	NNP
cord-011310-fm578rm5	166	24	containing	contain	VBG
cord-011310-fm578rm5	166	25	therapies	therapy	NNS
cord-011310-fm578rm5	166	26	,	,	,
cord-011310-fm578rm5	166	27	and	and	CC
cord-011310-fm578rm5	166	28	demonstrated	demonstrate	VBD
cord-011310-fm578rm5	166	29	significant	significant	JJ
cord-011310-fm578rm5	166	30	advantages	advantage	NNS
cord-011310-fm578rm5	166	31	of	of	IN
cord-011310-fm578rm5	166	32	the	the	DT
cord-011310-fm578rm5	166	33	PCAB	PCAB	NNP
cord-011310-fm578rm5	166	34	.	.	.
cord-011310-fm578rm5	167	1	Therefore	therefore	RB
cord-011310-fm578rm5	167	2	,	,	,
cord-011310-fm578rm5	167	3	one	one	CD
cord-011310-fm578rm5	167	4	directions	direction	NNS
cord-011310-fm578rm5	167	5	for	for	IN
cord-011310-fm578rm5	167	6	future	future	JJ
cord-011310-fm578rm5	167	7	therapies	therapy	NNS
cord-011310-fm578rm5	167	8	could	could	MD
cord-011310-fm578rm5	167	9	be	be	VB
cord-011310-fm578rm5	167	10	PCAB	PCAB	NNP
cord-011310-fm578rm5	167	11	and	and	CC
cord-011310-fm578rm5	167	12	high	high	JJ
cord-011310-fm578rm5	167	13	-	-	HYPH
cord-011310-fm578rm5	167	14	dose	dose	NN
cord-011310-fm578rm5	167	15	(	(	-LRB-
cord-011310-fm578rm5	167	16	multiple	multiple	JJ
cord-011310-fm578rm5	167	17	dose	dose	NN
cord-011310-fm578rm5	167	18	)	)	-RRB-
cord-011310-fm578rm5	167	19	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	167	20	in	in	IN
cord-011310-fm578rm5	167	21	combination	combination	NN
cord-011310-fm578rm5	167	22	.	.	.
cord-011310-fm578rm5	168	1	Another	another	DT
cord-011310-fm578rm5	168	2	approach	approach	NN
cord-011310-fm578rm5	168	3	would	would	MD
cord-011310-fm578rm5	168	4	be	be	VB
cord-011310-fm578rm5	168	5	the	the	DT
cord-011310-fm578rm5	168	6	use	use	NN
cord-011310-fm578rm5	168	7	of	of	IN
cord-011310-fm578rm5	168	8	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	168	9	agents	agent	NNS
cord-011310-fm578rm5	168	10	that	that	WDT
cord-011310-fm578rm5	168	11	are	be	VBP
cord-011310-fm578rm5	168	12	not	not	RB
cord-011310-fm578rm5	168	13	typically	typically	RB
cord-011310-fm578rm5	168	14	used	use	VBN
cord-011310-fm578rm5	168	15	in	in	IN
cord-011310-fm578rm5	168	16	managing	manage	VBG
cord-011310-fm578rm5	168	17	life	life	NN
cord-011310-fm578rm5	168	18	-	-	HYPH
cord-011310-fm578rm5	168	19	threatening	threaten	VBG
cord-011310-fm578rm5	168	20	disease	disease	NN
cord-011310-fm578rm5	168	21	,	,	,
cord-011310-fm578rm5	168	22	as	as	RB
cord-011310-fm578rm5	168	23	well	well	RB
cord-011310-fm578rm5	168	24	as	as	IN
cord-011310-fm578rm5	168	25	those	those	DT
cord-011310-fm578rm5	168	26	causing	cause	VBG
cord-011310-fm578rm5	168	27	less	less	JJR
cord-011310-fm578rm5	168	28	induction	induction	NN
cord-011310-fm578rm5	168	29	of	of	IN
cord-011310-fm578rm5	168	30	the	the	DT
cord-011310-fm578rm5	168	31	pool	pool	NN
cord-011310-fm578rm5	168	32	resistant	resistant	JJ
cord-011310-fm578rm5	168	33	genes	gene	NNS
cord-011310-fm578rm5	168	34	.	.	.
cord-011310-fm578rm5	169	1	Bismuth	Bismuth	NNP
cord-011310-fm578rm5	169	2	-	-	HYPH
cord-011310-fm578rm5	169	3	based	base	VBN
cord-011310-fm578rm5	169	4	therapies	therapy	NNS
cord-011310-fm578rm5	169	5	are	be	VBP
cord-011310-fm578rm5	169	6	mainly	mainly	RB
cord-011310-fm578rm5	169	7	used	use	VBN
cord-011310-fm578rm5	169	8	to	to	TO
cord-011310-fm578rm5	169	9	overcome	overcome	VB
cord-011310-fm578rm5	169	10	the	the	DT
cord-011310-fm578rm5	169	11	resistance	resistance	NN
cord-011310-fm578rm5	169	12	of	of	IN
cord-011310-fm578rm5	169	13	H.	H.	NNP
cord-011310-fm578rm5	169	14	pylori	pylori	NN
cord-011310-fm578rm5	169	15	to	to	TO
cord-011310-fm578rm5	169	16	commonly	commonly	RB
cord-011310-fm578rm5	169	17	used	use	VBN
cord-011310-fm578rm5	169	18	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	169	19	in	in	IN
cord-011310-fm578rm5	169	20	clinical	clinical	JJ
cord-011310-fm578rm5	169	21	settings	setting	NNS
cord-011310-fm578rm5	169	22	[	[	-LRB-
cord-011310-fm578rm5	169	23	10	10	CD
cord-011310-fm578rm5	169	24	,	,	,
cord-011310-fm578rm5	169	25	78	78	CD
cord-011310-fm578rm5	169	26	,	,	,
cord-011310-fm578rm5	169	27	79	79	CD
cord-011310-fm578rm5	169	28	]	]	-RRB-
cord-011310-fm578rm5	169	29	.	.	.
cord-011310-fm578rm5	170	1	An	an	DT
cord-011310-fm578rm5	170	2	additional	additional	JJ
cord-011310-fm578rm5	170	3	gain	gain	NN
cord-011310-fm578rm5	170	4	with	with	IN
cord-011310-fm578rm5	170	5	these	these	DT
cord-011310-fm578rm5	170	6	therapies	therapy	NNS
cord-011310-fm578rm5	170	7	is	be	VBZ
cord-011310-fm578rm5	170	8	avoiding	avoid	VBG
cord-011310-fm578rm5	170	9	the	the	DT
cord-011310-fm578rm5	170	10	use	use	NN
cord-011310-fm578rm5	170	11	of	of	IN
cord-011310-fm578rm5	170	12	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	170	13	and	and	CC
cord-011310-fm578rm5	170	14	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	170	15	.	.	.
cord-011310-fm578rm5	171	1	However	however	RB
cord-011310-fm578rm5	171	2	,	,	,
cord-011310-fm578rm5	171	3	bismuth	bismuth	NN
cord-011310-fm578rm5	171	4	is	be	VBZ
cord-011310-fm578rm5	171	5	not	not	RB
cord-011310-fm578rm5	171	6	available	available	JJ
cord-011310-fm578rm5	171	7	in	in	IN
cord-011310-fm578rm5	171	8	many	many	JJ
cord-011310-fm578rm5	171	9	countries	country	NNS
cord-011310-fm578rm5	171	10	.	.	.
cord-011310-fm578rm5	172	1	The	the	DT
cord-011310-fm578rm5	172	2	concern	concern	NN
cord-011310-fm578rm5	172	3	with	with	IN
cord-011310-fm578rm5	172	4	bismuth	bismuth	NN
cord-011310-fm578rm5	172	5	-	-	HYPH
cord-011310-fm578rm5	172	6	related	relate	VBN
cord-011310-fm578rm5	172	7	adverse	adverse	JJ
cord-011310-fm578rm5	172	8	events	event	NNS
cord-011310-fm578rm5	172	9	is	be	VBZ
cord-011310-fm578rm5	172	10	predominantly	predominantly	RB
cord-011310-fm578rm5	172	11	related	relate	VBN
cord-011310-fm578rm5	172	12	to	to	IN
cord-011310-fm578rm5	172	13	the	the	DT
cord-011310-fm578rm5	172	14	fact	fact	NN
cord-011310-fm578rm5	172	15	that	that	IN
cord-011310-fm578rm5	172	16	in	in	IN
cord-011310-fm578rm5	172	17	the	the	DT
cord-011310-fm578rm5	172	18	1970s	1970	NNS
cord-011310-fm578rm5	172	19	,	,	,
cord-011310-fm578rm5	172	20	use	use	NN
cord-011310-fm578rm5	172	21	of	of	IN
cord-011310-fm578rm5	172	22	high	high	JJ
cord-011310-fm578rm5	172	23	-	-	HYPH
cord-011310-fm578rm5	172	24	dose	dose	NN
cord-011310-fm578rm5	172	25	bismuth	bismuth	NN
cord-011310-fm578rm5	172	26	salts	salt	NNS
cord-011310-fm578rm5	172	27	for	for	IN
cord-011310-fm578rm5	172	28	long	long	JJ
cord-011310-fm578rm5	172	29	periods	period	NNS
cord-011310-fm578rm5	172	30	was	be	VBD
cord-011310-fm578rm5	172	31	associated	associate	VBN
cord-011310-fm578rm5	172	32	with	with	IN
cord-011310-fm578rm5	172	33	neurotoxicity	neurotoxicity	NN
cord-011310-fm578rm5	172	34	;	;	:
cord-011310-fm578rm5	172	35	however	however	RB
cord-011310-fm578rm5	172	36	,	,	,
cord-011310-fm578rm5	172	37	systemic	systemic	JJ
cord-011310-fm578rm5	172	38	review	review	NN
cord-011310-fm578rm5	172	39	and	and	CC
cord-011310-fm578rm5	172	40	meta	meta	NNP
cord-011310-fm578rm5	172	41	-	-	HYPH
cord-011310-fm578rm5	172	42	analysis	analysis	NN
cord-011310-fm578rm5	172	43	on	on	IN
cord-011310-fm578rm5	172	44	bismuth	bismuth	NN
cord-011310-fm578rm5	172	45	use	use	NN
cord-011310-fm578rm5	172	46	for	for	IN
cord-011310-fm578rm5	172	47	H.	h.	NN
cord-011310-fm578rm5	172	48	pylori	pylori	NN
cord-011310-fm578rm5	172	49	eradication	eradication	NN
cord-011310-fm578rm5	172	50	did	do	VBD
cord-011310-fm578rm5	172	51	not	not	RB
cord-011310-fm578rm5	172	52	reveal	reveal	VB
cord-011310-fm578rm5	172	53	serious	serious	JJ
cord-011310-fm578rm5	172	54	adverse	adverse	JJ
cord-011310-fm578rm5	172	55	events	event	NNS
cord-011310-fm578rm5	172	56	for	for	IN
cord-011310-fm578rm5	172	57	such	such	JJ
cord-011310-fm578rm5	172	58	therapy	therapy	NN
cord-011310-fm578rm5	172	59	[	[	-LRB-
cord-011310-fm578rm5	172	60	80	80	CD
cord-011310-fm578rm5	172	61	]	]	-RRB-
cord-011310-fm578rm5	172	62	.	.	.
cord-011310-fm578rm5	173	1	A	a	DT
cord-011310-fm578rm5	173	2	recent	recent	JJ
cord-011310-fm578rm5	173	3	meta	meta	JJ
cord-011310-fm578rm5	173	4	-	-	HYPH
cord-011310-fm578rm5	173	5	analysis	analysis	NN
cord-011310-fm578rm5	173	6	by	by	IN
cord-011310-fm578rm5	173	7	Ko	Ko	NNP
cord-011310-fm578rm5	173	8	et	et	NNP
cord-011310-fm578rm5	173	9	al	al	NNP
cord-011310-fm578rm5	173	10	.	.	.
cord-011310-fm578rm5	174	1	[	[	-LRB-
cord-011310-fm578rm5	174	2	81	81	CD
cord-011310-fm578rm5	174	3	]	]	-RRB-
cord-011310-fm578rm5	174	4	has	have	VBZ
cord-011310-fm578rm5	174	5	suggested	suggest	VBN
cord-011310-fm578rm5	174	6	the	the	DT
cord-011310-fm578rm5	174	7	superiority	superiority	NN
cord-011310-fm578rm5	174	8	of	of	IN
cord-011310-fm578rm5	174	9	bismuth	bismuth	NN
cord-011310-fm578rm5	174	10	-	-	HYPH
cord-011310-fm578rm5	174	11	containing	contain	VBG
cord-011310-fm578rm5	174	12	therapies	therapy	NNS
cord-011310-fm578rm5	174	13	over	over	IN
cord-011310-fm578rm5	174	14	nonbismuth	nonbismuth	NNP
cord-011310-fm578rm5	174	15	regimens	regimen	NNS
cord-011310-fm578rm5	174	16	;	;	:
cord-011310-fm578rm5	174	17	furthermore	furthermore	RB
cord-011310-fm578rm5	174	18	,	,	,
cord-011310-fm578rm5	174	19	adding	add	VBG
cord-011310-fm578rm5	174	20	bismuth	bismuth	NN
cord-011310-fm578rm5	174	21	to	to	IN
cord-011310-fm578rm5	174	22	conventional	conventional	JJ
cord-011310-fm578rm5	174	23	standard	standard	JJ
cord-011310-fm578rm5	174	24	eradication	eradication	NN
cord-011310-fm578rm5	174	25	regimens	regimen	NNS
cord-011310-fm578rm5	174	26	provides	provide	VBZ
cord-011310-fm578rm5	174	27	additional	additional	JJ
cord-011310-fm578rm5	174	28	gain	gain	NN
cord-011310-fm578rm5	174	29	in	in	IN
cord-011310-fm578rm5	174	30	the	the	DT
cord-011310-fm578rm5	174	31	efficacy	efficacy	NN
cord-011310-fm578rm5	174	32	of	of	IN
cord-011310-fm578rm5	174	33	the	the	DT
cord-011310-fm578rm5	174	34	therapies	therapy	NNS
cord-011310-fm578rm5	174	35	.	.	.
cord-011310-fm578rm5	175	1	Another	another	DT
cord-011310-fm578rm5	175	2	meta	meta	JJ
cord-011310-fm578rm5	175	3	-	-	HYPH
cord-011310-fm578rm5	175	4	analysis	analysis	NN
cord-011310-fm578rm5	175	5	on	on	IN
cord-011310-fm578rm5	175	6	a	a	DT
cord-011310-fm578rm5	175	7	single	single	JJ
cord-011310-fm578rm5	175	8	capsule	capsule	NN
cord-011310-fm578rm5	175	9	10-day	10-day	CD
cord-011310-fm578rm5	175	10	bismuth	bismuth	NN
cord-011310-fm578rm5	175	11	-	-	HYPH
cord-011310-fm578rm5	175	12	containing	contain	VBG
cord-011310-fm578rm5	175	13	quadruple	quadruple	JJ
cord-011310-fm578rm5	175	14	therapy	therapy	NN
cord-011310-fm578rm5	175	15	has	have	VBZ
cord-011310-fm578rm5	175	16	suggested	suggest	VBN
cord-011310-fm578rm5	175	17	~	~	CD
cord-011310-fm578rm5	175	18	90	90	CD
cord-011310-fm578rm5	175	19	%	%	NN
cord-011310-fm578rm5	175	20	eradication	eradication	NN
cord-011310-fm578rm5	175	21	success	success	NN
cord-011310-fm578rm5	175	22	both	both	CC
cord-011310-fm578rm5	175	23	in	in	IN
cord-011310-fm578rm5	175	24	first	first	JJ
cord-011310-fm578rm5	175	25	-	-	HYPH
cord-011310-fm578rm5	175	26	and	and	CC
cord-011310-fm578rm5	175	27	second	second	JJ
cord-011310-fm578rm5	175	28	-	-	HYPH
cord-011310-fm578rm5	175	29	line	line	NN
cord-011310-fm578rm5	175	30	therapy	therapy	NN
cord-011310-fm578rm5	175	31	[	[	-LRB-
cord-011310-fm578rm5	175	32	82	82	CD
cord-011310-fm578rm5	175	33	]	]	-RRB-
cord-011310-fm578rm5	175	34	.	.	.
cord-011310-fm578rm5	176	1	Short	short	JJ
cord-011310-fm578rm5	176	2	-	-	HYPH
cord-011310-fm578rm5	176	3	term	term	NN
cord-011310-fm578rm5	176	4	dysbiosis	dysbiosis	NN
cord-011310-fm578rm5	176	5	restoration	restoration	NN
cord-011310-fm578rm5	176	6	to	to	IN
cord-011310-fm578rm5	176	7	baseline	baseline	JJ
cord-011310-fm578rm5	176	8	levels	level	NNS
cord-011310-fm578rm5	176	9	within	within	IN
cord-011310-fm578rm5	176	10	an	an	DT
cord-011310-fm578rm5	176	11	8-week	8-week	CD
cord-011310-fm578rm5	176	12	period	period	NN
cord-011310-fm578rm5	176	13	following	follow	VBG
cord-011310-fm578rm5	176	14	14-day	14-day	CD
cord-011310-fm578rm5	176	15	bismuth	bismuth	NN
cord-011310-fm578rm5	176	16	quadruple	quadruple	JJ
cord-011310-fm578rm5	176	17	therapy	therapy	NN
cord-011310-fm578rm5	176	18	has	have	VBZ
cord-011310-fm578rm5	176	19	been	be	VBN
cord-011310-fm578rm5	176	20	reported	report	VBN
cord-011310-fm578rm5	176	21	from	from	IN
cord-011310-fm578rm5	176	22	Taiwan	Taiwan	NNP
cord-011310-fm578rm5	176	23	;	;	,
cord-011310-fm578rm5	176	24	16S	16S	NNP
cord-011310-fm578rm5	176	25	rRNA	rrna	NN
cord-011310-fm578rm5	176	26	gene	gene	NN
cord-011310-fm578rm5	176	27	sequencing	sequencing	NN
cord-011310-fm578rm5	176	28	of	of	IN
cord-011310-fm578rm5	176	29	the	the	DT
cord-011310-fm578rm5	176	30	V3-V4	V3-V4	NNP
cord-011310-fm578rm5	176	31	region	region	NN
cord-011310-fm578rm5	176	32	and	and	CC
cord-011310-fm578rm5	176	33	sampling	sampling	NN
cord-011310-fm578rm5	176	34	before	before	IN
cord-011310-fm578rm5	176	35	the	the	DT
cord-011310-fm578rm5	176	36	treatment	treatment	NN
cord-011310-fm578rm5	176	37	,	,	,
cord-011310-fm578rm5	176	38	as	as	RB
cord-011310-fm578rm5	176	39	well	well	RB
cord-011310-fm578rm5	176	40	as	as	IN
cord-011310-fm578rm5	176	41	2	2	CD
cord-011310-fm578rm5	176	42	,	,	,
cord-011310-fm578rm5	176	43	8	8	CD
cord-011310-fm578rm5	176	44	,	,	,
cord-011310-fm578rm5	176	45	and	and	CC
cord-011310-fm578rm5	176	46	48	48	CD
cord-011310-fm578rm5	176	47	weeks	week	NNS
cord-011310-fm578rm5	176	48	thereafter	thereafter	RB
cord-011310-fm578rm5	176	49	,	,	,
cord-011310-fm578rm5	176	50	was	be	VBD
cord-011310-fm578rm5	176	51	used	use	VBN
cord-011310-fm578rm5	176	52	[	[	-LRB-
cord-011310-fm578rm5	176	53	83	83	CD
cord-011310-fm578rm5	176	54	]	]	-RRB-
cord-011310-fm578rm5	176	55	.	.	.
cord-011310-fm578rm5	177	1	Therefore	therefore	RB
cord-011310-fm578rm5	177	2	,	,	,
cord-011310-fm578rm5	177	3	bismuth	bismuth	NN
cord-011310-fm578rm5	177	4	-	-	HYPH
cord-011310-fm578rm5	177	5	containing	contain	VBG
cord-011310-fm578rm5	177	6	quadruple	quadruple	JJ
cord-011310-fm578rm5	177	7	therapy	therapy	NN
cord-011310-fm578rm5	177	8	is	be	VBZ
cord-011310-fm578rm5	177	9	also	also	RB
cord-011310-fm578rm5	177	10	related	relate	VBN
cord-011310-fm578rm5	177	11	to	to	IN
cord-011310-fm578rm5	177	12	dysbiosis	dysbiosis	NN
cord-011310-fm578rm5	177	13	;	;	:
cord-011310-fm578rm5	177	14	other	other	JJ
cord-011310-fm578rm5	177	15	antibacterial	antibacterial	JJ
cord-011310-fm578rm5	177	16	agents	agent	NNS
cord-011310-fm578rm5	177	17	contained	contain	VBN
cord-011310-fm578rm5	177	18	in	in	IN
cord-011310-fm578rm5	177	19	this	this	DT
cord-011310-fm578rm5	177	20	treatment	treatment	NN
cord-011310-fm578rm5	177	21	,	,	,
cord-011310-fm578rm5	177	22	in	in	IN
cord-011310-fm578rm5	177	23	particular	particular	JJ
cord-011310-fm578rm5	177	24	metronidazole	metronidazole	NN
cord-011310-fm578rm5	177	25	,	,	,
cord-011310-fm578rm5	177	26	could	could	MD
cord-011310-fm578rm5	177	27	be	be	VB
cord-011310-fm578rm5	177	28	responsible	responsible	JJ
cord-011310-fm578rm5	177	29	for	for	IN
cord-011310-fm578rm5	177	30	perturbations	perturbation	NNS
cord-011310-fm578rm5	177	31	in	in	IN
cord-011310-fm578rm5	177	32	the	the	DT
cord-011310-fm578rm5	177	33	microbiota	microbiota	NN
cord-011310-fm578rm5	177	34	.	.	.
cord-011310-fm578rm5	178	1	There	there	EX
cord-011310-fm578rm5	178	2	are	be	VBP
cord-011310-fm578rm5	178	3	still	still	RB
cord-011310-fm578rm5	178	4	insufficient	insufficient	JJ
cord-011310-fm578rm5	178	5	data	datum	NNS
cord-011310-fm578rm5	178	6	on	on	IN
cord-011310-fm578rm5	178	7	the	the	DT
cord-011310-fm578rm5	178	8	potency	potency	NN
cord-011310-fm578rm5	178	9	of	of	IN
cord-011310-fm578rm5	178	10	bismuth	bismuth	NN
cord-011310-fm578rm5	178	11	-	-	HYPH
cord-011310-fm578rm5	178	12	based	base	VBN
cord-011310-fm578rm5	178	13	therapies	therapy	NNS
cord-011310-fm578rm5	178	14	to	to	TO
cord-011310-fm578rm5	178	15	induce	induce	VB
cord-011310-fm578rm5	178	16	and	and	CC
cord-011310-fm578rm5	178	17	cause	cause	VB
cord-011310-fm578rm5	178	18	persistent	persistent	JJ
cord-011310-fm578rm5	178	19	resistome	resistome	NNP
cord-011310-fm578rm5	178	20	.	.	.
cord-011310-fm578rm5	179	1	An	an	DT
cord-011310-fm578rm5	179	2	alternative	alternative	NN
cord-011310-fm578rm5	179	3	to	to	IN
cord-011310-fm578rm5	179	4	the	the	DT
cord-011310-fm578rm5	179	5	empiric	empiric	JJ
cord-011310-fm578rm5	179	6	eradication	eradication	NN
cord-011310-fm578rm5	179	7	regimen	regimen	NN
cord-011310-fm578rm5	179	8	is	be	VBZ
cord-011310-fm578rm5	179	9	a	a	DT
cord-011310-fm578rm5	179	10	H.	h.	NN
cord-011310-fm578rm5	179	11	pylori	pylori	NN
cord-011310-fm578rm5	179	12	susceptibility	susceptibility	NN
cord-011310-fm578rm5	179	13	-	-	HYPH
cord-011310-fm578rm5	179	14	based	base	VBN
cord-011310-fm578rm5	179	15	individual	individual	JJ
cord-011310-fm578rm5	179	16	therapy	therapy	NN
cord-011310-fm578rm5	179	17	.	.	.
cord-011310-fm578rm5	180	1	This	this	DT
cord-011310-fm578rm5	180	2	allows	allow	VBZ
cord-011310-fm578rm5	180	3	avoiding	avoid	VBG
cord-011310-fm578rm5	180	4	unnecessary	unnecessary	JJ
cord-011310-fm578rm5	180	5	use	use	NN
cord-011310-fm578rm5	180	6	of	of	IN
cord-011310-fm578rm5	180	7	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	180	8	and	and	CC
cord-011310-fm578rm5	180	9	increasing	increase	VBG
cord-011310-fm578rm5	180	10	the	the	DT
cord-011310-fm578rm5	180	11	effectiveness	effectiveness	NN
cord-011310-fm578rm5	180	12	of	of	IN
cord-011310-fm578rm5	180	13	the	the	DT
cord-011310-fm578rm5	180	14	treatment	treatment	NN
cord-011310-fm578rm5	180	15	[	[	-LRB-
cord-011310-fm578rm5	180	16	84	84	CD
cord-011310-fm578rm5	180	17	]	]	-RRB-
cord-011310-fm578rm5	180	18	.	.	.
cord-011310-fm578rm5	181	1	However	however	RB
cord-011310-fm578rm5	181	2	,	,	,
cord-011310-fm578rm5	181	3	this	this	DT
cord-011310-fm578rm5	181	4	is	be	VBZ
cord-011310-fm578rm5	181	5	considering	consider	VBG
cord-011310-fm578rm5	181	6	only	only	RB
cord-011310-fm578rm5	181	7	H.	h.	NN
cord-011310-fm578rm5	181	8	pylori	pylori	NN
cord-011310-fm578rm5	181	9	resistance	resistance	NN
cord-011310-fm578rm5	181	10	patterns	pattern	NNS
cord-011310-fm578rm5	181	11	,	,	,
cord-011310-fm578rm5	181	12	not	not	RB
cord-011310-fm578rm5	181	13	the	the	DT
cord-011310-fm578rm5	181	14	effects	effect	NNS
cord-011310-fm578rm5	181	15	upon	upon	IN
cord-011310-fm578rm5	181	16	the	the	DT
cord-011310-fm578rm5	181	17	other	other	JJ
cord-011310-fm578rm5	181	18	gut	gut	NN
cord-011310-fm578rm5	181	19	microbiome	microbiome	NN
cord-011310-fm578rm5	181	20	.	.	.
cord-011310-fm578rm5	182	1	Usually	usually	RB
cord-011310-fm578rm5	182	2	,	,	,
cord-011310-fm578rm5	182	3	even	even	RB
cord-011310-fm578rm5	182	4	after	after	IN
cord-011310-fm578rm5	182	5	H.	H.	NNP
cord-011310-fm578rm5	182	6	pylori	pylori	NN
cord-011310-fm578rm5	182	7	resistance	resistance	NN
cord-011310-fm578rm5	182	8	testing	testing	NN
cord-011310-fm578rm5	182	9	,	,	,
cord-011310-fm578rm5	182	10	several	several	JJ
cord-011310-fm578rm5	182	11	options	option	NNS
cord-011310-fm578rm5	182	12	for	for	IN
cord-011310-fm578rm5	182	13	eradication	eradication	NN
cord-011310-fm578rm5	182	14	therapies	therapy	NNS
cord-011310-fm578rm5	182	15	are	be	VBP
cord-011310-fm578rm5	182	16	remaining	remain	VBG
cord-011310-fm578rm5	182	17	,	,	,
cord-011310-fm578rm5	182	18	and	and	CC
cord-011310-fm578rm5	182	19	lower	low	JJR
cord-011310-fm578rm5	182	20	negative	negative	JJ
cord-011310-fm578rm5	182	21	effects	effect	NNS
cord-011310-fm578rm5	182	22	upon	upon	IN
cord-011310-fm578rm5	182	23	the	the	DT
cord-011310-fm578rm5	182	24	gut	gut	NN
cord-011310-fm578rm5	182	25	microbiome	microbiome	NN
cord-011310-fm578rm5	182	26	should	should	MD
cord-011310-fm578rm5	182	27	ideally	ideally	RB
cord-011310-fm578rm5	182	28	considered	consider	VBN
cord-011310-fm578rm5	182	29	to	to	TO
cord-011310-fm578rm5	182	30	be	be	VB
cord-011310-fm578rm5	182	31	the	the	DT
cord-011310-fm578rm5	182	32	choice	choice	NN
cord-011310-fm578rm5	182	33	.	.	.
cord-011310-fm578rm5	183	1	Finally	finally	RB
cord-011310-fm578rm5	183	2	,	,	,
cord-011310-fm578rm5	183	3	narrowing	narrow	VBG
cord-011310-fm578rm5	183	4	the	the	DT
cord-011310-fm578rm5	183	5	target	target	NN
cord-011310-fm578rm5	183	6	group	group	NN
cord-011310-fm578rm5	183	7	for	for	IN
cord-011310-fm578rm5	183	8	H.	H.	NNP
cord-011310-fm578rm5	183	9	pylori	pylori	NN
cord-011310-fm578rm5	183	10	eradication	eradication	NN
cord-011310-fm578rm5	183	11	,	,	,
cord-011310-fm578rm5	183	12	e.g.	e.g.	RB
cord-011310-fm578rm5	183	13	by	by	IN
cord-011310-fm578rm5	183	14	targeting	target	VBG
cord-011310-fm578rm5	183	15	young	young	JJ
cord-011310-fm578rm5	183	16	adults	adult	NNS
cord-011310-fm578rm5	183	17	before	before	IN
cord-011310-fm578rm5	183	18	family	family	NN
cord-011310-fm578rm5	183	19	planning	planning	NN
cord-011310-fm578rm5	183	20	and	and	CC
cord-011310-fm578rm5	183	21	,	,	,
cord-011310-fm578rm5	183	22	therefore	therefore	RB
cord-011310-fm578rm5	183	23	,	,	,
cord-011310-fm578rm5	183	24	before	before	IN
cord-011310-fm578rm5	183	25	the	the	DT
cord-011310-fm578rm5	183	26	potential	potential	JJ
cord-011310-fm578rm5	183	27	transmission	transmission	NN
cord-011310-fm578rm5	183	28	of	of	IN
cord-011310-fm578rm5	183	29	the	the	DT
cord-011310-fm578rm5	183	30	infection	infection	NN
cord-011310-fm578rm5	183	31	to	to	IN
cord-011310-fm578rm5	183	32	offspring	offspring	NN
cord-011310-fm578rm5	183	33	,	,	,
cord-011310-fm578rm5	183	34	could	could	MD
cord-011310-fm578rm5	183	35	be	be	VB
cord-011310-fm578rm5	183	36	another	another	DT
cord-011310-fm578rm5	183	37	approach	approach	NN
cord-011310-fm578rm5	183	38	in	in	IN
cord-011310-fm578rm5	183	39	decreasing	decrease	VBG
cord-011310-fm578rm5	183	40	the	the	DT
cord-011310-fm578rm5	183	41	misuse	misuse	NN
cord-011310-fm578rm5	183	42	of	of	IN
cord-011310-fm578rm5	183	43	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	183	44	.	.	.
cord-011310-fm578rm5	184	1	In	in	IN
cord-011310-fm578rm5	184	2	spite	spite	NN
cord-011310-fm578rm5	184	3	of	of	IN
cord-011310-fm578rm5	184	4	the	the	DT
cord-011310-fm578rm5	184	5	failures	failure	NNS
cord-011310-fm578rm5	184	6	mentioned	mention	VBN
cord-011310-fm578rm5	184	7	above	above	RB
cord-011310-fm578rm5	184	8	,	,	,
cord-011310-fm578rm5	184	9	individual	individual	JJ
cord-011310-fm578rm5	184	10	risk	risk	NN
cord-011310-fm578rm5	184	11	stratification	stratification	NN
cord-011310-fm578rm5	184	12	based	base	VBN
cord-011310-fm578rm5	184	13	on	on	IN
cord-011310-fm578rm5	184	14	gender	gender	NN
cord-011310-fm578rm5	184	15	,	,	,
cord-011310-fm578rm5	184	16	lifestyle	lifestyle	NN
cord-011310-fm578rm5	184	17	factors	factor	NNS
cord-011310-fm578rm5	184	18	,	,	,
cord-011310-fm578rm5	184	19	host	host	NN
cord-011310-fm578rm5	184	20	and	and	CC
cord-011310-fm578rm5	184	21	H.	H.	NNP
cord-011310-fm578rm5	184	22	pylori	pylori	NN
cord-011310-fm578rm5	184	23	genetics	genetic	NNS
cord-011310-fm578rm5	184	24	continue	continue	VBP
cord-011310-fm578rm5	184	25	to	to	TO
cord-011310-fm578rm5	184	26	be	be	VB
cord-011310-fm578rm5	184	27	of	of	IN
cord-011310-fm578rm5	184	28	interest	interest	NN
cord-011310-fm578rm5	184	29	in	in	IN
cord-011310-fm578rm5	184	30	risk	risk	NN
cord-011310-fm578rm5	184	31	stratification	stratification	NN
cord-011310-fm578rm5	184	32	.	.	.
cord-011310-fm578rm5	185	1	Several	several	JJ
cord-011310-fm578rm5	185	2	meta	meta	JJ
cord-011310-fm578rm5	185	3	-	-	HYPH
cord-011310-fm578rm5	185	4	analyses	analysis	NNS
cord-011310-fm578rm5	185	5	have	have	VBP
cord-011310-fm578rm5	185	6	suggested	suggest	VBN
cord-011310-fm578rm5	185	7	convincing	convincing	JJ
cord-011310-fm578rm5	185	8	cost	cost	NN
cord-011310-fm578rm5	185	9	-	-	HYPH
cord-011310-fm578rm5	185	10	effectiveness	effectiveness	NN
cord-011310-fm578rm5	185	11	of	of	IN
cord-011310-fm578rm5	185	12	population	population	NN
cord-011310-fm578rm5	185	13	-	-	HYPH
cord-011310-fm578rm5	185	14	wide	wide	JJ
cord-011310-fm578rm5	185	15	H.	h.	NN
cord-011310-fm578rm5	185	16	pylori	pylori	NN
cord-011310-fm578rm5	185	17	eradication	eradication	NN
cord-011310-fm578rm5	185	18	[	[	-LRB-
cord-011310-fm578rm5	185	19	85	85	CD
cord-011310-fm578rm5	185	20	]	]	-RRB-
cord-011310-fm578rm5	185	21	[	[	-LRB-
cord-011310-fm578rm5	185	22	86	86	CD
cord-011310-fm578rm5	185	23	]	]	-RRB-
cord-011310-fm578rm5	185	24	[	[	-LRB-
cord-011310-fm578rm5	185	25	87	87	CD
cord-011310-fm578rm5	185	26	]	]	-RRB-
cord-011310-fm578rm5	185	27	.	.	.
cord-011310-fm578rm5	186	1	The	the	DT
cord-011310-fm578rm5	186	2	benefit	benefit	NN
cord-011310-fm578rm5	186	3	is	be	VBZ
cord-011310-fm578rm5	186	4	likely	likely	JJ
cord-011310-fm578rm5	186	5	to	to	TO
cord-011310-fm578rm5	186	6	be	be	VB
cord-011310-fm578rm5	186	7	highest	high	JJS
cord-011310-fm578rm5	186	8	in	in	IN
cord-011310-fm578rm5	186	9	communities	community	NNS
cord-011310-fm578rm5	186	10	with	with	IN
cord-011310-fm578rm5	186	11	a	a	DT
cord-011310-fm578rm5	186	12	high	high	JJ
cord-011310-fm578rm5	186	13	risk	risk	NN
cord-011310-fm578rm5	186	14	of	of	IN
cord-011310-fm578rm5	186	15	gastric	gastric	JJ
cord-011310-fm578rm5	186	16	cancer	cancer	NN
cord-011310-fm578rm5	186	17	;	;	:
cord-011310-fm578rm5	186	18	in	in	IN
cord-011310-fm578rm5	186	19	developed	develop	VBN
cord-011310-fm578rm5	186	20	countries	country	NNS
cord-011310-fm578rm5	186	21	,	,	,
cord-011310-fm578rm5	186	22	such	such	PDT
cord-011310-fm578rm5	186	23	an	an	DT
cord-011310-fm578rm5	186	24	approach	approach	NN
cord-011310-fm578rm5	186	25	could	could	MD
cord-011310-fm578rm5	186	26	be	be	VB
cord-011310-fm578rm5	186	27	either	either	CC
cord-011310-fm578rm5	186	28	cost	cost	NN
cord-011310-fm578rm5	186	29	-	-	HYPH
cord-011310-fm578rm5	186	30	effective	effective	JJ
cord-011310-fm578rm5	186	31	or	or	CC
cord-011310-fm578rm5	186	32	cost	cost	NN
cord-011310-fm578rm5	186	33	-	-	HYPH
cord-011310-fm578rm5	186	34	neutral	neutral	JJ
cord-011310-fm578rm5	186	35	if	if	IN
cord-011310-fm578rm5	186	36	considered	consider	VBN
cord-011310-fm578rm5	186	37	on	on	IN
cord-011310-fm578rm5	186	38	the	the	DT
cord-011310-fm578rm5	186	39	positive	positive	JJ
cord-011310-fm578rm5	186	40	side	side	NN
cord-011310-fm578rm5	186	41	in	in	IN
cord-011310-fm578rm5	186	42	reducing	reduce	VBG
cord-011310-fm578rm5	186	43	the	the	DT
cord-011310-fm578rm5	186	44	cost	cost	NN
cord-011310-fm578rm5	186	45	of	of	IN
cord-011310-fm578rm5	186	46	dyspepsia	dyspepsia	NN
cord-011310-fm578rm5	186	47	treatment	treatment	NN
cord-011310-fm578rm5	186	48	[	[	-LRB-
cord-011310-fm578rm5	186	49	11	11	CD
cord-011310-fm578rm5	186	50	]	]	-RRB-
cord-011310-fm578rm5	186	51	.	.	.
cord-011310-fm578rm5	187	1	Few	few	JJ
cord-011310-fm578rm5	187	2	other	other	JJ
cord-011310-fm578rm5	187	3	cost	cost	NN
cord-011310-fm578rm5	187	4	-	-	HYPH
cord-011310-fm578rm5	187	5	effectiveness	effectiveness	NN
cord-011310-fm578rm5	187	6	studies	study	NNS
cord-011310-fm578rm5	187	7	have	have	VBP
cord-011310-fm578rm5	187	8	since	since	IN
cord-011310-fm578rm5	187	9	been	be	VBN
cord-011310-fm578rm5	187	10	published	publish	VBN
cord-011310-fm578rm5	187	11	.	.	.
cord-011310-fm578rm5	188	1	In	in	IN
cord-011310-fm578rm5	188	2	Denmark	Denmark	NNP
cord-011310-fm578rm5	188	3	,	,	,
cord-011310-fm578rm5	188	4	a	a	DT
cord-011310-fm578rm5	188	5	low	low	JJ
cord-011310-fm578rm5	188	6	H.	h.	NN
cord-011310-fm578rm5	188	7	pylori	pylori	NN
cord-011310-fm578rm5	188	8	prevalence	prevalence	NN
cord-011310-fm578rm5	188	9	country	country	NN
cord-011310-fm578rm5	188	10	,	,	,
cord-011310-fm578rm5	188	11	a	a	DT
cord-011310-fm578rm5	188	12	13-year	13-year	JJ
cord-011310-fm578rm5	188	13	follow	follow	NN
cord-011310-fm578rm5	188	14	-	-	HYPH
cord-011310-fm578rm5	188	15	up	up	NN
cord-011310-fm578rm5	188	16	of	of	IN
cord-011310-fm578rm5	188	17	a	a	DT
cord-011310-fm578rm5	188	18	randomized	randomized	JJ
cord-011310-fm578rm5	188	19	study	study	NN
cord-011310-fm578rm5	188	20	population	population	NN
cord-011310-fm578rm5	188	21	(	(	-LRB-
cord-011310-fm578rm5	188	22	20,011	20,011	CD
cord-011310-fm578rm5	188	23	individuals	individual	NNS
cord-011310-fm578rm5	188	24	aged	age	VBN
cord-011310-fm578rm5	188	25	40	40	CD
cord-011310-fm578rm5	188	26	-	-	SYM
cord-011310-fm578rm5	188	27	65	65	CD
cord-011310-fm578rm5	188	28	years	year	NNS
cord-011310-fm578rm5	188	29	at	at	IN
cord-011310-fm578rm5	188	30	enrollment	enrollment	NN
cord-011310-fm578rm5	188	31	)	)	-RRB-
cord-011310-fm578rm5	188	32	failed	fail	VBD
cord-011310-fm578rm5	188	33	to	to	TO
cord-011310-fm578rm5	188	34	achieve	achieve	VB
cord-011310-fm578rm5	188	35	either	either	CC
cord-011310-fm578rm5	188	36	quality	quality	NN
cord-011310-fm578rm5	188	37	-	-	HYPH
cord-011310-fm578rm5	188	38	of	of	IN
cord-011310-fm578rm5	188	39	-	-	HYPH
cord-011310-fm578rm5	188	40	life	life	NN
cord-011310-fm578rm5	188	41	or	or	CC
cord-011310-fm578rm5	188	42	cost	cost	NN
cord-011310-fm578rm5	188	43	-	-	HYPH
cord-011310-fm578rm5	188	44	effectiveness	effectiveness	NN
cord-011310-fm578rm5	188	45	[	[	-LRB-
cord-011310-fm578rm5	188	46	88	88	CD
cord-011310-fm578rm5	188	47	]	]	-RRB-
cord-011310-fm578rm5	188	48	,	,	,
cord-011310-fm578rm5	188	49	whereas	whereas	IN
cord-011310-fm578rm5	188	50	a	a	DT
cord-011310-fm578rm5	188	51	modelling	modelling	NN
cord-011310-fm578rm5	188	52	exercise	exercise	NN
cord-011310-fm578rm5	188	53	in	in	IN
cord-011310-fm578rm5	188	54	China	China	NNP
cord-011310-fm578rm5	188	55	proved	prove	VBD
cord-011310-fm578rm5	188	56	cost	cost	NN
cord-011310-fm578rm5	188	57	-	-	HYPH
cord-011310-fm578rm5	188	58	effective	effective	JJ
cord-011310-fm578rm5	188	59	in	in	IN
cord-011310-fm578rm5	188	60	a	a	DT
cord-011310-fm578rm5	188	61	population	population	NN
cord-011310-fm578rm5	188	62	-	-	HYPH
cord-011310-fm578rm5	188	63	based	base	VBN
cord-011310-fm578rm5	188	64	screen	screen	NN
cord-011310-fm578rm5	188	65	-	-	HYPH
cord-011310-fm578rm5	188	66	and	and	CC
cord-011310-fm578rm5	188	67	-	-	HYPH
cord-011310-fm578rm5	188	68	treat	treat	VB
cord-011310-fm578rm5	188	69	strategy	strategy	NN
cord-011310-fm578rm5	188	70	related	relate	VBN
cord-011310-fm578rm5	188	71	to	to	IN
cord-011310-fm578rm5	188	72	gastric	gastric	JJ
cord-011310-fm578rm5	188	73	cancer	cancer	NN
cord-011310-fm578rm5	188	74	,	,	,
cord-011310-fm578rm5	188	75	peptic	peptic	JJ
cord-011310-fm578rm5	188	76	ulcer	ulcer	NN
cord-011310-fm578rm5	188	77	disease	disease	NN
cord-011310-fm578rm5	188	78	and	and	CC
cord-011310-fm578rm5	188	79	dyspepsia	dyspepsia	JJ
cord-011310-fm578rm5	188	80	reduction	reduction	NN
cord-011310-fm578rm5	188	81	.	.	.
cord-011310-fm578rm5	189	1	Furthermore	furthermore	RB
cord-011310-fm578rm5	189	2	,	,	,
cord-011310-fm578rm5	189	3	the	the	DT
cord-011310-fm578rm5	189	4	highest	high	JJS
cord-011310-fm578rm5	189	5	effectiveness	effectiveness	NN
cord-011310-fm578rm5	189	6	was	be	VBD
cord-011310-fm578rm5	189	7	in	in	IN
cord-011310-fm578rm5	189	8	the	the	DT
cord-011310-fm578rm5	189	9	age	age	NN
cord-011310-fm578rm5	189	10	group	group	NN
cord-011310-fm578rm5	189	11	of	of	IN
cord-011310-fm578rm5	189	12	20	20	CD
cord-011310-fm578rm5	189	13	years	year	NNS
cord-011310-fm578rm5	189	14	[	[	-LRB-
cord-011310-fm578rm5	189	15	89	89	CD
cord-011310-fm578rm5	189	16	]	]	-RRB-
cord-011310-fm578rm5	189	17	.	.	.
cord-011310-fm578rm5	190	1	Screen	screen	NN
cord-011310-fm578rm5	190	2	-	-	HYPH
cord-011310-fm578rm5	190	3	and	and	CC
cord-011310-fm578rm5	190	4	-	-	HYPH
cord-011310-fm578rm5	190	5	treat	treat	NN
cord-011310-fm578rm5	190	6	has	have	VBZ
cord-011310-fm578rm5	190	7	also	also	RB
cord-011310-fm578rm5	190	8	been	be	VBN
cord-011310-fm578rm5	190	9	estimated	estimate	VBN
cord-011310-fm578rm5	190	10	as	as	IN
cord-011310-fm578rm5	190	11	cost	cost	NN
cord-011310-fm578rm5	190	12	-	-	HYPH
cord-011310-fm578rm5	190	13	effective	effective	JJ
cord-011310-fm578rm5	190	14	for	for	IN
cord-011310-fm578rm5	190	15	employees	employee	NNS
cord-011310-fm578rm5	190	16	in	in	IN
cord-011310-fm578rm5	190	17	Japan	Japan	NNP
cord-011310-fm578rm5	190	18	[	[	-LRB-
cord-011310-fm578rm5	190	19	90	90	CD
cord-011310-fm578rm5	190	20	]	]	-RRB-
cord-011310-fm578rm5	190	21	.	.	.
cord-011310-fm578rm5	191	1	However	however	RB
cord-011310-fm578rm5	191	2	,	,	,
cord-011310-fm578rm5	191	3	these	these	DT
cord-011310-fm578rm5	191	4	studies	study	NNS
cord-011310-fm578rm5	191	5	have	have	VBP
cord-011310-fm578rm5	191	6	not	not	RB
cord-011310-fm578rm5	191	7	considered	consider	VBN
cord-011310-fm578rm5	191	8	the	the	DT
cord-011310-fm578rm5	191	9	potential	potential	JJ
cord-011310-fm578rm5	191	10	costs	cost	NNS
cord-011310-fm578rm5	191	11	associated	associate	VBN
cord-011310-fm578rm5	191	12	to	to	IN
cord-011310-fm578rm5	191	13	the	the	DT
cord-011310-fm578rm5	191	14	increase	increase	NN
cord-011310-fm578rm5	191	15	in	in	IN
cord-011310-fm578rm5	191	16	the	the	DT
cord-011310-fm578rm5	191	17	pool	pool	NN
cord-011310-fm578rm5	191	18	of	of	IN
cord-011310-fm578rm5	191	19	resistant	resistant	JJ
cord-011310-fm578rm5	191	20	bacteria	bacteria	NNS
cord-011310-fm578rm5	191	21	.	.	.
cord-011310-fm578rm5	192	1	The	the	DT
cord-011310-fm578rm5	192	2	real	real	JJ
cord-011310-fm578rm5	192	3	costs	cost	NNS
cord-011310-fm578rm5	192	4	behind	behind	IN
cord-011310-fm578rm5	192	5	the	the	DT
cord-011310-fm578rm5	192	6	resistome	resistome	NNP
cord-011310-fm578rm5	192	7	are	be	VBP
cord-011310-fm578rm5	192	8	difficult	difficult	JJ
cord-011310-fm578rm5	192	9	to	to	TO
cord-011310-fm578rm5	192	10	estimate	estimate	VB
cord-011310-fm578rm5	192	11	;	;	:
cord-011310-fm578rm5	192	12	at	at	RB
cord-011310-fm578rm5	192	13	least	least	RBS
cord-011310-fm578rm5	192	14	two	two	CD
cord-011310-fm578rm5	192	15	major	major	JJ
cord-011310-fm578rm5	192	16	issues	issue	NNS
cord-011310-fm578rm5	192	17	must	must	MD
cord-011310-fm578rm5	192	18	be	be	VB
cord-011310-fm578rm5	192	19	considered	consider	VBN
cord-011310-fm578rm5	192	20	:	:	:
cord-011310-fm578rm5	192	21	1	1	LS
cord-011310-fm578rm5	192	22	)	)	-RRB-
cord-011310-fm578rm5	192	23	cost	cost	NN
cord-011310-fm578rm5	192	24	of	of	IN
cord-011310-fm578rm5	192	25	the	the	DT
cord-011310-fm578rm5	192	26	resistance	resistance	NN
cord-011310-fm578rm5	192	27	and	and	CC
cord-011310-fm578rm5	192	28	2	2	LS
cord-011310-fm578rm5	192	29	)	)	-RRB-
cord-011310-fm578rm5	192	30	cost	cost	NN
cord-011310-fm578rm5	192	31	-	-	HYPH
cord-011310-fm578rm5	192	32	effectiveness	effectiveness	NN
cord-011310-fm578rm5	192	33	of	of	IN
cord-011310-fm578rm5	192	34	interventions	intervention	NNS
cord-011310-fm578rm5	192	35	to	to	TO
cord-011310-fm578rm5	192	36	reduce	reduce	VB
cord-011310-fm578rm5	192	37	it	-PRON-	PRP
cord-011310-fm578rm5	192	38	[	[	-LRB-
cord-011310-fm578rm5	192	39	91	91	CD
cord-011310-fm578rm5	192	40	]	]	-RRB-
cord-011310-fm578rm5	192	41	.	.	.
cord-011310-fm578rm5	193	1	There	there	EX
cord-011310-fm578rm5	193	2	is	be	VBZ
cord-011310-fm578rm5	193	3	also	also	RB
cord-011310-fm578rm5	193	4	a	a	DT
cord-011310-fm578rm5	193	5	huge	huge	JJ
cord-011310-fm578rm5	193	6	range	range	NN
cord-011310-fm578rm5	193	7	in	in	IN
cord-011310-fm578rm5	193	8	the	the	DT
cord-011310-fm578rm5	193	9	estimates	estimate	NNS
cord-011310-fm578rm5	193	10	of	of	IN
cord-011310-fm578rm5	193	11	additional	additional	JJ
cord-011310-fm578rm5	193	12	cost	cost	NN
cord-011310-fm578rm5	193	13	,	,	,
cord-011310-fm578rm5	193	14	varying	vary	VBG
cord-011310-fm578rm5	193	15	from	from	IN
cord-011310-fm578rm5	193	16	<	<	XX
cord-011310-fm578rm5	193	17	$	$	$
cord-011310-fm578rm5	193	18	5	5	CD
cord-011310-fm578rm5	193	19	to	to	IN
cord-011310-fm578rm5	193	20	>	>	XX
cord-011310-fm578rm5	193	21	$	$	$
cord-011310-fm578rm5	193	22	55,000	55,000	CD
cord-011310-fm578rm5	193	23	per	per	IN
cord-011310-fm578rm5	193	24	patient	patient	JJ
cord-011310-fm578rm5	193	25	episode	episode	NN
cord-011310-fm578rm5	193	26	[	[	-LRB-
cord-011310-fm578rm5	193	27	91	91	CD
cord-011310-fm578rm5	193	28	]	]	-RRB-
cord-011310-fm578rm5	193	29	.	.	.
cord-011310-fm578rm5	194	1	However	however	RB
cord-011310-fm578rm5	194	2	,	,	,
cord-011310-fm578rm5	194	3	generally	generally	RB
cord-011310-fm578rm5	194	4	the	the	DT
cord-011310-fm578rm5	194	5	current	current	JJ
cord-011310-fm578rm5	194	6	costings	costing	NNS
cord-011310-fm578rm5	194	7	could	could	MD
cord-011310-fm578rm5	194	8	be	be	VB
cord-011310-fm578rm5	194	9	an	an	DT
cord-011310-fm578rm5	194	10	underestimated	underestimated	JJ
cord-011310-fm578rm5	194	11	,	,	,
cord-011310-fm578rm5	194	12	and	and	CC
cord-011310-fm578rm5	194	13	therefore	therefore	RB
cord-011310-fm578rm5	194	14	,	,	,
cord-011310-fm578rm5	194	15	interventions	intervention	NNS
cord-011310-fm578rm5	194	16	in	in	IN
cord-011310-fm578rm5	194	17	using	use	VBG
cord-011310-fm578rm5	194	18	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	194	19	on	on	IN
cord-011310-fm578rm5	194	20	a	a	DT
cord-011310-fm578rm5	194	21	wide	wide	JJ
cord-011310-fm578rm5	194	22	-	-	HYPH
cord-011310-fm578rm5	194	23	scale	scale	NN
cord-011310-fm578rm5	194	24	could	could	MD
cord-011310-fm578rm5	194	25	reflect	reflect	VB
cord-011310-fm578rm5	194	26	as	as	IN
cord-011310-fm578rm5	194	27	highly	highly	RB
cord-011310-fm578rm5	194	28	cost	cost	NN
cord-011310-fm578rm5	194	29	-	-	HYPH
cord-011310-fm578rm5	194	30	saving	save	VBG
cord-011310-fm578rm5	194	31	benefit	benefit	NN
cord-011310-fm578rm5	194	32	.	.	.
cord-011310-fm578rm5	195	1	The	the	DT
cord-011310-fm578rm5	195	2	hidden	hidden	JJ
cord-011310-fm578rm5	195	3	costs	cost	NNS
cord-011310-fm578rm5	195	4	of	of	IN
cord-011310-fm578rm5	195	5	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	195	6	resistance	resistance	NN
cord-011310-fm578rm5	195	7	in	in	IN
cord-011310-fm578rm5	195	8	the	the	DT
cord-011310-fm578rm5	195	9	United	United	NNP
cord-011310-fm578rm5	195	10	States	States	NNP
cord-011310-fm578rm5	195	11	have	have	VBP
cord-011310-fm578rm5	195	12	recently	recently	RB
cord-011310-fm578rm5	195	13	been	be	VBN
cord-011310-fm578rm5	195	14	estimated	estimate	VBN
cord-011310-fm578rm5	195	15	by	by	IN
cord-011310-fm578rm5	195	16	Michaelidis	Michaelidis	NNP
cord-011310-fm578rm5	195	17	et	et	NNP
cord-011310-fm578rm5	195	18	al	al	NNP
cord-011310-fm578rm5	195	19	.	.	.
cord-011310-fm578rm5	196	1	[	[	-LRB-
cord-011310-fm578rm5	196	2	92	92	CD
cord-011310-fm578rm5	196	3	]	]	-RRB-
cord-011310-fm578rm5	196	4	who	who	WP
cord-011310-fm578rm5	196	5	considered	consider	VBD
cord-011310-fm578rm5	196	6	:	:	:
cord-011310-fm578rm5	196	7	(	(	-LRB-
cord-011310-fm578rm5	196	8	1	1	LS
cord-011310-fm578rm5	196	9	)	)	-RRB-
cord-011310-fm578rm5	196	10	hospitalization	hospitalization	NN
cord-011310-fm578rm5	196	11	costs	cost	NNS
cord-011310-fm578rm5	196	12	;	;	,
cord-011310-fm578rm5	196	13	(	(	-LRB-
cord-011310-fm578rm5	196	14	2	2	LS
cord-011310-fm578rm5	196	15	)	)	-RRB-
cord-011310-fm578rm5	196	16	secondline	secondline	JJ
cord-011310-fm578rm5	196	17	inpatient	inpatient	JJ
cord-011310-fm578rm5	196	18	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	196	19	costs	cost	NNS
cord-011310-fm578rm5	196	20	;	;	,
cord-011310-fm578rm5	196	21	(	(	-LRB-
cord-011310-fm578rm5	196	22	3	3	LS
cord-011310-fm578rm5	196	23	)	)	-RRB-
cord-011310-fm578rm5	196	24	second	second	JJ
cord-011310-fm578rm5	196	25	-	-	HYPH
cord-011310-fm578rm5	196	26	line	line	NN
cord-011310-fm578rm5	196	27	out	out	IN
cord-011310-fm578rm5	196	28	-	-	HYPH
cord-011310-fm578rm5	196	29	patient	patient	NN
cord-011310-fm578rm5	196	30	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	196	31	costs	cost	NNS
cord-011310-fm578rm5	196	32	,	,	,
cord-011310-fm578rm5	196	33	and	and	CC
cord-011310-fm578rm5	196	34	(	(	-LRB-
cord-011310-fm578rm5	196	35	4	4	LS
cord-011310-fm578rm5	196	36	)	)	-RRB-
cord-011310-fm578rm5	196	37	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	196	38	stewardship	stewardship	NN
cord-011310-fm578rm5	196	39	costs	cost	NNS
cord-011310-fm578rm5	196	40	.	.	.
cord-011310-fm578rm5	197	1	The	the	DT
cord-011310-fm578rm5	197	2	authors	author	NNS
cord-011310-fm578rm5	197	3	estimated	estimate	VBD
cord-011310-fm578rm5	197	4	that	that	IN
cord-011310-fm578rm5	197	5	the	the	DT
cord-011310-fm578rm5	197	6	total	total	JJ
cord-011310-fm578rm5	197	7	hidden	hide	VBN
cord-011310-fm578rm5	197	8	cost	cost	NN
cord-011310-fm578rm5	197	9	attributable	attributable	JJ
cord-011310-fm578rm5	197	10	to	to	IN
cord-011310-fm578rm5	197	11	each	each	DT
cord-011310-fm578rm5	197	12	ambulatory	ambulatory	JJ
cord-011310-fm578rm5	197	13	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	197	14	prescription	prescription	NN
cord-011310-fm578rm5	197	15	was	be	VBD
cord-011310-fm578rm5	197	16	$	$	$
cord-011310-fm578rm5	197	17	13	13	CD
cord-011310-fm578rm5	197	18	(	(	-LRB-
cord-011310-fm578rm5	197	19	range	range	NN
cord-011310-fm578rm5	197	20	:	:	:
cord-011310-fm578rm5	197	21	$	$	$
cord-011310-fm578rm5	197	22	3	3	CD
cord-011310-fm578rm5	197	23	-	-	SYM
cord-011310-fm578rm5	197	24	95	95	CD
cord-011310-fm578rm5	197	25	)	)	-RRB-
cord-011310-fm578rm5	197	26	,	,	,
cord-011310-fm578rm5	197	27	and	and	CC
cord-011310-fm578rm5	197	28	each	each	DT
cord-011310-fm578rm5	197	29	ambulatory	ambulatory	JJ
cord-011310-fm578rm5	197	30	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	197	31	prescription	prescription	NN
cord-011310-fm578rm5	197	32	would	would	MD
cord-011310-fm578rm5	197	33	increase	increase	VB
cord-011310-fm578rm5	197	34	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	197	35	costs	cost	NNS
cord-011310-fm578rm5	197	36	by	by	IN
cord-011310-fm578rm5	197	37	65	65	CD
cord-011310-fm578rm5	197	38	%	%	NN
cord-011310-fm578rm5	197	39	(	(	-LRB-
cord-011310-fm578rm5	197	40	range	range	NN
cord-011310-fm578rm5	197	41	:	:	:
cord-011310-fm578rm5	197	42	15	15	CD
cord-011310-fm578rm5	197	43	-	-	SYM
cord-011310-fm578rm5	197	44	475	475	CD
cord-011310-fm578rm5	197	45	%	%	NN
cord-011310-fm578rm5	197	46	)	)	-RRB-
cord-011310-fm578rm5	197	47	,	,	,
cord-011310-fm578rm5	197	48	if	if	IN
cord-011310-fm578rm5	197	49	the	the	DT
cord-011310-fm578rm5	197	50	cost	cost	NN
cord-011310-fm578rm5	197	51	of	of	IN
cord-011310-fm578rm5	197	52	the	the	DT
cord-011310-fm578rm5	197	53	resistance	resistance	NN
cord-011310-fm578rm5	197	54	was	be	VBD
cord-011310-fm578rm5	197	55	incorporated	incorporate	VBN
cord-011310-fm578rm5	197	56	into	into	IN
cord-011310-fm578rm5	197	57	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	197	58	costs	cost	NNS
cord-011310-fm578rm5	197	59	paid	pay	VBN
cord-011310-fm578rm5	197	60	by	by	IN
cord-011310-fm578rm5	197	61	patients	patient	NNS
cord-011310-fm578rm5	197	62	or	or	CC
cord-011310-fm578rm5	197	63	payers	payer	NNS
cord-011310-fm578rm5	197	64	[	[	-LRB-
cord-011310-fm578rm5	197	65	92	92	CD
cord-011310-fm578rm5	197	66	]	]	-RRB-
cord-011310-fm578rm5	197	67	.	.	.
cord-011310-fm578rm5	198	1	Applying	apply	VBG
cord-011310-fm578rm5	198	2	this	this	DT
cord-011310-fm578rm5	198	3	estimate	estimate	NN
cord-011310-fm578rm5	198	4	to	to	IN
cord-011310-fm578rm5	198	5	the	the	DT
cord-011310-fm578rm5	198	6	cost	cost	NN
cord-011310-fm578rm5	198	7	-	-	HYPH
cord-011310-fm578rm5	198	8	effectiveness	effectiveness	NN
cord-011310-fm578rm5	198	9	estimates	estimate	NNS
cord-011310-fm578rm5	198	10	of	of	IN
cord-011310-fm578rm5	198	11	H.	h.	NN
cord-011310-fm578rm5	198	12	pylori	pylori	NN
cord-011310-fm578rm5	198	13	eradication	eradication	NN
cord-011310-fm578rm5	198	14	and	and	CC
cord-011310-fm578rm5	198	15	modelling	model	VBG
cord-011310-fm578rm5	198	16	the	the	DT
cord-011310-fm578rm5	198	17	costs	cost	NNS
cord-011310-fm578rm5	198	18	of	of	IN
cord-011310-fm578rm5	198	19	resistome	resistome	VBN
cord-011310-fm578rm5	198	20	for	for	IN
cord-011310-fm578rm5	198	21	other	other	JJ
cord-011310-fm578rm5	198	22	countries	country	NNS
cord-011310-fm578rm5	198	23	globally	globally	RB
cord-011310-fm578rm5	198	24	probably	probably	RB
cord-011310-fm578rm5	198	25	would	would	MD
cord-011310-fm578rm5	198	26	change	change	VB
cord-011310-fm578rm5	198	27	the	the	DT
cord-011310-fm578rm5	198	28	very	very	RB
cord-011310-fm578rm5	198	29	beneficial	beneficial	JJ
cord-011310-fm578rm5	198	30	cost	cost	NN
cord-011310-fm578rm5	198	31	-	-	HYPH
cord-011310-fm578rm5	198	32	effectiveness	effectiveness	NN
cord-011310-fm578rm5	198	33	picture	picture	NN
cord-011310-fm578rm5	198	34	of	of	IN
cord-011310-fm578rm5	198	35	screen	screen	NN
cord-011310-fm578rm5	198	36	-	-	HYPH
cord-011310-fm578rm5	198	37	and	and	CC
cord-011310-fm578rm5	198	38	-	-	HYPH
cord-011310-fm578rm5	198	39	treat	treat	VB
cord-011310-fm578rm5	198	40	strategy	strategy	NN
cord-011310-fm578rm5	198	41	.	.	.
cord-011310-fm578rm5	199	1	The	the	DT
cord-011310-fm578rm5	199	2	cost	cost	NN
cord-011310-fm578rm5	199	3	-	-	HYPH
cord-011310-fm578rm5	199	4	effectiveness	effectiveness	NN
cord-011310-fm578rm5	199	5	estimates	estimate	NNS
cord-011310-fm578rm5	199	6	should	should	MD
cord-011310-fm578rm5	199	7	also	also	RB
cord-011310-fm578rm5	199	8	incorporate	incorporate	VB
cord-011310-fm578rm5	199	9	those	those	DT
cord-011310-fm578rm5	199	10	of	of	IN
cord-011310-fm578rm5	199	11	organizing	organize	VBG
cord-011310-fm578rm5	199	12	the	the	DT
cord-011310-fm578rm5	199	13	activities	activity	NNS
cord-011310-fm578rm5	199	14	and	and	CC
cord-011310-fm578rm5	199	15	governance	governance	NN
cord-011310-fm578rm5	199	16	of	of	IN
cord-011310-fm578rm5	199	17	the	the	DT
cord-011310-fm578rm5	199	18	process	process	NN
cord-011310-fm578rm5	199	19	,	,	,
cord-011310-fm578rm5	199	20	exactly	exactly	RB
cord-011310-fm578rm5	199	21	as	as	IN
cord-011310-fm578rm5	199	22	in	in	IN
cord-011310-fm578rm5	199	23	traditional	traditional	JJ
cord-011310-fm578rm5	199	24	cancer	cancer	NN
cord-011310-fm578rm5	199	25	screening	screening	NN
cord-011310-fm578rm5	199	26	program	program	NN
cord-011310-fm578rm5	199	27	settings	setting	NNS
cord-011310-fm578rm5	199	28	[	[	-LRB-
cord-011310-fm578rm5	199	29	93	93	CD
cord-011310-fm578rm5	199	30	]	]	-RRB-
cord-011310-fm578rm5	199	31	.	.	.
cord-011310-fm578rm5	200	1	Finally	finally	RB
cord-011310-fm578rm5	200	2	,	,	,
cord-011310-fm578rm5	200	3	compliance	compliance	NN
cord-011310-fm578rm5	200	4	rates	rate	NNS
cord-011310-fm578rm5	200	5	of	of	IN
cord-011310-fm578rm5	200	6	the	the	DT
cord-011310-fm578rm5	200	7	target	target	NN
cord-011310-fm578rm5	200	8	population	population	NN
cord-011310-fm578rm5	200	9	,	,	,
cord-011310-fm578rm5	200	10	equal	equal	JJ
cord-011310-fm578rm5	200	11	participation	participation	NN
cord-011310-fm578rm5	200	12	of	of	IN
cord-011310-fm578rm5	200	13	both	both	DT
cord-011310-fm578rm5	200	14	genders	gender	NNS
cord-011310-fm578rm5	200	15	and	and	CC
cord-011310-fm578rm5	200	16	coverage	coverage	NN
cord-011310-fm578rm5	200	17	of	of	IN
cord-011310-fm578rm5	200	18	the	the	DT
cord-011310-fm578rm5	200	19	lower	low	JJR
cord-011310-fm578rm5	200	20	socioeconomic	socioeconomic	JJ
cord-011310-fm578rm5	200	21	class	class	NN
cord-011310-fm578rm5	200	22	members	member	NNS
cord-011310-fm578rm5	200	23	is	be	VBZ
cord-011310-fm578rm5	200	24	critical	critical	JJ
cord-011310-fm578rm5	200	25	for	for	IN
cord-011310-fm578rm5	200	26	the	the	DT
cord-011310-fm578rm5	200	27	success	success	NN
cord-011310-fm578rm5	200	28	for	for	IN
cord-011310-fm578rm5	200	29	any	any	DT
cord-011310-fm578rm5	200	30	preventive	preventive	JJ
cord-011310-fm578rm5	200	31	strategy	strategy	NN
cord-011310-fm578rm5	200	32	,	,	,
cord-011310-fm578rm5	200	33	and	and	CC
cord-011310-fm578rm5	200	34	should	should	MD
cord-011310-fm578rm5	200	35	be	be	VB
cord-011310-fm578rm5	200	36	considered	consider	VBN
cord-011310-fm578rm5	200	37	in	in	IN
cord-011310-fm578rm5	200	38	cost	cost	NN
cord-011310-fm578rm5	200	39	-	-	HYPH
cord-011310-fm578rm5	200	40	effectiveness	effectiveness	NN
cord-011310-fm578rm5	200	41	modelling	modelling	NN
cord-011310-fm578rm5	200	42	.	.	.
cord-011310-fm578rm5	201	1	Because	because	IN
cord-011310-fm578rm5	201	2	of	of	IN
cord-011310-fm578rm5	201	3	the	the	DT
cord-011310-fm578rm5	201	4	necessity	necessity	NN
cord-011310-fm578rm5	201	5	of	of	IN
cord-011310-fm578rm5	201	6	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	201	7	use	use	NN
cord-011310-fm578rm5	201	8	and	and	CC
cord-011310-fm578rm5	201	9	potential	potential	JJ
cord-011310-fm578rm5	201	10	adverse	adverse	JJ
cord-011310-fm578rm5	201	11	events	event	NNS
cord-011310-fm578rm5	201	12	,	,	,
cord-011310-fm578rm5	201	13	participation	participation	NN
cord-011310-fm578rm5	201	14	rates	rate	NNS
cord-011310-fm578rm5	201	15	could	could	MD
cord-011310-fm578rm5	201	16	be	be	VB
cord-011310-fm578rm5	201	17	lower	low	JJR
cord-011310-fm578rm5	201	18	for	for	IN
cord-011310-fm578rm5	201	19	an	an	DT
cord-011310-fm578rm5	201	20	H.	h.	NN
cord-011310-fm578rm5	201	21	pylori	pylori	NN
cord-011310-fm578rm5	201	22	screen	screen	NN
cord-011310-fm578rm5	201	23	-	-	HYPH
cord-011310-fm578rm5	201	24	and	and	CC
cord-011310-fm578rm5	201	25	-	-	HYPH
cord-011310-fm578rm5	201	26	treat	treat	VB
cord-011310-fm578rm5	201	27	strategy	strategy	NN
cord-011310-fm578rm5	201	28	than	than	IN
cord-011310-fm578rm5	201	29	for	for	IN
cord-011310-fm578rm5	201	30	traditional	traditional	JJ
cord-011310-fm578rm5	201	31	screening	screening	NN
cord-011310-fm578rm5	201	32	approaches	approach	NNS
cord-011310-fm578rm5	201	33	.	.	.
cord-011310-fm578rm5	202	1	This	this	DT
cord-011310-fm578rm5	202	2	has	have	VBZ
cord-011310-fm578rm5	202	3	been	be	VBN
cord-011310-fm578rm5	202	4	suggested	suggest	VBN
cord-011310-fm578rm5	202	5	by	by	IN
cord-011310-fm578rm5	202	6	the	the	DT
cord-011310-fm578rm5	202	7	participation	participation	NN
cord-011310-fm578rm5	202	8	results	result	NNS
cord-011310-fm578rm5	202	9	in	in	IN
cord-011310-fm578rm5	202	10	the	the	DT
cord-011310-fm578rm5	202	11	Danish	danish	JJ
cord-011310-fm578rm5	202	12	community	community	NN
cord-011310-fm578rm5	202	13	H.	h.	NN
cord-011310-fm578rm5	202	14	pylori	pylori	NN
cord-011310-fm578rm5	202	15	screening	screening	NN
cord-011310-fm578rm5	202	16	trial	trial	NN
cord-011310-fm578rm5	202	17	[	[	-LRB-
cord-011310-fm578rm5	202	18	94	94	CD
cord-011310-fm578rm5	202	19	]	]	-RRB-
cord-011310-fm578rm5	203	1	and	and	CC
cord-011310-fm578rm5	203	2	is	be	VBZ
cord-011310-fm578rm5	203	3	currently	currently	RB
cord-011310-fm578rm5	203	4	being	be	VBG
cord-011310-fm578rm5	203	5	addressed	address	VBN
cord-011310-fm578rm5	203	6	in	in	IN
cord-011310-fm578rm5	203	7	the	the	DT
cord-011310-fm578rm5	203	8	GISTAR	GISTAR	NNP
cord-011310-fm578rm5	203	9	cohort	cohort	NN
cord-011310-fm578rm5	203	10	in	in	IN
cord-011310-fm578rm5	203	11	Latvia	Latvia	NNP
cord-011310-fm578rm5	203	12	[	[	-LRB-
cord-011310-fm578rm5	203	13	95	95	CD
cord-011310-fm578rm5	203	14	]	]	-RRB-
cord-011310-fm578rm5	203	15	.	.	.
cord-011310-fm578rm5	204	1	The	the	DT
cord-011310-fm578rm5	204	2	Screen	screen	NN
cord-011310-fm578rm5	204	3	-	-	HYPH
cord-011310-fm578rm5	204	4	and	and	CC
cord-011310-fm578rm5	204	5	-	-	HYPH
cord-011310-fm578rm5	204	6	treat	treat	VB
cord-011310-fm578rm5	204	7	strategy	strategy	NN
cord-011310-fm578rm5	204	8	clearly	clearly	RB
cord-011310-fm578rm5	204	9	increases	increase	VBZ
cord-011310-fm578rm5	204	10	the	the	DT
cord-011310-fm578rm5	204	11	consumption	consumption	NN
cord-011310-fm578rm5	204	12	of	of	IN
cord-011310-fm578rm5	204	13	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	204	14	on	on	IN
cord-011310-fm578rm5	204	15	a	a	DT
cord-011310-fm578rm5	204	16	population	population	NN
cord-011310-fm578rm5	204	17	level	level	NN
cord-011310-fm578rm5	204	18	.	.	.
cord-011310-fm578rm5	205	1	In	in	IN
cord-011310-fm578rm5	205	2	avoiding	avoid	VBG
cord-011310-fm578rm5	205	3	the	the	DT
cord-011310-fm578rm5	205	4	problems	problem	NNS
cord-011310-fm578rm5	205	5	of	of	IN
cord-011310-fm578rm5	205	6	treating	treat	VBG
cord-011310-fm578rm5	205	7	life	life	NN
cord-011310-fm578rm5	205	8	-	-	HYPH
cord-011310-fm578rm5	205	9	threatening	threaten	VBG
cord-011310-fm578rm5	205	10	diseases	disease	NNS
cord-011310-fm578rm5	205	11	due	due	JJ
cord-011310-fm578rm5	205	12	to	to	IN
cord-011310-fm578rm5	205	13	increased	increase	VBN
cord-011310-fm578rm5	205	14	resistome	resistome	NNP
cord-011310-fm578rm5	205	15	,	,	,
cord-011310-fm578rm5	205	16	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	205	17	with	with	IN
cord-011310-fm578rm5	205	18	high	high	JJ
cord-011310-fm578rm5	205	19	potential	potential	NN
cord-011310-fm578rm5	205	20	for	for	IN
cord-011310-fm578rm5	205	21	resistome	resistome	JJ
cord-011310-fm578rm5	205	22	induction	induction	NN
cord-011310-fm578rm5	205	23	,	,	,
cord-011310-fm578rm5	205	24	and	and	CC
cord-011310-fm578rm5	205	25	use	use	VB
cord-011310-fm578rm5	205	26	for	for	IN
cord-011310-fm578rm5	205	27	treating	treat	VBG
cord-011310-fm578rm5	205	28	life	life	NN
cord-011310-fm578rm5	205	29	-	-	HYPH
cord-011310-fm578rm5	205	30	threatening	threaten	VBG
cord-011310-fm578rm5	205	31	diseases	disease	NNS
cord-011310-fm578rm5	205	32	(	(	-LRB-
cord-011310-fm578rm5	205	33	such	such	JJ
cord-011310-fm578rm5	205	34	as	as	IN
cord-011310-fm578rm5	205	35	macrolides	macrolide	NNS
cord-011310-fm578rm5	205	36	)	)	-RRB-
cord-011310-fm578rm5	205	37	should	should	MD
cord-011310-fm578rm5	205	38	be	be	VB
cord-011310-fm578rm5	205	39	avoided	avoid	VBN
cord-011310-fm578rm5	205	40	in	in	IN
cord-011310-fm578rm5	205	41	populationbased	populationbased	JJ
cord-011310-fm578rm5	205	42	H.	H.	NNP
cord-011310-fm578rm5	205	43	pylori	pylori	NN
cord-011310-fm578rm5	205	44	eradication	eradication	NN
cord-011310-fm578rm5	205	45	regimens	regimen	NNS
cord-011310-fm578rm5	205	46	for	for	IN
cord-011310-fm578rm5	205	47	otherwise	otherwise	RB
cord-011310-fm578rm5	205	48	healthy	healthy	JJ
cord-011310-fm578rm5	205	49	people	people	NNS
cord-011310-fm578rm5	205	50	.	.	.
cord-011310-fm578rm5	206	1	Narrowing	narrow	VBG
cord-011310-fm578rm5	206	2	of	of	IN
cord-011310-fm578rm5	206	3	the	the	DT
cord-011310-fm578rm5	206	4	target	target	NN
cord-011310-fm578rm5	206	5	groups	group	NNS
cord-011310-fm578rm5	206	6	for	for	IN
cord-011310-fm578rm5	206	7	the	the	DT
cord-011310-fm578rm5	206	8	screen	screen	NN
cord-011310-fm578rm5	206	9	-	-	HYPH
cord-011310-fm578rm5	206	10	andtreat	andtreat	NN
cord-011310-fm578rm5	206	11	strategy	strategy	NN
cord-011310-fm578rm5	206	12	is	be	VBZ
cord-011310-fm578rm5	206	13	desirable	desirable	JJ
cord-011310-fm578rm5	206	14	,	,	,
cord-011310-fm578rm5	206	15	e.g.	e.g.	RB
cord-011310-fm578rm5	206	16	for	for	IN
cord-011310-fm578rm5	206	17	young	young	JJ
cord-011310-fm578rm5	206	18	people	people	NNS
cord-011310-fm578rm5	206	19	before	before	IN
cord-011310-fm578rm5	206	20	family	family	NN
cord-011310-fm578rm5	206	21	planning	planning	NN
cord-011310-fm578rm5	206	22	and	and	CC
cord-011310-fm578rm5	206	23	potential	potential	JJ
cord-011310-fm578rm5	206	24	transmission	transmission	NN
cord-011310-fm578rm5	206	25	of	of	IN
cord-011310-fm578rm5	206	26	H.	h.	NN
cord-011310-fm578rm5	206	27	pylori	pylori	NN
cord-011310-fm578rm5	206	28	to	to	IN
cord-011310-fm578rm5	206	29	their	-PRON-	PRP$
cord-011310-fm578rm5	206	30	offspring	offspring	NN
cord-011310-fm578rm5	206	31	.	.	.
cord-011310-fm578rm5	207	1	Finally	finally	RB
cord-011310-fm578rm5	207	2	,	,	,
cord-011310-fm578rm5	207	3	in	in	IN
cord-011310-fm578rm5	207	4	implementing	implement	VBG
cord-011310-fm578rm5	207	5	any	any	DT
cord-011310-fm578rm5	207	6	screen	screen	NN
cord-011310-fm578rm5	207	7	-	-	HYPH
cord-011310-fm578rm5	207	8	and	and	CC
cord-011310-fm578rm5	207	9	-	-	HYPH
cord-011310-fm578rm5	207	10	treat	treat	VB
cord-011310-fm578rm5	207	11	strategy	strategy	NN
cord-011310-fm578rm5	207	12	,	,	,
cord-011310-fm578rm5	207	13	this	this	DT
cord-011310-fm578rm5	207	14	should	should	MD
cord-011310-fm578rm5	207	15	be	be	VB
cord-011310-fm578rm5	207	16	done	do	VBN
cord-011310-fm578rm5	207	17	under	under	IN
cord-011310-fm578rm5	207	18	thorough	thorough	JJ
cord-011310-fm578rm5	207	19	surveillance	surveillance	NN
cord-011310-fm578rm5	207	20	corresponding	correspond	VBG
cord-011310-fm578rm5	207	21	to	to	IN
cord-011310-fm578rm5	207	22	the	the	DT
cord-011310-fm578rm5	207	23	general	general	JJ
cord-011310-fm578rm5	207	24	principles	principle	NNS
cord-011310-fm578rm5	207	25	of	of	IN
cord-011310-fm578rm5	207	26	screening	screening	NN
cord-011310-fm578rm5	207	27	governance	governance	NN
cord-011310-fm578rm5	207	28	,	,	,
cord-011310-fm578rm5	207	29	including	include	VBG
cord-011310-fm578rm5	207	30	surveillance	surveillance	NN
cord-011310-fm578rm5	207	31	of	of	IN
cord-011310-fm578rm5	207	32	the	the	DT
cord-011310-fm578rm5	207	33	incidence	incidence	NN
cord-011310-fm578rm5	207	34	of	of	IN
cord-011310-fm578rm5	207	35	serious	serious	JJ
cord-011310-fm578rm5	207	36	infections	infection	NNS
cord-011310-fm578rm5	207	37	and	and	CC
cord-011310-fm578rm5	207	38	all	all	DT
cord-011310-fm578rm5	207	39	-	-	HYPH
cord-011310-fm578rm5	207	40	cause	cause	NN
cord-011310-fm578rm5	207	41	mortality	mortality	NN
cord-011310-fm578rm5	207	42	.	.	.
cord-011310-fm578rm5	208	1	fr/	fr/	JJ
cord-011310-fm578rm5	209	1	Book	book	NN
cord-011310-fm578rm5	209	2	-	-	HYPH
cord-011310-fm578rm5	209	3	And	and	CC
cord-011310-fm578rm5	209	4	-	-	HYPH
cord-011310-fm578rm5	209	5	Repor	Repor	NNP
cord-011310-fm578rm5	209	6	t	t	NN
cord-011310-fm578rm5	209	7	-	-	HYPH
cord-011310-fm578rm5	209	8	Serie	Serie	NNP
cord-011310-fm578rm5	209	9	s	s	NNP
cord-011310-fm578rm5	209	10	/	/	SYM
cord-011310-fm578rm5	209	11	Iarc	Iarc	NNP
cord-011310-fm578rm5	210	1	-Worki	-Worki	:
cord-011310-fm578rm5	210	2	ng	ng	NNP
cord-011310-fm578rm5	210	3	-	-	HYPH
cord-011310-fm578rm5	210	4	Group	Group	NNP
cord-011310-fm578rm5	211	1	-Repor	-Repor	NNP
cord-011310-fm578rm5	211	2	ts/-Em	ts/-Em	NNP
cord-011310-fm578rm5	211	3	-	-	HYPH
cord-011310-fm578rm5	211	4	Helic	Helic	NNP
cord-011310-fm578rm5	211	5	obact	obact	NN
cord-011310-fm578rm5	211	6	er	er	JJ
cord-011310-fm578rm5	211	7	-	-	HYPH
cord-011310-fm578rm5	211	8	Pylor	Pylor	NNP
cord-011310-fm578rm5	211	9	i	i	NNP
cord-011310-fm578rm5	211	10	-	-	HYPH
cord-011310-fm578rm5	211	11	Em	Em	NNP
cord-011310-fm578rm5	211	12	-	-	HYPH
cord-011310-fm578rm5	211	13	Eradi	Eradi	NNP
cord-011310-fm578rm5	212	1	catio	catio	NNP
cord-011310-fm578rm5	212	2	n	n	NNP
cord-011310-fm578rm5	212	3	-	-	HYPH
cord-011310-fm578rm5	212	4	As	as	IN
cord-011310-fm578rm5	212	5	-	-	HYPH
cord-011310-fm578rm5	212	6	A	A	NNP
cord-011310-fm578rm5	212	7	-	-	HYPH
cord-011310-fm578rm5	212	8	Strat	Strat	NNP
cord-011310-fm578rm5	212	9	egy	egy	NNP
cord-011310-fm578rm5	212	10	-	-	HYPH
cord-011310-fm578rm5	212	11	For	for	IN
cord-011310-fm578rm5	212	12	-	-	HYPH
cord-011310-fm578rm5	212	13	Preve	Preve	NNP
cord-011310-fm578rm5	212	14	nting	nting	NN
cord-011310-fm578rm5	212	15	-Gastr	-gastr	NN
cord-011310-fm578rm5	212	16	ic	ic	NNP
cord-011310-fm578rm5	212	17	-	-	HYPH
cord-011310-fm578rm5	212	18	Cance	Cance	NNP
cord-011310-fm578rm5	212	19	r-2014	r-2014	VBZ
cord-011310-fm578rm5	212	20	Global	global	JJ
cord-011310-fm578rm5	212	21	cancer	cancer	NN
cord-011310-fm578rm5	212	22	statistics	statistic	NNS
cord-011310-fm578rm5	212	23	2018	2018	CD
cord-011310-fm578rm5	212	24	:	:	:
cord-011310-fm578rm5	213	1	GLOBOCAN	GLOBOCAN	NNP
cord-011310-fm578rm5	213	2	estimates	estimate	VBZ
cord-011310-fm578rm5	213	3	of	of	IN
cord-011310-fm578rm5	213	4	incidence	incidence	NN
cord-011310-fm578rm5	213	5	and	and	CC
cord-011310-fm578rm5	213	6	mortality	mortality	NN
cord-011310-fm578rm5	213	7	worldwide	worldwide	RB
cord-011310-fm578rm5	213	8	for	for	IN
cord-011310-fm578rm5	213	9	36	36	CD
cord-011310-fm578rm5	213	10	cancers	cancer	NNS
cord-011310-fm578rm5	213	11	in	in	IN
cord-011310-fm578rm5	213	12	185	185	CD
cord-011310-fm578rm5	213	13	countries	country	NNS
cord-011310-fm578rm5	213	14	fr	fr	NNP
cord-011310-fm578rm5	213	15	/	/	SYM
cord-011310-fm578rm5	213	16	Book	Book	NNP
cord-011310-fm578rm5	213	17	-	-	HYPH
cord-011310-fm578rm5	213	18	And	and	CC
cord-011310-fm578rm5	213	19	-	-	HYPH
cord-011310-fm578rm5	213	20	Repor	Repor	NNP
cord-011310-fm578rm5	214	1	t-	t-	XX
cord-011310-fm578rm5	215	1	Serie	Serie	NNP
cord-011310-fm578rm5	215	2	s	s	NNP
cord-011310-fm578rm5	215	3	/	/	SYM
cord-011310-fm578rm5	215	4	Iarc	Iarc	NNP
cord-011310-fm578rm5	216	1	-Worki	-Worki	:
cord-011310-fm578rm5	216	2	ng	ng	NNP
cord-011310-fm578rm5	216	3	-	-	HYPH
cord-011310-fm578rm5	216	4	Group	Group	NNP
cord-011310-fm578rm5	217	1	-Repor	-Repor	NNP
cord-011310-fm578rm5	217	2	ts/-Em	ts/-Em	NNP
cord-011310-fm578rm5	217	3	-	-	HYPH
cord-011310-fm578rm5	217	4	Helic	Helic	NNP
cord-011310-fm578rm5	217	5	obact	obact	NN
cord-011310-fm578rm5	217	6	er	er	JJ
cord-011310-fm578rm5	217	7	-	-	HYPH
cord-011310-fm578rm5	217	8	Pylor	Pylor	NNP
cord-011310-fm578rm5	217	9	i	i	NNP
cord-011310-fm578rm5	217	10	-	-	HYPH
cord-011310-fm578rm5	217	11	Em	Em	NNP
cord-011310-fm578rm5	217	12	-	-	HYPH
cord-011310-fm578rm5	217	13	Eradi	Eradi	NNP
cord-011310-fm578rm5	218	1	catio	catio	NNP
cord-011310-fm578rm5	218	2	n	n	NNP
cord-011310-fm578rm5	218	3	-	-	HYPH
cord-011310-fm578rm5	218	4	As	as	IN
cord-011310-fm578rm5	218	5	-	-	HYPH
cord-011310-fm578rm5	218	6	A	A	NNP
cord-011310-fm578rm5	218	7	-	-	HYPH
cord-011310-fm578rm5	218	8	Strat	Strat	NNP
cord-011310-fm578rm5	218	9	egy	egy	NNP
cord-011310-fm578rm5	218	10	-	-	HYPH
cord-011310-fm578rm5	218	11	For	for	IN
cord-011310-fm578rm5	218	12	-	-	HYPH
cord-011310-fm578rm5	218	13	Preve	Preve	NNP
cord-011310-fm578rm5	218	14	nting	nting	NN
cord-011310-fm578rm5	218	15	-Gastr	-gastr	NN
cord-011310-fm578rm5	218	16	ic	ic	NNP
cord-011310-fm578rm5	218	17	-	-	HYPH
cord-011310-fm578rm5	218	18	Cance	Cance	NNP
cord-011310-fm578rm5	218	19	r-2014	r-2014	VBZ
cord-011310-fm578rm5	218	20	Global	global	JJ
cord-011310-fm578rm5	218	21	burden	burden	NN
cord-011310-fm578rm5	218	22	of	of	IN
cord-011310-fm578rm5	218	23	cancers	cancer	NNS
cord-011310-fm578rm5	218	24	attributable	attributable	JJ
cord-011310-fm578rm5	218	25	to	to	IN
cord-011310-fm578rm5	218	26	infections	infection	NNS
cord-011310-fm578rm5	218	27	in	in	IN
cord-011310-fm578rm5	218	28	2012	2012	CD
cord-011310-fm578rm5	218	29	:	:	:
cord-011310-fm578rm5	218	30	a	a	DT
cord-011310-fm578rm5	218	31	synthetic	synthetic	JJ
cord-011310-fm578rm5	218	32	analysis	analysis	NN
cord-011310-fm578rm5	218	33	Global	global	JJ
cord-011310-fm578rm5	218	34	burden	burden	NN
cord-011310-fm578rm5	218	35	of	of	IN
cord-011310-fm578rm5	218	36	gastric	gastric	JJ
cord-011310-fm578rm5	218	37	cancer	cancer	NN
cord-011310-fm578rm5	218	38	attributable	attributable	JJ
cord-011310-fm578rm5	218	39	to	to	IN
cord-011310-fm578rm5	218	40	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	218	41	pylori	pylori	NN
cord-011310-fm578rm5	218	42	Review	Review	NNP
cord-011310-fm578rm5	218	43	article	article	NN
cord-011310-fm578rm5	218	44	:	:	:
cord-011310-fm578rm5	218	45	exploring	explore	VBG
cord-011310-fm578rm5	218	46	the	the	DT
cord-011310-fm578rm5	218	47	link	link	NN
cord-011310-fm578rm5	218	48	between	between	IN
cord-011310-fm578rm5	218	49	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	218	50	pylori	pylori	NN
cord-011310-fm578rm5	218	51	and	and	CC
cord-011310-fm578rm5	218	52	gastric	gastric	JJ
cord-011310-fm578rm5	218	53	cancer	cancer	NN
cord-011310-fm578rm5	218	54	Review	Review	NNP
cord-011310-fm578rm5	218	55	article	article	NN
cord-011310-fm578rm5	219	1	:	:	:
cord-011310-fm578rm5	219	2	Helicobacter	helicobacter	NN
cord-011310-fm578rm5	219	3	pylori	pylori	NN
cord-011310-fm578rm5	219	4	eradication	eradication	NN
cord-011310-fm578rm5	219	5	for	for	IN
cord-011310-fm578rm5	219	6	the	the	DT
cord-011310-fm578rm5	219	7	prevention	prevention	NN
cord-011310-fm578rm5	219	8	of	of	IN
cord-011310-fm578rm5	219	9	gastric	gastric	JJ
cord-011310-fm578rm5	219	10	cancer	cancer	NN
cord-011310-fm578rm5	219	11	Management	management	NN
cord-011310-fm578rm5	219	12	of	of	IN
cord-011310-fm578rm5	219	13	epithelial	epithelial	JJ
cord-011310-fm578rm5	219	14	precancerous	precancerous	JJ
cord-011310-fm578rm5	219	15	conditions	condition	NNS
cord-011310-fm578rm5	219	16	and	and	CC
cord-011310-fm578rm5	219	17	lesions	lesion	NNS
cord-011310-fm578rm5	219	18	in	in	IN
cord-011310-fm578rm5	219	19	the	the	DT
cord-011310-fm578rm5	219	20	stomach	stomach	NN
cord-011310-fm578rm5	219	21	(	(	-LRB-
cord-011310-fm578rm5	219	22	MAPS	map	NNS
cord-011310-fm578rm5	219	23	II	ii	CD
cord-011310-fm578rm5	219	24	)	)	-RRB-
cord-011310-fm578rm5	219	25	:	:	:
cord-011310-fm578rm5	219	26	European	European	NNP
cord-011310-fm578rm5	219	27	Society	Society	NNP
cord-011310-fm578rm5	219	28	of	of	IN
cord-011310-fm578rm5	219	29	Gastrointestinal	Gastrointestinal	NNP
cord-011310-fm578rm5	219	30	Endoscopy	Endoscopy	NNP
cord-011310-fm578rm5	219	31	(	(	-LRB-
cord-011310-fm578rm5	219	32	ESGE	ESGE	NNP
cord-011310-fm578rm5	219	33	)	)	-RRB-
cord-011310-fm578rm5	219	34	,	,	,
cord-011310-fm578rm5	219	35	European	European	NNP
cord-011310-fm578rm5	219	36	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	219	37	and	and	CC
cord-011310-fm578rm5	219	38	Microbiota	Microbiota	NNP
cord-011310-fm578rm5	219	39	Study	Study	NNP
cord-011310-fm578rm5	219	40	Group	Group	NNP
cord-011310-fm578rm5	219	41	(	(	-LRB-
cord-011310-fm578rm5	219	42	EHMSG	EHMSG	NNP
cord-011310-fm578rm5	219	43	)	)	-RRB-
cord-011310-fm578rm5	219	44	,	,	,
cord-011310-fm578rm5	219	45	European	European	NNP
cord-011310-fm578rm5	219	46	Society	Society	NNP
cord-011310-fm578rm5	219	47	of	of	IN
cord-011310-fm578rm5	219	48	Pathology	Pathology	NNP
cord-011310-fm578rm5	219	49	(	(	-LRB-
cord-011310-fm578rm5	219	50	ESP	ESP	NNP
cord-011310-fm578rm5	219	51	)	)	-RRB-
cord-011310-fm578rm5	219	52	,	,	,
cord-011310-fm578rm5	219	53	and	and	CC
cord-011310-fm578rm5	219	54	Sociedade	Sociedade	NNP
cord-011310-fm578rm5	219	55	Portuguesa	Portuguesa	NNP
cord-011310-fm578rm5	219	56	de	de	NNP
cord-011310-fm578rm5	219	57	Endoscopia	Endoscopia	NNP
cord-011310-fm578rm5	219	58	Digestiva	Digestiva	NNP
cord-011310-fm578rm5	219	59	(	(	-LRB-
cord-011310-fm578rm5	219	60	SPED	sped	NN
cord-011310-fm578rm5	219	61	)	)	-RRB-
cord-011310-fm578rm5	219	62	guideline	guideline	NN
cord-011310-fm578rm5	219	63	update	update	NN
cord-011310-fm578rm5	219	64	2019	2019	CD
cord-011310-fm578rm5	220	1	How	how	WRB
cord-011310-fm578rm5	220	2	far	far	RB
cord-011310-fm578rm5	220	3	are	be	VBP
cord-011310-fm578rm5	220	4	we	-PRON-	PRP
cord-011310-fm578rm5	220	5	from	from	IN
cord-011310-fm578rm5	220	6	vaccination	vaccination	NN
cord-011310-fm578rm5	220	7	against	against	IN
cord-011310-fm578rm5	220	8	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	220	9	pylori	pylori	NN
cord-011310-fm578rm5	220	10	infection	infection	NN
cord-011310-fm578rm5	220	11	?	?	.
cord-011310-fm578rm5	221	1	Reconciliation	reconciliation	NN
cord-011310-fm578rm5	221	2	of	of	IN
cord-011310-fm578rm5	221	3	recent	recent	JJ
cord-011310-fm578rm5	221	4	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	221	5	pylori	pylori	NN
cord-011310-fm578rm5	221	6	treatment	treatment	NN
cord-011310-fm578rm5	221	7	guidelines	guideline	NNS
cord-011310-fm578rm5	221	8	in	in	IN
cord-011310-fm578rm5	221	9	a	a	DT
cord-011310-fm578rm5	221	10	time	time	NN
cord-011310-fm578rm5	221	11	of	of	IN
cord-011310-fm578rm5	221	12	increasing	increase	VBG
cord-011310-fm578rm5	221	13	resistance	resistance	NN
cord-011310-fm578rm5	221	14	to	to	IN
cord-011310-fm578rm5	221	15	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	221	16	Management	Management	NNP
cord-011310-fm578rm5	221	17	of	of	IN
cord-011310-fm578rm5	221	18	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	221	19	pylori	pylori	NN
cord-011310-fm578rm5	221	20	infection	infection	NN
cord-011310-fm578rm5	221	21	-	-	:
cord-011310-fm578rm5	221	22	the	the	DT
cord-011310-fm578rm5	221	23	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	221	24	V	V	NNP
cord-011310-fm578rm5	221	25	/	/	SYM
cord-011310-fm578rm5	221	26	Florence	Florence	NNP
cord-011310-fm578rm5	221	27	consensus	consensus	NN
cord-011310-fm578rm5	221	28	report	report	NN
cord-011310-fm578rm5	221	29	Cancer	Cancer	NNP
cord-011310-fm578rm5	221	30	screening	screening	NN
cord-011310-fm578rm5	221	31	:	:	:
cord-011310-fm578rm5	221	32	policy	policy	NN
cord-011310-fm578rm5	221	33	recommendations	recommendation	NNS
cord-011310-fm578rm5	221	34	on	on	IN
cord-011310-fm578rm5	221	35	governance	governance	NN
cord-011310-fm578rm5	221	36	,	,	,
cord-011310-fm578rm5	221	37	organization	organization	NN
cord-011310-fm578rm5	221	38	and	and	CC
cord-011310-fm578rm5	221	39	evaluation	evaluation	NN
cord-011310-fm578rm5	221	40	of	of	IN
cord-011310-fm578rm5	221	41	cancer	cancer	NN
cord-011310-fm578rm5	221	42	screening	screening	NN
cord-011310-fm578rm5	222	1	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	222	2	pylori	pylori	NN
cord-011310-fm578rm5	222	3	resistance	resistance	NN
cord-011310-fm578rm5	222	4	to	to	IN
cord-011310-fm578rm5	222	5	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	222	6	in	in	IN
cord-011310-fm578rm5	222	7	Europe	Europe	NNP
cord-011310-fm578rm5	222	8	and	and	CC
cord-011310-fm578rm5	222	9	its	-PRON-	PRP$
cord-011310-fm578rm5	222	10	relationship	relationship	NN
cord-011310-fm578rm5	222	11	to	to	IN
cord-011310-fm578rm5	222	12	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	222	13	consumption	consumption	NN
cord-011310-fm578rm5	223	1	The	the	DT
cord-011310-fm578rm5	223	2	threat	threat	NN
cord-011310-fm578rm5	223	3	of	of	IN
cord-011310-fm578rm5	223	4	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	223	5	resistance	resistance	NN
cord-011310-fm578rm5	223	6	on	on	IN
cord-011310-fm578rm5	223	7	the	the	DT
cord-011310-fm578rm5	223	8	human	human	JJ
cord-011310-fm578rm5	223	9	microbiome	microbiome	NN
cord-011310-fm578rm5	224	1	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	224	2	pylori	pylori	NN
cord-011310-fm578rm5	224	3	eradication	eradication	NN
cord-011310-fm578rm5	224	4	causes	cause	VBZ
cord-011310-fm578rm5	224	5	perturbation	perturbation	NN
cord-011310-fm578rm5	224	6	of	of	IN
cord-011310-fm578rm5	224	7	the	the	DT
cord-011310-fm578rm5	224	8	human	human	JJ
cord-011310-fm578rm5	224	9	gut	gut	NN
cord-011310-fm578rm5	224	10	microbiome	microbiome	NN
cord-011310-fm578rm5	224	11	in	in	IN
cord-011310-fm578rm5	224	12	young	young	JJ
cord-011310-fm578rm5	224	13	adults	adult	NNS
cord-011310-fm578rm5	224	14	Effect	Effect	NNP
cord-011310-fm578rm5	224	15	of	of	IN
cord-011310-fm578rm5	224	16	azithromycin	azithromycin	NNP
cord-011310-fm578rm5	224	17	and	and	CC
cord-011310-fm578rm5	224	18	clarithromycin	clarithromycin	NNP
cord-011310-fm578rm5	224	19	therapy	therapy	NN
cord-011310-fm578rm5	224	20	on	on	IN
cord-011310-fm578rm5	224	21	pharyngeal	pharyngeal	JJ
cord-011310-fm578rm5	224	22	carriage	carriage	NN
cord-011310-fm578rm5	224	23	of	of	IN
cord-011310-fm578rm5	224	24	macrolide	macrolide	JJ
cord-011310-fm578rm5	224	25	-	-	HYPH
cord-011310-fm578rm5	224	26	resistant	resistant	JJ
cord-011310-fm578rm5	224	27	streptococci	streptococcus	NNS
cord-011310-fm578rm5	224	28	in	in	IN
cord-011310-fm578rm5	224	29	healthy	healthy	JJ
cord-011310-fm578rm5	224	30	volunteers	volunteer	NNS
cord-011310-fm578rm5	224	31	:	:	:
cord-011310-fm578rm5	225	1	a	a	DT
cord-011310-fm578rm5	225	2	randomised	randomised	JJ
cord-011310-fm578rm5	225	3	,	,	,
cord-011310-fm578rm5	225	4	double	double	JJ
cord-011310-fm578rm5	225	5	-	-	HYPH
cord-011310-fm578rm5	225	6	blind	blind	JJ
cord-011310-fm578rm5	225	7	,	,	,
cord-011310-fm578rm5	225	8	placebo	placebo	NN
cord-011310-fm578rm5	225	9	-	-	HYPH
cord-011310-fm578rm5	225	10	controlled	control	VBN
cord-011310-fm578rm5	225	11	study	study	NN
cord-011310-fm578rm5	225	12	Kyoto	Kyoto	NNP
cord-011310-fm578rm5	225	13	global	global	JJ
cord-011310-fm578rm5	225	14	consensus	consensus	NN
cord-011310-fm578rm5	225	15	report	report	NN
cord-011310-fm578rm5	225	16	on	on	IN
cord-011310-fm578rm5	225	17	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	225	18	pylori	pylori	NN
cord-011310-fm578rm5	225	19	gastritis	gastritis	NN
cord-011310-fm578rm5	225	20	IVth	IVth	NNP
cord-011310-fm578rm5	225	21	Brazilian	brazilian	JJ
cord-011310-fm578rm5	225	22	consensus	consensus	NN
cord-011310-fm578rm5	225	23	conference	conference	NN
cord-011310-fm578rm5	225	24	on	on	IN
cord-011310-fm578rm5	225	25	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	225	26	pylori	pylori	NN
cord-011310-fm578rm5	225	27	infection	infection	NN
cord-011310-fm578rm5	226	1	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	226	2	pylori	pylori	NN
cord-011310-fm578rm5	226	3	management	management	NN
cord-011310-fm578rm5	226	4	in	in	IN
cord-011310-fm578rm5	226	5	ASEAN	ASEAN	NNP
cord-011310-fm578rm5	226	6	:	:	:
cord-011310-fm578rm5	226	7	the	the	DT
cord-011310-fm578rm5	226	8	Bangkok	Bangkok	NNP
cord-011310-fm578rm5	226	9	consensus	consensus	NN
cord-011310-fm578rm5	226	10	report	report	NN
cord-011310-fm578rm5	226	11	Second	Second	NNP
cord-011310-fm578rm5	226	12	Asia	Asia	NNP
cord-011310-fm578rm5	226	13	-	-	HYPH
cord-011310-fm578rm5	226	14	Pacific	Pacific	NNP
cord-011310-fm578rm5	226	15	consensus	consensus	NN
cord-011310-fm578rm5	226	16	guidelines	guideline	NNS
cord-011310-fm578rm5	226	17	for	for	IN
cord-011310-fm578rm5	226	18	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	226	19	pylori	pylori	NN
cord-011310-fm578rm5	226	20	infection	infection	NN
cord-011310-fm578rm5	227	1	ACG	ACG	NNP
cord-011310-fm578rm5	227	2	clinical	clinical	JJ
cord-011310-fm578rm5	227	3	guideline	guideline	NN
cord-011310-fm578rm5	227	4	:	:	:
cord-011310-fm578rm5	228	1	treatment	treatment	NN
cord-011310-fm578rm5	228	2	of	of	IN
cord-011310-fm578rm5	228	3	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	228	4	pylori	pylori	NN
cord-011310-fm578rm5	228	5	infection	infection	NN
cord-011310-fm578rm5	228	6	Prevention	prevention	NN
cord-011310-fm578rm5	228	7	of	of	IN
cord-011310-fm578rm5	228	8	gastric	gastric	JJ
cord-011310-fm578rm5	228	9	cancer	cancer	NN
cord-011310-fm578rm5	228	10	Impact	impact	NN
cord-011310-fm578rm5	228	11	of	of	IN
cord-011310-fm578rm5	228	12	health	health	NN
cord-011310-fm578rm5	228	13	insurance	insurance	NN
cord-011310-fm578rm5	228	14	coverage	coverage	NN
cord-011310-fm578rm5	228	15	for	for	IN
cord-011310-fm578rm5	228	16	Helicobacter	helicobacter	NN
cord-011310-fm578rm5	228	17	pylori	pylori	NN
cord-011310-fm578rm5	228	18	gastritis	gastritis	NN
cord-011310-fm578rm5	228	19	on	on	IN
cord-011310-fm578rm5	228	20	the	the	DT
cord-011310-fm578rm5	228	21	trends	trend	NNS
cord-011310-fm578rm5	228	22	in	in	IN
cord-011310-fm578rm5	228	23	eradication	eradication	NN
cord-011310-fm578rm5	228	24	therapy	therapy	NN
cord-011310-fm578rm5	228	25	in	in	IN
cord-011310-fm578rm5	228	26	Japan	Japan	NNP
cord-011310-fm578rm5	228	27	:	:	:
cord-011310-fm578rm5	228	28	retrospective	retrospective	JJ
cord-011310-fm578rm5	228	29	observational	observational	JJ
cord-011310-fm578rm5	228	30	study	study	NN
cord-011310-fm578rm5	228	31	and	and	CC
cord-011310-fm578rm5	228	32	simulation	simulation	NN
cord-011310-fm578rm5	228	33	study	study	NN
cord-011310-fm578rm5	228	34	based	base	VBN
cord-011310-fm578rm5	228	35	on	on	IN
cord-011310-fm578rm5	228	36	real	real	JJ
cord-011310-fm578rm5	228	37	-	-	HYPH
cord-011310-fm578rm5	228	38	world	world	NN
cord-011310-fm578rm5	228	39	data	datum	NNS
cord-011310-fm578rm5	228	40	Effect	effect	NN
cord-011310-fm578rm5	228	41	of	of	IN
cord-011310-fm578rm5	228	42	endoscopy	endoscopy	NN
cord-011310-fm578rm5	228	43	screening	screening	NN
cord-011310-fm578rm5	228	44	on	on	IN
cord-011310-fm578rm5	228	45	stage	stage	NN
cord-011310-fm578rm5	228	46	at	at	IN
cord-011310-fm578rm5	228	47	gastric	gastric	JJ
cord-011310-fm578rm5	228	48	cancer	cancer	NN
cord-011310-fm578rm5	228	49	diagnosis	diagnosis	NN
cord-011310-fm578rm5	228	50	:	:	:
cord-011310-fm578rm5	228	51	results	result	NNS
cord-011310-fm578rm5	228	52	of	of	IN
cord-011310-fm578rm5	228	53	the	the	DT
cord-011310-fm578rm5	228	54	national	national	JJ
cord-011310-fm578rm5	228	55	cancer	cancer	NN
cord-011310-fm578rm5	228	56	screening	screening	NN
cord-011310-fm578rm5	228	57	programme	programme	NN
cord-011310-fm578rm5	228	58	in	in	IN
cord-011310-fm578rm5	228	59	Korea	Korea	NNP
cord-011310-fm578rm5	228	60	Guidelines	Guidelines	NNPS
cord-011310-fm578rm5	228	61	for	for	IN
cord-011310-fm578rm5	228	62	the	the	DT
cord-011310-fm578rm5	228	63	diagnosis	diagnosis	NN
cord-011310-fm578rm5	228	64	and	and	CC
cord-011310-fm578rm5	228	65	treatment	treatment	NN
cord-011310-fm578rm5	228	66	of	of	IN
cord-011310-fm578rm5	228	67	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	228	68	pylori	pylori	NN
cord-011310-fm578rm5	228	69	infection	infection	NN
cord-011310-fm578rm5	228	70	in	in	IN
cord-011310-fm578rm5	228	71	Korea	Korea	NNP
cord-011310-fm578rm5	228	72	Slovenian	slovenian	JJ
cord-011310-fm578rm5	228	73	society	society	NN
cord-011310-fm578rm5	228	74	for	for	IN
cord-011310-fm578rm5	228	75	gastroenterology	gastroenterology	NN
cord-011310-fm578rm5	228	76	and	and	CC
cord-011310-fm578rm5	228	77	hepatology	hepatology	NN
cord-011310-fm578rm5	228	78	guidelines	guideline	NNS
cord-011310-fm578rm5	228	79	on	on	IN
cord-011310-fm578rm5	228	80	the	the	DT
cord-011310-fm578rm5	228	81	management	management	NN
cord-011310-fm578rm5	228	82	of	of	IN
cord-011310-fm578rm5	228	83	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	228	84	pylori	pylori	NN
cord-011310-fm578rm5	228	85	infection	infection	NN
cord-011310-fm578rm5	229	1	The	the	DT
cord-011310-fm578rm5	229	2	Toronto	Toronto	NNP
cord-011310-fm578rm5	229	3	consensus	consensus	NN
cord-011310-fm578rm5	229	4	for	for	IN
cord-011310-fm578rm5	229	5	the	the	DT
cord-011310-fm578rm5	229	6	treatment	treatment	NN
cord-011310-fm578rm5	229	7	of	of	IN
cord-011310-fm578rm5	229	8	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	229	9	pylori	pylori	NN
cord-011310-fm578rm5	229	10	infection	infection	NN
cord-011310-fm578rm5	229	11	in	in	IN
cord-011310-fm578rm5	229	12	adults	adult	NNS
cord-011310-fm578rm5	229	13	Current	current	JJ
cord-011310-fm578rm5	229	14	concepts	concept	NNS
cord-011310-fm578rm5	229	15	in	in	IN
cord-011310-fm578rm5	229	16	the	the	DT
cord-011310-fm578rm5	229	17	management	management	NN
cord-011310-fm578rm5	229	18	of	of	IN
cord-011310-fm578rm5	229	19	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	229	20	pylori	pylori	NN
cord-011310-fm578rm5	229	21	infection	infection	NN
cord-011310-fm578rm5	229	22	:	:	:
cord-011310-fm578rm5	229	23	the	the	DT
cord-011310-fm578rm5	229	24	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	229	25	III	III	NNP
cord-011310-fm578rm5	229	26	consensus	consensus	NN
cord-011310-fm578rm5	229	27	report	report	NN
cord-011310-fm578rm5	229	28	Management	Management	NNP
cord-011310-fm578rm5	229	29	of	of	IN
cord-011310-fm578rm5	229	30	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	229	31	pylori	pylori	NN
cord-011310-fm578rm5	229	32	infection	infection	NN
cord-011310-fm578rm5	229	33	-	-	:
cord-011310-fm578rm5	229	34	the	the	DT
cord-011310-fm578rm5	229	35	Maastricht	Maastricht	NNP
cord-011310-fm578rm5	229	36	IV	IV	NNP
cord-011310-fm578rm5	229	37	/	/	SYM
cord-011310-fm578rm5	229	38	Florence	Florence	NNP
cord-011310-fm578rm5	229	39	consensus	consensus	NN
cord-011310-fm578rm5	229	40	report	report	NN
cord-011310-fm578rm5	229	41	Principles	principle	NNS
cord-011310-fm578rm5	229	42	and	and	CC
cord-011310-fm578rm5	229	43	practice	practice	NN
cord-011310-fm578rm5	229	44	of	of	IN
cord-011310-fm578rm5	229	45	mass	mass	NN
cord-011310-fm578rm5	229	46	screening	screening	NN
cord-011310-fm578rm5	229	47	for	for	IN
cord-011310-fm578rm5	229	48	disease	disease	NN
cord-011310-fm578rm5	229	49	Revisiting	revisit	VBG
cord-011310-fm578rm5	229	50	Wilson	Wilson	NNP
cord-011310-fm578rm5	229	51	and	and	CC
cord-011310-fm578rm5	229	52	Jungner	Jungner	NNP
cord-011310-fm578rm5	229	53	in	in	IN
cord-011310-fm578rm5	229	54	the	the	DT
cord-011310-fm578rm5	229	55	genomic	genomic	JJ
cord-011310-fm578rm5	229	56	age	age	NN
cord-011310-fm578rm5	229	57	:	:	:
cord-011310-fm578rm5	229	58	a	a	DT
cord-011310-fm578rm5	229	59	review	review	NN
cord-011310-fm578rm5	229	60	of	of	IN
cord-011310-fm578rm5	229	61	screening	screen	VBG
cord-011310-fm578rm5	229	62	criteria	criterion	NNS
cord-011310-fm578rm5	229	63	over	over	IN
cord-011310-fm578rm5	229	64	the	the	DT
cord-011310-fm578rm5	229	65	past	past	JJ
cord-011310-fm578rm5	229	66	40	40	CD
cord-011310-fm578rm5	229	67	years	year	NNS
cord-011310-fm578rm5	229	68	Systematic	systematic	JJ
cord-011310-fm578rm5	229	69	review	review	NN
cord-011310-fm578rm5	229	70	with	with	IN
cord-011310-fm578rm5	229	71	meta	meta	NNP
cord-011310-fm578rm5	229	72	-	-	HYPH
cord-011310-fm578rm5	229	73	analysis	analysis	NN
cord-011310-fm578rm5	229	74	:	:	:
cord-011310-fm578rm5	230	1	the	the	DT
cord-011310-fm578rm5	230	2	worldwide	worldwide	JJ
cord-011310-fm578rm5	230	3	prevalence	prevalence	NN
cord-011310-fm578rm5	230	4	of	of	IN
cord-011310-fm578rm5	230	5	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	230	6	pylori	pylori	NN
cord-011310-fm578rm5	230	7	infection	infection	NN
cord-011310-fm578rm5	230	8	Prevalence	prevalence	NN
cord-011310-fm578rm5	230	9	of	of	IN
cord-011310-fm578rm5	230	10	chronic	chronic	JJ
cord-011310-fm578rm5	230	11	atrophic	atrophic	JJ
cord-011310-fm578rm5	230	12	gastritis	gastritis	NN
cord-011310-fm578rm5	230	13	in	in	IN
cord-011310-fm578rm5	230	14	different	different	JJ
cord-011310-fm578rm5	230	15	parts	part	NNS
cord-011310-fm578rm5	230	16	of	of	IN
cord-011310-fm578rm5	230	17	the	the	DT
cord-011310-fm578rm5	230	18	world	world	NN
cord-011310-fm578rm5	230	19	Eradication	Eradication	NNP
cord-011310-fm578rm5	230	20	therapy	therapy	NN
cord-011310-fm578rm5	230	21	in	in	IN
cord-011310-fm578rm5	230	22	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	230	23	pylori	pylori	VB
cord-011310-fm578rm5	230	24	positive	positive	JJ
cord-011310-fm578rm5	230	25	peptic	peptic	JJ
cord-011310-fm578rm5	230	26	ulcer	ulcer	NN
cord-011310-fm578rm5	230	27	disease	disease	NN
cord-011310-fm578rm5	230	28	:	:	:
cord-011310-fm578rm5	230	29	systematic	systematic	JJ
cord-011310-fm578rm5	230	30	review	review	NN
cord-011310-fm578rm5	230	31	and	and	CC
cord-011310-fm578rm5	230	32	economic	economic	JJ
cord-011310-fm578rm5	230	33	analysis	analysis	NN
cord-011310-fm578rm5	230	34	National	National	NNP
cord-011310-fm578rm5	230	35	Institute	Institute	NNP
cord-011310-fm578rm5	230	36	for	for	IN
cord-011310-fm578rm5	230	37	Health	Health	NNP
cord-011310-fm578rm5	230	38	and	and	CC
cord-011310-fm578rm5	230	39	Care	Care	NNP
cord-011310-fm578rm5	230	40	Excellence	Excellence	NNP
cord-011310-fm578rm5	230	41	N.	n.	NN
cord-011310-fm578rm5	230	42	Clostridium	clostridium	NN
cord-011310-fm578rm5	230	43	difficile	difficile	NN
cord-011310-fm578rm5	230	44	infection	infection	NN
cord-011310-fm578rm5	230	45	:	:	:
cord-011310-fm578rm5	230	46	risk	risk	NN
cord-011310-fm578rm5	230	47	with	with	IN
cord-011310-fm578rm5	230	48	broad	broad	JJ
cord-011310-fm578rm5	230	49	-	-	HYPH
cord-011310-fm578rm5	230	50	spectrum	spectrum	NN
cord-011310-fm578rm5	230	51	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	230	52	.	.	.
cord-011310-fm578rm5	231	1	2015	2015	CD
cord-011310-fm578rm5	231	2	;	;	:
cord-011310-fm578rm5	231	3	nice.org.uk/guida	nice.org.uk/guida	NNP
cord-011310-fm578rm5	231	4	nce	nce	NNP
cord-011310-fm578rm5	231	5	/	/	SYM
cord-011310-fm578rm5	231	6	esmpb	esmpb	NNP
cord-011310-fm578rm5	231	7	1	1	CD
cord-011310-fm578rm5	231	8	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	231	9	-	-	HYPH
cord-011310-fm578rm5	231	10	associated	associate	VBN
cord-011310-fm578rm5	231	11	risk	risk	NN
cord-011310-fm578rm5	231	12	factors	factor	NNS
cord-011310-fm578rm5	231	13	for	for	IN
cord-011310-fm578rm5	231	14	Clostridium	clostridium	NN
cord-011310-fm578rm5	231	15	difficile	difficile	NN
cord-011310-fm578rm5	231	16	infection	infection	NN
cord-011310-fm578rm5	232	1	Pseudomembranous	pseudomembranous	JJ
cord-011310-fm578rm5	232	2	colitis	colitis	NN
cord-011310-fm578rm5	232	3	associated	associate	VBN
cord-011310-fm578rm5	232	4	with	with	IN
cord-011310-fm578rm5	232	5	a	a	DT
cord-011310-fm578rm5	232	6	triple	triple	JJ
cord-011310-fm578rm5	232	7	therapy	therapy	NN
cord-011310-fm578rm5	232	8	for	for	IN
cord-011310-fm578rm5	232	9	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	232	10	pylori	pylori	NN
cord-011310-fm578rm5	232	11	eradication	eradication	NN
cord-011310-fm578rm5	232	12	Recovery	recovery	NN
cord-011310-fm578rm5	232	13	of	of	IN
cord-011310-fm578rm5	232	14	gut	gut	NN
cord-011310-fm578rm5	232	15	microbiota	microbiota	NN
cord-011310-fm578rm5	232	16	of	of	IN
cord-011310-fm578rm5	232	17	healthy	healthy	JJ
cord-011310-fm578rm5	232	18	adults	adult	NNS
cord-011310-fm578rm5	232	19	following	follow	VBG
cord-011310-fm578rm5	232	20	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	232	21	exposure	exposure	NN
cord-011310-fm578rm5	233	1	Gut	gut	JJ
cord-011310-fm578rm5	233	2	bacterial	bacterial	JJ
cord-011310-fm578rm5	233	3	microbiota	microbiota	NN
cord-011310-fm578rm5	233	4	and	and	CC
cord-011310-fm578rm5	233	5	its	-PRON-	PRP$
cord-011310-fm578rm5	233	6	resistome	resistome	NN
cord-011310-fm578rm5	233	7	rapidly	rapidly	RB
cord-011310-fm578rm5	233	8	recover	recover	VBP
cord-011310-fm578rm5	233	9	to	to	IN
cord-011310-fm578rm5	233	10	basal	basal	NN
cord-011310-fm578rm5	233	11	state	state	NN
cord-011310-fm578rm5	233	12	levels	level	NNS
cord-011310-fm578rm5	233	13	after	after	IN
cord-011310-fm578rm5	233	14	short	short	JJ
cord-011310-fm578rm5	233	15	-	-	HYPH
cord-011310-fm578rm5	233	16	term	term	NN
cord-011310-fm578rm5	233	17	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	233	18	-	-	HYPH
cord-011310-fm578rm5	233	19	clavulanic	clavulanic	NNP
cord-011310-fm578rm5	233	20	acid	acid	NN
cord-011310-fm578rm5	233	21	treatment	treatment	NN
cord-011310-fm578rm5	233	22	in	in	IN
cord-011310-fm578rm5	233	23	healthy	healthy	JJ
cord-011310-fm578rm5	233	24	adults	adult	NNS
cord-011310-fm578rm5	234	1	The	the	DT
cord-011310-fm578rm5	234	2	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	234	3	resistome	resistome	NNP
cord-011310-fm578rm5	234	4	:	:	:
cord-011310-fm578rm5	234	5	the	the	DT
cord-011310-fm578rm5	234	6	nexus	nexus	NN
cord-011310-fm578rm5	234	7	of	of	IN
cord-011310-fm578rm5	234	8	chemical	chemical	JJ
cord-011310-fm578rm5	234	9	and	and	CC
cord-011310-fm578rm5	234	10	genetic	genetic	JJ
cord-011310-fm578rm5	234	11	diversity	diversity	NN
cord-011310-fm578rm5	234	12	nature	nature	NN
cord-011310-fm578rm5	234	13	reviews	review	NNS
cord-011310-fm578rm5	235	1	The	the	DT
cord-011310-fm578rm5	235	2	human	human	JJ
cord-011310-fm578rm5	235	3	gut	gut	NN
cord-011310-fm578rm5	235	4	resistome	resistome	NNP
cord-011310-fm578rm5	235	5	Country	country	NN
cord-011310-fm578rm5	235	6	-	-	HYPH
cord-011310-fm578rm5	235	7	specific	specific	JJ
cord-011310-fm578rm5	235	8	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	235	9	use	use	NN
cord-011310-fm578rm5	235	10	practices	practice	NNS
cord-011310-fm578rm5	235	11	impact	impact	VBP
cord-011310-fm578rm5	235	12	the	the	DT
cord-011310-fm578rm5	235	13	human	human	JJ
cord-011310-fm578rm5	235	14	gut	gut	NN
cord-011310-fm578rm5	235	15	resistome	resistome	VBN
cord-011310-fm578rm5	235	16	Clarithromycin	Clarithromycin	NNP
cord-011310-fm578rm5	235	17	treatment	treatment	NN
cord-011310-fm578rm5	235	18	selects	select	VBZ
cord-011310-fm578rm5	235	19	for	for	IN
cord-011310-fm578rm5	235	20	persistent	persistent	JJ
cord-011310-fm578rm5	235	21	macrolide	macrolide	JJ
cord-011310-fm578rm5	235	22	-	-	HYPH
cord-011310-fm578rm5	235	23	resistant	resistant	JJ
cord-011310-fm578rm5	235	24	bacteria	bacteria	NNS
cord-011310-fm578rm5	235	25	in	in	IN
cord-011310-fm578rm5	235	26	throat	throat	NN
cord-011310-fm578rm5	236	1	commensal	commensal	JJ
cord-011310-fm578rm5	236	2	flora	flora	NNS
cord-011310-fm578rm5	236	3	Macrolide	Macrolide	NNP
cord-011310-fm578rm5	236	4	resistance	resistance	NN
cord-011310-fm578rm5	236	5	in	in	IN
cord-011310-fm578rm5	236	6	the	the	DT
cord-011310-fm578rm5	236	7	normal	normal	JJ
cord-011310-fm578rm5	236	8	microbiota	microbiota	NN
cord-011310-fm578rm5	236	9	after	after	IN
cord-011310-fm578rm5	236	10	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	236	11	pylori	pylori	NN
cord-011310-fm578rm5	236	12	treatment	treatment	NN
cord-011310-fm578rm5	236	13	Long	long	JJ
cord-011310-fm578rm5	236	14	-	-	HYPH
cord-011310-fm578rm5	236	15	term	term	NN
cord-011310-fm578rm5	236	16	persistence	persistence	NN
cord-011310-fm578rm5	236	17	of	of	IN
cord-011310-fm578rm5	236	18	resistant	resistant	JJ
cord-011310-fm578rm5	236	19	Enterococcus	enterococcus	NN
cord-011310-fm578rm5	236	20	species	specie	NNS
cord-011310-fm578rm5	236	21	after	after	IN
cord-011310-fm578rm5	236	22	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	236	23	to	to	TO
cord-011310-fm578rm5	236	24	eradicate	eradicate	VB
cord-011310-fm578rm5	236	25	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	236	26	pylori	pylori	VB
cord-011310-fm578rm5	237	1	Short	short	JJ
cord-011310-fm578rm5	237	2	-	-	HYPH
cord-011310-fm578rm5	237	3	term	term	NN
cord-011310-fm578rm5	237	4	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	237	5	treatment	treatment	NN
cord-011310-fm578rm5	237	6	has	have	VBZ
cord-011310-fm578rm5	237	7	differing	differ	VBG
cord-011310-fm578rm5	237	8	long	long	JJ
cord-011310-fm578rm5	237	9	-	-	HYPH
cord-011310-fm578rm5	237	10	term	term	NN
cord-011310-fm578rm5	237	11	impacts	impact	NNS
cord-011310-fm578rm5	237	12	on	on	IN
cord-011310-fm578rm5	237	13	the	the	DT
cord-011310-fm578rm5	237	14	human	human	JJ
cord-011310-fm578rm5	237	15	throat	throat	NN
cord-011310-fm578rm5	237	16	and	and	CC
cord-011310-fm578rm5	237	17	gut	gut	NN
cord-011310-fm578rm5	237	18	microbiome	microbiome	NN
cord-011310-fm578rm5	238	1	Long	long	JJ
cord-011310-fm578rm5	238	2	term	term	NN
cord-011310-fm578rm5	238	3	changes	change	NNS
cord-011310-fm578rm5	238	4	of	of	IN
cord-011310-fm578rm5	238	5	gut	gut	NN
cord-011310-fm578rm5	238	6	microbiota	microbiota	NN
cord-011310-fm578rm5	238	7	,	,	,
cord-011310-fm578rm5	238	8	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	238	9	resistance	resistance	NN
cord-011310-fm578rm5	238	10	,	,	,
cord-011310-fm578rm5	238	11	and	and	CC
cord-011310-fm578rm5	238	12	metabolic	metabolic	JJ
cord-011310-fm578rm5	238	13	parameters	parameter	NNS
cord-011310-fm578rm5	238	14	after	after	IN
cord-011310-fm578rm5	238	15	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	238	16	pylori	pylori	NN
cord-011310-fm578rm5	238	17	eradication	eradication	NN
cord-011310-fm578rm5	238	18	a	a	DT
cord-011310-fm578rm5	238	19	multicentre	multicentre	NNP
cord-011310-fm578rm5	238	20	randomised	randomised	JJ
cord-011310-fm578rm5	238	21	trial	trial	NN
cord-011310-fm578rm5	238	22	Finnish	Finnish	NNP
cord-011310-fm578rm5	238	23	Study	Study	NNP
cord-011310-fm578rm5	238	24	Group	Group	NNP
cord-011310-fm578rm5	238	25	for	for	IN
cord-011310-fm578rm5	238	26	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	238	27	R.	R.	NNP
cord-011310-fm578rm5	238	28	Macrolide	Macrolide	NNP
cord-011310-fm578rm5	238	29	and	and	CC
cord-011310-fm578rm5	238	30	azithromycin	azithromycin	NNP
cord-011310-fm578rm5	238	31	use	use	NN
cord-011310-fm578rm5	238	32	are	be	VBP
cord-011310-fm578rm5	238	33	linked	link	VBN
cord-011310-fm578rm5	238	34	to	to	IN
cord-011310-fm578rm5	238	35	increased	increase	VBN
cord-011310-fm578rm5	238	36	macrolide	macrolide	JJ
cord-011310-fm578rm5	238	37	resistance	resistance	NN
cord-011310-fm578rm5	238	38	in	in	IN
cord-011310-fm578rm5	238	39	Streptococcus	Streptococcus	NNP
cord-011310-fm578rm5	238	40	pneumoniae	pneumoniae	NN
cord-011310-fm578rm5	238	41	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	238	42	drug	drug	NN
cord-011310-fm578rm5	238	43	use	use	NN
cord-011310-fm578rm5	238	44	and	and	CC
cord-011310-fm578rm5	238	45	methicillin	methicillin	NN
cord-011310-fm578rm5	238	46	-	-	HYPH
cord-011310-fm578rm5	238	47	resistant	resistant	JJ
cord-011310-fm578rm5	238	48	Staphylococcus	Staphylococcus	NNP
cord-011310-fm578rm5	238	49	aureus	aureus	NN
cord-011310-fm578rm5	238	50	Editorial	Editorial	NNP
cord-011310-fm578rm5	238	51	commentary	commentary	NN
cord-011310-fm578rm5	238	52	:	:	:
cord-011310-fm578rm5	238	53	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	238	54	for	for	IN
cord-011310-fm578rm5	238	55	treatment	treatment	NN
cord-011310-fm578rm5	238	56	of	of	IN
cord-011310-fm578rm5	238	57	acute	acute	JJ
cord-011310-fm578rm5	238	58	respiratory	respiratory	JJ
cord-011310-fm578rm5	238	59	tract	tract	NN
cord-011310-fm578rm5	238	60	infections	infection	NNS
cord-011310-fm578rm5	238	61	:	:	:
cord-011310-fm578rm5	238	62	decreasing	decrease	VBG
cord-011310-fm578rm5	238	63	benefit	benefit	NN
cord-011310-fm578rm5	238	64	,	,	,
cord-011310-fm578rm5	238	65	increasing	increase	VBG
cord-011310-fm578rm5	238	66	risk	risk	NN
cord-011310-fm578rm5	238	67	,	,	,
cord-011310-fm578rm5	238	68	and	and	CC
cord-011310-fm578rm5	238	69	the	the	DT
cord-011310-fm578rm5	238	70	irrelevance	irrelevance	NN
cord-011310-fm578rm5	238	71	of	of	IN
cord-011310-fm578rm5	238	72	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	238	73	resistance	resistance	NN
cord-011310-fm578rm5	238	74	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	238	75	stewardship	stewardship	NN
cord-011310-fm578rm5	238	76	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	238	77	stewardship	stewardship	NN
cord-011310-fm578rm5	238	78	in	in	IN
cord-011310-fm578rm5	238	79	small	small	JJ
cord-011310-fm578rm5	238	80	animal	animal	NN
cord-011310-fm578rm5	238	81	veterinary	veterinary	JJ
cord-011310-fm578rm5	238	82	practice	practice	NN
cord-011310-fm578rm5	238	83	:	:	:
cord-011310-fm578rm5	238	84	from	from	IN
cord-011310-fm578rm5	238	85	theory	theory	NN
cord-011310-fm578rm5	238	86	to	to	TO
cord-011310-fm578rm5	238	87	practice	practice	VB
cord-011310-fm578rm5	238	88	Minnesota	Minnesota	NNP
cord-011310-fm578rm5	238	89	Department	Department	NNP
cord-011310-fm578rm5	238	90	of	of	IN
cord-011310-fm578rm5	238	91	Health	Health	NNP
cord-011310-fm578rm5	238	92	.	.	.
cord-011310-fm578rm5	239	1	One	one	CD
cord-011310-fm578rm5	239	2	Health	Health	NNP
cord-011310-fm578rm5	239	3	Antibiotic	Antibiotic	NNP
cord-011310-fm578rm5	239	4	Stewardship	Stewardship	NNP
cord-011310-fm578rm5	239	5	Collaborative	Collaborative	NNP
cord-011310-fm578rm5	239	6	World	World	NNP
cord-011310-fm578rm5	239	7	Health	Health	NNP
cord-011310-fm578rm5	239	8	Organization	Organization	NNP
cord-011310-fm578rm5	239	9	.	.	.
cord-011310-fm578rm5	240	1	2nd	2nd	NNP
cord-011310-fm578rm5	240	2	Consultation	Consultation	NNP
cord-011310-fm578rm5	240	3	of	of	IN
cord-011310-fm578rm5	240	4	Member	Member	NNP
cord-011310-fm578rm5	240	5	States	States	NNP
cord-011310-fm578rm5	240	6	and	and	CC
cord-011310-fm578rm5	240	7	Partners	Partners	NNPS
cord-011310-fm578rm5	240	8	on	on	IN
cord-011310-fm578rm5	240	9	the	the	DT
cord-011310-fm578rm5	240	10	Global	Global	NNP
cord-011310-fm578rm5	240	11	Development	Development	NNP
cord-011310-fm578rm5	240	12	and	and	CC
cord-011310-fm578rm5	240	13	Stewardship	Stewardship	NNP
cord-011310-fm578rm5	240	14	Framework	Framework	NNP
cord-011310-fm578rm5	240	15	to	to	IN
cord-011310-fm578rm5	240	16	What	what	WP
cord-011310-fm578rm5	240	17	is	be	VBZ
cord-011310-fm578rm5	240	18	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	240	19	stewardship	stewardship	NN
cord-011310-fm578rm5	240	20	?	?	.
cord-011310-fm578rm5	241	1	Lessons	lesson	NNS
cord-011310-fm578rm5	241	2	learnt	learn	VBD
cord-011310-fm578rm5	241	3	during	during	IN
cord-011310-fm578rm5	241	4	20	20	CD
cord-011310-fm578rm5	241	5	years	year	NNS
cord-011310-fm578rm5	241	6	of	of	IN
cord-011310-fm578rm5	241	7	the	the	DT
cord-011310-fm578rm5	241	8	Swedish	swedish	JJ
cord-011310-fm578rm5	241	9	strategic	strategic	JJ
cord-011310-fm578rm5	241	10	programme	programme	NN
cord-011310-fm578rm5	241	11	against	against	IN
cord-011310-fm578rm5	241	12	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	241	13	resistance	resistance	NN
cord-011310-fm578rm5	241	14	European	European	NNP
cord-011310-fm578rm5	241	15	Centre	Centre	NNP
cord-011310-fm578rm5	241	16	for	for	IN
cord-011310-fm578rm5	241	17	Disease	Disease	NNP
cord-011310-fm578rm5	241	18	Prevention	Prevention	NNP
cord-011310-fm578rm5	241	19	and	and	CC
cord-011310-fm578rm5	241	20	Control	Control	NNP
cord-011310-fm578rm5	241	21	.	.	.
cord-011310-fm578rm5	242	1	Antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	242	2	consumption	consumption	NN
cord-011310-fm578rm5	242	3	National	national	JJ
cord-011310-fm578rm5	242	4	action	action	NN
cord-011310-fm578rm5	242	5	plan	plan	NN
cord-011310-fm578rm5	242	6	for	for	IN
cord-011310-fm578rm5	242	7	combating	combat	VBG
cord-011310-fm578rm5	242	8	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	242	9	-	-	HYPH
cord-011310-fm578rm5	242	10	resistant	resistant	JJ
cord-011310-fm578rm5	242	11	bacteria	bacteria	NNS
cord-011310-fm578rm5	242	12	Guideline	Guideline	NNP
cord-011310-fm578rm5	242	13	Development	Development	NNP
cord-011310-fm578rm5	242	14	G.	G.	NNP
cord-011310-fm578rm5	242	15	Diagnosis	Diagnosis	NNP
cord-011310-fm578rm5	242	16	and	and	CC
cord-011310-fm578rm5	242	17	management	management	NN
cord-011310-fm578rm5	242	18	of	of	IN
cord-011310-fm578rm5	242	19	community	community	NN
cord-011310-fm578rm5	242	20	and	and	CC
cord-011310-fm578rm5	242	21	hospital	hospital	NN
cord-011310-fm578rm5	242	22	acquired	acquire	VBD
cord-011310-fm578rm5	242	23	pneumonia	pneumonia	NN
cord-011310-fm578rm5	242	24	in	in	IN
cord-011310-fm578rm5	242	25	adults	adult	NNS
cord-011310-fm578rm5	242	26	:	:	:
cord-011310-fm578rm5	242	27	summary	summary	NN
cord-011310-fm578rm5	242	28	of	of	IN
cord-011310-fm578rm5	242	29	NICE	nice	JJ
cord-011310-fm578rm5	242	30	guidance	guidance	NN
cord-011310-fm578rm5	242	31	Management	Management	NNP
cord-011310-fm578rm5	242	32	of	of	IN
cord-011310-fm578rm5	242	33	community	community	NN
cord-011310-fm578rm5	242	34	-	-	HYPH
cord-011310-fm578rm5	242	35	acquired	acquire	VBN
cord-011310-fm578rm5	242	36	pneumonia	pneumonia	NN
cord-011310-fm578rm5	242	37	in	in	IN
cord-011310-fm578rm5	242	38	adults	adult	NNS
cord-011310-fm578rm5	242	39	:	:	:
cord-011310-fm578rm5	243	1	2016	2016	CD
cord-011310-fm578rm5	243	2	guideline	guideline	NN
cord-011310-fm578rm5	243	3	update	update	NN
cord-011310-fm578rm5	243	4	from	from	IN
cord-011310-fm578rm5	243	5	the	the	DT
cord-011310-fm578rm5	243	6	Dutch	Dutch	NNP
cord-011310-fm578rm5	243	7	Working	Working	NNP
cord-011310-fm578rm5	243	8	Party	Party	NNP
cord-011310-fm578rm5	243	9	on	on	IN
cord-011310-fm578rm5	243	10	Antibiotic	Antibiotic	NNP
cord-011310-fm578rm5	243	11	Policy	Policy	NNP
cord-011310-fm578rm5	243	12	(	(	-LRB-
cord-011310-fm578rm5	243	13	SWAB	swab	NN
cord-011310-fm578rm5	243	14	)	)	-RRB-
cord-011310-fm578rm5	243	15	and	and	CC
cord-011310-fm578rm5	243	16	Dutch	Dutch	NNP
cord-011310-fm578rm5	243	17	Association	Association	NNP
cord-011310-fm578rm5	243	18	of	of	IN
cord-011310-fm578rm5	243	19	Chest	Chest	NNP
cord-011310-fm578rm5	243	20	Physicians	Physicians	NNPS
cord-011310-fm578rm5	243	21	Swedish	swedish	JJ
cord-011310-fm578rm5	243	22	guidelines	guideline	NNS
cord-011310-fm578rm5	243	23	on	on	IN
cord-011310-fm578rm5	243	24	the	the	DT
cord-011310-fm578rm5	243	25	management	management	NN
cord-011310-fm578rm5	243	26	of	of	IN
cord-011310-fm578rm5	243	27	community	community	NN
cord-011310-fm578rm5	243	28	-	-	HYPH
cord-011310-fm578rm5	243	29	acquired	acquire	VBN
cord-011310-fm578rm5	243	30	pneumonia	pneumonia	NN
cord-011310-fm578rm5	243	31	in	in	IN
cord-011310-fm578rm5	243	32	immunocompetent	immunocompetent	JJ
cord-011310-fm578rm5	243	33	adults	adult	NNS
cord-011310-fm578rm5	243	34	-	-	:
cord-011310-fm578rm5	243	35	Swedish	swedish	JJ
cord-011310-fm578rm5	243	36	society	society	NN
cord-011310-fm578rm5	243	37	of	of	IN
cord-011310-fm578rm5	243	38	infectious	infectious	JJ
cord-011310-fm578rm5	243	39	diseases	disease	NNS
cord-011310-fm578rm5	243	40	2012	2012	CD
cord-011310-fm578rm5	243	41	Infectious	infectious	JJ
cord-011310-fm578rm5	243	42	diseases	disease	NNS
cord-011310-fm578rm5	243	43	society	society	NN
cord-011310-fm578rm5	243	44	of	of	IN
cord-011310-fm578rm5	243	45	America	America	NNP
cord-011310-fm578rm5	243	46	/	/	SYM
cord-011310-fm578rm5	243	47	American	american	JJ
cord-011310-fm578rm5	243	48	thoracic	thoracic	JJ
cord-011310-fm578rm5	243	49	society	society	NN
cord-011310-fm578rm5	243	50	consensus	consensus	NN
cord-011310-fm578rm5	243	51	guidelines	guideline	NNS
cord-011310-fm578rm5	243	52	on	on	IN
cord-011310-fm578rm5	243	53	the	the	DT
cord-011310-fm578rm5	243	54	management	management	NN
cord-011310-fm578rm5	243	55	of	of	IN
cord-011310-fm578rm5	243	56	community	community	NN
cord-011310-fm578rm5	243	57	-	-	HYPH
cord-011310-fm578rm5	243	58	acquired	acquire	VBN
cord-011310-fm578rm5	243	59	pneumonia	pneumonia	NN
cord-011310-fm578rm5	243	60	in	in	IN
cord-011310-fm578rm5	243	61	adults	adult	NNS
cord-011310-fm578rm5	244	1	Antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	244	2	resistance	resistance	NN
cord-011310-fm578rm5	244	3	following	follow	VBG
cord-011310-fm578rm5	244	4	mass	mass	NN
cord-011310-fm578rm5	244	5	azithromycin	azithromycin	NN
cord-011310-fm578rm5	244	6	distribution	distribution	NN
cord-011310-fm578rm5	244	7	for	for	IN
cord-011310-fm578rm5	244	8	trachoma	trachoma	NN
cord-011310-fm578rm5	244	9	:	:	:
cord-011310-fm578rm5	244	10	a	a	DT
cord-011310-fm578rm5	244	11	systematic	systematic	JJ
cord-011310-fm578rm5	244	12	review	review	NN
cord-011310-fm578rm5	244	13	Global	Global	NNP
cord-011310-fm578rm5	244	14	Cancer	Cancer	NNP
cord-011310-fm578rm5	244	15	Observatory	Observatory	NNP
cord-011310-fm578rm5	244	16	:	:	:
cord-011310-fm578rm5	245	1	Cancer	Cancer	NNP
cord-011310-fm578rm5	245	2	Today	today	NN
cord-011310-fm578rm5	245	3	.	.	.
cord-011310-fm578rm5	246	1	Lyon	Lyon	NNP
cord-011310-fm578rm5	246	2	:	:	:
cord-011310-fm578rm5	247	1	International	International	NNP
cord-011310-fm578rm5	247	2	Agency	Agency	NNP
cord-011310-fm578rm5	247	3	for	for	IN
cord-011310-fm578rm5	247	4	Research	Research	NNP
cord-011310-fm578rm5	247	5	on	on	IN
cord-011310-fm578rm5	247	6	Cancer	Cancer	NNP
cord-011310-fm578rm5	247	7	Prevalence	prevalence	NN
cord-011310-fm578rm5	247	8	of	of	IN
cord-011310-fm578rm5	247	9	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	247	10	pylori	pylori	NN
cord-011310-fm578rm5	247	11	infection	infection	NN
cord-011310-fm578rm5	247	12	and	and	CC
cord-011310-fm578rm5	247	13	atrophic	atrophic	JJ
cord-011310-fm578rm5	247	14	gastritis	gastritis	NN
cord-011310-fm578rm5	247	15	in	in	IN
cord-011310-fm578rm5	247	16	Latvia	Latvia	NNP
cord-011310-fm578rm5	248	1	A	a	DT
cord-011310-fm578rm5	248	2	systematic	systematic	JJ
cord-011310-fm578rm5	248	3	review	review	NN
cord-011310-fm578rm5	248	4	of	of	IN
cord-011310-fm578rm5	248	5	treating	treat	VBG
cord-011310-fm578rm5	248	6	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	248	7	pylori	pylori	NN
cord-011310-fm578rm5	248	8	infection	infection	NN
cord-011310-fm578rm5	248	9	with	with	IN
cord-011310-fm578rm5	248	10	traditional	traditional	JJ
cord-011310-fm578rm5	248	11	Chinese	chinese	JJ
cord-011310-fm578rm5	248	12	medicine	medicine	NN
cord-011310-fm578rm5	248	13	Antimicrobial	Antimicrobial	NNP
cord-011310-fm578rm5	248	14	activity	activity	NN
cord-011310-fm578rm5	248	15	of	of	IN
cord-011310-fm578rm5	248	16	natural	natural	JJ
cord-011310-fm578rm5	248	17	products	product	NNS
cord-011310-fm578rm5	248	18	against	against	IN
cord-011310-fm578rm5	248	19	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	248	20	pylori	pylori	NN
cord-011310-fm578rm5	248	21	:	:	:
cord-011310-fm578rm5	248	22	a	a	DT
cord-011310-fm578rm5	248	23	review	review	NN
cord-011310-fm578rm5	248	24	Review	review	NN
cord-011310-fm578rm5	248	25	:	:	:
cord-011310-fm578rm5	248	26	pharmacological	pharmacological	JJ
cord-011310-fm578rm5	248	27	ins	in	NNS
cord-011310-fm578rm5	248	28	and	and	CC
cord-011310-fm578rm5	248	29	outs	out	NNS
cord-011310-fm578rm5	248	30	of	of	IN
cord-011310-fm578rm5	248	31	medicinal	medicinal	JJ
cord-011310-fm578rm5	248	32	plants	plant	NNS
cord-011310-fm578rm5	248	33	against	against	IN
cord-011310-fm578rm5	248	34	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	248	35	pylori	pylori	NN
cord-011310-fm578rm5	248	36	:	:	:
cord-011310-fm578rm5	248	37	a	a	DT
cord-011310-fm578rm5	248	38	review	review	NN
cord-011310-fm578rm5	248	39	Non	non	JJ
cord-011310-fm578rm5	248	40	-	-	JJ
cord-011310-fm578rm5	248	41	pharmacological	pharmacological	JJ
cord-011310-fm578rm5	248	42	treatment	treatment	NN
cord-011310-fm578rm5	248	43	of	of	IN
cord-011310-fm578rm5	248	44	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	248	45	pylori	pylori	NN
cord-011310-fm578rm5	249	1	Probiotic	probiotic	JJ
cord-011310-fm578rm5	249	2	monotherapy	monotherapy	NN
cord-011310-fm578rm5	249	3	and	and	CC
cord-011310-fm578rm5	249	4	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	249	5	pylori	pylori	NN
cord-011310-fm578rm5	249	6	eradication	eradication	NN
cord-011310-fm578rm5	249	7	:	:	:
cord-011310-fm578rm5	249	8	a	a	DT
cord-011310-fm578rm5	249	9	systematic	systematic	JJ
cord-011310-fm578rm5	249	10	review	review	NN
cord-011310-fm578rm5	249	11	with	with	IN
cord-011310-fm578rm5	249	12	pooled	pool	VBN
cord-011310-fm578rm5	249	13	-	-	HYPH
cord-011310-fm578rm5	249	14	data	data	NN
cord-011310-fm578rm5	249	15	analysis	analysis	NN
cord-011310-fm578rm5	250	1	Selective	selective	JJ
cord-011310-fm578rm5	250	2	killing	killing	NN
cord-011310-fm578rm5	250	3	of	of	IN
cord-011310-fm578rm5	250	4	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	250	5	pylori	pylori	NN
cord-011310-fm578rm5	250	6	with	with	IN
cord-011310-fm578rm5	250	7	pH	ph	NN
cord-011310-fm578rm5	250	8	-	-	HYPH
cord-011310-fm578rm5	250	9	responsive	responsive	JJ
cord-011310-fm578rm5	250	10	helix	helix	NN
cord-011310-fm578rm5	250	11	-	-	HYPH
cord-011310-fm578rm5	250	12	coil	coil	NN
cord-011310-fm578rm5	250	13	conformation	conformation	NN
cord-011310-fm578rm5	250	14	transitionable	transitionable	NN
cord-011310-fm578rm5	250	15	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	250	16	polypeptides	polypeptide	NNS
cord-011310-fm578rm5	250	17	Docosahexaenoic	Docosahexaenoic	NNP
cord-011310-fm578rm5	250	18	acid	acid	NN
cord-011310-fm578rm5	250	19	loaded	loaded	JJ
cord-011310-fm578rm5	250	20	lipid	lipid	NN
cord-011310-fm578rm5	250	21	nanoparticles	nanoparticle	NNS
cord-011310-fm578rm5	250	22	with	with	IN
cord-011310-fm578rm5	250	23	bactericidal	bactericidal	JJ
cord-011310-fm578rm5	250	24	activity	activity	NN
cord-011310-fm578rm5	250	25	against	against	IN
cord-011310-fm578rm5	250	26	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	250	27	pylori	pylori	NN
cord-011310-fm578rm5	250	28	Lipid	lipid	NN
cord-011310-fm578rm5	250	29	nanoparticles	nanoparticle	NNS
cord-011310-fm578rm5	250	30	to	to	TO
cord-011310-fm578rm5	250	31	counteract	counteract	VB
cord-011310-fm578rm5	250	32	gastric	gastric	JJ
cord-011310-fm578rm5	250	33	infection	infection	NN
cord-011310-fm578rm5	250	34	without	without	IN
cord-011310-fm578rm5	250	35	affecting	affect	VBG
cord-011310-fm578rm5	250	36	gut	gut	NN
cord-011310-fm578rm5	250	37	microbiota	microbiota	NN
cord-011310-fm578rm5	250	38	High	High	NNP
cord-011310-fm578rm5	250	39	dose	dose	NN
cord-011310-fm578rm5	250	40	ilaprazole/	ilaprazole/	CD
cord-011310-fm578rm5	250	41	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	250	42	as	as	IN
cord-011310-fm578rm5	250	43	first	first	JJ
cord-011310-fm578rm5	250	44	-	-	HYPH
cord-011310-fm578rm5	250	45	line	line	NN
cord-011310-fm578rm5	250	46	regimen	regimen	NN
cord-011310-fm578rm5	250	47	for	for	IN
cord-011310-fm578rm5	250	48	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	250	49	pylori	pylori	NN
cord-011310-fm578rm5	250	50	infection	infection	NN
cord-011310-fm578rm5	250	51	in	in	IN
cord-011310-fm578rm5	250	52	Korea	Korea	NNP
cord-011310-fm578rm5	250	53	High	High	NNP
cord-011310-fm578rm5	250	54	and	and	CC
cord-011310-fm578rm5	250	55	frequent	frequent	JJ
cord-011310-fm578rm5	250	56	dose	dose	NN
cord-011310-fm578rm5	250	57	of	of	IN
cord-011310-fm578rm5	250	58	dexlansoprazole	dexlansoprazole	NNP
cord-011310-fm578rm5	250	59	and	and	CC
cord-011310-fm578rm5	250	60	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	250	61	dual	dual	JJ
cord-011310-fm578rm5	250	62	therapy	therapy	NN
cord-011310-fm578rm5	250	63	for	for	IN
cord-011310-fm578rm5	250	64	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	250	65	pylori	pylori	NN
cord-011310-fm578rm5	250	66	infections	infection	NNS
cord-011310-fm578rm5	250	67	:	:	:
cord-011310-fm578rm5	251	1	a	a	DT
cord-011310-fm578rm5	251	2	single	single	JJ
cord-011310-fm578rm5	251	3	arm	arm	NN
cord-011310-fm578rm5	251	4	prospective	prospective	JJ
cord-011310-fm578rm5	251	5	study	study	NN
cord-011310-fm578rm5	251	6	High	High	NNP
cord-011310-fm578rm5	251	7	-	-	HYPH
cord-011310-fm578rm5	251	8	dose	dose	NN
cord-011310-fm578rm5	251	9	esomeprazole	esomeprazole	NNP
cord-011310-fm578rm5	251	10	and	and	CC
cord-011310-fm578rm5	251	11	amoxicillin	amoxicillin	NNP
cord-011310-fm578rm5	251	12	dual	dual	JJ
cord-011310-fm578rm5	251	13	therapy	therapy	NN
cord-011310-fm578rm5	251	14	for	for	IN
cord-011310-fm578rm5	251	15	first	first	JJ
cord-011310-fm578rm5	251	16	-	-	HYPH
cord-011310-fm578rm5	251	17	line	line	NN
cord-011310-fm578rm5	251	18	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	251	19	pylori	pylori	NN
cord-011310-fm578rm5	251	20	eradication	eradication	NN
cord-011310-fm578rm5	251	21	:	:	:
cord-011310-fm578rm5	251	22	a	a	DT
cord-011310-fm578rm5	251	23	proof	proof	NN
cord-011310-fm578rm5	251	24	of	of	IN
cord-011310-fm578rm5	251	25	concept	concept	NN
cord-011310-fm578rm5	251	26	study	study	NN
cord-011310-fm578rm5	251	27	Role	role	NN
cord-011310-fm578rm5	251	28	of	of	IN
cord-011310-fm578rm5	251	29	bismuth	bismuth	NN
cord-011310-fm578rm5	251	30	in	in	IN
cord-011310-fm578rm5	251	31	improving	improve	VBG
cord-011310-fm578rm5	251	32	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	251	33	pylori	pylori	NN
cord-011310-fm578rm5	251	34	eradication	eradication	NN
cord-011310-fm578rm5	251	35	with	with	IN
cord-011310-fm578rm5	251	36	triple	triple	JJ
cord-011310-fm578rm5	251	37	therapy	therapy	NN
cord-011310-fm578rm5	252	1	Understanding	understand	VBG
cord-011310-fm578rm5	252	2	treatment	treatment	NN
cord-011310-fm578rm5	252	3	guidelines	guideline	NNS
cord-011310-fm578rm5	252	4	with	with	IN
cord-011310-fm578rm5	252	5	bismuth	bismuth	NN
cord-011310-fm578rm5	252	6	and	and	CC
cord-011310-fm578rm5	252	7	non	non	JJ
cord-011310-fm578rm5	252	8	-	-	JJ
cord-011310-fm578rm5	252	9	bismuth	bismuth	JJ
cord-011310-fm578rm5	252	10	quadruple	quadruple	JJ
cord-011310-fm578rm5	252	11	Helicobacter	helicobacter	NN
cord-011310-fm578rm5	253	1	pylori	pylori	NN
cord-011310-fm578rm5	253	2	eradication	eradication	NN
cord-011310-fm578rm5	253	3	therapies	therapy	NNS
cord-011310-fm578rm5	254	1	Adverse	adverse	JJ
cord-011310-fm578rm5	254	2	events	event	NNS
cord-011310-fm578rm5	254	3	with	with	IN
cord-011310-fm578rm5	254	4	bismuth	bismuth	NN
cord-011310-fm578rm5	254	5	salts	salt	NNS
cord-011310-fm578rm5	254	6	for	for	IN
cord-011310-fm578rm5	254	7	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	254	8	pylori	pylori	NN
cord-011310-fm578rm5	254	9	eradication	eradication	NN
cord-011310-fm578rm5	254	10	:	:	:
cord-011310-fm578rm5	254	11	systematic	systematic	JJ
cord-011310-fm578rm5	254	12	review	review	NN
cord-011310-fm578rm5	254	13	and	and	CC
cord-011310-fm578rm5	254	14	meta	meta	NNP
cord-011310-fm578rm5	254	15	-	-	HYPH
cord-011310-fm578rm5	254	16	analysis	analysis	NN
cord-011310-fm578rm5	254	17	Bismuth	Bismuth	NNP
cord-011310-fm578rm5	254	18	supplements	supplement	NNS
cord-011310-fm578rm5	254	19	as	as	IN
cord-011310-fm578rm5	254	20	the	the	DT
cord-011310-fm578rm5	254	21	first	first	JJ
cord-011310-fm578rm5	254	22	-	-	HYPH
cord-011310-fm578rm5	254	23	line	line	NN
cord-011310-fm578rm5	254	24	regimen	regimen	NN
cord-011310-fm578rm5	254	25	for	for	IN
cord-011310-fm578rm5	254	26	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	255	1	pylori	pylori	NNP
cord-011310-fm578rm5	255	2	eradication	eradication	NN
cord-011310-fm578rm5	255	3	therapy	therapy	NN
cord-011310-fm578rm5	255	4	:	:	:
cord-011310-fm578rm5	255	5	systemic	systemic	JJ
cord-011310-fm578rm5	255	6	review	review	NN
cord-011310-fm578rm5	255	7	and	and	CC
cord-011310-fm578rm5	255	8	meta	meta	NNP
cord-011310-fm578rm5	255	9	-	-	HYPH
cord-011310-fm578rm5	255	10	analysis	analysis	NN
cord-011310-fm578rm5	255	11	Meta	Meta	NNP
cord-011310-fm578rm5	255	12	-	-	HYPH
cord-011310-fm578rm5	255	13	analysis	analysis	NN
cord-011310-fm578rm5	255	14	of	of	IN
cord-011310-fm578rm5	255	15	threein	threein	NNP
cord-011310-fm578rm5	255	16	-	-	HYPH
cord-011310-fm578rm5	255	17	one	one	CD
cord-011310-fm578rm5	255	18	single	single	JJ
cord-011310-fm578rm5	255	19	capsule	capsule	NN
cord-011310-fm578rm5	255	20	bismuth	bismuth	NN
cord-011310-fm578rm5	255	21	-	-	HYPH
cord-011310-fm578rm5	255	22	containing	contain	VBG
cord-011310-fm578rm5	255	23	quadruple	quadruple	JJ
cord-011310-fm578rm5	255	24	therapy	therapy	NN
cord-011310-fm578rm5	255	25	for	for	IN
cord-011310-fm578rm5	255	26	the	the	DT
cord-011310-fm578rm5	255	27	eradication	eradication	NN
cord-011310-fm578rm5	255	28	of	of	IN
cord-011310-fm578rm5	255	29	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	255	30	pylori	pylori	NN
cord-011310-fm578rm5	255	31	Helicobacter	helicobacter	NN
cord-011310-fm578rm5	255	32	pylori	pylori	NN
cord-011310-fm578rm5	256	1	eradication	eradication	NN
cord-011310-fm578rm5	256	2	with	with	IN
cord-011310-fm578rm5	256	3	bismuth	bismuth	NN
cord-011310-fm578rm5	256	4	quadruple	quadruple	NN
cord-011310-fm578rm5	256	5	therapy	therapy	NN
cord-011310-fm578rm5	256	6	leads	lead	VBZ
cord-011310-fm578rm5	256	7	to	to	IN
cord-011310-fm578rm5	256	8	dysbiosis	dysbiosis	NN
cord-011310-fm578rm5	256	9	of	of	IN
cord-011310-fm578rm5	256	10	gut	gut	NN
cord-011310-fm578rm5	256	11	microbiota	microbiota	NN
cord-011310-fm578rm5	256	12	with	with	IN
cord-011310-fm578rm5	256	13	an	an	DT
cord-011310-fm578rm5	256	14	increased	increase	VBN
cord-011310-fm578rm5	256	15	relative	relative	JJ
cord-011310-fm578rm5	256	16	abundance	abundance	NN
cord-011310-fm578rm5	256	17	of	of	IN
cord-011310-fm578rm5	256	18	Proteobacteria	Proteobacteria	NNP
cord-011310-fm578rm5	256	19	and	and	CC
cord-011310-fm578rm5	256	20	decreased	decrease	VBD
cord-011310-fm578rm5	256	21	relative	relative	JJ
cord-011310-fm578rm5	256	22	abundances	abundance	NNS
cord-011310-fm578rm5	256	23	of	of	IN
cord-011310-fm578rm5	256	24	Bacteroidetes	Bacteroidetes	NNPS
cord-011310-fm578rm5	256	25	and	and	CC
cord-011310-fm578rm5	256	26	Actinobacteria	Actinobacteria	NNP
cord-011310-fm578rm5	256	27	Treating	treat	VBG
cord-011310-fm578rm5	256	28	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	256	29	pylori	pylori	NN
cord-011310-fm578rm5	256	30	effectively	effectively	RB
cord-011310-fm578rm5	256	31	while	while	IN
cord-011310-fm578rm5	256	32	minimizing	minimize	VBG
cord-011310-fm578rm5	256	33	misuse	misuse	NN
cord-011310-fm578rm5	256	34	of	of	IN
cord-011310-fm578rm5	256	35	antibiotics	antibiotic	NNS
cord-011310-fm578rm5	256	36	Screening	screen	VBG
cord-011310-fm578rm5	256	37	for	for	IN
cord-011310-fm578rm5	256	38	gastric	gastric	JJ
cord-011310-fm578rm5	256	39	cancer	cancer	NN
cord-011310-fm578rm5	256	40	and	and	CC
cord-011310-fm578rm5	256	41	surveillance	surveillance	NN
cord-011310-fm578rm5	256	42	of	of	IN
cord-011310-fm578rm5	256	43	premalignant	premalignant	JJ
cord-011310-fm578rm5	256	44	lesions	lesion	NNS
cord-011310-fm578rm5	256	45	:	:	:
cord-011310-fm578rm5	256	46	a	a	DT
cord-011310-fm578rm5	256	47	systematic	systematic	JJ
cord-011310-fm578rm5	256	48	review	review	NN
cord-011310-fm578rm5	256	49	of	of	IN
cord-011310-fm578rm5	256	50	cost	cost	NN
cord-011310-fm578rm5	256	51	-	-	HYPH
cord-011310-fm578rm5	256	52	effectiveness	effectiveness	NN
cord-011310-fm578rm5	256	53	studies	study	NNS
cord-011310-fm578rm5	256	54	Cost	cost	NN
cord-011310-fm578rm5	256	55	-	-	HYPH
cord-011310-fm578rm5	256	56	effectiveness	effectiveness	NN
cord-011310-fm578rm5	256	57	of	of	IN
cord-011310-fm578rm5	256	58	screening	screening	NN
cord-011310-fm578rm5	256	59	and	and	CC
cord-011310-fm578rm5	256	60	treating	treat	VBG
cord-011310-fm578rm5	256	61	Helicobacter	helicobacter	NN
cord-011310-fm578rm5	256	62	pylori	pylori	NN
cord-011310-fm578rm5	256	63	for	for	IN
cord-011310-fm578rm5	256	64	gastric	gastric	JJ
cord-011310-fm578rm5	256	65	cancer	cancer	NN
cord-011310-fm578rm5	256	66	prevention	prevention	NN
cord-011310-fm578rm5	257	1	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	257	2	pylori	pylori	NN
cord-011310-fm578rm5	257	3	eradication	eradication	NN
cord-011310-fm578rm5	257	4	therapy	therapy	NN
cord-011310-fm578rm5	257	5	to	to	TO
cord-011310-fm578rm5	257	6	prevent	prevent	VB
cord-011310-fm578rm5	257	7	gastric	gastric	JJ
cord-011310-fm578rm5	257	8	cancer	cancer	NN
cord-011310-fm578rm5	257	9	in	in	IN
cord-011310-fm578rm5	257	10	healthy	healthy	JJ
cord-011310-fm578rm5	257	11	asymptomatic	asymptomatic	JJ
cord-011310-fm578rm5	257	12	infected	infected	JJ
cord-011310-fm578rm5	257	13	individuals	individual	NNS
cord-011310-fm578rm5	257	14	:	:	:
cord-011310-fm578rm5	257	15	systematic	systematic	JJ
cord-011310-fm578rm5	257	16	review	review	NN
cord-011310-fm578rm5	257	17	and	and	CC
cord-011310-fm578rm5	257	18	metaanalysis	metaanalysis	NN
cord-011310-fm578rm5	257	19	of	of	IN
cord-011310-fm578rm5	257	20	randomised	randomised	JJ
cord-011310-fm578rm5	257	21	controlled	control	VBN
cord-011310-fm578rm5	257	22	trials	trial	NNS
cord-011310-fm578rm5	258	1	The	the	DT
cord-011310-fm578rm5	258	2	cost	cost	NN
cord-011310-fm578rm5	258	3	effectiveness	effectiveness	NN
cord-011310-fm578rm5	258	4	of	of	IN
cord-011310-fm578rm5	258	5	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	258	6	pylori	pylori	NN
cord-011310-fm578rm5	258	7	population	population	NN
cord-011310-fm578rm5	258	8	screening	screening	NN
cord-011310-fm578rm5	258	9	-	-	HYPH
cord-011310-fm578rm5	258	10	economic	economic	JJ
cord-011310-fm578rm5	258	11	evaluation	evaluation	NN
cord-011310-fm578rm5	258	12	alongside	alongside	IN
cord-011310-fm578rm5	258	13	a	a	DT
cord-011310-fm578rm5	258	14	randomised	randomised	JJ
cord-011310-fm578rm5	258	15	controlled	control	VBN
cord-011310-fm578rm5	258	16	trial	trial	NN
cord-011310-fm578rm5	258	17	with	with	IN
cord-011310-fm578rm5	258	18	13-year	13-year	JJ
cord-011310-fm578rm5	258	19	follow	follow	NN
cord-011310-fm578rm5	258	20	-	-	HYPH
cord-011310-fm578rm5	258	21	up	up	NN
cord-011310-fm578rm5	258	22	Cost	cost	NN
cord-011310-fm578rm5	258	23	-	-	HYPH
cord-011310-fm578rm5	258	24	effectiveness	effectiveness	NN
cord-011310-fm578rm5	258	25	analysis	analysis	NN
cord-011310-fm578rm5	258	26	of	of	IN
cord-011310-fm578rm5	258	27	screen	screen	NN
cord-011310-fm578rm5	258	28	-	-	HYPH
cord-011310-fm578rm5	258	29	and	and	CC
cord-011310-fm578rm5	258	30	-	-	HYPH
cord-011310-fm578rm5	258	31	treat	treat	VB
cord-011310-fm578rm5	258	32	strategy	strategy	NN
cord-011310-fm578rm5	258	33	in	in	IN
cord-011310-fm578rm5	258	34	asymptomatic	asymptomatic	JJ
cord-011310-fm578rm5	258	35	Chinese	Chinese	NNP
cord-011310-fm578rm5	258	36	for	for	IN
cord-011310-fm578rm5	258	37	preventing	prevent	VBG
cord-011310-fm578rm5	258	38	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	258	39	pylori	pylori	NN
cord-011310-fm578rm5	258	40	-	-	HYPH
cord-011310-fm578rm5	258	41	associated	associate	VBN
cord-011310-fm578rm5	258	42	diseases	disease	NNS
cord-011310-fm578rm5	258	43	Cost	cost	NN
cord-011310-fm578rm5	258	44	-	-	HYPH
cord-011310-fm578rm5	258	45	effectiveness	effectiveness	NN
cord-011310-fm578rm5	258	46	of	of	IN
cord-011310-fm578rm5	258	47	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	258	48	pylori	pylori	NN
cord-011310-fm578rm5	258	49	screening	screening	NN
cord-011310-fm578rm5	258	50	followed	follow	VBN
cord-011310-fm578rm5	258	51	by	by	IN
cord-011310-fm578rm5	258	52	eradication	eradication	NN
cord-011310-fm578rm5	258	53	treatment	treatment	NN
cord-011310-fm578rm5	258	54	for	for	IN
cord-011310-fm578rm5	258	55	employees	employee	NNS
cord-011310-fm578rm5	258	56	in	in	IN
cord-011310-fm578rm5	258	57	Japan	Japan	NNP
cord-011310-fm578rm5	259	1	The	the	DT
cord-011310-fm578rm5	259	2	true	true	JJ
cord-011310-fm578rm5	259	3	cost	cost	NN
cord-011310-fm578rm5	259	4	of	of	IN
cord-011310-fm578rm5	259	5	antimicrobial	antimicrobial	JJ
cord-011310-fm578rm5	259	6	resistance	resistance	NN
cord-011310-fm578rm5	260	1	The	the	DT
cord-011310-fm578rm5	260	2	hidden	hidden	JJ
cord-011310-fm578rm5	260	3	societal	societal	JJ
cord-011310-fm578rm5	260	4	cost	cost	NN
cord-011310-fm578rm5	260	5	of	of	IN
cord-011310-fm578rm5	260	6	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	260	7	resistance	resistance	NN
cord-011310-fm578rm5	260	8	per	per	IN
cord-011310-fm578rm5	260	9	antibiotic	antibiotic	JJ
cord-011310-fm578rm5	260	10	prescribed	prescribe	VBN
cord-011310-fm578rm5	260	11	in	in	IN
cord-011310-fm578rm5	260	12	the	the	DT
cord-011310-fm578rm5	260	13	United	United	NNP
cord-011310-fm578rm5	260	14	States	States	NNP
cord-011310-fm578rm5	260	15	:	:	:
cord-011310-fm578rm5	260	16	an	an	DT
cord-011310-fm578rm5	260	17	exploratory	exploratory	JJ
cord-011310-fm578rm5	260	18	analysis	analysis	NN
cord-011310-fm578rm5	260	19	Mass	Mass	NNP
cord-011310-fm578rm5	260	20	eradication	eradication	NN
cord-011310-fm578rm5	260	21	of	of	IN
cord-011310-fm578rm5	260	22	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	260	23	pylori	pylori	NN
cord-011310-fm578rm5	260	24	to	to	TO
cord-011310-fm578rm5	260	25	prevent	prevent	VB
cord-011310-fm578rm5	260	26	gastric	gastric	JJ
cord-011310-fm578rm5	260	27	cancer	cancer	NN
cord-011310-fm578rm5	260	28	:	:	:
cord-011310-fm578rm5	260	29	theoretical	theoretical	JJ
cord-011310-fm578rm5	260	30	and	and	CC
cord-011310-fm578rm5	260	31	practical	practical	JJ
cord-011310-fm578rm5	260	32	considerations	consideration	NNS
cord-011310-fm578rm5	260	33	Effects	effect	NNS
cord-011310-fm578rm5	260	34	of	of	IN
cord-011310-fm578rm5	260	35	community	community	NN
cord-011310-fm578rm5	260	36	screening	screening	NN
cord-011310-fm578rm5	260	37	for	for	IN
cord-011310-fm578rm5	260	38	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	260	39	pylori	pylori	NN
cord-011310-fm578rm5	260	40	:	:	:
cord-011310-fm578rm5	261	1	13-year	13-year	JJ
cord-011310-fm578rm5	261	2	follow	follow	NN
cord-011310-fm578rm5	261	3	-	-	HYPH
cord-011310-fm578rm5	261	4	up	up	NN
cord-011310-fm578rm5	261	5	evaluation	evaluation	NN
cord-011310-fm578rm5	261	6	of	of	IN
cord-011310-fm578rm5	261	7	a	a	DT
cord-011310-fm578rm5	261	8	randomized	randomized	JJ
cord-011310-fm578rm5	261	9	controlled	control	VBN
cord-011310-fm578rm5	261	10	trial	trial	NN
cord-011310-fm578rm5	261	11	Multicentric	Multicentric	NNP
cord-011310-fm578rm5	261	12	randomised	randomised	JJ
cord-011310-fm578rm5	261	13	study	study	NN
cord-011310-fm578rm5	261	14	of	of	IN
cord-011310-fm578rm5	261	15	Helicobacter	Helicobacter	NNP
cord-011310-fm578rm5	261	16	pylori	pylori	NN
cord-011310-fm578rm5	261	17	eradication	eradication	NN
cord-011310-fm578rm5	261	18	and	and	CC
cord-011310-fm578rm5	261	19	pepsinogen	pepsinogen	NN
cord-011310-fm578rm5	261	20	testing	testing	NN
cord-011310-fm578rm5	261	21	for	for	IN
cord-011310-fm578rm5	261	22	prevention	prevention	NN
cord-011310-fm578rm5	261	23	of	of	IN
cord-011310-fm578rm5	261	24	gastric	gastric	JJ
cord-011310-fm578rm5	261	25	cancer	cancer	NN
cord-011310-fm578rm5	261	26	mortality	mortality	NN
cord-011310-fm578rm5	261	27	:	:	:
cord-011310-fm578rm5	262	1	the	the	DT
cord-011310-fm578rm5	262	2	GISTAR	GISTAR	NNP
cord-011310-fm578rm5	262	3	study	study	NN
cord-011310-fm578rm5	262	4	Acknowledgments	acknowledgment	NNS
cord-011310-fm578rm5	263	1	The	the	DT
cord-011310-fm578rm5	263	2	work	work	NN
cord-011310-fm578rm5	263	3	was	be	VBD
cord-011310-fm578rm5	263	4	supported	support	VBN
cord-011310-fm578rm5	263	5	by	by	IN
cord-011310-fm578rm5	263	6	ERDF	ERDF	NNP
cord-011310-fm578rm5	263	7	(	(	-LRB-
cord-011310-fm578rm5	263	8	European	European	NNP
cord-011310-fm578rm5	263	9	Regional	Regional	NNP
cord-011310-fm578rm5	263	10	Development	Development	NNP
cord-011310-fm578rm5	263	11	Fund	Fund	NNP
cord-011310-fm578rm5	263	12	)	)	-RRB-
cord-011310-fm578rm5	263	13	in	in	IN
cord-011310-fm578rm5	263	14	Latvia	Latvia	NNP
cord-011310-fm578rm5	263	15	,	,	,
cord-011310-fm578rm5	263	16	Project	Project	NNP
cord-011310-fm578rm5	263	17	i	-PRON-	PRP
cord-011310-fm578rm5	263	18	d	d	NN
cord-011310-fm578rm5	263	19	.	.	.
cord-011310-fm578rm5	263	20	nr	nr	NNP
cord-011310-fm578rm5	263	21	.	.	.
cord-011310-fm578rm5	264	1	1.1.1.1/18/A/184	1.1.1.1/18/a/184	CD
cord-011310-fm578rm5	264	2	'	'	POS
cord-011310-fm578rm5	264	3	Optimisation	Optimisation	NNP
cord-011310-fm578rm5	264	4	of	of	IN
cord-011310-fm578rm5	264	5	H.	H.	NNP
cord-011310-fm578rm5	264	6	pylori	pylori	NN
cord-011310-fm578rm5	264	7	eradication	eradication	NN
cord-011310-fm578rm5	264	8	therapy	therapy	NN
cord-011310-fm578rm5	264	9	for	for	IN
cord-011310-fm578rm5	264	10	population	population	NN
cord-011310-fm578rm5	264	11	-	-	HYPH
cord-011310-fm578rm5	264	12	based	base	VBN
cord-011310-fm578rm5	264	13	gastric	gastric	JJ
cord-011310-fm578rm5	264	14	cancer	cancer	NN
cord-011310-fm578rm5	264	15	prevention	prevention	NN
cord-011310-fm578rm5	264	16	'	'	''
cord-011310-fm578rm5	264	17	.	.	.
cord-011310-fm578rm5	265	1	Conflict	conflict	NN
cord-011310-fm578rm5	265	2	of	of	IN
cord-011310-fm578rm5	265	3	interest	interest	NN
cord-011310-fm578rm5	266	1	The	the	DT
cord-011310-fm578rm5	266	2	authors	author	NNS
cord-011310-fm578rm5	266	3	declare	declare	VBP
cord-011310-fm578rm5	266	4	that	that	IN
cord-011310-fm578rm5	266	5	they	-PRON-	PRP
cord-011310-fm578rm5	266	6	have	have	VBP
cord-011310-fm578rm5	266	7	no	no	DT
cord-011310-fm578rm5	266	8	conflict	conflict	NN
cord-011310-fm578rm5	266	9	of	of	IN
cord-011310-fm578rm5	266	10	interest	interest	NN
cord-011310-fm578rm5	266	11	.	.	.